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writing effortreamble
t is important that the medical profession play a significant
ole in critically evaluating the use of diagnostic procedures and
herapies in the detection, management, or prevention of
isease states. Rigorous and expert analysis of the available data
ocumenting absolute and relative benefits and risks of those
rocedures and therapies can produce helpful guidelines that
mprove the effectiveness of care, optimize patient outcomes,
nd favorably affect the overall cost of care by focusing
esources on the most effective strategies.
The American College of Cardiology Foundation (ACCF)
nd the American Heart Association (AHA) have jointly
ngaged in the production of such guidelines in the area ofardiology (ACC)/AHA Task Force on Practice Guidelines,
hose charge is to develop, update, or revise practice guidelines
or important cardiovascular diseases and procedures, directs
his effort. Writing committees are charged with the task of
erforming an assessment of the evidence and acting as an
ndependent group of authors to develop, update, or revise
ritten recommendations for clinical practice.
Experts in the subject under consideration have been
elected from both organizations to examine subject-specific
ata and write guidelines. The process includes additional
epresentatives from other medical practitioner and specialty
roups when appropriate. Writing committees are specifi-
ally charged to perform a formal literature review, weigh
he strength of evidence for or against a particular treatment
r procedure, and include estimates of expected health
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ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:e1–157utcomes where data exist. Patient-specific modifiers, co-
orbidities, and issues of patient preference that might
nfluence the choice of particular tests or therapies are
onsidered, as well as frequency of follow-up and cost
ffectiveness. When available, information from studies on
ost will be considered; however, review of data on efficacy
nd clinical outcomes will constitute the primary basis for
reparing recommendations in these guidelines.
The ACC/AHA Task Force on Practice Guidelines
akes every effort to avoid any actual, potential, or per-
eived conflict of interest that may arise as a result of an
ndustry relationship or personal interest of a member of the
riting Committee. Specifically, all members of the Writ-
ng Committee, as well as peer reviewers of the document,
ere asked to provide disclosure statements of all such
elationships that may be perceived as real or potential
onflicts of interest. Writing Committee members are also
trongly encouraged to declare a previous relationship with
ndustry that may be perceived as relevant to guideline
evelopment. If a Writing Committee member develops a
ew relationship with industry during their tenure, they are
equired to notify guideline staff in writing. The continued
articipation of the Writing Committee member will be
eviewed. These statements are reviewed by the parent task
orce, reported orally to all members of the Writing Com-
ittee at each meeting, and updated and reviewed by the
riting Committee as changes occur. Please refer to the
ethodology manual for ACC/AHA Guideline Writing
ommittees further description of relationships with indus-
ry policy, available on the ACC and AHA World Wide
eb sites (http://www.acc.org/qualityandscience/clinical/
anual/manual%5Fi.htm and http://www.circ.ahajournals.
rg/manual/). See Appendix 1 for a list of Writing Committee
ember relationships with industry and Appendix 2 for a
isting of peer reviewer relationships with industry that are
ertinent to this guideline.
These practice guidelines are intended to assist health
are providers in clinical decision making by describing a
ange of generally acceptable approaches for the diagnosis,
anagement, and prevention of specific diseases or condi-
ions. Clinical decision making should consider the quality
nd availability of expertise in the area where care is
rovided. These guidelines attempt to define practices that
eet the needs of most patients in most circumstances.
hese guideline recommendations reflect a consensus of
xpert opinion after a thorough review of the available,
urrent scientific evidence and are intended to improve
atient care.
Patient adherence to prescribed and agreed upon medical
egimens and lifestyles is an important aspect of treatment.
rescribed courses of treatment in accordance with these
ecommendations will only be effective if they are followed.
ince lack of patient understanding and adherence may
dversely affect treatment outcomes, physicians and other
ealth care providers should make every effort to engage the oatient in active participation with prescribed medical reg-
mens and lifestyles.
If these guidelines are used as the basis for regulatory/
ayer decisions, the ultimate goal is quality of care and
erving the patient’s best interests. The ultimate judgment
egarding care of a particular patient must be made by the
ealth care provider and patient in light of all the circum-
tances presented by that patient. There are circumstances
n which deviations from these guidelines are appropriate.
The guidelines will be reviewed annually by the ACC/
HA Task Force on Practice Guidelines and will be
onsidered current unless they are updated, revised, or
unsetted and withdrawn from distribution. The executive
ummary and recommendations are published in the August
, 2007, issue of the Journal of the American College of
ardiology and August 7, 2007, issue of Circulation. The
ull- text guidelines are e-published in the same issue of the
ournals noted above, as well as posted on the ACC
www.acc.org) and AHA (www.americanheart.org) World
ide Web sites. Copies of the full text and the executive
ummary are available from both organizations.
Sidney C. Smith, Jr, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
. Introduction
.1. Organization of Committee and
vidence Review
he ACC/AHA Task Force on Practice Guidelines was
ormed to make recommendations regarding the diagnosis and
reatment of patients with known or suspected cardiovascular
isease (CVD). Coronary artery disease (CAD) is the leading
ause of death in the United States. Unstable angina (UA) and
he closely related condition of non–ST-segment elevation
yocardial infarction (NSTEMI) are very common manifes-
ations of this disease.
The committee members reviewed and compiled pub-
ished reports through a series of computerized literature
earches of the English-language literature since 2002 and a
nal manual search of selected articles. Details of the
pecific searches conducted for particular sections are pro-
ided when appropriate. Detailed evidence tables were
eveloped whenever necessary with the specific criteria
utlined in the individual sections. The recommendations
ade were based primarily on these published data. The
eight of the evidence was ranked highest (A) to lowest
C). The final recommendations for indications for a diag-
ostic procedure, a particular therapy, or an intervention in
atients with UA/NSTEMI summarize both clinical evi-
ence and expert opinion.
lassification of Recommendations
he schema for classification of recommendations and level
f evidence is summarized in Table 1, which also illustrates
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August 14, 2007:e1–157 ACC/AHA UA/NSTEMI Guideline Revisionow the grading system provides an estimate of the size of
he treatment effect and an estimate of the certainty of the
reatment effect.
A complete list of the thousands of publications on
arious aspects of this subject is beyond the scope of these
uidelines; only selected references are included. The
ommittee consisted of acknowledged experts in general
nternal medicine representing the American College of
hysicians (ACP), family medicine from the American
cademy of Family Physicians (AAFP), emergency med-
cine from the American College of Emergency Physi-
ians (ACEP), thoracic surgery from the Society of
horacic Surgeons (STS), interventional cardiology from
he Society for Cardiovascular Angiography and Inter-
entions (SCAI), and general and critical care cardiology,
s well as individuals with recognized expertise in more
able 1. Applying Classification of Recommendations and Leve
Data available from clinical trials or registries about the usefulness/efficacy in different subpopu
ailure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply th
end themselves to clinical trials. Even though randomized trials are not available, there may b
CC/AHA Task Force on Practice Guidelines developed a list of suggested phrases to use when wr
complete thought, such that a recommendation, even if separated and presented apart from
ull intent of the recommendation. It is hoped that this will increase readers’ comprehension ofpecialized areas, including noninvasive testing, preven- Sive cardiology, coronary intervention, and cardiovascular
urgery. Both the academic and private practice sectors
ere represented. This document was reviewed by 2
utside reviewers nominated by each of the ACC and
HA and by 49 peer reviewers. These guidelines will be
onsidered current unless the Task Force revises them or
ithdraws them from distribution.
These guidelines overlap several previously published ACC/
HA practice guidelines, including the ACC/AHA Guide-
ines for the Management of Patients With ST-Elevation
yocardial Infarction (1), the ACC/AHA/SCAI 2005
uideline Update for Percutaneous Coronary Intervention (2),
he AHA/ACC Guidelines for Secondary Prevention for
atients With Coronary and Other Atherosclerotic Vascular
isease: 2006 Update (3), and the ACC/AHA 2002 Guide-
ine Update for the Management of Patients With Chronic
vidence†
, such as gender, age, history of diabetes, history of prior myocardial infarction, history of heart
ecommendation is weak. Many important clinical questions addressed in the guidelines do not
y clear clinical consensus that a particular test or therapy is useful or effective. †In 2003, the
commendations. All guideline recommendations have been written in full sentences that express
t of the document (including headings above sets of recommendations), would still convey the
idelines and will allow queries at the individual recommendation level.l of E
lations
at the r
e a ver
iting re
the restable Angina (4).
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hese guidelines address the diagnosis and management of
atients with UA and the closely related condition of
STEMI. These life-threatening disorders are a major
ause of emergency medical care and hospitalization in the
nited States. In 2004, the National Center for Health
tatistics reported 1,565,000 hospitalizations for primary or
econdary diagnosis of an acute coronary syndrome (ACS),
69,000 for UA and 896,000 for myocardial infarction (MI)
5). The average age of a person having a first heart attack
s 65.8 years for men and 70.4 years for women, and 43% of
CS patients of all ages are women. In 2003, there were
,497,000 visits to US emergency departments (EDs) for
rimary diagnosis of CVD (5). The prevalence of this
resentation of CVD ensures that many health care provid-
rs who are not cardiovascular specialists will encounter
atients with UA/NSTEMI in the course of the treatment
f other diseases, especially in outpatient and ED settings.
hese guidelines are intended to assist both cardiovascular
pecialists and nonspecialists in the proper evaluation and
anagement of patients with an acute onset of symptoms
uggestive of these conditions. These clinical practice guide-
able 2. Guidelines for the Identification of ACS Patients by ED
egistration/clerical staff
Patients with the following chief complaints require immediate assessment b
•Chest pain, pressure, tightness, or heaviness; pain that radiates to neck, jaw
•Indigestion or “heartburn”; nausea and/or vomiting associated with chest dis
•Persistent shortness of breath
•Weakness, dizziness, lightheadedness, loss of consciousness
riage nurse
Patients with the following symptoms and signs require immediate assessme
•Chest pain or severe epigastric pain, nontraumatic in origin, with component
X Central/substernal compression or crushing chest pain
X Pressure, tightness, heaviness, cramping, burning, aching sensation
X Unexplained indigestion, belching, epigastric pain
X Radiating pain in neck, jaw, shoulders, back, or 1 or both arms
•Associated dyspnea
•Associated nausea and/or vomiting
•Associated diaphoresis
If these symptoms are present, obtain stat ECG.
edical history
The triage nurse should take a brief, targeted, initial history with an assessme
•CABG, PCI, CAD, angina on effort, or MI
•NTG use to relieve chest discomfort
•Risk factors, including smoking, hyperlipidemia, hypertension, diabetes mell
•Regular and recent medication use
The brief history must not delay entry into the ACS protocol.
pecial considerations
Women may present more frequently than men with atypical chest pain and s
Diabetic patients may have atypical presentations due to autonomic dysfunct
Elderly patients may have atypical symptoms such as generalized weakness,
dapted from National Heart Attack Alert Program. Emergency Department: rapid identification a
uman Services. US Public Health Service. National Institutes of Health. National Heart, Lung andACS acute coronary syndrome; CABG coronary artery bypass graft surgery; CAD coronary artery d
nitroglycerin; PCI  percutaneous coronary intervention.ines also provide recommendations and supporting evi-
ence for the continued management of patients with these
onditions in both inpatient and outpatient settings. The
iagnostic and therapeutic strategies that are recommended
re supported by the best available evidence and expert
pinion. The application of these principles with carefully
easoned clinical judgment reduces but does not eliminate
he risk of cardiac damage and death in patients who present
ith symptoms suggestive of UA/NSTEMI.
.3. Overview of the Acute Coronary Syndromes
.3.1. Definition of Terms
nstable angina/NSTEMI constitutes a clinical syndrome
ubset of the ACS that is usually, but not always, caused by
therosclerotic CAD and is associated with an increased risk
f cardiac death and subsequent MI. In the spectrum of
CS, UA/NSTEMI is defined by electrocardiographic
ECG) ST-segment depression or prominent T-wave in-
ersion and/or positive biomarkers of necrosis (e.g., tropo-
in) in the absence of ST-segment elevation and in an
ppropriate clinical setting (chest discomfort or anginal
quivalent) (Table 2, Fig. 1). The results of angiographic
istration Clerks or Triage Nurses
riage nurse and should be referred for further evaluation:
lders, back, or 1 or both arms
ort
the triage nurse for the initiation of the ACS protocol:
cal of myocardial ischemia or MI:
current or past history of:
mily history, and cocaine or methamphetamine use
oms.
, syncope, or a change in mental status.
tment of patients with acute myocardial infarction. Bethesda, MD: US Department of Health and
Institute, September 1993. NIH Publication No. 93-3278 (6).Reg
y the t
, shou
comf
nt by
s typi
nt of
itus, fa
ympt
ion.
stroke
nd trea
Bloodisease; ECG electrocardiogram; ED emergency department; MImyocardial infarction; NTG
FT
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he top half of the figure illustrates the chronology of the interface between the patient and the clinician through the progression of plaque formation, onset, and complica-
ions of UA/NSTEMI, along with relevant management considerations at each stage. The longitudinal section of an artery depicts the “timeline” of atherogenesis from (1) a
ormal artery to (2) lesion initiation and accumulation of extracellular lipid in the intima, to (3) the evolution to the fibrofatty stage, to (4) lesion progression with procoagu-
ant expression and weakening of the fibrous cap. An acute coronary syndrome (ACS) develops when the vulnerable or high-risk plaque undergoes disruption of the fibrous
ap (5); disruption of the plaque is the stimulus for thrombogenesis. Thrombus resorption may be followed by collagen accumulation and smooth muscle cell growth (6).
fter disruption of a vulnerable or high-risk plaque, patients experience ischemic discomfort that results from a reduction of flow through the affected epicardial coronary
rtery. The flow reduction may be caused by a completely occlusive thrombus (bottom half, right side) or subtotally occlusive thrombus (bottom half, left side). Patients with
schemic discomfort may present with or without ST-segment elevation on the ECG. Among patients with ST-segment elevation, most (thick white arrow in bottom panel) ulti-
ately develop a Q-wave MI (QwMI), although a few (thin white arrow) develop a non–Q-wave MI (NQMI). Patients who present without ST-segment elevation are suffering
rom either unstable angina (UA) or a non–ST-segment elevation MI (NSTEMI) (thick red arrows), a distinction that is ultimately made on the basis of the presence or
bsence of a serum cardiac marker such as CK-MB or a cardiac troponin detected in the blood. Most patients presenting with NSTEMI ultimately develop a NQMI on the
CG; a few may develop a QwMI. The spectrum of clinical presentations ranging from UA through NSTEMI and STEMI is referred to as the acute coronary syndromes. This
A/NSTEMI guideline, as diagrammed in the upper panel, includes sections on initial management before UA/NSTEMI, at the onset of UA/NSTEMI, and during the hospital
hase. Secondary prevention and plans for long-term management begin early during the hospital phase of treatment. *Positive serum cardiac marker. Modified with permis-
ion from Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001;104:365 (7); © 2001 Lippincott, Williams & Wilkins; The Lancet,
58, Hamm CW, Bertrand M, Braunwald E. Acute coronary syndrome without ST elevation: implementation of new guidelines, 1553–8. Copyright 2001, with permission from
lsevier (8); and Davies MJ. The pathophysiology of acute coronary syndromes. Heart 2000;83:361–6 (9). © 2000 Lippincott, Williams & Wilkins. CK-MB  MB fraction of
reatine kinase; Dx  diagnosis; ECG  electrocardiogram.
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ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:e1–157nd angioscopic studies suggest that UA/NSTEMI often
esults from the disruption or erosion of an atherosclerotic
laque and a subsequent cascade of pathological processes
hat decrease coronary blood flow. Most patients who die
uring UA/NSTEMI do so because of sudden death or the
evelopment (or recurrence) of acute MI. The efficient
iagnosis and optimal management of these patients must
erive from information readily available at the time of the
nitial clinical presentation. The clinical presentation of
atients with a life-threatening ACS often overlaps that of
atients subsequently found not to have CAD. Moreover,
ome forms of MI cannot always be differentiated from UA
t the time of initial presentation.
“Acute coronary syndrome” has evolved as a useful
perational term to refer to any constellation of clinical
ymptoms that are compatible with acute myocardial isch-
mia (Fig. 1). It encompasses MI (ST-segment elevation
nd depression, Q wave and non-Q wave) and UA. These
uidelines focus on 2 components of this syndrome: UA and
STEMI. In practice, the term “possible ACS” is often
ssigned first by ancillary personnel, such as emergency
edical technicians and triage nurses, early in the evaluation
rocess. A guideline of the National Heart Attack Alert
rogram (6) summarizes the clinical information needed to
ake the diagnosis of possible ACS at the earliest phase of
linical evaluation (Table 2). The implication of this early
iagnosis for clinical management is that a patient who is
onsidered to have an ACS should be placed in an environ-
ent with continuous ECG monitoring and defibrillation
apability, where a 12-lead ECG can be obtained expeditiously
nd definitively interpreted, ideally within 10 min of arrival in
he ED. The most urgent priority of early evaluation is to
dentify patients with ST-elevation MI (STEMI) who should
e considered for immediate reperfusion therapy and to rec-
gnize other potentially catastrophic causes of patient symp-
oms, such as aortic dissection.
Patients diagnosed as having STEMI are excluded from
anagement according to these guidelines and should be
anaged as indicated according to the ACC/AHA Guide-
ines for the Management of Patients With ST-Elevation
yocardial Infarction (1,10). Similarly, management of
lectrocardiographic true posterior MI, which can masquer-
de as NSTEMI, is covered in the STEMI guidelines (1).
he management of patients who experience periprocedural
yocardial damage, as reflected in the release of biomarkers
f necrosis, such as the MB isoenzyme of creatine kinase
CK-MB) or troponin, also is not considered here.
Patients with MI and with definite ischemic ECG changes
or whom acute reperfusion therapy is not suitable should be
iagnosed and managed as patients with UA. The residual
roup of patients with an initial diagnosis of ACS will include
any patients who will ultimately be proven to have a
oncardiac cause for the initial clinical presentation that was
uggestive of ACS. Therefore, at the conclusion of the initial
valuation, which is frequently performed in the ED but
ometimes occurs during the initial hours of inpatient hospi-alization, each patient should have a provisional diagnosis of
) ACS (Fig. 1), which in turn is classified as a) STEMI, a
ondition for which immediate reperfusion therapy (fibrinoly-
is or percutaneous coronary intervention [PCI]) should be
onsidered, b) NSTEMI, or c) UA (definite, probable, or
ossible); 2) a non-ACS cardiovascular condition (e.g., acute
ericarditis); 3) a noncardiac condition with another specific
isease (e.g., chest pain secondary to esophageal spasm); or 4)
noncardiac condition that is undefined. In addition, the
nitial evaluation should be used to determine risk and to treat
ife-threatening events.
In these guidelines, UA and NSTEMI are considered to be
losely related conditions whose pathogenesis and clinical
resentations are similar but of differing severity; that is, they
iffer primarily in whether the ischemia is severe enough to
ause sufficient myocardial damage to release detectable quan-
ities of a marker of myocardial injury, most commonly
roponin I (TnI), troponin T (TnT), or CK-MB. Once it has
een established that no biomarker of myocardial necrosis has
een released (based on 2 or more samples collected at least 6 h
part, with a reference limit of the 99th percentile of the
ormal population) (11), the patient with ACS may be
onsidered to have experienced UA, whereas the diagnosis of
STEMI is established if a biomarker has been released.
arkers of myocardial injury can be detected in the blood-
tream with a delay of up to several hours after the onset of
schemic chest pain, which then allows the differentiation
etween UA (i.e., no biomarkers in circulation; usually tran-
ient, if any, ECG changes of ischemia) and NSTEMI (i.e.,
levated biomarkers). Thus, at the time of presentation, pa-
ients with UA and NSTEMI can be indistinguishable and
herefore are considered together in these guidelines.
.3.2. Pathogenesis of UA/NSTEMI
hese conditions are characterized by an imbalance between
yocardial oxygen supply and demand. They are not a
pecific disease, such as pneumococcal pneumonia, but
ather a syndrome, analogous to hypertension. A relatively
ew nonexclusive causes are recognized (12) (Table 3).
The most common mechanisms involve an imbalance
hat is caused primarily by a reduction in oxygen supply to
he myocardium, whereas with the fifth mechanism noted
elow, the imbalance is principally due to increased myo-
ardial oxygen requirements, usually in the presence of a
xed, restricted oxygen supply:
The most common cause of UA/NSTEMI is reduced
myocardial perfusion that results from coronary artery
narrowing caused by a thrombus that developed on a
disrupted atherosclerotic plaque and is usually nonocclu-
sive. Microembolization of platelet aggregates and com-
ponents of the disrupted plaque are believed to be
responsible for the release of myocardial markers in many
of these patients. An occlusive thrombus/plaque also can
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collateral blood supply.
The most common underlying molecular and cellular
pathophysiology of disrupted atherosclerotic plaque is
arterial inflammation, caused by noninfectious (e.g., ox-
idized lipids) and, possibly, infectious stimuli, which can
lead to plaque expansion and destabilization, rupture or
erosion, and thrombogenesis. Activated macrophages
and T lymphocytes located at the shoulder of a plaque
increase the expression of enzymes such as metallopro-
teinases that cause thinning and disruption of the plaque,
which in turn can lead to UA/NSTEMI.
A less common cause is dynamic obstruction, which may
be triggered by intense focal spasm of a segment of an
epicardial coronary artery (Prinzmetal’s angina) (see Sec-
tion 6.7). This local spasm is caused by hypercontractility
of vascular smooth muscle and/or by endothelial dysfunc-
tion. Large-vessel spasm can occur on top of obstructive
or destabilized plaque, resulting in angina of “mixed”
origin or UA/NSTEMI. Dynamic coronary obstruction
can also be caused by diffuse microvascular dysfunction;
for example, due to endothelial dysfunction or the ab-
normal constriction of small intramural resistance vessels.
Coronary spasm also is the presumed mechanism under-
lying cocaine-induced UA/NSTEMI.
A third cause of UA/NSTEMI is severe narrowing without
spasm or thrombus. This occurs in some patients with
progressive atherosclerosis or with restenosis after a PCI.
A fourth cause of UA/NSTEMI is coronary artery
dissection (e.g., as a cause of ACS in peripartal women).
The fifth mechanism is secondary UA, in which the
precipitating condition is extrinsic to the coronary arterial
bed. Patients with secondary UA usually, but not always,
have underlying coronary atherosclerotic narrowing that
limits myocardial perfusion, and they often have chronic
stable angina. Secondary UA is precipitated by conditions
able 3. Causes of UA/NSTEMI*
hrombus or thromboembolism, usually arising on disrupted or eroded plaque
● Occlusive thrombus, usually with collateral vessels†
● Subtotally occlusive thrombus on pre-existing plaque
● Distal microvascular thromboembolism from plaque-associated thrombus
hromboembolism from plaque erosion
● Non–plaque-associated coronary thromboembolism
ynamic obstruction (coronary spasm‡ or vasoconstriction) of epicardial and/
r microvascular vessels
rogressive mechanical obstruction to coronary flow
oronary arterial inflammation
econdary UA
oronary artery dissection§
These causes are not mutually exclusive; some patients have 2 or more causes. †DeWood MA,
tifter WF, Simpson CS, et al. Coronary arteriographic findings soon after non–Q-wave myocardial
nfarction. N Engl J Med 1986;315:417–23 (13). ‡May occur on top of an atherosclerotic plaque,
roducingmissed-etiology angina or UA/NSTEMI. §Rare. Modified with permission fromBraunwald E.
nstable angina: an etiologic approach to management. Circulation 1998;98:2219–22 (12).
UA  unstable angina; UA/NSTEMI  unstable angina/non–ST-elevation myocardial infarction.that 1) increase myocardial oxygen requirements, such as
1fever, tachycardia, or thyrotoxicosis; 2) reduce coronary
blood flow, such as hypotension; or 3) reduce myocardial
oxygen delivery, such as anemia or hypoxemia.
These causes of UA/NSTEMI are not mutually exclusive.
.3.3. Presentations of UA and NSTEMI
here are 3 principal presentations of UA: 1) rest angina
angina commencing when the patient is at rest), 2) new-
nset (less than 2 months) severe angina, and 3) increasing
ngina (increasing in intensity, duration, and/or frequency)
Table 4) (14). Criteria for the diagnosis of UA are based on
he duration and intensity of angina as graded according to
he Canadian Cardiovascular Society classification (Table 5)
15). Non–ST-elevation MI generally presents as pro-
onged, more intense rest angina or angina equivalent.
.4. Management Before UA/NSTEMI and Onset of
A/NSTEMI
he ACS spectrum (UA/MI) has a variable but potentially
erious prognosis. The major risk factors for development of
oronary heart disease (CHD) and UA/NSTEMI are well
stablished. Clinical trials have demonstrated that modifi-
able 4. Three Principal Presentations of UA
Class Presentation
est angina* Angina occurring at rest and prolonged, usually greater
than 20 min
ew-onset angina New-onset angina of at least CCS class III severity
ncreasing angina Previously diagnosed angina that has become
distinctly more frequent, longer in duration, or lower
in threshold (i.e., increased by 1 or more CCS class
to at least CCS class III severity)
Patients with non–ST-elevated myocardial infarction usually present with angina at rest. Adapted
ith permission from Braunwald E. Unstable angina: a classification. Circulation 1989;80:410–4
14).
CCS  Canadian Cardiovascular Society classification; UA  unstable angina.
able 5. Grading of Angina Pectoris
ccording to CCS Classification
Class Description of Stage
I “Ordinary physical activity does not cause . . . angina,” such as
walking or climbing stairs. Angina occurs with strenuous, rapid,
or prolonged exertion at work or recreation.
II “Slight limitation of ordinary activity.” Angina occurs on walking or
climbing stairs rapidly; walking uphill; walking or stair climbing
after meals; in cold, in wind, or under emotional stress; or only
during the few hours after awakening. Angina occurs on
walking more than 2 blocks on the level and climbing more
than 1 flight of ordinary stairs at a normal pace and under
normal conditions.
III “Marked limitations of ordinary physical activity.” Angina occurs
on walking
1 to 2 blocks on the level and climbing 1 flight of stairs under
normal conditions and at a normal pace.
IV “Inability to carry on any physical activity without discomfort—
anginal symptoms may be present at rest.”
dapted with permission from Campeau L. Grading of angina pectoris (letter). Circulation
976;54:522–3 (15).
CCS  Canadian Cardiovascular Society.
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ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:e1–157ation of those risk factors can prevent the development of
HD (primary prevention) or reduce the risk of experienc-
ng UA/NSTEMI in patients who have CHD (secondary
revention). All practitioners should emphasize prevention
nd refer patients to primary care providers for appropriate
ong-term preventive care. In addition to internists and
amily physicians, cardiologists have an important leader-
hip role in primary (and secondary) prevention efforts.
.4.1. Identification of Patients at Risk of UA/NSTEMI
LASS I
. Primary care providers should evaluate the presence and status of
control of major risk factors for CHD for all patients at regular
intervals (approximately every 3 to 5 years). (Level of Evidence: C)
. Ten-year risk (National Cholesterol Education Program [NCEP]
global risk) of developing symptomatic CHD should be calculated
for all patients who have 2 or more major risk factors to assess
the need for primary prevention strategies (16,17). (Level of
Evidence: B)
. Patients with established CHD should be identified for secondary
prevention efforts, and patients with a CHD risk equivalent (e.g.,
atherosclerosis in other vascular beds, diabetes mellitus, chronic
kidney disease, or 10-year risk greater than 20% as calculated by
Framingham equations) should receive equally intensive risk factor
intervention as those with clinically apparent CHD. (Level of Evi-
dence: A)
Major risk factors for developing CHD (i.e., smoking,
amily history, adverse lipid profiles, diabetes mellitus, and
levated blood pressure) have been established from large,
ong-term epidemiological studies (18,19). These risk fac-
ors are predictive for most populations in the United States.
rimary and secondary prevention interventions aimed at
hese risk factors are effective when used properly. They can
lso be costly in terms of primary care provider time,
iversion of attention from other competing and important
ealth care needs, and expense, and they may not be
ffective unless targeted at higher-risk patients (20). It is
herefore important for primary care providers to make the
dentification of patients at risk, who are most likely to
enefit from primary prevention, a routine part of everyone’s
ealth care. The Third Report of the NCEP provides
uidance on identifying such patients (18). Furthermore,
he Writing Committee supports public health efforts to
each all adults at risk, not just those under the care of a
rimary care physician.
Patients with 2 or more risk factors who are at increased
0-year and lifetime risk will have the greatest benefit from
rimary prevention, but any individual with a single elevated
isk factor is a candidate for primary prevention (19). Waiting
ntil the patient develops multiple risk factors and increased
0-year risk contributes to the high prevalence of CHD in
he United States (18,21). Such patients should have their
isk specifically calculated by any of the several valid prog-
ostic tools available in print (18,22), on the Internet (23),
r for use on a personal computer or personal digital
ssistant (PDA) (18). Patients’ specific risk levels determine mhe absolute risk reductions they can obtain from preventive
nterventions and guide selection and prioritization of those
nterventions. For example, target levels for lipid lowering
nd for antihypertensive therapy vary by patients’ baseline
isk. A specific risk number can also serve as a powerful
ducational intervention to motivate lifestyle changes (24).
The detection of subclinical atherosclerosis by noninva-
ive imaging represents a new, evolving approach for refin-
ng individual risk in asymptomatic individuals beyond
raditional risk factor assessment alone. A recent AHA
cientific statement indicates that it may be reasonable to
easure atherosclerosis burden using electron-beam or mul-
idetector computed tomography (CT) in clinically selected
ntermediate-CAD-risk individuals (e.g., those with a 10%
o 20% Framingham 10-year risk estimate) to refine clinical
isk prediction and to select patients for aggressive target
alues for lipid-lowering therapies (Class IIb, Level of
vidence: B) (25).
.4.2. Interventions to Reduce Risk of UA/NSTEMI
he benefits of prevention of UA/NSTEMI in patients
ith CHD are well documented and of large magnitude
3,21,26–28). Patients with established CHD should be
dentified for secondary prevention efforts, and patients with
CHD risk equivalent should receive equally intensive risk
actor intervention for high-risk primary prevention regard-
ess of sex (29). Patients with diabetes mellitus and periph-
ral vascular disease have baseline risks of UA/NSTEMI
imilar to patients with known CHD, as do patients with
ultiple risk factors that predict a calculated risk of greater
han 20% over 10 years as estimated by the Framingham
quations (18). Such patients should be considered to have
he risk equivalents of CHD, and they can be expected to
ave an absolute benefit similar to those with established
HD.
All patients who use tobacco should be encouraged to
uit and should be provided with help in quitting at every
pportunity (30). Recommendations by a clinician to avoid
obacco can have a meaningful impact on the rate of
essation of tobacco use. The most effective strategies for
ncouraging quitting are those that identify the patient’s
evel or stage of readiness and provide information, support,
nd, if necessary, pharmacotherapy targeted at the individ-
al’s readiness and specific needs (26,31). Pharmacotherapy
ay include nicotine replacement or withdrawal-relieving
edication such as bupropion. Varenicline, a nicotine ace-
ylcholine receptor partial antagonist, is a newly approved
onnicotine replacement therapy for tobacco avoidance
32–35). Many patients require several attempts before they
ucceed in quitting permanently (36,37). Additional discus-
ion in this area can be found in other contemporary
ocuments (e.g., the ACC/AHA 2002 Guideline Update
or the Management of Patients With Chronic Stable
ngina [4]).
All patients should be instructed in and encouraged to
aintain appropriate low-saturated-fat, low-trans-fat, and
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August 14, 2007:e1–157 ACC/AHA UA/NSTEMI Guideline Revisionow-cholesterol diets high in soluble (viscous) fiber and rich
n vegetables, fruits, and whole grains. All patients also
hould be encouraged to be involved with a regular aerobic
xercise program, including 30 to 60 min of moderate-
ntensity physical activity (such as brisk walking) on most
nd preferably all days of the week (3,38). For those who
eed to weigh less, an appropriate balance of increased
hysical activity (i.e., 60 to 90 min daily), caloric restriction,
nd formal behavioral programs is encouraged to achieve
nd maintain a body mass index between 18.5 and 24.9
g/m2 and a waist circumference of less than or equal to 35
nches in women and less than or equal to 40 inches in men.
or those who need lipid lowering beyond lifestyle mea-
ures, the statin drugs have the best outcome evidence
upporting their use and should be the mainstay of phar-
acological intervention (21). The appropriate levels for
ipid management are dependent on baseline risk; the reader
s referred to the NCEP report (http://www.nhlbi.nih.gov/
uidelines/cholesterol/index.htm) for details (17,18,39–41).
Primary prevention patients with high blood pressure
hould be treated according to the recommendations of the
eventh Joint National Committee on High Blood Pressure
JNC 7) (42,43). Specific treatment recommendations are
ased on the level of hypertension and the patient’s other
isk factors. A diet low in salt and rich in vegetables, fruits,
nd low-fat dairy products should be encouraged for all
ypertensive patients, as should a regular aerobic exercise
rogram (44–47). Most patients will require more than 1
edication to achieve blood pressure control, and pharma-
otherapy should begin with known outcome-improving
edications (primarily thiazide diuretics as first choice, with
he addition of beta blockers, angiotensin-converting en-
yme [ACE] inhibitors, angiotensin receptor blockers,
nd/or long-acting calcium channel blockers) (42,48). Sys-
olic hypertension is a powerful predictor of adverse out-
ome, particularly among the elderly, and it should be
reated even if diastolic pressures are normal (49).
Detection of hyperglycemic risk (e.g., metabolic syn-
rome) and diabetes mellitus should be pursued as part of
isk assessment. Lifestyle changes and pharmacotherapy are
ndicated in individuals with diabetes mellitus to achieve a
lycosylated hemoglobin [HbA1c] level less than 7% but to
void hypoglycemia (3,50,51).
Aspirin prophylaxis can uncommonly result in hemor-
hagic complications and should only be used in primary
revention when the level of risk justifies it. Patients whose
0-year risk of CHD is 10% or more are most likely to
enefit, and 75 to 162 mg of aspirin (ASA) per day as
rimary prophylaxis should be discussed with such patients
29,38,52–55).
.5. Onset of UA/NSTEMI
.5.1. Recognition of Symptoms by Patient
arly recognition of symptoms of UA/NSTEMI by the
atient or someone with the patient is the first step that wust occur before evaluation and life-saving treatment can
e obtained. Although many laypersons are generally aware
hat chest pain is a presenting symptom of UA/NSTEMI,
hey are unaware of the other common symptoms, such as
rm pain, lower jaw pain, shortness of breath (56), and
iaphoresis (57) or anginal equivalents, such as dyspnea or
xtreme fatigue (56,58). The average patient with NSTEMI
r prolonged rest UA (e.g., longer than 20 min) does not
eek medical care for approximately 2 h after symptom
nset, and this pattern appears unchanged over the last
ecade (58–60). A baseline analysis from the Rapid Early
ction for Coronary Treatment (REACT) research pro-
ram demonstrated longer delay times among non-Hispanic
lacks, older patients, and Medicaid-only recipients and
horter delay times among Medicare recipients (compared
ith privately insured patients) and patients who came to
he hospital by ambulance (58). In the majority of studies
xamined to date, women in both univariate- and
ultivariate-adjusted analyses (in which age and other
otentially confounding variables have been controlled)
xhibit more prolonged delay patterns than men (61).
A number of studies have provided insight into why
atients delay in seeking early care for heart symptoms
62). Focus groups conducted for the REACT research
rogram (63,64) revealed that patients commonly hold a
reexisting expectation that a heart attack would present
ramatically with severe, crushing chest pain, such that
here would be no doubt that one was occurring. This was
n contrast to their actual reported symptom experience
f a gradual onset of discomfort involving midsternal
hest pressure or tightness, with other associated symp-
oms often increasing in intensity. The ambiguity of
hese symptoms, due to this disconnect between prior
xpectations and actual experience, resulted in uncer-
ainty about the origin of symptoms and thus a “wait-
nd-see” posture by patients and those around them (62).
ther reported reasons for delay were that patients
hought the symptoms were self-limited and would go
way or were not serious (65– 67); that they attributed
ymptoms to other preexisting chronic conditions, espe-
ially among older adults with multiple chronic condi-
ions (e.g., arthritis), or sometimes to a common illness
uch as influenza; that they were afraid of being embar-
assed if symptoms turned out to be a “false alarm”; that
hey were reluctant to trouble others (e.g., health care
roviders, Emergency Medical Services [EMS]) unless
hey were “really sick” (65– 67); that they held stereotypes
f who is at risk for a heart attack; and that they lacked
wareness of the importance of rapid action, knowledge
f reperfusion treatment, or knowledge of the benefits of
alling EMS/9-1-1 to ensure earlier treatment (62). Notably,
omen did not perceive themselves to be at risk (69).
.5.2. Silent and Unrecognized Events
atients experiencing UA/NSTEMI do not always present
ith chest discomfort (70). The Framingham Study was the
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ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:e1–157rst to show that as many as half of all MIs may be clinically
ilent and unrecognized by the patient (71). Canto et al.
72) found that one third of the 434,877 patients with
onfirmed MI in the National Registry of Myocardial
nfarction presented to the hospital with symptoms other
han chest discomfort. Compared with MI patients with
hest discomfort, MI patients without chest discomfort
ere more likely to be older, to be women, to have diabetes,
nd/or to have prior heart failure [HF]. Myocardial infarc-
ion patients without chest discomfort delayed longer before
hey went to the hospital (mean 7.9 vs. 5.3 h) and were less
ikely to be diagnosed as having an MI when admitted
22.2% vs. 50.3%). They also were less likely to receive
brinolysis or primary PCI, ASA, beta blockers, or heparin.
ilent MI patients were 2.2 times more likely to die during
he hospitalization (in-hospital mortality rate 23.3% vs.
.3%). Unexplained dyspnea, even without angina, is a
articularly worrisome symptom, with more than twice the
isk of death than for typical angina in patients undergoing
ardiovascular evaluation (56). Recently, the prognostic
ignificance of dyspnea has been emphasized in patients
ndergoing cardiac evaluation. Self-reported dyspnea alone
mong 17,991 patients undergoing stress perfusion testing
as an independent predictor of cardiac and total mortality
igure 2. Algorithm for Evaluation and Management of Patients Su
o facilitate interpretation of this algorithm and a more detailed discussion in the te
er that is allocated from left to right across the diagram on a given level. ACC/AHA  Am
yndrome; ECG  electrocardiogram; LV  left ventricular.nd increased the risk of sudden cardiac death 4-fold even in
hose with no prior history of CAD (56).
Health care providers should maintain a high index of
uspicion for UA/NSTEMI when evaluating women, pa-
ients with diabetes mellitus, older patients, those with
nexplained dyspnea (56), and those with a history of HF or
troke, as well as those patients who complain of chest
iscomfort but who have a permanent pacemaker that may
onfound recognition of UA/NSTEMI on their 12-lead
CG (73).
. Initial Evaluation and Management
.1. Clinical Assessment
ecause symptoms are similar and the differentiation of
A/NSTEMI and STEMI requires medical evaluation, we
ill refer to prediagnostic clinical presentation as ACS,
efined as UA or MI (NSTEMI or STEMI) (Fig. 2).
RECOMMENDATIONS
LASS I
1. Patients with symptoms that may represent ACS (Table 2) should
not be evaluated solely over the telephone but should be referred to
a facility that allows evaluation by a physician and the recording of
ted of Having ACS
h box is assigned a letter code that reflects its level in the algorithm and a num-spec
xt, eac
erican College of Cardiology/American Heart Association; ACS  acute coronary
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August 14, 2007:e1–157 ACC/AHA UA/NSTEMI Guideline Revisiona 12-lead ECG and biomarker determination (e.g., an ED or other
acute care facility). (Level of Evidence: C)
2. Patients with symptoms of ACS (chest discomfort with or without
radiation to the arm[s], back, neck, jaw or epigastrium; shortness of
breath; weakness; diaphoresis; nausea; lightheadedness) should
be instructed to call 9-1-1 and should be transported to the hospital
by ambulance rather than by friends or relatives. (Level of Evidence: B)
3. Health care providers should actively address the following issues
regarding ACS with patients with or at risk for CHD and their
families or other responsible caregivers:
a. The patient’s heart attack risk; (Level of Evidence: C)
b. How to recognize symptoms of ACS; (Level of Evidence: C)
c. The advisability of calling 9-1-1 if symptoms are unimproved or
worsening after 5 min, despite feelings of uncertainty about the
symptoms and fear of potential embarrassment; (Level of Evi-
dence: C)
d. A plan for appropriate recognition and response to a potential
acute cardiac event, including the phone number to access
EMS, generally 9-1-1 (74). (Level of Evidence: C)
4. Prehospital EMS providers should administer 162 to 325 mg of
ASA (chewed) to chest pain patients suspected of having ACS
unless contraindicated or already taken by the patient. Although
some trials have used enteric-coated ASA for initial dosing, more
rapid buccal absorption occurs with non–enteric-coated formula-
tions. (Level of Evidence: C)
5. Health care providers should instruct patients with suspected ACS
for whom nitroglycerin [NTG] has been prescribed previously to take
not more than 1 dose of NTG sublingually in response to chest
discomfort/pain. If chest discomfort/pain is unimproved or is wors-
ening 5 min after 1 NTG dose has been taken, it is recommended
that the patient or family member/friend/caregiver call 9-1-1
immediately to access EMS before taking additional NTG. In pa-
tients with chronic stable angina, if symptoms are significantly
improved by 1 dose of NTG, it is appropriate to instruct the patient
or family member/friend/caregiver to repeat NTG every 5 min for a
maximum of 3 doses and call 9-1-1 if symptoms have not resolved
completely. (Level of Evidence: C)
6. Patients with a suspected ACS with chest discomfort or other
ischemic symptoms at rest for greater than 20 min, hemodynamic
instability, or recent syncope or presyncope should be referred
immediately to an ED. Other patients with suspected ACS who are
experiencing less severe symptoms and who have none of the
above high-risk features, including those who respond to an NTG
dose, may be seen initially in an ED or an outpatient facility able to
provide an acute evaluation. (Level of Evidence: C)
LASS IIa
. It is reasonable for health care providers and 9-1-1 dispatchers to
advise patients without a history of ASA allergy who have symptoms
of ACS to chew ASA (162 to 325 mg) while awaiting arrival of
prehospital EMS providers. Although some trials have used enteric-
coated ASA for initial dosing, more rapid buccal absorption occurs
with non–enteric-coated formulations. (Level of Evidence: B)
. It is reasonable for health care providers and 9-1-1 dispatchers to
advise patients who tolerate NTG to repeat NTG every 5 min for a
maximum of 3 doses while awaiting ambulance arrival. (Level of
Evidence: C)
. It is reasonable that all prehospital EMS providers perform and
evaluate 12-lead ECGs in the field (if available) on chest pain
patients suspected of ACS to assist in triage decisions. Electrocar- pdiographs with validated computer-generated interpretation algo-
rithms are recommended for this purpose. (Level of Evidence: B)
. If the 12-lead ECG shows evidence of acute injury or ischemia, it is
reasonable that prehospital ACLS providers relay the ECG to a
predetermined medical control facility and/or receiving hospital.
(Level of Evidence: B)
Patients with suspected ACS must be evaluated rapidly.
ecisions made on the basis of the initial evaluation have
ubstantial clinical and economic consequences (75). The
rst triage decision is made by the patient, who must decide
hether to access the health care system. Media campaigns
uch as “Act in Time,” sponsored by the National Heart,
ung, and Blood Institute (NHLBI), provide patient edu-
ation regarding this triage decision (www.nhlbi.nih.gov/
ctintime). The campaign urges both men and women who
eel heart attack symptoms or observe the signs in others to
ait no more than a few minutes, 5 min at most, before
alling 9-1-1 (76,77). Campaign materials point out that
atients can increase their chance of surviving a heart attack
y learning the symptoms and filling out a survival plan.
hey also are advised to talk with their doctor about heart
ttacks and how to reduce their risk of having one. The
atient materials include a free brochure about symptoms
nd recommended actions for survival, in English (78) and
panish (79), as well as a free wallet card that can be filled
n with emergency medical information (80). Materials
eared directly to providers include a Patient Action Plan
ablet (81), which contains the heart attack warning symp-
oms and steps for developing a survival plan, individualized
ith the patient’s name; a quick reference card for address-
ng common patient questions about seeking early treatment
o survive a heart attack (82), including a PDA version (83);
nd a warning signs wall chart (84). These materials and
thers are available on the “Act in Time” Web page
www.nhlbi.nih.gov/health/public/heart/mi/core_bk.pdf)
77).
When the patient first makes contact with the medical
are system, a critical decision must be made about where
he evaluation will take place. The health care provider then
ust place the evaluation in the context of 2 critical
uestions: Are the symptoms a manifestation of an ACS? If
o, what is the prognosis? The answers to these 2 questions
ead logically to a series of decisions about where the patient
ill be best managed, what medications will be prescribed,
nd whether an angiographic evaluation will be required.
Given the large number of patients with symptoms
ompatible with ACS, the heterogeneity of the population,
nd a clustering of events shortly after the onset of symp-
oms, a strategy for the initial evaluation and management is
ssential. Health care providers may be informed about
igns and symptoms of ACS over the telephone or in person
y the patient or family members. The objectives of the
nitial evaluation are first to identify signs of immediate
ife-threatening instability and then to ensure that the
atient is moved rapidly to the most appropriate environ-
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ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:e1–157ent for the level of care needed based on diagnostic criteria
nd an estimation of the underlying risk of specific negative
utcomes.
Health practitioners frequently receive telephone calls
rom patients or family members/friends/caregivers who are
oncerned that their symptoms could reflect heart disease.
ost such calls regarding chest discomfort of possible
ardiac origin in patients without known CAD do not
epresent an emergency; rather, these patients usually seek
eassurance that they do not have heart disease or that there
s little risk due to their symptoms. Despite the frequent
nclination to dismiss such symptoms over the telephone,
ealth care providers, EMS dispatchers, and staff positioned
o receive these calls should advise patients with possible
ccelerating angina or angina at rest that an evaluation
annot be performed solely via the telephone. This advice is
ssential because of the need for timely evaluation, including
physical examination, ECG, and appropriate blood tests
o measure cardiac biomarkers.
Patients with known CAD—including those with
hronic stable angina, recent MI, or prior intervention (i.e.,
oronary artery bypass graft surgery [CABG] or PCI)—who
ontact a physician or other appropriate member of the
ealth care team because of worsening or recurrent symp-
oms should be instructed to proceed rapidly to an ED,
referably one equipped to perform prompt reperfusion
herapy. When the discomfort is moderate to severe or
ustained, they should be instructed to access the EMS
ystem directly by calling 9-1-1. Patients who have been
valuated recently and who are calling for advice regarding
odification of medications as part of an ongoing treatment
lan represent exceptions.
Even in the most urgent subgroup of patients who
resent with acute-onset chest pain, there usually is ade-
uate time for transport to an environment in which they
an be evaluated and treated (85). In a large study of
onsecutive patients with chest pain suspected to be of
ardiac origin who were transported to the ED via ambu-
ance, one third had a final diagnosis of MI, one third had
final diagnosis of UA, and one third had a final diagnosis
f a noncardiac cause; 1.5% of these patients developed
ardiopulmonary arrest before arrival at the hospital or in
he ED (86).
Every community should have a written protocol that
uides EMS system personnel in determining where to take
atients with suspected or confirmed ACS. Active involve-
ent of local health care providers, particularly cardiologists
nd emergency physicians, is needed to formulate local
MS destination protocols for these patients. In general,
atients with suspected ACS should be taken to the nearest
ppropriate hospital; however, patients with known STEMI
nd/or cardiogenic shock should be sent as directly as
ossible to hospitals with interventional and surgical capa-
ility (1).
The advent of highly effective, time-dependent treatmentor ACS, coupled with the need to reduce health care costs, pdds further incentive for clinicians to get the right answer
uickly and to reduce unnecessary admissions and length of
ospital stay. Investigators have tried various diagnostic
ools, such as clinical decision algorithms, cardiac biomar-
ers, serial ECGs, echocardiography, myocardial perfusion
maging, and multidetector (e.g., 64-slice) coronary CT
ngiography (CCTA), in an attempt to avoid missing
atients with MI or UA. The most successful strategies to
merge thus far are designed to identify MI patients and,
hen clinically appropriate, screen for UA and underlying
AD. Most strategies use a combination of cardiac biomar-
ers, short-term observation, diagnostic imaging, and pro-
ocative stress testing. An increasing number of high-
uality centers now use structured protocols, checklists, or
ritical pathways to screen patients with suspected MI or
A (87–99). It does not appear to matter whether the
nstitution designates itself a chest pain center; rather, it is
he multifaceted, multidisciplinary, standardized, and struc-
ured approach to the problem that appears to provide
linical, cost-effective benefit (100,101). One randomized
rial has confirmed the safety, efficacy, and cost-effectiveness
f the structured decision-making approach compared with
tandard, unstructured care (102).
Regardless of the approach used, all patients presenting to
he ED with chest discomfort or other symptoms suggestive
f MI or UA should be considered high-priority triage cases
nd should be evaluated and treated on the basis of a
redetermined, institution-specific chest pain protocol. The
rotocol should include several diagnostic possibilities (Fig.
) (103). The patient should be placed on a cardiac monitor
mmediately, with emergency resuscitation equipment, in-
luding a defibrillator, nearby. An ECG also should be
erformed immediately and evaluated by an experienced
mergency medicine physician, with a goal of within 10 min
f ED arrival. If STEMI is present, the decision as to
hether the patient will be treated with fibrinolytic therapy
r primary PCI should be made within the next 10 min (1).
or cases in which the initial diagnosis and treatment plan
re unclear to the emergency medicine physician or are not
overed directly by an institutionally agreed-upon protocol,
mmediate cardiology consultation is advisable.
Morbidity and mortality from ACS can be reduced
ignificantly if patients and bystanders recognize symptoms
arly, activate the EMS system, and thereby shorten the
ime to definitive treatment. Patients with possible symp-
oms of MI should be transported to the hospital by
mbulance rather than by friends or relatives, because there
s a significant association between arrival at the ED by
mbulance and early reperfusion therapy in STEMI patients
104–107). In addition, emergency medical technicians and
aramedics can provide life-saving interventions (e.g., early
ardiopulmonary resuscitation [CPR] and defibrillation) if
he patient develops cardiac arrest. Approximately 1 in every
00 patients with chest pain transported to the ED by
rivate vehicle goes into cardiac arrest en route (108).
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August 14, 2007:e1–157 ACC/AHA UA/NSTEMI Guideline RevisionSeveral studies have confirmed that patients with ACS
requently do not call 9-1-1 and are not transported to the
ospital by ambulance. A follow-up survey of chest pain
atients presenting to participating EDs in 20 US commu-
ities who were either released or admitted to the hospital
ith a confirmed coronary event revealed that the average
roportion of patients who used EMS was 23%, with
ignificant geographic difference (range 10% to 48%). Most
atients were driven by someone else (60%) or drove
hemselves to the hospital (16%) (109). In the National
egistry of Myocardial Infarction 2, just over half (53%) of
ll patients with MI were transported to the hospital by
mbulance (105).
Even in areas of the country that have undertaken
ubstantial public education campaigns about the warning
igns of ACS and the need to activate the EMS system
apidly, either there were no increases in EMS use (58,110–
13) or EMS use increased (as a secondary outcome
easure) but was still suboptimal, with a 20% increase from
baseline of 33% in all 20 communities in the REACT
tudy (63) and an increase from 27% to 41% in southern
innesota after a community campaign (114). Given the
mportance of patients using EMS for possible acute cardiac
ymptoms, communities, including medical providers, EMS
ystems, health care insurers, hospitals, and policy makers at
he state and local level, need to have agreed-upon emer-
igure 3. Patient (Advance) Instructions for NTG Use and EMS Co
f patients experience chest discomfort/pain and have been previously prescribed N
nstructed (in advance) to take 1 dose of NTG immediately in response to symptoms
ually, it is recommended that the patient call 9-1-1 immediately to access EMS. In
ng 1 NTG, it is appropriate to instruct the patient or family member/friend/caregive
ot totally resolved. If patients are not previously prescribed NTG (left side of algorit
orsening 5 min after it starts. If the symptoms subside within 5 min of when they b
nset chest discomfort who have not been prescribed NTG, it is appropriate to disco
ive].) *Although some trials have used enteric-coated aspirin for initial dosing, more rapid
edical services; NTG  nitroglycerin.ency protocols to ensure patients with possible heart attack
ymptoms will be able to access 9-1-1 without barriers, to
ecure their timely evaluation and treatment (115).
As part of making a plan with the patient for timely
ecognition and response to an acute event, providers should
eview instructions for taking NTG in response to chest
iscomfort/pain (Fig. 3). If a patient has previously been
rescribed NTG, it is recommended that the patient be
dvised to take 1 NTG dose sublingually promptly for chest
iscomfort/pain. If symptoms are unimproved or worsening
min after 1 NTG dose has been taken, it also is
ecommended that the patient be instructed to call 9-1-1
mmediately to access EMS. Although the traditional rec-
mmendation is for patients to take 1 NTG dose sublin-
ually, 5 min apart, for up to 3 doses before calling for
mergency evaluation, this recommendation has been mod-
fied by the UA/NSTEMI Writing Committee to encour-
ge earlier contacting of EMS by patients with symptoms
uggestive of ACS. While awaiting ambulance arrival,
atients tolerating NTG can be instructed by health care
roviders or 9-1-1 dispatchers to take additional NTG every
min up to 3 doses. Self-treatment with prescription
edication, including nitrates, and with nonprescription
edication (e.g., antacids) has been documented as a
requent cause of delay among patients with ACS, including
hose with a history of MI or angina (65,116). Both the rate
in the Setting of Non–Trauma-Related Chest Discomfort/Pain
have it available (right side of algorithm), it is recommended that they be
est discomfort/pain is unimproved or worsening 5 min after taking 1 NTG sublin-
ts with chronic stable angina, if the symptoms are significantly improved after tak-
eat NTG every 5 min for a maximum of 3 doses and call 9-1-1 if symptoms have
is recommended that they call 9-1-1 if chest discomfort/pain is unimproved or
patients should notify their physician of the episode. (For those patients with new-
them from seeking someone else’s NTG [e.g., from a neighbor, friend, or rela-ntact
TG and
. If ch
patien
r to rep
hm), it
egan,
uragebuccal absorption occurs with non–enteric-coated formulations. EMS  emergency
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ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:e1–157f use of these medications and the number of doses taken
ere positively correlated with delay time to hospital arrival
65).
Family members, close friends, caregivers, or advocates
hould be included in these discussions and enlisted as
einforcement for rapid action when the patient experiences
ymptoms of a possible ACS (74,117,118) (Fig. 3). For
atients known to their providers to have frequent angina,
hysicians may consider a selected, more tailored message
hat takes into account the frequency and character of the
atient’s angina and their typical time course of response to
TG. In many of these patients with chronic stable angina,
f chest pain is significantly improved by 1 NTG, it is still
ppropriate to instruct the patient or family member/friend/
aregiver to repeat NTG every 5 min for a maximum of 3
oses and to call 9-1-1 if symptoms have not resolved
ompletely. Avoidance of patient delay associated with
elf-medication and prolonged reevaluation of symptoms
re paramount. An additional consideration in high-risk
HD patients is to train family members in CPR and/or to
ave home access to an automatic external defibrillator, now
vailable commercially to the public.
The taking of aspirin by patients in response to acute
ymptoms has been reported to be associated with a delay in
alling EMS (109). Patients should focus on calling 9-1-1,
hich activates the EMS system, where they may receive
nstructions from emergency medical dispatchers to chew
spirin (162 to 325 mg) while emergency personnel are en
oute, or emergency personnel can give an aspirin while
ransporting the patient to the hospital (119). Alternatively,
atients may receive an aspirin as part of their early
reatment once they arrive at the hospital if it has not been
iven in the prehospital setting (117).
Providers should target those patients at increased risk for
CS, focusing on patients with known CHD, peripheral
ascular disease, or cerebral vascular disease, those with
iabetes, and patients with a 10-year Framingham risk of
HD of more than 20% (120). They should stress that the
hest discomfort will usually not be dramatic, such as is
ommonly misrepresented on television or in the movies as
“Hollywood heart attack.” Providers also should describe
nginal equivalents and the commonly associated symptoms
f ACS (e.g., shortness of breath, a cold sweat, nausea, or
ightheadedness) in both men and women (56,106), as well
s the increased frequency of atypical symptoms in elderly
atients (72).
.1.1. Emergency Department or Outpatient Facility
resentation
t is recommended that patients with a suspected ACS with
hest discomfort or other ischemic symptoms at rest for
ore than 20 min, hemodynamic instability, or recent
yncope or presyncope to be referred immediately to an ED
r a specialized chest pain unit. For other patients with a
uspected ACS who are experiencing less severe symptoms
nd are having none of the above high-risk features, theecommendation is to be seen initially in an ED, a chest
ain unit, or an appropriate outpatient facility. Outcomes
ata that firmly support these recommendations are not
vailable; however, these recommendations are of practical
mportance because differing ACS presentations require
iffering levels of emergent medical interventions, such as
brinolytics or emergency coronary angiography leading to
CI or surgery, or sophisticated diagnostic evaluation such
s nuclear stress testing or CCTA. When symptoms have
een unremitting for more than 20 min, the possibility of
I must be considered. Given the strong evidence for a
elationship between delay in treatment and death (121–
23), an immediate assessment that includes a 12-lead
CG is essential. Patients who present with hemodynamic
nstability require an environment in which therapeutic
nterventions can be provided, and for those with presyn-
ope or syncope, the major concern is the risk of sudden
eath. Such patients should be encouraged to seek emer-
ency transportation when it is available. Transport as a
assenger in a private vehicle is an acceptable alternative
nly if the wait for an emergency vehicle would impose a
elay of greater than 20 to 30 min.
.1.2. Questions to Be Addressed at the Initial Evaluation
he initial evaluation should be used to provide information
bout the diagnosis and prognosis. The attempt should be
ade to simultaneously answer 2 questions:
What is the likelihood that the signs and symptoms
represent ACS secondary to obstructive CAD (Table 6)?
What is the likelihood of an adverse clinical outcome
(Table 7)? Outcomes of concern include death, MI (or
recurrent MI), stroke, HF, recurrent symptomatic isch-
emia, and serious arrhythmia.
For the most part, the answers to these questions form a
equence of contingent probabilities. Thus, the likelihood that
he signs and symptoms represent ACS is contingent on the
ikelihood that the patient has underlying CAD. Similarly, the
rognosis is contingent on the likelihood that the symptoms
epresent acute ischemia. However, in patients with symptoms
f possible ACS, traditional risk factors for CAD are less
mportant than are symptoms, ECG findings, and cardiac
iomarkers. Therefore, the presence or absence of these tradi-
ional risk factors ordinarily should not be heavily weighed in
etermining whether an individual patient should be admitted
r treated for ACS.
.2. Early Risk Stratification
RECOMMENDATIONS FOR EARLY RISK STRATIFICATION
LASS I
. A rapid clinical determination of the likelihood risk of obstructive
CAD (i.e., high, intermediate, or low) should be made in all
patients with chest discomfort or other symptoms suggestive of
an ACS and considered in patient management. (Level of Evi-
dence: C)
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August 14, 2007:e1–157 ACC/AHA UA/NSTEMI Guideline Revision. Patients who present with chest discomfort or other ischemic
symptoms should undergo early risk stratification for the risk of
cardiovascular events (e.g., death or [re]MI) that focuses on history,
including anginal symptoms, physical findings, ECG findings, and
able 6. Likelihood That Signs and Symptoms Represent an AC
Feature
High Likelihood
Any of the following:
Absen
pre
istory Chest or left arm pain or discomfort as chief
symptom reproducing prior documented
angina
Known history of CAD, including MI
Chest or l
sympto
Age great
Male sex
Diabetes
xamination Transient MR murmur, hypotension,
diaphoresis, pulmonary edema, or rales
Extracard
CG New, or presumably new, transient ST-segment
deviation (1 mm or greater) or T-wave
inversion in multiple precordial leads
Fixed Q w
ST depres
greater
ardiac
markers
Elevated cardiac TnI, TnT, or CK-MB Normal
odified with permission from Braunwald E, Mark DB, Jones RH, et al. Unstable angina: diagnosi
ung, and Blood Institute, U.S. Public Health Service, U.S. Department of Health and Human S
ACS  acute coronary syndrome; CAD  coronary artery disease; CK-MB  MB fraction of cr
roponin I; TnT  troponin T.
able 7. Short-Term Risk of Death or Nonfatal MI in Patients W
Feature
High Risk
At least 1 of the following features must
be present:
No high-ri
istory Accelerating tempo of ischemic symptoms
in preceding 48 h
Prior MI, p
or CABG
haracter of pain Prolonged ongoing (greater than 20 min)
rest pain
Prolonged
now res
likelihoo
Rest angin
with res
Nocturnal
New-onset
angina
prolong
but with
CAD (se
linical findings Pulmonary edema, most likely due to
ischemia
New or worsening MR murmur
S3 or new/worsening rales
Hypotension, bradycardia, tachycardia
Age greater than 75 years
Age greate
CG Angina at rest with transient ST-segment
changes greater than 0.5 mm
Bundle-branch block, new or presumed
new
Sustained ventricular tachycardia
T-wave cha
Pathologic
less tha
(anterio
ardiac markers Elevated cardiac TnT, TnI, or CK-MB (e.g.,
TnT or TnI greater than 0.1 ng per ml)
Slightly ele
(e.g., Tn
0.1 ng p
Estimation of the short-term risks of death and nonfatal cardiac ischemic events in UA (or NSTE
his table is meant to offer general guidance and illustration rather than rigid algorithms. Adapte
994 (124).
CABG  coronary artery bypass graft surgery; CAD  coronary artery disease; CCS  Canadian Ca
yocardial infarction; MR  mitral regurgitation; NTG  nitroglycerin; TnI  troponin I; TnT  troponinbiomarkers of cardiac injury, and results should be considered in
patient management. (Level of Evidence: C)
. A 12-lead ECG should be performed and shown to an experienced
emergency physician as soon as possible after ED arrival, with a
condary to CAD
rmediate Likelihood Low Likelihood
high-likelihood features and
of any of the following:
Absence of high- or intermediate-
likelihood features but may have:
pain or discomfort as chief
n 70 years
s
Probable ischemic symptoms in absence
of any of the intermediate likelihood
characteristics
Recent cocaine use
cular disease Chest discomfort reproduced by palpation
.5 to 1 mm or T-wave inversion
1 mm
T-wave flattening or inversion less than
1 mm in leads with dominant R waves
Normal ECG
Normal
anagement. Rockville, MD: Agency for Health Care Policy and Research and the National Heart,
1994. AHCPR publication no. 94-0602 (124).
inase; ECG  electrocardiogram; MI  myocardial infarction; MR  mitral regurgitation; TnI 
A/NSTEMI*
termediate Risk Low Risk
ture, but must have 1 of the
following:
No high- or intermediate-risk feature but
may have any of the following features:
ral or cerebrovascular disease,
aspirin use
er than 20 min) rest angina,
with moderate or high
AD
ater than 20 min) or relieved
blingual NTG
gressive CCS class III or IV
past 2 weeks without
ater than 20 min) rest pain
ediate or high likelihood of
le 6)
Increased angina frequency, severity, or
duration
Angina provoked at a lower threshold
New onset angina with onset 2 weeks to
2 months prior to presentation
70 years
aves or resting ST-depression
m in multiple lead groups
rior, lateral)
Normal or unchanged ECG
cardiac TnT, TnI, or CK-MB
ter than 0.01 but less than
)
Normal
complex multivariable problem that cannot be fully specified in a table such as this; therefore,
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ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:e1–157goal of within 10 min of ED arrival for all patients with chest
discomfort (or anginal equivalent) or other symptoms suggestive of
ACS. (Level of Evidence: B)
. If the initial ECG is not diagnostic but the patient remains symptom-
atic and there is high clinical suspicion for ACS, serial ECGs, initially
at 15- to 30-min intervals, should be performed to detect the
potential for development of ST-segment elevation or depression.
(Level of Evidence: B)
. Cardiac biomarkers should be measured in all patients who present
with chest discomfort consistent with ACS. (Level of Evidence: B)
. A cardiac-specific troponin is the preferred marker, and if available,
it should be measured in all patients who present with chest
discomfort consistent with ACS. (Level of Evidence: B)
. Patients with negative cardiac biomarkers within 6 h of the onset of
symptoms consistent with ACS should have biomarkers remea-
sured in the time frame of 8 to 12 h after symptom onset. (The exact
timing of serummarker measurement should take into account the
uncertainties often present with the exact timing of onset of pain
and the sensitivity, precision, and institutional norms of the assay
being utilized as well as the release kinetics of the marker being
measured.) (Level of Evidence: B)
. The initial evaluation of the patient with suspected ACS should
include the consideration of noncoronary causes for the develop-
ment of unexplained symptoms. (Level of Evidence: C)
LASS IIa
. Use of risk-stratification models, such as the Thrombolysis In Myo-
cardial Infarction (TIMI) or Global Registry of Acute Coronary Events
(GRACE) risk score or the Platelet Glycoprotein IIb/IIIa in Unstable
Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT)
risk model, can be useful to assist in decision making with regard to
treatment options in patients with suspected ACS. (Level of Evi-
dence: B)
. It is reasonable to remeasure positive biomarkers at 6- to 8-h
intervals 2 to 3 times or until levels have peaked, as an index of
infarct size and dynamics of necrosis. (Level of Evidence: B)
. It is reasonable to obtain supplemental ECG leads V7 through V9 in
patients whose initial ECG is nondiagnostic to rule out MI due to left
circumflex occlusion. (Level of Evidence: B)
. Continuous 12-lead ECG monitoring is a reasonable alternative to
serial 12-lead recordings in patients whose initial ECG is nondiag-
nostic. (Level of Evidence: B)
LASS IIb
. For patients who present within 6 h of the onset of symptoms
consistent with ACS, assessment of an early marker of cardiac
injury (e.g., myoglobin) in conjunction with a late marker (e.g.,
troponin) may be considered. (Level of Evidence: B)
. For patients who present within 6 h of symptoms suggestive of ACS,
a 2-h delta CK-MB mass in conjunction with 2-h delta troponin may
be considered. (Level of Evidence: B)
. For patients who present within 6 h of symptoms suggestive of ACS,
myoglobin in conjunction with CK-MB mass or troponin when mea-
sured at baseline and 90 min may be considered. (Level of Evi-
dence: B)
. Measurement of B-type natriuretic peptide (BNP) or NT-pro-BNP
may be considered to supplement assessment of global risk inpatients with suspected ACS. (Level of Evidence: B) wLASS III
otal CK (without MB), aspartate aminotransferase (AST, SGOT), ala-
ine transaminase, beta-hydroxybutyric dehydrogenase, and/or lactate
ehydrogenase should not be utilized as primary tests for the detection
f myocardial injury in patients with chest discomfort suggestive of
CS. (Level of Evidence: C)
.2.1. Estimation of the Level of Risk
he medical history, physical examination, ECG, assess-
ent of renal function, and cardiac biomarker measure-
ents in patients with symptoms suggestive of ACS at the
ime of the initial presentation can be integrated into an
stimation of the risk of death and nonfatal cardiac ischemic
vents. The latter include new or recurrent MI, recurrent
A, disabling angina that requires hospitalization, and
rgent coronary revascularization. Estimation of the level of
isk is a multivariable problem that cannot be accurately
uantified with a simple table; therefore, Tables 6 and 7 are
eant to be illustrative of the general relationships between
istory, clinical and ECG findings, and the categorization
f patients into those at low, intermediate, or high risk of
he presence of obstructive CAD and the short-term risk of
ardiovascular events, respectively. Optimal risk stratifica-
ion requires accounting for multiple prognostic factors
imultaneously by a multivariable approach (e.g., the TIMI
nd GRACE risk score algorithms [see below]).
.2.2. Rationale for Risk Stratification
ecause patients with ischemic discomfort at rest as a group
re heterogeneous in terms of risk of cardiac death and
onfatal ischemic events, an assessment of the prognosis
uides the initial evaluation and treatment. An estimation of
isk is useful in 1) selection of the site of care (coronary care
nit, monitored step-down unit, or outpatient setting) and
) selection of therapy, including platelet glycoprotein (GP)
Ib/IIIa inhibitors (see Section 3.2) and invasive manage-
ent strategy (see Section 3.3). For all modes of presenta-
ion of an ACS, a strong relationship exists between
ndicators of the likelihood of ischemia due to CAD and
rognosis (Tables 6 and 7). Patients with a high likelihood
f ischemia due to CAD are at a greater risk of an untoward
ardiac event than are patients with a lower likelihood of
AD. Therefore, an assessment of the likelihood of CAD
s the starting point for the determination of prognosis in
atients who present with symptoms suggestive of ACS.
ther important elements for prognostic assessment are the
empo of the patient’s clinical course, which relates to the
hort-term risk of future cardiac events, principally MI, and
he patient’s likelihood of survival should an MI occur.
Patients can present with ischemic discomfort but with-
ut ST-segment deviation on the 12-lead ECG in a variety
f clinical scenarios, including no known prior history of
AD, a prior history of stable CAD, soon after MI, and
fter myocardial revascularization with CABG or PCI
12,125,126). As a clinical syndrome, ischemic discomfort
ithout ST-segment elevation (UA and NSTEMI) shares
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August 14, 2007:e1–157 ACC/AHA UA/NSTEMI Guideline Revisionll-defined borders with severe chronic stable angina, a
ondition associated with lower immediate risk, and
TEMI, a presentation with a higher risk of early death and
ardiac ischemic events. The risk is highest at the time of
resentation and subsequently declines. Yet, the risk re-
ains high past the acute phase. By 6 months, UA/
STEMI mortality rates higher than that after STEMI can
e seen (127); and by 12 months, the rates of death, MI, and
ecurrent instability in contemporary randomized controlled
rials and registry studies exceed 10% and are often related
o specific risk factors such as age, diabetes mellitus, renal
ailure, and impairment of left ventricular (LV) function.
hereas the early events are related to the activity of 1
ulprit coronary plaque that has ruptured and is the site of
hrombus formation, events that occur later are more related
o the underlying pathophysiological mechanisms that trig-
er plaque activity and that mark active atherosclerosis
128–134).
A few risk scores have been developed that regroup
arkers of the acute thrombotic process and other markers
f high risk to identify high-risk patients with UA/
STEMI. The TIMI, GRACE, and PURSUIT risk scores
re discussed in detail in Section 2.2.6.
.2.3. History
atients with suspected UA/NSTEMI may be divided into
hose with and those without a history of documented
AD. Particularly when the patient does not have a known
istory of CAD, the physician must determine whether the
atient’s presentation, with its constellation of specific
ymptoms and signs, is most consistent with chronic isch-
mia, acute ischemia, or an alternative disease process. The
most important factors derived from the initial history
hat relate to the likelihood of ischemia due to CAD, ranked
n the order of importance, are 1) the nature of the anginal
ymptoms, 2) prior history of CAD, 3) sex, 4) age, and 5)
he number of traditional risk factors present (135–139). In
atients with suspected ACS but without preexisting clin-
cal CHD, older age appears to be the most important
actor. One study found that for males, age younger than 40
ears, 40 to 55 years, and older than 55 years and for
emales, age younger than 50 years, 50 to 65 years, and older
han 65 years was correlated with low, intermediate, and
igh risk for CAD, respectively (138). Another study found
hat the risk of CAD increased in an incremental fashion for
ach decade above age 40 years, with male sex being
ssigned an additional risk point (139,140). In these studies,
eing a male older than 55 years or a female older than 65
ears outweighed the importance of all historical factors,
ncluding the nature of the chest pain (138,139).
.2.4. Anginal Symptoms and Anginal Equivalents
he characteristics of angina, which are thoroughly de-
cribed in the ACC/AHA 2002 Guideline Update for the
anagement of Patients With Chronic Stable Angina (4),
nclude deep, poorly localized chest or arm discomfort that Cs reproducibly associated with physical exertion or emo-
ional stress and is relieved promptly (i.e., in less than 5 min)
ith rest and/or the use of sublingual NTG. Patients with
A/NSTEMI may have discomfort that has all of the
ualities of typical angina except that the episodes are more
evere and prolonged, may occur at rest, or may be precip-
tated by less exertion than in the past. Although it is
raditional to use the simple term “chest pain” to refer to the
iscomfort of ACS, patients often do not perceive these
ymptoms to be true pain, especially when they are mild or
typical. Terms such as “ischemic-type chest discomfort” or
symptoms suggestive of ACS” have been proposed to more
recisely capture the character of ischemic symptoms. Al-
hough “chest discomfort” or “chest press” is frequently used
n these guidelines for uniformity and brevity, the following
aveats should be kept clearly in mind. Some patients may
ave no chest discomfort but present solely with jaw, neck,
ar, arm, shoulder, back, or epigastric discomfort or with
nexplained dyspnea without discomfort (56,141,142). If
hese symptoms have a clear relationship to exertion or
tress or are relieved promptly with NTG, they should be
onsidered equivalent to angina. Occasionally, such “anginal
quivalents” that occur at rest are the mode of presentation
f a patient with UA/NSTEMI, but without the exertional
istory or known prior history of CAD, it may be difficult to
ecognize their cardiac origin. Other difficult presentations
f the patient with UA/NSTEMI include those without any
hest (or equivalent) discomfort. Isolated unexplained new-
nset or worsened exertional dyspnea is the most common
nginal equivalent symptom, especially in older patients; less
ommon isolated presentations, primarily in older adults,
nclude nausea and vomiting, diaphoresis, and unexplained
atigue. Indeed, older adults and women with ACS not
nfrequently present with atypical angina or nonanginal
ymptoms. Rarely do patients with ACS present with syncope
s the primary symptom or with other nonanginal symptoms.
Features that are not characteristic of myocardial isch-
mia include the following:
Pleuritic pain (i.e., sharp or knifelike pain brought on by
respiratory movements or cough)
Primary or sole location of discomfort in the middle or
lower abdominal region
Pain that may be localized at the tip of 1 finger,
particularly over the left ventricular apex or a costochon-
dral junction
Pain reproduced with movement or palpation of the
chest wall or arms
Very brief episodes of pain that last a few seconds or less
Pain that radiates into the lower extremities
Documentation of the evaluation of a patient with sus-
ected UA/NSTEMI should include the physician’s opin-
on of whether the discomfort is in 1 of 3 categories: high,
ntermediate, or low likelihood of acute ischemia caused by
AD (Table 6).
p
a
o
I
d
s
p
w
n
T
p
p
c
s
e
N
O
t
e
7
t
(
i
v
d
2
R
I
a
(
T
w
w
w
t
l
s
w
S
e
c
w
a
N
u
m
y
b
g
s
e
l
m
t
l
o
i
b
t
w
A
t
A
a
b
g
u
a
s
t
f
t
o
o
S
c
a
g
m
a
a
p
i
r
A
t
e
c
t
y
i
t
p
p
d
t
a
s
m
t
1
p
e20 Anderson et al. JACC Vol. 50, No. 7, 2007
ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:e1–157Although typical characteristics substantially increase the
robability of CAD, features not characteristic of typical
ngina, such as sharp stabbing pain or reproduction of pain
n palpation, do not entirely exclude the possibility of ACS.
n the Multicenter Chest Pain Study, acute ischemia was
iagnosed in 22% of patients who presented to the ED with
harp or stabbing pain and in 13% of patients with pain with
leuritic qualities. Furthermore, 7% of patients whose pain
as fully reproduced with palpation were ultimately recog-
ized to have ACS (143). The Acute Cardiac Ischemia
ime-Insensitive Predictive Instrument (ACI-TIPI)
roject (144,145) found that older age, male sex, the
resence of chest or left arm pain, and the identification of
hest pain or pressure as the most important presenting
ymptom all increased the likelihood that the patient was
xperiencing acute ischemia.
The relief of chest pain by administration of sublingual
TG in the ED setting is not always predictive of ACS.
ne study reported that sublingual NTG relieved symp-
oms in 35% of patients with active CAD (defined as
levated cardiac biomarkers, coronary vessel with at least
0% stenosis on coronary angiography, or positive stress
est) compared with 41% of patients without active CAD
146). Furthermore, the relief of chest pain by the admin-
stration of a “GI cocktail” (e.g., a mixture of liquid antacid,
iscous lidocaine, and anticholinergic agent) does not pre-
ict the absence of ACS (147).
.2.5. Demographics and History in Diagnosis and
isk Stratification
n most studies of ACS, a prior history of MI has been
ssociated not only with a high risk of obstructive CAD
148) but also with an increased risk of multivessel CAD.
here are differences in the presentations of men and
omen with ACS (see Section 6.1). A smaller percentage of
omen than men present with STEMI, and of the patients
ho present without ST-segment elevation, fewer women
han men have MIs (149). Women with suspected ACS are
ess likely to have obstructive CAD than are men with a
imilar clinical presentation, and when CAD is present in
omen, it tends to be less severe. On the other hand, when
TEMI is present, the outcome in women tends to be worse
ven when adjustment is made for the older age and greater
omorbidity of women. However, the outcome for women
ith UA is significantly better than the outcome for men,
nd the outcomes are similar for men and women with
STEMI (150,151).
Older adults (see Section 6.4) have increased risks of both
nderlying CAD (152,153) and multivessel CAD; further-
ore, they are at higher risk for an adverse outcome than are
ounger patients. The slope of the increased risk is steepest
eyond age 70 years. This increased risk is related in part to the
reater extent and severity of underlying CAD and the more
evere LV dysfunction in older patients; however, age itself
xerts a strong, independent prognostic risk as well, perhaps at peast in part because of comorbidities. Older adults also are
ore likely to have atypical symptoms on presentation.
In patients with symptoms of possible ACS, some of the
raditional risk factors for CAD (e.g., hypertension, hypercho-
esterolemia, and cigarette smoking) are only weakly predictive
f the likelihood of acute ischemia (145,154) and are far less
mportant than are symptoms, ECG findings, and cardiac
iomarkers. Therefore, the presence or absence of these tradi-
ional risk factors ordinarily should not be used to determine
hether an individual patient should be admitted or treated for
CS. However, the presence of these risk factors does appear
o relate to poor outcomes in patients with established ACS.
lthough not as well investigated as the traditional risk factors,
family history of premature CAD has been demonstrated to
e associated with increased coronary artery calcium scores
reater than the 75th age percentile in asymptomatic individ-
als (155) and increased risk of 30-d cardiac events in patients
dmitted for UA/NSTEMI (156). Of special interest is that
ibling history of premature CAD has a stronger relationship
han parental history (157). However, several of these risk
actors have important prognostic and therapeutic implica-
ions. Diabetes and the presence of extracardiac (carotid, aortic,
r peripheral) vascular disease are major risk factors for poor
utcome in patients with ACS (see Section 6.2). For both
TEMI (158) and UA/NSTEMI (128), patients with these
onditions have a significantly higher mortality rate and risk of
cute HF. For the most part, this increase in risk is due to a
reater extent of underlying CAD and LV dysfunction, but in
any studies, diabetes carries prognostic significance over and
bove these findings. Similarly, a history of hypertension is
ssociated with an increased risk of a poor outcome.
The current or prior use of ASA at the time and
resentation of ACS has been associated in 1 database with
ncreased cardiovascular event risk (159). Although the
ationale is not fully elucidated, it appears those taking prior
SA therapy have more multivessel CAD, are more likely
o present with thrombus present, may present later in the
volution of ACS, or may be ASA resistant. Surprisingly,
urrent smoking is associated with a lower risk of death in
he setting of ACS (159–161), primarily because of the
ounger age of smokers with ACS and less severe underly-
ng CAD. This “smokers’ paradox” seems to represent a
endency for smokers to develop thrombi on less severe
laques and at an earlier age than nonsmokers.
Being overweight and/or obese at the time of ACS
resentation is associated with lower short-term risk of
eath; however, this “obesity paradox” is primarily a func-
ion of younger age at time of presentation, referral for
ngiography at an earlier stage of disease, and more aggres-
ive ACS management (160). Although short-term risk
ay be lower for overweight/obese individuals, these pa-
ients have a higher long-term total mortality risk (161–
65). Increased long-term cardiovascular risk appears to be
rimarily limited to severe obesity (166).
Cocaine use has been implicated as a cause of ACS,resumably owing to the ability of this drug to cause
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August 14, 2007:e1–157 ACC/AHA UA/NSTEMI Guideline Revisionoronary vasospasm and thrombosis in addition to its direct
ffects on heart rate and arterial pressure and its myocardial
oxic properties (see Section 6.6) (167). Recently, the use of
ethamphetamine has grown, and its association with ACS
lso should be considered. It is important to inquire about
he use of cocaine and methamphetamine in patients with
uspected ACS, especially in younger patients (age less than
0 years) and others with few risk factors for CAD. Urine
oxicology should be considered when substance abuse is
uspected as a cause of or contributor to ACS.
.2.6. Estimation of Early Risk at Presentation
number of risk assessment tools have been developed to
ssist in assessing risk of death and ischemic events in
atients with UA/NSTEMI, thereby providing a basis for
herapeutic decision making (Table 8; Fig. 4) (158,168,169).
t should be recognized that the predictive ability of these
ommonly used risk assessment scores for nonfatal CHD
isk is only moderate.
Antman et al. developed the TIMI risk score (159), a
imple tool composed of 7 (1-point) risk indicators rated on
resentation (Table 8). The composite end points (all-cause
ortality, new or recurrent MI, or severe recurrent ischemia
rompting urgent revascularization within 14 d) increase as
he TIMI risk score increases. The TIMI risk score has been
alidated internally within the TIMI 11B trial and 2
eparate cohorts of patients from the Efficacy and Safety of
ubcutaneous Enoxaparin in Unstable Angina and Non-Q-
ave Myocardial Infarction (ESSENCE) trial (169). The
odel remained a significant predictor of events and ap-
eared relatively insensitive to missing information, such as
nowledge of previously documented coronary stenosis of
0% or more. The model’s predictive ability remained intact
ith a cutoff of 65 years of age. The TIMI risk score was
ecently studied in an unselected ED population with chest
ain syndrome; its performance was similar to that in the
able 8. TIMI Risk Score for
nstable Angina/Non–ST-Elevation MI
TIMI Risk
Score
All-Cause Mortality, New or Recurrent MI, or Severe
Recurrent Ischemia Requiring Urgent Revascularization
Through 14 d After Randomization, %
0–1 4.7
2 8.3
3 13.2
4 19.9
5 26.2
6–7 40.9
he TIMI risk score is determined by the sum of the presence of 7 variables at admission; 1 point
s given for each of the following variables: age 65 y or older; at least 3 risk factors for CAD; prior
oronary stenosis of 50% or more; ST-segment deviation on ECG presentation; at least 2 anginal
vents in prior 24 h; use of aspirin in prior 7 d; elevated serum cardiac biomarkers. Prior coronary
tenosis of 50% or more remained relatively insensitive to missing information and remained a
ignificant predictor of events. Reprinted with permission from Antman EM, Cohen M, Bernink PJ,
t al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication
nd therapeutic decision making. JAMA 2000;284:835–42 (159). Copyright © 2000 American
edical Association.b
CAD  coronary artery disease; ECG  electrocardiogram; MI  myocardial infarction; y 
ear.CS population in which it was derived and validated (170).
he TIMI risk calculator is available at www.timi.org. The
IMI risk index, a modification of the TIMI risk score that
ses the variables age, systolic blood pressure, and heart rate,
as not only been shown to predict short-term mortality in
TEMI but has also been useful in the prediction of 30-d and
-year mortality across the spectrum of patients with ACS,
ncluding UA/NSTEMI (171).
The PURSUIT risk model, developed by Boersma et al.
172), based on patients enrolled in the PURSUIT trial, is
nother useful tool to guide the clinical decision-making
rocess when the patient is admitted to the hospital. In the
URSUIT risk model, critical clinical features associated with
n increased 30-d incidence of death and the composite of
eath or myocardial (re)infarction were (in order of strength)
ge, heart rate, systolic blood pressure, ST-segment depression,
igns of HF, and cardiac biomarkers (172).
The GRACE risk model, which predicts in-hospital
ortality (and death or MI), can be useful to clinicians to
uide treatment type and intensity (168,173). The GRACE
isk tool was developed on the basis of 11,389 patients in
RACE, validated in subsequent GRACE and GUSTO
Ib cohorts, and predicts in-hospital death in patients with
TEMI, NSTEMI, or UA (C statistic  0.83). The 8
ariables used in the GRACE risk model are older age (odds
atio [OR] 1.7 per 10 years), Killip class (OR 2.0 per class),
ystolic blood pressure (OR 1.4 per 20 mm Hg decrease),
T-segment deviation (OR 2.4), cardiac arrest during pre-
entation (OR 4.3), serum creatinine level (OR 1.2 per
-mg per dL increase), positive initial cardiac biomarkers
OR 1.6), and heart rate (OR 1.3 per 30-beat per min
ncrease). The sum of scores is applied to a reference
onogram to determine the corresponding all-cause mor-
ality from hospital discharge to 6 mo. The GRACE clinical
pplication tool can be downloaded to a handheld PDA to be
sed at the bedside and is available at www.outcomes-
massmed.org/grace (Fig. 4) (173). An analysis comparing the
risk scores (TIMI, GRACE, and PURSUIT) concluded that
ll 3 demonstrated good predictive accuracy for death and MI
t 1 year, thus identifying patients who might be likely to
enefit from aggressive therapy, including early myocardial
evascularization (174).
The ECG provides unique and important diagnostic and
rognostic information (see also Section 2.2.6.1 below).
ccordingly, ECG changes have been incorporated into
uantitative decision aids for the triage of patients present-
ng with chest discomfort (175). Although ST elevation
arries the highest early risk of death, ST depression on the
resenting ECG portends the highest risk of death at 6
onths, with the degree of ST depression showing a strong
elationship to outcome (176).
Dynamic risk modeling is a new frontier in modeling that
ccounts for the common observation that levels and pre-
ictors of risk constantly evolve as patients pass through
heir disease process. Excellent models have been developed
ased on presenting features, but information the next day
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ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:e1–157bout clinical (e.g., complications), laboratory (e.g., biomar-
er evolution), and ECG (e.g., ST resolution for STEMI)
hanges provides additional data relevant to decisions at key
decision-node” points in care (177). Dynamic modeling
oncepts promise more sophisticated, adaptive, and individ-
igure 4. GRACE Prediction Score Card and Nomogram for All-Cau
eprinted with permission from Eagle KA, Lim MJ, Dabbous OH, et al. A validated pr
ostdischarge death in an international registry. JAMA 2004;291:2727–33 (168). Coally predictive modeling of risk in the future. lRenal impairment has been recognized as an additional
igh-risk feature in patients with ACS (178). Mild to
oderate renal dysfunction is associated with moderately
ncreased short- and long-term risks, and severe renal
ysfunction is associated with severely increased short- and
ortality From Discharge to 6 Months
n model for all forms of acute coronary syndrome: estimating the risk of 6-month
t © 2004 American Medical Association.se Mong-term mortality risks. Patients with renal dysfunction
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August 14, 2007:e1–157 ACC/AHA UA/NSTEMI Guideline Revisionxperience increased bleeding risks, have higher rates of HF
nd arrhythmias, have been underrepresented in cardiovas-
ular trials, and may not enjoy the same magnitude of
enefit with some therapies observed in patients with
ormal renal function (179) (see also Section 6.5).
Among patients with UA/NSTEMI, there is a progres-
ively greater benefit from newer, more aggressive therapies
uch as low-molecular-weight heparin (LMWH) (169,180),
latelet GP IIb/IIIa inhibition (181), and an invasive
trategy (182) with increasing risk score.
.2.6.1. ELECTROCARDIOGRAM
he ECG is critical not only to add support to the clinical
uspicion of CAD but also to provide prognostic informa-
ion based on the pattern and magnitude of the abnormal-
ties (127,175,183,184). A recording made during an epi-
ode of the presenting symptoms is particularly valuable.
mportantly, transient ST-segment changes (greater than or
qual to 0.05 mV [i.e., 0.5 mm]) that develop during a
ymptomatic episode at rest and that resolve when the
atient becomes asymptomatic strongly suggest acute isch-
mia and a very high likelihood of underlying severe CAD.
atients whose current ECG suggests ischemia can be
ssessed with greater diagnostic accuracy if a prior ECG is
vailable for comparison (Table 6) (185).
Although it is imperfect, the 12-lead ECG lies at the
enter of the decision pathway for the evaluation and
anagement of patients with acute ischemic discomfort
Fig. 1; Table 6). The diagnosis of MI is confirmed with
erial cardiac biomarkers in more than 90% of patients who
resent with ST-segment elevation of greater than or equal
o 1 mm (0.1 mV) in at least 2 contiguous leads, and such
atients should be considered candidates for acute reperfu-
ion therapy. Patients who present with ST-segment de-
ression are initially considered to have either UA or
STEMI; the distinction between the 2 diagnoses is
ltimately based on the detection of markers of myocardial
ecrosis in the blood (11,126,186).
Up to 25% of patients with NSTEMI and elevated
K-MB go on to develop Q-wave MI during their hospital
tay, whereas the remaining 75% have non–Q-wave MI.
cute fibrinolytic therapy is contraindicated for ACS pa-
ients without ST-segment elevation, except for those with
lectrocardiographic true posterior MI manifested as ST-
egment depression in 2 contiguous anterior precordial leads
nd/or isolated ST-segment elevation in posterior chest
eads (187–189). Inverted T waves may also indicate UA/
STEMI. In patients suspected of having ACS on clinical
rounds, marked (greater than or equal to 2 mm [0.2 mV])
ymmetrical precordial T-wave inversion strongly suggests
cute ischemia, particularly that due to a critical stenosis of
he left anterior descending coronary artery (LAD) (190).
atients with this ECG finding often exhibit hypokinesis of
he anterior wall and are at high risk if given medical
reatment alone (191). Revascularization will often reverse
oth the T-wave inversion and wall-motion disorder (192). Ponspecific ST-segment and T-wave changes, usually de-
ned as ST-segment deviation of less than 0.5 mm (0.05
V) or T-wave inversion of less than or equal to 2 mm (0.2
V), are less diagnostically helpful than the foregoing
ndings. Established Q waves greater than or equal to 0.04 s
re also less helpful in the diagnosis of UA, although by
uggesting prior MI, they do indicate a high likelihood of
ignificant CAD. Isolated Q waves in lead III may be a
ormal finding, especially in the absence of repolarization
bnormalities in any of the inferior leads. A completely
ormal ECG in a patient with chest pain does not exclude
he possibility of ACS, because 1% to 6% of such patients
ventually are proved to have had an MI (by definition, an
STEMI), and at least 4% will be found to have UA
184,193,194).
The common alternative causes of ST-segment and
-wave changes must be considered. In patients with
T-segment elevation, the diagnoses of LV aneurysm,
ericarditis, myocarditis, Prinzmetal’s angina, early repolar-
zation (e.g., in young black males), apical LV ballooning
yndrome (Takotsubo cardiomyopathy; see Section 6.9),
nd Wolff-Parkinson-White syndrome represent several
xamples to be considered. Central nervous system events
nd drug therapy with tricyclic antidepressants or phe-
othiazines can cause deep T-wave inversion.
Acute MI due to occlusion of the left circumflex coronary
rtery can present with a nondiagnostic 12-lead ECG.
pproximately 4% of acute MI patients show the presence
T elevation isolated to the posterior chest leads V7 through
9 and “hidden” from the standard 12 leads (187,195,196).
he presence of posterior ST elevation is diagnostically
mportant because it qualifies the patient for acute reperfu-
ion therapy as an acute STEMI (1,197). The presence or
bsence of ST-segment elevation in the right ventricular
V4R through V6R) or posterior chest leads (V7 through V9)
lso adds prognostic information in the presence of inferior
T-segment elevation, predicting high and low rates of
n-hospital life-threatening complications, respectively
196).
With reference to electrocardiographic true posterior
I, new terminology recently has been proposed based
n the standard of cardiac magnetic resonance (CMR)
maging localization. CMR studies indicate that abnor-
ally increased R waves, the Q-wave equivalent in leads
1 and V2, indicate an MI localized to the lateral LV wall
nd that abnormal Q waves in I and VL (but not V6)
ndicate a mid-anterior wall MI. Thus, the electrocardio-
raphic terms “posterior” and “high lateral MI” refer to
natomic “lateral wall MI” and “mid-anterior wall MI”
198). The impact of these findings and recommenda-
ions for standard electrocardiographic terminology are
nresolved as of this writing.
Several investigators have shown that a gradient of risk of
eath and cardiac ischemic events can be established based
n the nature of the ECG abnormality (183,199,200).
atients with ACS and confounding ECG patterns such as
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t the highest risk for death, followed by patients with
T-segment deviation (ST-segment elevation or depres-
ion); at the lowest risk are patients with isolated T-wave
nversion or normal ECG patterns. Importantly, the prog-
ostic information contained within the ECG pattern
emains an independent predictor of death even after
djustment for clinical findings and cardiac biomarker
easurements (199–202).
In addition to the presence or absence of ST-segment
eviation or T-wave inversion patterns as noted earlier,
here is evidence that the magnitude of the ECG abnor-
ality provides important prognostic information. Thus,
loyd-Jones et al. (203) reported that the diagnosis of acute
on–Q-wave MI was 3 to 4 times more likely in patients
ith ischemic discomfort who had at least 3 ECG leads that
howed ST-segment depression and maximal ST depression
f greater than or equal to 0.2 mV. Investigators from the
IMI III Registry (199) reported that the 1-year incidence
f death or new MI in patients with at least 0.5 mm (0.05
V) of ST-segment deviation was 16.3% compared with
.8% for patients with isolated T-wave changes and 8.2%
or patients with no ECG changes.
Physicians frequently seek out a previous ECG for
omparison in patients with suspected ACS. Studies have
emonstrated that patients with an unchanged ECG
ave a reduced risk of MI and a very low risk of
n-hospital life-threatening complications even in the
resence of confounding ECG patterns such as LV
ypertrophy (204 –206).
Because a single 12-lead ECG recording provides only a
napshot view of a dynamic process (207), the usefulness of
btaining serial ECG tracings or performing continuous
T-segment monitoring has been studied (175,208). Al-
hough serial ECGs increase the ability to diagnose UA and
I (208–212), the yield is higher with serial cardiac
iomarker measurements (212–214). However, identifica-
ion of new injury on serial 12-lead ECG (and not elevated
ardiac biomarkers) is the principal eligibility criterion for
mergency reperfusion therapy, so that monitoring of both
s recommended. Continuous 12-lead ECG monitoring to
etect ST-segment shifts, both symptomatic and asymp-
omatic, also can be performed with microprocessor-
ontrolled programmable devices. An injury current was
etected in an additional 16% of chest pain patients in 1
tudy (213). The identification of ischemic ECG changes
n serial or continuous ECG recordings frequently alters
herapy and provides independent prognostic information
212,215,216).
.2.6.2. PHYSICAL EXAMINATION
he major objectives of the physical examination are to
dentify potential precipitating causes of myocardial isch-
mia, such as uncontrolled hypertension, thyrotoxicosis, or
astrointestinal bleeding, and comorbid conditions that
ould impact therapeutic risk and decision making, such as dulmonary disease and malignancies, as well as to assess the
emodynamic impact of the ischemic event. Every patient
ith suspected ACS should have his or her vital signs
easured (blood pressure in both arms if dissection is
uspected, as well as heart rate and temperature) and should
ndergo a thorough cardiovascular and chest examination.
atients with evidence of LV dysfunction on examination
rales, S3 gallop) or with acute mitral regurgitation have a
igher likelihood of severe underlying CAD and are at a
igh risk of a poor outcome. Just as the history of extracar-
iac vascular disease is important, the physical examination
f the peripheral vessels can also provide important prog-
ostic information. The presence of bruits or pulse deficits
hat suggest extracardiac vascular disease identifies patients
ith a higher likelihood of significant CAD.
Elements of the physical examination can be critical in
aking an important alternative diagnosis in patients with
hest pain. In particular, several disorders carry a significant
hreat to life and function if not diagnosed acutely. Aortic
issection is suggested by pain in the back, unequal pulses,
r a murmur of aortic regurgitation. Acute pericarditis is
uggested by a pericardial friction rub, and cardiac tampon-
de can be evidenced by pulsus paradoxus. Pneumothorax is
uspected when acute dyspnea, pleuritic chest pain, and
ifferential breath sounds are present.
The importance of cardiogenic shock in patients with
STEMI should be emphasized. Although most literature
n cardiogenic shock has focused on STEMI, the SHould
e emergently revascularize Occluded Coronaries for car-
iogenic shocK (SHOCK) study (217) found that approx-
mately 20% of all cardiogenic shock complicating MI was
ssociated with NSTEMI. The Global Use of Strategies to
pen Occluded Coronary Arteries (GUSTO)-II (218) and
URSUIT (128) trials found that cardiogenic shock occurs
n up to 5% of patients with NSTEMI and that mortality
ates are greater than 60%. Thus, hypotension and evidence
f organ hypoperfusion can occur and constitute a medical
mergency in NSTEMI.
.2.7. Noncardiac Causes of Symptoms and Secondary
auses of Myocardial Ischemia
nformation from the initial history, physical examination,
nd ECG (Table 6) can enable the physician to classify and
xclude from further assessment patients “not having isch-
mic discomfort.” This includes patients with noncardiac
ain (e.g., pulmonary embolism, musculoskeletal pain, or
sophageal discomfort) or cardiac pain not caused by myo-
ardial ischemia (e.g., acute pericarditis). The remaining
atients should undergo a more complete evaluation of the
econdary causes of UA that might alter management. This
valuation should include a physical examination for evi-
ence of other cardiac disease, an ECG to screen for
rrhythmias, measurement of body temperature and blood
ressure, and determination of hemoglobin or hematocrit.
ardiac disorders other than CAD that can cause myocar-
ial ischemia include aortic stenosis and hypertrophic car-
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and or decrease oxygen delivery to the heart can provoke
r exacerbate ischemia in the presence of significant under-
ying CAD or secondary angina; previously unrecognized
astrointestinal bleeding that causes anemia is a common
econdary cause of worsening angina or the development of
ymptoms of ACS. Acute worsening of chronic obstructive
ulmonary disease (with or without superimposed infection)
an lower oxygen saturation levels sufficiently to intensify
schemic symptoms in patients with CAD. Evidence of
ncreased cardiac oxygen demand can be suspected in the
resence of fever, signs of hyperthyroidism, sustained tachy-
rrhythmias, or markedly elevated blood pressure. Another
ause of increased myocardial oxygen demand is arterio-
enous fistula in patients receiving dialysis.
The majority of patients seen in the ED with symptoms
f possible ACS will be judged after their workup not to
ave a cardiac problem. One clinical trial of a predictive
nstrument evaluated 10,689 patients with suspected ACS
75). To participate, patients were required to be greater
han 30 years of age with a chief symptom of chest, left arm,
aw, or epigastric pain or discomfort; shortness of breath;
izziness; palpitations; or other symptoms suggestive of
cute ischemia. After evaluation, 7,996 patients (75%) were
eemed not to have acute ischemia.
.2.8. Cardiac Biomarkers of Necrosis and the
edefinition of AMI
ardiac biomarkers have proliferated over recent years to
ddress various facets of the complex pathophysiology of
CS. Some, like the cardiac troponins, have become essen-
ial for risk stratification of patients with UA/NSTEMI and
or the diagnosis of MI. Others, such as the inflammatory
arkers, are opening new perspectives on pathophysiology
nd risk stratification, and the use in clinical practice of
elected new markers may be recommended for clinical use
n the near future. Still other promising markers are being
eveloped as part of translational research and await pro-
pective validation in various populations. New develop-
ents are expected in the fields of proteomic and genomics,
ell markers and circulating microparticles, and microtech-
ology and nanotechnology imaging.
Current markers of necrosis leak from cardiomyocytes
fter the loss of membrane integrity and diffuse into the
ardiac interstitium, then into the lymphatics and cardiac
icrovasculature. Eventually, these macromolecules, collec-
ively referred to as cardiac biomarkers, are detectable in the
eripheral circulation. Features that favor their diagnostic
erformance are high concentrations in the myocardium
nd absence in nonmyocardial tissue, release into the blood
ithin a convenient diagnostic time window and in propor-
ion to the extent of myocardial injury, and quantification
ith reproducible, inexpensive, and rapid and easily applied
ssays (11). The cardiac troponins possess many of these
eatures and have gained wide acceptance as the biomarkers mf choice in the evaluation of patients with ACS for
iagnosis, risk stratification, and treatment selection.
The traditional definitions of MI were revisited in 2000
n a consensus document of a joint committee of the
uropean Society of Cardiology (ESC) and ACC (219) and
t the time of publication is being updated by an expanded
oint task force of the ESC, ACC, AHA, World Heart
ederation (WHF), and World Health Organization. The
ew definitions are inspired by the emergence of new highly
ensitive and specific diagnostic methods that allow the
etection of areas of cell necrosis as small as 1 g. Myocardial
ecrosis in the task force document is defined by an
levation of troponin above the 99th percentile of normal.
yocardial infarction, which is necrosis related to ischemia,
s further defined by the addition to the troponin elevation
f at least 1 of the following criteria: ischemic ST and
-wave changes, new left bundle-branch block, new Q
aves, PCI-related marker elevation, or positive imaging for
new loss of viable myocardium. Myocardial infarction can
till be diagnosed in the absence of measurement of tropo-
in when there is evidence of a new loss of viable myocar-
ium, ST-segment elevation, or new left bundle-branch
lock with sudden cardiac death within 1 h of symptoms, or
postmortem pathological diagnosis. Coronary artery by-
ass graft-related MI is diagnosed by an increase of cardiac
iomarkers to more than 5 to 10-fold the 99th percentile of
ormal, new Q waves or new left bundle-branch block on
he ECG, or a positive imaging test. The task force further
ecommended further defining MI by the circumstances
hat cause it (spontaneous or in the setting of a diagnostic or
herapeutic procedure), by the amount of cell loss (infarct
ize), and by the timing of MI (evolving, healing, or healed)
219,220). Providing fold-elevations above normal for di-
gnostic biomarkers, to allow for meaningful comparisons
mong clinical trials, is also endorsed.
At the present time, the implications of using the new
SC/ACC redefinition of MI have not been fully explored;
uch of the present database for UA/NSTEMI derives
rom CK/CK-MB–based definitions of MI. Moreover,
roponin assays have rapidly evolved through several gener-
tions over the past decade, becoming increasingly more
ensitive and specific. Thus, it is important to recognize that
he recommendations in this section are formulated from
tudies that frequently utilize modified World Health Or-
anization criteria or definitions of MI based on earlier-
eneration troponin assays.
.2.8.1. CREATINE KINASE-MB
reatine kinase-MB, a cytosolic carrier protein for high-
nergy phosphates, has long been the standard marker for
he diagnosis of MI. Creatine kinase-MB, however, is less
ensitive and less specific for MI than the cardiac troponins.
ow levels of CK-MB can be found in the blood of healthy
ersons, and elevated levels occur with damage to skeletal
uscle (221).
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ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:e1–157When a cardiac troponin is available, the determination
f CK-MB remains useful in a few specific clinical situa-
ions. One is the diagnosis of early infarct extension (rein-
arction), because the short half-life of CK-MB compared
ith troponin permits the detection of a diagnostic new
ncrease after initial peak. Although routine determination
f CK-MB has been suggested for the diagnosis of an
ventual infarct extension, a single CK-MB determination
btained when symptoms recur may serve as the baseline
alue for comparison with samples obtained 6 to 12 h later.
nother situation is the diagnosis of a periprocedural MI,
ecause the diagnostic and prognostic value of CK-MB in
hese situations has been extensively validated. When as-
essed, CK-MB should be measured by mass immunoassays
nd not by other methods previously used (222). The use of
ther, older biochemistry assays of nonspecific markers such
s alanine transaminase, aspartate transaminase, and lactate
ehydrogenase should generally be avoided in contemporary
ractice.
.2.8.2. CARDIAC TROPONINS
he troponin complex consists of 3 subunits: T (TnT), I
TnI), and C (TnC) (223). The latter is expressed by both
ardiac and skeletal muscle, whereas TnT and TnI are
erived from heart-specific genes. Therefore, the term
cardiac troponins” (cTn) in these guidelines refers specifi-
ally to either cTnT or cTnI. Cardiac troponin as a
iomarker provides robust results that are highly sensitive
nd specific in detecting cell necrosis; an early release is
ttributable to a cytosolic pool and a late release to the
tructural pool (219,224).
Because cTnT and cTnI generally are not detected in the
lood of healthy persons, the cutoff value for elevated cTnT
nd cTnI levels may be set to slightly above the upper limit
f the performance characteristics of the assay for a normal
ealthy population. High-quality analytic methods are
eeded to achieve these high standards (225). One issue
ith the use of cTnI is the multiplicity of existing assays
hat have different analytical sensitivities, some being unable
o detect the lower values with a reasonable precision (226).
hysicians therefore need to know the sensitivity of the tests
sed for TnI in their hospitals at the cutoff concentrations
sed for clinical decisions. Such heterogeneity does not exist
or cTnT, which exists as a single test; this test is now a
hird-generation immunoassay that uses recombinant
onoclonal human antibodies (224). Rare patients may
ave blocking antibodies to part of the troponin molecule,
hich would result in false-negative results (227).
.2.8.2.1. CLINICAL USE
lthough troponins can be detected in blood as early as 2 to
h after the onset of symptoms, elevation can be delayed for
p to 8 to 12 h. This timing of elevation is similar to that of
K-MB but persists longer, for up to 5 to 14 d (Fig. 5). An
ncreasing pattern in serial levels best helps determine
hether the event is acute, distinct from a previous event,ubacute, or chronic.
t
aThe proportion of patients showing a positive cTn value
epends on the population of patients under evaluation.
pproximately 30% of patients with typical rest chest
iscomfort without ST-segment elevation who would be
iagnosed as having UA because of a lack of CK-MB
levation actually have NSTEMI when assessed with
ardiac-specific troponin assays. The diagnosis of MI in the
ommunity at large when cTn is used results in a large
ncrease in the incidence of MIs, by as much as 41%
ompared with use of only CK-MB alone, and a change in
he case mix, with a survival rate that is better than that of
I identified by the previous criteria (228). Troponin
levation conveys prognostic information beyond that sup-
lied by the clinical characteristics of the patient, the ECG
t presentation, and the predischarge exercise test
200,201,229–231). Furthermore, a quantitative relation-
hip exists between the amount of elevation of cTn and the
isk of death (200,201) (Fig. 6). The incremental risk of
eath or MI in troponin-positive versus troponin-negative
atients is summarized in Table 9. It should be cautioned,
owever, that cTn should not be used as the sole marker of
isk, because patients without troponin elevations can still
ave a substantial risk of an adverse outcome.
igure 5. Timing of Release of Various Biomarkers
fter Acute Myocardial Infarction
he biomarkers are plotted showing the multiples of the cutoff for acute myocardial
nfarction (AMI) over time. The dashed horizontal line shows the upper limit of nor-
al (ULN; defined as the 99th percentile from a normal reference population with-
ut myocardial necrosis; the coefficient of variation of the assay should be 10% or
ess). The earliest rising biomarkers are myoglobin and CK isoforms (leftmost
urve). CKMB (dashed curve) rises to a peak of 2 to 5 times the ULN and typically
eturns to the normal range within 2 to 3 d after AMI. The cardiac-specific troponins
how small elevations above the ULN in small infarctions (e.g., as is often the
ase with NSTEMI) but rise to 20 to 50 times the ULN in the setting of large infarc-
ions (e.g., as is typically the case in STEMI). The troponin levels may stay elevated
bove the ULN for 7 d or more after AMI. Modified from Shapiro BP, Jaffe AS. Car-
iac biomarkers. In: Murphy JG, Lloyd MA, editors. Mayo Clinic Cardiology: Concise
extbook. 3rd ed. Rochester, MN: Mayo Clinic Scientific Press and New York:
nforma Healthcare USA, 2007:773–80 (70). Used with permission of Mayo Foun-
ation for Medical Education and Research. CK  creatine kinase; CKMB  MB
raction of creatine kinase; CV  coefficient of variation; MI  myocardial infarc-
ion; NSTEMI  non–ST-elevation myocardial infarction; UA/NSTEMI  unstable
ngina/non–ST-elevation myocardial infarction.
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August 14, 2007:e1–157 ACC/AHA UA/NSTEMI Guideline RevisionAlthough cTn accurately identifies myocardial necrosis, it
oes not inform as to the cause or causes of necrosis; these
an be multiple (224) and include noncoronary causes such
s tachyarrhythmia, cardiac trauma by interventions, chest
rauma from motor vehicle accidents, HF, LV hypertrophy,
yocarditis, and pericarditis, as well as severe noncardiac
onditions such as sepsis, burns, respiratory failure, acute
eurological diseases, pulmonary embolism, pulmonary hy-
ertension, drug toxicity, cancer chemotherapy, and renal
nsufficiency (230). Therefore, in making the diagnosis of
igure 6. Troponin I Levels to Predict the Risk
f Mortality in Acute Coronary Syndromes
ortality rates are at 42 d (without adjustment for baseline characteristics) in
atients with acute coronary syndrome. The numbers at the bottom of each bar are
he numbers of patients with cardiac troponin I levels in each range, and the num-
ers above the bars are percentages. p less than 0.001 for the increase in the
ortality rate (and the risk ratio for mortality) with increasing levels of cardiac tro-
onin I at enrollment. Reprinted with permission from Antman EM, Tanasijevic MJ,
hompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality
n patients with acute coronary syndromes. N Engl J Med 1996;335:1342–9 (201).
opyright © 1996 Massachusetts Medical Society. All rights reserved.
able 9. Risk of Death Associated With a Positive Troponin Te
Subgroup
Events/Total
Negative Troponin Positive Tr
nT
Total death 32/1,187 46/473
Cardiac death 31/1,689 52/744
UA patients* 21/397 26/198
Chest pain patients* 43/2,479 73/1,0
nI
Total death 34/1,451 49/815
Cardiac death 3/905 26/384
UA patients* 2/70 2/22
Chest pain patients* 35/2,286 73/1,1
nT and TnI combined†
Total death 42/2,088 69/1,0
Cardiac death 28/1,641 55/792
Outcomes of cardiac death and total death are pooled. †Some studies provided both troponin T
ith permission from Heidenreich PA, Go A, Melsop KA, et al. Prediction of risk for patients wi
vidence-Based Practice Center under contract no. 290-97-0013). AHRQ publication no. 01
ttp://www.ncbi.nlm.nih.gov/books/bv.fcgi?ridhstat1.chapter.45627. Accessed August 10, 2006 (2
ACS  acute coronary syndrome; CI  confidence interval; RR  relative risk; UA  unstable angSTEMI, cTns should be used in conjunction with other
riteria of MI, including characteristics of the ischemic
ymptoms and the ECG.
In all of these situations, equivalent information is gen-
rally obtained with cTnI and cTnT, except in patients with
enal dysfunction, in whom cTnI assessment appears to
ave a specific role (227). Among patients with end-stage
enal disease and no clinical evidence of acute myocardial
ecrosis, 15% to 53% show increased cTnT, but fewer than
0% have increased cTnI; dialysis generally increases cTnT
ut decreases cTnI. The exact reasons for the high rates of
levation in the cTn, especially cTnT, in renal failure are not
lear; they can relate to cardiac damage, differential clear-
nce, or to other biochemical or metabolic abnormalities (227).
hatever the reasons and the sources, an elevation of cTn,
ncluding cTnT, in patients with renal insufficiency is associ-
ted with a higher risk of morbidity regardless of the presence
f cardiac symptoms or documented CAD. Among 7,033
atients enrolled in the GUSTO IV trial with suspected ACS,
nT level was independently predictive of risk across the entire
pectrum of renal function enrolled (233).
Aggressive preventive measures for patients with renal
nsufficiency have been suggested, because most deaths in
enal failure are of cardiac origin (227). Unfortunately, some
tandard therapies, such as lipid lowering with statins or PCI,
ave been less effective in improving survival in certain patient
opulations with advanced renal insufficiency (234,235). Fur-
hermore, patients with suspected UA/NSTEMI have partic-
larly unfavorable outcomes when in renal failure, with an
vent rate that correlates with the decrease in creatinine
learance (236–239). A sequential change in cTn levels in the
rst 24 h of observation for a suspected ACS supports new
yocardial injury, whereas unchanging levels are more consis-
ent with a chronic disease state without ACS.
Patients With Suspected ACS
Summary RR 95% CI No. of Studiesn
3.1 2.0 to 4.9 5
3.8 2.4 to 6.0 7
2.5 1.4 to 4.5 5
4.0 2.7 to 5.9 7
3.1 2.0 to 4.9 3
25.0 11 to 55 2
3.2 0.3 to 40 1
5.1 3.4 to 7.6 4
3.3 2.2 to 4.8 7
5.0 3.2 to 7.9 7
nd I (TnI) data. For the combined analysis, data from 1 marker were chosen randomly. Reprinted
able angina. Evidence Report/Technology Assessment No. 31 (prepared by the UCSF-Stanford
Rockville, MD: Agency for Healthcare Research and Quality, December 2000. Available at:st in
oponi
19
77
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(TnT) a
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-E001.32).
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ions. It permits the identification of high-risk patients and
f subsets of patients who will benefit from specific thera-
ies. Thus, among patients with UA/NSTEMI, those with
levated cTn benefit from treatment with platelet GP
Ib/IIIa inhibitors, whereas those without such elevation
ay not benefit or may even experience a deleterious effect.
or example, in the c7E3 Fab Antiplatelet Therapy in
nstable Refractory Angina (CAPTURE) trial, the rates of
eath or nonfatal MI with cTnT elevation were 23.9% with
lacebo versus 9.5% with abciximab (p  0.002) (240).
imilar results have been reported for cTnI and cTnT with
se of tirofiban (241). The benefit of LMWH was also
reater in UA/NSTEMI patients with positive cTn. In the
ragmin during Instability in Coronary Artery Disease
FRISC) trial, the rates of death or nonfatal MI through 40
increased progressively in the placebo group from 5.7% in
he lowest tertile to 12.6% and 15.7% in the second and
hird tertiles, respectively, compared with rates of 4.7%,
.7%, and 8.9%, respectively, in the dalteparin group, which
epresents risk reductions in events by increasing tertiles of
7.5%, 43%, and 55% (242). Similar differential benefits
ere observed with enoxaparin versus unfractionated hepa-
in (UFH) in the ESSENCE trial (169). By contrast and of
nterest, patients with UA/NSTEMI but without elevated
TnT in the Clopidogrel in Unstable angina to prevent
ecurrent ischemic Events (CURE) trial benefited as much
rom clopidogrel, a platelet P2Y12 adenosine diphosphate
ADP) receptor inhibitor, as patients with elevated levels
243). The placebo-controlled Intracoronary Stenting and
ntithrombotic Regimen–Rapid Early Action for Coronary
reatment (ISAR-REACT)-2 trial compared triple-
ntiplatelet therapy with ASA, clopidogrel, and abciximab
o double therapy with ASA and clopidogrel in patients
ith UA/NSTEMI undergoing PCI; 52% of patients were
roponin positive, and 48% were troponin negative. The
0-d event rates were similar at 4.6% in patients with
ormal cTnT levels but were reduced by close to 30% with
he triple therapy (13.1% vs. 18.3%) in patients with
levated levels (244). The reasons for the differential benefit
ould pertain to a benefit that does not emerge in the
ow-risk patient, or that is overshadowed by complications
elated to treatment.
Such also appears to be the case with the GP IIb/IIIa
ntagonists and with an invasive management strategy that
ncludes application of interventional procedures. Indeed, in 2
rials that compared an early routine invasive strategy to a
outine noninvasive strategy, the FRISC-II and Treat Angina
ith Aggrastat and determine Cost of Therapy with Invasive
r Conservative Strategy (TACTICS) TIMI-18 trials, patients
ho profited from the early invasive treatment strategy were
hose at high risk as determined by cTnT levels and the
dmission ECG. In the FRISC study, the invasive strategy
educed the 12-month risk of death or MI by 40% (13.2% vs.
2.1%, p 0.001) in the cohort with both ST depression and
cTnT level of 0.03 mcg per liter or greater, but the absolute main of the invasive strategy was insignificant in the cohorts
ith either ST depression, cTnT level elevation, or neither of
hese findings (245). In the TACTICS TIMI-28 study,
ubgroups of patients with no ECG changes, a low TIMI
core, and no cTn elevation showed no benefit from the
nvasive strategy, whereas those with positive cTn, indepen-
ent of the presence of elevated CK-MB levels, showed
arkedly reduced odds of adverse clinical events of 0.13 at 30
(95% confidence interval [CI]  0.04 to 0.39) and 0.29 at
80 d (95% CI  0.16 to 0.52) (246).
.2.8.2.1.1. CLINICAL USE OF MARKER CHANGE SCORES. A
ewer method to both identify and exclude MI within 6 h
f symptoms is to rely on changes in serum marker levels
delta values) over an abbreviated time interval (e.g., 2 h) as
pposed to the traditional approach of performing serial
easurements over 6 to 8 h (212,214,247–250). Because
ssays are becoming more sensitive and precise, this method
ermits the identification of increasing values while they are
till in the normal or indeterminate range of the assay. By
elying on delta values for the identification or exclusion of
I, higher-risk patients with positive delta values can be
elected earlier for more aggressive anti-ischemic therapy
e.g., GP IIb/IIIa inhibitors), and lower-risk patients with
egative delta values can be considered for early stress
esting (212,214,249–251). One study of 1,042 patients
ound the addition of a 3-h delta CK-MB to result in a
ensitivity of 93% and a specificity of 94% for MI (248). In
nother study of 2,074 consecutive ED chest pain patients,
2-h delta CK-MB in conjunction with a 2-h delta
roponin I measurement had a sensitivity for acute MI of
3% and specificity of 94% in patients whose initial ECG
as nondiagnostic for injury. When combined with physi-
ian judgment and selective nuclear stress testing, the
ensitivity for MI was 100% with specificity of 82%, and the
ensitivity for 30-d ACS was 99.1% with specificity of 87%
214). Because there are no manufacturer-recommended delta
utoff values, the appropriate delta values for identification
nd exclusion of MI should take into account the sensitivity
nd precision of the specific assay utilized and should be
onfirmed by in-house studies. It also is important for delta
alues to be measured on the same instrument owing to
ubtle variations in calibration among individual instru-
ents, even of the same model.
Another method to exclude MI within 6 h of symptom
nset is the multimarker approach, which utilizes the serial
easurement of myoglobin (i.e., a very early marker) in
ombination with the serial measurements of cTn and/or
K-MB (i.e., a later marker) (252–256). Studies have
eported that multimarker measurements at baseline and 90
in have a sensitivity for MI of approximately 95% with a
igh negative predictive value, thus allowing for the early
xclusion of MI when combined with clinical judgment
254,255). However, because of the low specificity of the
ultimarker strategy (mainly due to the lower specificity of
yoglobin), a positive multimarker test is inadequate to
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ppearing definitive marker (254,257).
.2.8.2.1.2. BEDSIDE TESTING FOR CARDIAC MARKERS. Car-
iac markers can be measured in the central chemistry
aboratory or with point-of-care instruments in the ED with
esktop devices or handheld bedside rapid qualitative assays
229). When a central laboratory is used, results should be
vailable as soon as possible, with a goal of within 60 min.
oint-of-care systems, if implemented at the bedside, have
he advantage of reducing delays due to transportation and
rocessing in a central laboratory and can eliminate delays
ue to the lack of availability of central laboratory assays at
ll hours. Certain portable devices can simultaneously mea-
ure myoglobin, CK-MB, and troponin I (249). These
dvantages of point-of-care systems must be weighed
gainst the need for stringent quality control and appropri-
te training of ED personnel in assay performance and the
igher costs of point-of-care testing devices relative to
eterminations in the central laboratory. In addition, these
oint-of-care assays at present are qualitative or, at best,
emiquantitative. To date, bedside testing has not succeeded
n becoming widely accepted or applied.
.2.8.3. MYOGLOBIN AND CK-MB SUBFORMS COMPARED WITH TROPONINS
yoglobin, a low-molecular-weight heme protein found in
oth cardiac and skeletal muscle, is not cardiac specific, but
t is released more rapidly from infarcted myocardium than
re CK-MB and cTn and can be detected as early as 2 h
fter the onset of myocardial necrosis. However, the clinical
alue of serial determinations of myoglobin for the diagnosis
f MI is limited by its brief duration of elevation of less than
4 h. Thus, an isolated early elevation in patients with a
ondiagnostic ECG should not be relied on to make the
iagnosis of MI but should be supplemented by a more
ardiac-specific marker (258). Creatine kinase-MB sub-
orms are also efficient for the early diagnosis of MI and
ave a similar specificity to that of CK-MB but require
pecial expertise, with no real advantage over better stan-
ardized and more easily applied cTn testing.
.2.8.4. SUMMARY COMPARISON OF BIOMARKERS OF NECROSIS: SINGLY AND
N COMBINATION
able 10 compares the advantages and disadvantages of
ardiac biomarkers of necrosis that are currently used for the
valuation and management of patients with suspected ACS
ut without ST-segment elevation on the 12-lead ECG.
iven the overlapping time frame of the release pattern of
ardiac biomarkers, it is important that clinicians incorpo-
ate the time from the onset of the patient’s symptoms into
heir assessment of the results of biomarker measurements
11,252,259,260) (Fig. 5).
Many patients with suspected ACS have combined as-
essments of troponin and CK-MB. When baseline tropo-
in and CK-MB were used together for diagnostic and risk
ssessment across the spectrum of chest pain syndromes in
large database that consisted of several clinical trials, those fith positive results for both markers were at highest
hort-term (24 h and 30 d) risk of death or MI (261).
owever, those with baseline troponin elevation without
K-MB elevation also were at increased 30-d risk, whereas
isk with isolated CK-MB elevation was lower and not
ignificantly different than if both markers were negative
261).
In summary, the cTns are currently the markers of choice
or the diagnosis of MI. They have a sensitivity and
pecificity as yet unsurpassed, which allows for the recogni-
ion of very small amounts of myocardial necrosis. These
mall areas of infarction are the consequence of severe
schemia and/or distal microembolization of debris from an
nstable thrombogenic plaque. The unstable plaques are
ikely responsible for the high-risk situation. Thus, cTns as
iomarkers are not only markers of cell necrosis but also of
n active thrombogenic plaque, and hence, they indicate
rognosis and are useful in guiding therapies. Although not
uite as sensitive or specific as the cTns, CK-MB by mass
ssay is a second-choice marker that remains useful for the
iagnosis of MI extension and of periprocedural MI. Rou-
ine use of myoglobin and other markers is not generally
ecommended.
Because many methods exist, many with multiple test
enerations, for cardiac biomarker testing in practice and in
ublished reports, physicians should work with their clinical
aboratories to ensure use of and familiarity with contem-
orary test technology, with appropriate, accurate ranges of
ormal and diagnostic cutoffs, specific to the assay used.
.2.9. Other Markers and Multimarker Approaches
esides markers of myocardial necrosis, markers of patho-
hysiological mechanisms implicated in ACS are under
nvestigation and could become useful to determine patho-
hysiology, individualize treatment, and evaluate therapeu-
ic effects. In considering the clinical application of new
iomarkers, it is important to determine that they provide
ncremental value over existing biomarkers. A multimarker
pproach to risk stratification of UA/NSTEMI (e.g., simul-
aneous assessment of cTnI, C-reactive protein [CRP], and
NP) has been advocated as a potential advance over single
iomarker assessment (262,263). Further evaluation of a
ultimarker approach will be of interest.
.2.9.1. ISCHEMIA
ther new biochemical markers for the detection of myo-
ardial necrosis are either less useful or have been less well
tudied than those mentioned above. An example is
schemia-modified albumin found soon after transient cor-
nary occlusion and preceding any significant elevations in
yoglobin, CK-MB, or cTnI. This modified albumin
epends on a reduced capacity of human albumin to bind
xogenous cobalt during ischemia (264,265). Choline is
eleased upon the cleavage of phospholipids and could also
erve as a marker of ischemia. Growth-differentiation
actor-15 (GDF-15), a member of the transforming growth
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schemia-and-reperfusion injury, is a new biomarker that
as been reported to be of incremental prognostic value for
eath in patients with UA/NSTEMI (265a).
.2.9.2. COAGULATION
arkers of activity of the coagulation cascade, including
levated plasma levels of fibrinogen, the prothrombin
ragments, fibrinopeptide, and D-dimers, are elevated in
CS but have little discriminative ability for a specific patho-
hysiology, diagnosis, or treatment assessments (266,267). In
xperimental studies, markers of thrombin generation are
locked by anticoagulants but reactivate after their discon-
inuation (268) and are not affected by clopidogrel (269).
.2.9.3. PLATELETS
latelet activation currently is difficult to assess directly in
ivo. New methods, however, are emerging that should
able 10. Biochemical Cardiac Markers for the Evaluation and
atients With Suspected ACS But Without ST-Segment Elevati
Marker Advantages Disadvantag
ardiac troponins 1. Powerful tool for risk stratification
2. Greater sensitivity and specificity
than CK-MB
3. Detection of recent MI up to
2 weeks after onset
4. Useful for selection of therapy
5. Detection of reperfusion
1. Low sensitivit
early phase o
(less than 6 h
symptom ons
requires repe
measuremen
12 h, if negat
2. Limited abilit
detect late m
reinfarction
K-MB 1. Rapid, cost-efficient, accurate
assays
2. Ability to detect early reinfarction
1. Loss of specifi
in setting of s
muscle disea
injury, includi
surgery
2. Low sensitivit
very early MI
6 h after sym
onset) or late
symptom ons
than 36 h) an
minor myoca
damage (dete
with troponin
yoglobin 1. High sensitivity
2. Useful in early detection of MI
3. Detection of reperfusion
4. Most useful in ruling out MI
1. Very low spec
setting of ske
muscle injury
disease
2. Rapid return
range limits s
for later prese
CS  acute coronary syndrome; CK-MB  MB fraction of creatine kinase; ECG  electrocardiollow a better and more efficient appraisal of their state of pctivation and of drug effects (270–272). Alternative mark-
rs of platelet activity are also being studied, including
D40L, platelet-neutrophil coaggregates, P-selectin, and
latelet microparticles.
.2.9.4. INFLAMMATION
ystemic markers of inflammation are being widely studied
nd show promise for providing additional insights into
athophysiological mechanisms proximal to and triggering
hrombosis, as well as suggesting novel therapeutic ap-
roaches. White blood cell counts are elevated in patients
ith MI, and this elevation has prognostic implications.
atients without biochemical evidence of myocardial necro-
is but who have elevated CRP levels on admission or past
he acute-phase reaction after 1 month and who have values
n the highest quartile are at an increased risk of an adverse
utcome (273–275). Elevated levels of interleukin-6, which
agement of
12-Lead ECG
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Test
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Recommendation
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performance and potential
therapeutic implications
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Useful as a single tes
to efficiently
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(including minor
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used in their local
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alue (276). Other potentially useful markers are levels of
irculating soluble adhesion molecules, such as intercellular
dhesion molecule-1, vascular cell adhesion molecule-1, and
-selectin (277); the pregnancy–associated plasma protein-A,
hich is a zinc-binding matrix metalloproteinase released
ith neorevascularization and believed to be a marker of
ncipient plaque rupture (278); myeloperoxidase, a
eukocyte-derived protein that generates reactive oxidant
pecies that contribute to tissue damage, inflammation, and
mmune processes within atherosclerotic lesions (279); and
thers. At this writing, none of these have been adequately
tudied or validated to be recommended for routine clinical
pplication in UA/NSTEMI.
.2.9.5. B-TYPE NATRIURETIC PEPTIDES
ne newer biomarker of considerable interest that now may
e considered in the guidelines recommendations is BNP.
-type natriuretic peptide is a cardiac neurohormone re-
eased upon ventricular myocyte stretch as proBNP, which
s enzymatically cleaved to the N-terminal proBNP (NT-
roBNP) and, subsequently, to BNP. The usefulness of
ssessing this neurohormone was first shown for the diag-
osis and evaluation of HF. Since then, numerous prospec-
ive studies and data from large data sets have documented
ts powerful prognostic value independent of conventional
isk factors for mortality in patients with stable and unstable
AD (263,280–284). A review of available studies in ACS
howed that when measured at first patient contact or
uring the hospital stay, the natriuretic peptides are strong
redictors of both short- and long-term mortality in pa-
ients with STEMI and UA/NSTEMI (280). Increasing
evels of NT-proBNP are associated with proportionally
igher short- and long-term mortality rates; at 1 year,
ortality rates with increasing quartiles were 1.8%, 3.9%,
.7%, and 19.2%, respectively (p less than 0.001) in the
USTO-IV trial of 6,809 patients (284). This prognostic
alue was independent of a previous history of HF and of
linical or laboratory signs of LV dysfunction on admission
r during hospital stay (280). B-type natriuretic peptide and
T-proBNP levels can now be measured easily and rapidly
n most hospital laboratories.
.3. Immediate Management
RECOMMENDATIONS
LASS I
. The history, physical examination, 12-lead ECG, and initial cardiac
biomarker tests should be integrated to assign patients with chest
pain into 1 of 4 categories: a noncardiac diagnosis, chronic stable
angina, possible ACS, and definite ACS. (Level of Evidence: C)
. Patients with probable or possible ACS but whose initial 12-lead
ECG and cardiac biomarker levels are normal should be observed in
a facility with cardiac monitoring (e.g., chest pain unit or hospital
telemetry ward), and repeat ECG (or continuous 12-lead ECG mon-
itoring) and repeat cardiac biomarker measurement(s) should be cobtained at predetermined, specified time intervals (see Section
2.2.8). (Level of Evidence: B)
. In patients with suspected ACS in whom ischemic heart disease is
present or suspected, if the follow-up 12-lead ECG and cardiac
biomarkers measurements are normal, a stress test (exercise or
pharmacological) to provoke ischemia should be performed in the
ED, in a chest pain unit, or on an outpatient basis in a timely
fashion (within 72 h) as an alternative to inpatient admission.
Low-risk patients with a negative diagnostic test can be managed
as outpatients. (Level of Evidence: C)
. In low-risk patients who are referred for outpatient stress testing
(see above), precautionary appropriate pharmacotherapy (e.g., ASA,
sublingual NTG, and/or beta blockers) should be given while await-
ing results of the stress test. (Level of Evidence: C)
. Patients with definite ACS and ongoing ischemic symptoms, posi-
tive cardiac biomarkers, new ST-segment deviations, new deep
T-wave inversions, hemodynamic abnormalities, or a positive stress
test should be admitted to the hospital for further management.
Admission to the critical care unit is recommended for those with
active, ongoing ischemia/injury or hemodynamic or electrical insta-
bility. Otherwise, a telemetry step-down unit is reasonable. (Level of
Evidence: C)
. Patients with possible ACS and negative cardiac biomarkers who
are unable to exercise or who have an abnormal resting ECG should
undergo a pharmacological stress test. (Level of Evidence: B)
. Patients with definite ACS and ST-segment elevation in leads V7 to
V9 due to left circumflex occlusion should be evaluated for immedi-
ate reperfusion therapy. (Level of Evidence: A)
. Patients discharged from the ED or chest pain unit should be given
specific instructions for activity, medications, additional testing, and
follow-up with a personal physician. (Level of Evidence: C)
LASS IIa
n patients with suspected ACS with a low or intermediate probability of
AD, in whom the follow-up 12-lead ECG and cardiac biomarkers
easurements are normal, performance of a noninvasive coronary
maging test (i.e., CCTA) is reasonable as an alternative to stress
esting. (Level of Evidence: B)
By integrating information from the history, physical
xamination, 12-lead ECG, and initial cardiac biomarker
ests, clinicians can assign patients to 1 of 4 categories:
oncardiac diagnosis, chronic stable angina, possible ACS,
nd definite ACS (Fig. 2).
Patients who arrive at a medical facility in a pain-free
tate, have unchanged or normal ECGs, are hemodynami-
ally stable, and do not have elevated cardiac biomarkers
epresent more of a diagnostic than an urgent therapeutic
hallenge. Evaluation begins in these patients by obtaining
nformation from the history, physical examination, and
CG (Tables 6 and 7) to be used to confirm or reject the
iagnosis of UA/NSTEMI.
Patients with a low likelihood of CAD should be evalu-
ted for other causes of the noncardiac presentation, includ-
ng musculoskeletal pain; gastrointestinal disorders, such as
sophageal spasm, gastritis, peptic ulcer disease, or chole-
ystitis; intrathoracic disease, such as musculoskeletal dis-
omfort, pneumonia, pleurisy, pneumothorax, pulmonary
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arditis; and neuropsychiatric disease, such as hyperventila-
ion or panic disorder (Fig. 2, B1). Patients who are found
o have evidence of 1 of these alternative diagnoses should
e excluded from management with these guidelines and
eferred for appropriate follow-up care (Fig. 2, C1). Reas-
urance should be balanced with instructions to return for
urther evaluation if symptoms worsen or if the patient fails
o respond to symptomatic treatment. Chronic stable angina
ay also be diagnosed in this setting (Fig. 2, B2), and
atients with this diagnosis should be managed according to
he ACC/AHA 2002 Guideline Update for the Manage-
ent of Patients With Chronic Stable Angina (4).
Patients with possible ACS (Fig. 2, B3 and D1) are
andidates for additional observation in a specialized facility
e.g., chest pain unit) (Fig. 2, E1). Patients with definite
CS (Fig. 2, B4) are triaged on the basis of the pattern of
he 12-lead ECG. Patients with ST-segment elevation (Fig.
, C3) are evaluated for immediate reperfusion therapy (Fig.
, D3) and managed according to the ACC/AHA Guide-
ines for the Management of Patients With ST-Elevation
yocardial Infarction (1), whereas those without ST-
egment elevation (Fig. 2, C2) are either managed by
dditional observation (Fig. 2, E1) or admitted to the
ospital (Fig. 2, H3). Patients with low-risk ACS (Table 6)
ithout transient ST-segment depressions greater than or
qual to 0.05 mV (0.5 mm) or T-wave inversions greater
han or equal to 0.2 mV (2 mm), without positive cardiac
iomarkers, and with a negative stress test or CCTA (Fig.
, H1) may be discharged and treated as outpatients (Fig. 2,
1). Low-risk patients may have a stress test within 3 d of
ischarge.
.3.1. Chest Pain Units
o facilitate a more definitive evaluation while avoiding the
nnecessary hospital admission of patients with possible
CS (Fig. 2, B3) and low-risk ACS (Fig. 2, F1), as well as
he inappropriate discharge of patients with active myocar-
ial ischemia without ST-segment elevation (Fig. 2, C2),
pecial units have been established that are variously referred
o as “chest pain units” and “short-stay ED coronary care
nits.” Personnel in these units use critical pathways or
rotocols designed to arrive at a decision about the presence
r absence of myocardial ischemia and, if present, to
haracterize it further as UA or NSTEMI and to define the
ptimal next step in the care of the patient (e.g., admission,
cute intervention) (87,214,285,286). The goal is to arrive at
uch a decision after a finite amount of time, which usually
s between 6 and 12 h but may extend up to 24 h depending
n the policies in individual hospitals. Typically, the patient
ndergoes a predetermined observation period with serial
ardiac biomarkers and ECGs. At the end of the observa-
ion period, the patient is reevaluated and then generally
ndergoes functional cardiac testing (e.g., resting nuclear
can or echocardiography) and/or stress testing (e.g., tread-
ill, stress echocardiography, or stress nuclear testing) or aoninvasive coronary imaging study (i.e., CCTA) (see
ection 2.3.2). Those patients who have a recurrence of
hest pain strongly suggestive of ACS, a positive biomarker
alue, a significant ECG change, or a positive functional/
tress test or CCTA are generally admitted for inpatient
valuation and treatment. Although chest pain units are
seful, other appropriate observation areas in which patients
ith chest pain can be evaluated may be used as well, such
s a section of the hospital’s cardiac telemetry ward.
The physical location of the chest pain unit or the site
here patients with chest pain are observed is variable,
anging from a specifically designated area of the ED to a
eparate hospital unit with the appropriate equipment to
bservational status (24-h admission) on a regular hospital
elemetry ward (287). Similarly, the chest pain unit may be
dministratively a part of the ED and staffed by emergency
hysicians or may be administered and staffed separately or
s part of the hospital cardiovascular service. Capability of
hest pain units generally includes continuous monitoring of
he patient’s ECG, ready availability of cardiac resuscitation
quipment and medications, and appropriate staffing with
urses and physicians. The ACEP has published guidelines
hat recommend a program for the continuous monitoring
f outcomes of patients evaluated in such units and the
mpact on hospital resources (288). A consensus panel
tatement from ACEP emphasized that chest pain units
hould be considered as part of a multifaceted program that
ncludes efforts to minimize patient delays in seeking med-
cal care and delays in the ED itself (288).
It has been reported, both from studies with historical
ontrols and from randomized trials, that the use of chest
ain units is cost-saving compared with an in-hospital
valuation to “rule out MI” (289,290). The potential cost
avings of a chest pain unit varies depending on the practice
attern for the disposition of chest pain patients at individ-
al hospitals (289). Hospitals with a high admission rate of
ow-risk patients to rule out MI (70% to 80%) will experi-
nce the largest cost savings by implementing a chest pain
nit approach but will have the smallest impact on the
umber of missed MI patients. In contrast, hospitals with
elatively low admission rates of such patients (30% to 40%)
ill experience greater improvements in the quality of care
ecause fewer MI patients will be missed but will experience
smaller impact on costs because of the low baseline
dmission rate.
Farkouh et al. (102) extended the use of a chest pain unit
n a separate portion of the ED to include patients at an
ntermediate risk of adverse clinical outcome on the basis of
he previously published Agency for Healthcare Research
nd Quality guidelines for the management of UA (124)
Table 7). They reported a 46% reduction in the ultimate
eed for hospital admission in intermediate-risk patients
fter a median stay of 9.2 h in the chest pain unit. Extension
f the use of chest pain units to intermediate-risk patients in
n effort to reduce inpatient costs is facilitated by making
vailable diagnostic testing modalities such as treadmill
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agnetic resonance) or CCTA 7 d a week (291).
Patients with chest discomfort for whom a specific
iagnosis cannot be made after a review of the history,
hysical examination, initial 12-lead ECG, and cardiac
iomarker data should undergo a more definitive evaluation.
everal categories of patients should be considered accord-
ng to the algorithm shown in Figure 2:
Patients with possible ACS (Fig. 2, B3) are those who
had a recent episode of chest discomfort at rest not
entirely typical of ischemia but who are pain free when
initially evaluated, have a normal or unchanged ECG,
and have no elevations of cardiac biomarkers.
Patients with a recent episode of typical ischemic dis-
comfort that either is of new onset or is severe or that
exhibits an accelerating pattern of previous stable angina
(especially if it has occurred at rest or is within 2 weeks of
a previously documented MI) should initially be consid-
ered to have a “definite ACS” (Fig. 2, B4). However,
such patients may be at a low risk if their ECG obtained
at presentation has no diagnostic abnormalities and the
initial serum cardiac biomarkers (especially cardiac-
specific troponins) are normal (Fig. 2, C2 and D1). As
indicated in the algorithm, patients with either “possible
ACS” (Fig. 2, B3) or “definite ACS” (Fig. 2, B4) but
with nondiagnostic ECGs and normal initial cardiac
markers (Fig. 2, D1) are candidates for additional obser-
vation in the ED or in a specialized area such as a chest
pain unit (Fig. 2, E1). In contrast, patients who present
without ST-segment elevation but who have features
indicative of active ischemia (ongoing pain, ST-segment
and/or T-wave changes, positive cardiac biomarkers, or
hemodynamic instability; Fig. 2, D2) should be admitted
to the hospital (Fig. 2, H3).
.3.2. Discharge From ED or Chest Pain Unit
he initial assessment of whether a patient has UA/
STEMI and which triage option is most suitable generally
hould be made immediately on the patient’s arrival at a
edical facility. Rapid assessment of a patient’s candidacy
or additional observation can be accomplished based on the
tatus of the symptoms, ECG findings, and initial serum
ardiac biomarker measurement.
Patients who experience recurrent ischemic discomfort,
volve abnormalities on a follow-up 12-lead ECG or on
ardiac biomarker measurements, or develop hemodynamic
bnormalities such as new or worsening HF (Fig. 2, D2)
hould be admitted to the hospital (Fig. 2, H3) and
anaged as described in Section 3.
Patients who are pain free, have either a normal or
ondiagnostic ECG or one that is unchanged from previous
racings, and have a normal set of initial cardiac biomarker
easurements are candidates for further evaluation to screen
or nonischemic discomfort (Fig. 2, B1) versus a low-risk
CS (Fig. 2, D1). If the patient is low risk (Table 7) and coes not experience any further ischemic discomfort and a
ollow-up 12-lead ECG and cardiac biomarker measure-
ents after 6 to 8 h of observation are normal (Fig. 2, F1),
he patient may be considered for an early stress test to
rovoke ischemia or CCTA to assess for obstructive CAD
Fig. 2, G1). This test can be performed before the
ischarge and should be supervised by an experienced
hysician. Alternatively, the patient may be discharged and
eturn for stress testing as an outpatient within 72 h. The
xact nature of the test may vary depending on the patient’s
bility to exercise on either a treadmill or bicycle and the
ocal expertise in a given hospital setting (e.g., availability of
ifferent testing modalities at different times of the day or
ifferent days of the week) (292). Patients who are capable
f exercise and who are free of confounding features on the
aseline ECG, such as bundle-branch block, LV hypertro-
hy, or paced rhythms, can be evaluated with routine
ymptom-limited conventional exercise stress testing. Pa-
ients who are incapable of exercise or who have an
ninterpretable baseline ECG should be considered for
harmacological stress testing with either nuclear perfusion
maging or 2-dimensional echocardiography, or magnetic
esonance (175,293,294). Alternatively, it is reasonable to
erform a non-invasive coronary imaging test (i.e., CCTA).
n imaging-enhanced test also may be more predictive in
omen than conventional ECG exercise stress testing (see
ection 6.1.).
Two imaging modalities, CMR and multidetector com-
uted tomography for coronary calcification and CCTA, are
ncreasingly becoming clinically validated and applied and
old promise as alternative or supplementary imaging mo-
alities for assessing patients who present with chest pain
yndromes (25,294,295). Cardiac magnetic resonance has
he capability of assessing cardiac function, perfusion, and
iability in the same setting. Its advantages are excellent
esolution (approximately 1 mm) of cardiac structures and
voidance of exposure to radiation and iodinated contrast.
isadvantages include long study time, confined space
claustrophobia), and (current) contraindication to the pres-
nce of pacemakers/defibrillators. To evaluate for ischemic
eart disease, an adenosine first-pass gadolinium perfusion
tudy is combined with assessment of regional and global
unction and viability (gadolinium delayed study). Direct
oronary artery imaging is better assessed by CCTA (see
elow). One study indicated a sensitivity of 89% and
pecificity of 87% for combined adenosine stress and gado-
inium delayed enhancement (viability) CMR testing for
AD (296). Dobutamine CMR stress testing can be used as
n alternative to adenosine perfusion CMR (e.g., in asth-
atic patients).
Coronary CT angiography with current multidetector
echnology (i.e., 64 slices beginning in 2005) has been
eported to give 90% to 95% or greater sensitivity and
pecificity for occlusive CAD in early clinical trial experi-
nce (297–299). For evaluation of potential UA/NSTEMI,
oronary artery calcium scoring followed by CCTA is
t
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re good to excellent resolution (approximately 0.6 mm) of
oronary artery anatomy and short study time (single breath
old). Disadvantages are radiation dose (8 to 24 mSv),
ontrast dye exposure, and necessity to achieve a slow,
egular heart rate (beta blockers are usually required). A lack
f large controlled comparative trials and reimbursement
ssues are current limitations to these technologies. In
ummary, the high negative predictive value of CCTA is its
reatest advantage: if no evidence of either calcified or
oncalcified (soft/fibrous) plaque is found, then it is highly
nlikely that the patient’s symptoms are due to UA/
STEMI of an atherosclerotic origin. (Note that primary
micro]vascular dysfunction causes of chest pain are not
xcluded.) In contrast, the positive predictive value of
CTA in determining whether a given plaque or stenosis is
ausing the signs and symptoms of possible UA/NSTEMI
s less clear because although it gives valuable anatomic
nformation, it does not provide functional or physiological
ssessment. Coronary CT angiography has been judged to
e useful for evaluation of obstructive CAD in symptomatic
atients (Class IIa, Level of Evidence: B) (25) and appro-
riate for acute chest pain evaluation for those with inter-
ediate and possibly low pretest probability of CAD when
erial ECG and biomarkers are negative (294). It may be
articularly appropriate for those with acute chest pain
yndromes with intermediate pretest probability of CAD in
he setting of nondiagnostic ECG and negative cardiac
iomarkers (294).
Because LV function is so integrally related to prognosis
nd greatly affects therapeutic options, strong consideration
hould be given to the assessment of LV function with
chocardiography or another modality (i.e., CMR, radionu-
lide, CCTA, or contrast angiography) in patients with
ocumented ischemia. In sites at which stress tests are not
vailable, low-risk patients may be discharged and referred
or outpatient stress testing in a timely fashion. Prescription
f precautionary anti-ischemic treatment (e.g., ASA, sub-
ingual NTG, and beta blockers) should be considered in
hese patients while awaiting results of stress testing. Spe-
ific instructions also should be given on whether or not to
ake these medications (e.g., beta blockers) before testing,
hich may vary depending on the test ordered and patient-
pecific factors. These patients also should be given specific
nstructions on what to do and how to seek emergency care
or recurrence or worsening of symptoms while awaiting the
tress test.
Patients who develop recurrent symptoms during ob-
ervation suggestive of ACS or in whom the follow-up
tudies (12-lead ECG, cardiac biomarkers) show new
bnormalities (Fig. 2, F2) should be admitted to the
ospital (Fig. 2, H3). Patients in whom ACS has been
xcluded should be reassessed for need for further eval-
ation of other potentially serious medical conditions
hat may mimic ACS symptomatology (e.g., pulmonary
mbolism and aortic dissection).
H
iBecause continuity of care is important in the overall
anagement of patients with a chest pain syndrome, the
atient’s primary physician (if not involved in the care of the
atient during the initial episode) should be notified of the
esults of the evaluation and should receive a copy of the
elevant test results. Patients with a noncardiac diagnosis
nd those with low risk or possible ACS with a negative
tress test should be counseled to make an appointment with
heir primary care physician as outpatients for further
nvestigation into the cause of their symptoms (Fig. 2, I1).
hey should be seen by a physician as soon after discharge
rom the ED or chest pain unit as practical and appropriate,
hat is, usually within 72 h.
Patients with possible ACS (Fig. 5, B3) and those with a
efinite ACS but a nondiagnostic ECG and normal cardiac
iomarkers when they are initially seen (Fig. 2, D1) at
nstitutions without a chest pain unit (or equivalent facility)
hould be admitted to an inpatient unit. The inpatient unit
o which such patients are to be admitted should have the
ame provisions for continuous ECG monitoring, availabil-
ty of resuscitation equipment, and staffing arrangements as
escribed above for the design of chest pain units.
. Early Hospital Care
atients with UA/NSTEMI, recurrent symptoms sugges-
ive of ACS and/or ECG ST-segment deviations, or posi-
ive cardiac biomarkers who are stable hemodynamically
hould be admitted to an inpatient unit for bed rest with
ontinuous rhythm monitoring and careful observation for
ecurrent ischemia (a step-down unit) and managed with
ither an invasive or conservative strategy (Table 11).
atients with continuing discomfort and/or hemodynamic
able 11. Selection of Initial Treatment Strategy:
nvasive Versus Conservative Strategy
Preferred Strategy Patient Characteristics
nvasive Recurrent angina or ischemia at rest or with low-level
activities despite intensive medical therapy
Elevated cardiac biomarkers (TnT or TnI)
New or presumably new ST-segment depression
Signs or symptoms of HF or new or worsening mitral
regurgitation
High-risk findings from noninvasive testing
Hemodynamic instability
Sustained ventricular tachycardia
PCI within 6 months
Prior CABG
High risk score (e.g., TIMI, GRACE)
Reduced left ventricular function (LVEF less than 40%)
onservative Low risk score (e.g., TIMI, GRACE)
Patient or physician preference in the absence of high-
risk features
ABG coronary artery bypass graft surgery; GRACE Global Registry of Acute Coronary Events;
F  heart failure; LVEF  left ventricular ejection fraction; PCI  percutaneous coronary
ntervention; TIMI  Thrombolysis In Myocardial Infarction; TnI  troponin I; TnT  troponin T.
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oronary care unit characterized by a nursing-to-patient
atio sufficient to provide 1) continuous rhythm monitoring,
) frequent assessment of vital signs and mental status, 3)
ocumented ability to perform defibrillation quickly after
he onset of ventricular fibrillation, and 4) adequate staff to
erform these functions. Patients should be maintained at
hat level of care until they have been observed for an
dequate period of time, generally at least 24 h, without any
f the following major complications: sustained ventricular
achycardia or fibrillation, sinus tachycardia, high-degree
trioventricular (AV) block, sustained hypotension, recur-
ent ischemia documented by symptoms or ST-segment
hange, new mechanical defect (ventricular septal defect or
itral regurgitation), or HF. Shorter periods of monitoring
ight be appropriate for selected patients who are success-
ully reperfused and who have normal LV function and
inimal or no necrosis.
Once a patient with documented high-risk ACS is
dmitted, standard medical therapy is indicated as dis-
ussed later. Unless a contraindication exists, these pa-
ients generally should be treated with ASA, a beta
locker, anticoagulant therapy, a GP IIb/IIIa inhibitor,
nd a thienopyridine (i.e., clopidogrel; initiation may be
eferred until a revascularization decision is made).
ritical decisions are required regarding the angiographic
invasive) strategy. One option is a routine angiographic
pproach in which coronary angiography and revascular-
zation are performed unless a contraindication exists.
ithin this approach, a common past strategy has called
or a period of medical stabilization. Increasingly, physi-
ians are taking a more aggressive approach, with coro-
ary angiography and revascularization performed within
4 h of admission; the rationale for the more aggressive
pproach is the protective effect of carefully administered
nticoagulant and antiplatelet therapy on procedural
utcome. The alternative approach, commonly referred
o as the “initial conservative strategy” (see Section 3.3),
s guided by ischemia, with angiography reserved for
atients with recurrent ischemia or a high-risk stress test
espite medical therapy. Regardless of the angiographic
trategy, an assessment of LV function is recommended
n patients with documented ischemia because of the
mperative to treat patients who have impaired LV
unction with ACE inhibitors, beta blockers, and, when
F or diabetes mellitus is present, aldosterone antago-
ists; when the coronary anatomy is appropriate (e.g.,
-vessel coronary disease), CABG is appropriate (see
ection 4). When the coronary angiogram is obtained, a
eft ventriculogram may be obtained at the same time.
hen coronary angiography is not scheduled, echocar-
iography, nuclear ventriculography, or magnetic reso-
ance imaging or CT angiography can be used to evaluate
V function.
b
l.1. Anti-Ischemic and Analgesic Therapy
RECOMMENDATIONS FOR ANTI-ISCHEMIC THERAPY
LASS I
. Bed/chair rest with continuous ECGmonitoring is recommended for
all UA/NSTEMI patients during the early hospital phase. (Level of
Evidence: C)
. Supplemental oxygen should be administered to patients with
UA/NSTEMI with an arterial saturation less than 90%, respiratory
distress, or other high-risk features for hypoxemia. (Pulse oxime-
try is useful for continuous measurement of SaO2.) (Level of
Evidence: B)
. Patients with UA/NSTEMI with ongoing ischemic discomfort should
receive sublingual NTG (0.4 mg) every 5 min for a total of 3 doses,
after which assessment should be made about the need for intra-
venous NTG, if not contraindicated. (Level of Evidence: C)
. Intravenous NTG is indicated in the first 48 h after UA/NSTEMI for
treatment of persistent ischemia, HF, or hypertension. The decision
to administer intravenous NTG and the dose used should not
preclude therapy with other proven mortality-reducing interventions
such as beta blockers or ACE inhibitors. (Level of Evidence: B)
. Oral beta-blocker therapy should be initiated within the first 24 h for
patients who do not have 1 or more of the following: 1) signs of HF,
2) evidence of a low-output state, 3) increased risk* for cardiogenic
shock, or 4) other relative contraindications to beta blockade (PR
interval greater than 0.24 s, second or third degree heart block,
active asthma, or reactive airway disease). (Level of Evidence: B)
. In UA/NSTEMI patients with continuing or frequently recurring isch-
emia and in whom beta blockers are contraindicated, a nondihydro-
pyridine calcium channel blocker (e.g., verapamil or diltiazem)
should be given as initial therapy in the absence of clinically
significant LV dysfunction or other contraindications. (Level of Evi-
dence: B)
. An ACE inhibitor should be administered orally within the first 24 h
to UA/NSTEMI patients with pulmonary congestion or LV ejection
fraction (LVEF) less than or equal to 0.40, in the absence of
hypotension (systolic blood pressure less than 100 mm Hg or less
than 30 mm Hg below baseline) or known contraindications to that
class of medications. (Level of Evidence: A)
. An angiotensin receptor blocker should be administered to UA/
NSTEMI patients who are intolerant of ACE inhibitors and have
either clinical or radiological signs of HF or LVEF less than or equal
to 0.40. (Level of Evidence: A)
. Because of the increased risks of mortality, reinfarction, hyperten-
sion, HF, and myocardial rupture associated with their use, nonste-
roidal anti-inflammatory drugs (NSAIDs), except for ASA, whether
nonselective or cyclooxygenase (COX)-2–selective agents, should be
discontinued at the time a patient presents with UA/NSTEMI. (Level
of Evidence: C)
Risk factors for cardiogenic shock (the greater the number of risk factors present, the
igher the risk of developing cardiogenic shock): age greater than 70 years, systolic
lood pressure less than 120 mmHg, sinus tachycardia greater than 110 or heart rate
ess than 60, increased time since onset of symptoms of UA/NSTEMI.
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. It is reasonable to administer supplemental oxygen to all patients
with UA/NSTEMI during the first 6 h after presentation. (Level of
Evidence: C)
. In the absence of contradictions to its use, it is reasonable to
administer morphine sulfate intravenously to UA/NSTEMI patients if
there is uncontrolled ischemic chest discomfort despite NTG, pro-
vided that additional therapy is used to manage the underlying
ischemia. (Level of Evidence: B)
. It is reasonable to administer intravenous (IV) beta blockers at the
time of presentation for hypertension to UA/NSTEMI patients who
do not have 1 or more of the following: 1) signs of HF, 2) evidence of
a low-output state, 3) increased risk* for cardiogenic shock, or 4)
other relative contraindications to beta blockade (PR interval
greater than 0.24 s, second or third degree heart block, active
asthma, or reactive airway disease). (Level of Evidence: B)
. Oral long-acting nondihydropyridine calcium channel blockers are
reasonable for use in UA/NSTEMI patients for recurrent ischemia in
the absence of contraindications after beta blockers and nitrates
have been fully used. (Level of Evidence: C)
. An ACE inhibitor administered orally within the first 24 h of UA/
NSTEMI can be useful in patients without pulmonary congestion or
LVEF less than or equal to 0.40 in the absence of hypotension
(systolic blood pressure less than 100 mm Hg or less than 30 mm
Hg below baseline) or known contraindications to that class of
medications. (Level of Evidence: B)
. Intra-aortic balloon pump (IABP) counterpulsation is reasonable in
UA/NSTEMI patients for severe ischemia that is continuing or recurs
frequently despite intensive medical therapy, for hemodynamic
instability in patients before or after coronary angiography, and for
mechanical complications of MI. (Level of Evidence: C)
LASS IIb
. The use of extended-release forms of nondihydropyridine calcium
channel blockers instead of a beta blocker may be considered in
patients with UA/NSTEMI. (Level of Evidence: B)
. Immediate-release dihydropyridine calcium channel blockers in the
presence of adequate beta blockade may be considered in patients
with UA/NSTEMI with ongoing ischemic symptoms or hypertension.
(Level of Evidence: B)
LASS III
. Nitrates should not be administered to UA/NSTEMI patients with
systolic blood pressure less than 90 mm Hg or greater than or equal
to 30 mm Hg below baseline, severe bradycardia (less than 50
beats per minute), tachycardia (more than 100 beats per minute) in
the absence of symptomatic HF, or right ventricular infarction.
(Level of Evidence: C)
. Nitroglycerin or other nitrates should not be administered to pa-
tients with UA/NSTEMI who had received a phosphodiesterase
inhibitor for erectile dysfunction within 24 h of sildenafil or 48 h of
tadalafil use. The suitable time for the administration of nitrates
after vardenafil has not been determined. (Level of Evidence: C)
. Immediate-release dihydropyridine calcium channel blockers
should not be administered to patients with UA/NSTEMI in the
absence of a beta blocker. (Level of Evidence: A)
Risk factors for cardiogenic shock (the greater the number of risk factors present, the
igher the risk of developing cardiogenic shock): age greater than 70 years, systolicp
lood pressure less than 120 mmHg, sinus tachycardia greater than 110 or heart rate
ess than 60, increased time since onset of symptoms of UA/NSTEMI.. An intravenous ACE inhibitor should not be given to patients within
the first 24 h of UA/NSTEMI because of the increased risk of
hypotension. (A possible exception may be patients with refractory
hypertension.) (Level of Evidence: B)
. It may be harmful to administer intravenous beta blockers to
UA/NSTEMI patients who have contraindications to beta blockade,
signs of HF or low-output state, or other risk factors* for cardiogenic
shock. (Level of Evidence: A)
. Nonsteroidal anti-inflammatory drugs (except for ASA), whether non-
selective or COX-2–selective agents, should not be administered during
hospitalization for UA/NSTEMI because of the increased risks of mor-
tality, reinfarction, hypertension, HF, and myocardial rupture associ-
ated with their use. (Level of Evidence: C)
The optimal management of UA/NSTEMI has the
win goals of the immediate relief of ischemia and the
revention of serious adverse outcomes (i.e., death or
yocardial [re]infarction). This is best accomplished
ith an approach that includes anti-ischemic therapy
Table 12), antithrombotic therapy (Table 13), ongoing
isk stratification, and the use of invasive procedures.
atients who are at intermediate or high risk for adverse
utcomes, including those with ongoing ischemia refrac-
ory to initial medical therapy and those with evidence of
emodynamic instability, should be admitted whenever
able 12. Class I Recommendations for Anti-Ischemic
herapy: Continuing Ischemia/Other Clinical High-Risk
eatures Present*
ed/chair rest with continuous ECG monitoring
upplemental oxygen with an arterial saturation less than 90%, respiratory
distress, or other high-risk features for hypoxemia. Pulse oximetry can be
useful for continuous measurement of SaO2.
TG 0.4 mg sublingually every 5 min for a total of 3 doses; afterward, assess
need for IV NTG
TG IV for first 48 h after UA/NSTEMI for treatment of persistent ischemia, HF,
or hypertension
ecision to administer NTG IV and dose should not preclude therapy with other
mortality-reducing interventions such as beta blockers or ACE inhibitors
eta blockers (via oral route) within 24 h without a contraindication (e.g., HF)
irrespective of concomitant performance of PCI
hen beta blockers are contraindicated, a nondihydropyridine calcium channel
blocker (e.g., verapamil or diltiazem) should be given as initial therapy in the
absence of severe LV dysfunction or other contraindications
CE inhibitor (via oral route) within first 24 h with pulmonary congestion, or
LVEF less than or equal to 0.40, in the absence of hypotension (systolic
blood pressure less than 100 mm Hg or less than 30 mm Hg below
baseline) or known contraindications to that class of medications
RB should be administered to UA/NSTEMI patients who are intolerant of ACE
inhibitors and have either clinical or radiological signs of heart failure or
LVEF less than or equal to 0.40.
Recurrent angina and/or ischemia-related ECG changes (0.05 mV or greater ST-segment
epression or bundle-branch block) at rest or with low-level activity; or ischemia associated with
F symptoms, S3 gallop, or new or worsening mitral regurgitation; or hemodynamic instability or
epressed LV function (LVEF less than 0.40 on noninvasive study); or serious ventricular
rrhythmia.
ACE angiotensin-converting enzyme; ARB angiotensin receptor blocker; HF heart failure;
V  intravenous; LV  left ventricular; LVEF  left ventricular ejection fraction; NTG 
itroglycerin; MI  myocardial infarction; PCI  percutaneous coronary intervention; UA/NSTEMI
unstable angina/non–ST-elevation myocardial infarction.ossible to a critical care environment with ready access
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Drug* Initial Medical Treatment
During PCI
After PCI At Hospital Discharge
Patient Received
Initial Medical
Treatment
Patient Did Not
Receive Initial
Medical Treatment
Oral Antiplatelet Therapy
spirin 162 to 325 mg nonenteric
formulation, orally or
chewed
No additional treatment 162 to 325 mg
nonenteric
formulation orally
or chewed
162 to 325 mg daily should
be given† for at least
1 month after BMS
implantation, 3 months
after SES implantation,
and 6 months after PES
implantation, after which
daily chronic aspirin
should be continued
indefinitely at a dose of
75 to 162 mg
162 to 325 mg daily should
be given† for at least
1 month after BMS
implantation, 3 months
after SES implantation,
and 6 months after PES
implantation, after which
daily chronic aspirin
should be continued
indefinitely at a dose of
75 to 162 mg
lopidogrel LD of 300 to 600 mg
orally
MD of 75 mg orally per
day
A second LD of 300 mg
orally may be given
to supplement a
prior LD of 300 mg
LD of 300 to 600 mg
orally
For BMS: 75 mg daily for at
least 1 month and ideally
up to 1 year. For DES, 75
mg daily for at least 1
year (in patients who are
not at high risk of
bleeding) (See Fig. 11)
For BMS: 75 mg daily for at
least 1 month and
ideally up to 1 year. For
DES, 75 mg daily for at
least 1 year (in patients
who are not at high risk
of bleeding) (See Fig. 11)
iclopidine LD of 500 mg orally
MD of 250 mg orally twice
daily
No additional treatment LD of 500 mg orally MD of 250 mg orally twice
daily (duration same as
clopidogrel)
MD of 250 mg orally twice
daily (duration same as
clopidogrel)
Anticoagulants
ivalirudin 0.1 mg per kg bolus,
0.25 mg per kg per h
infusion
0.5 mg per kg bolus,
increase infusion to
1.75 mg per kg per h
0.75 mg per kg
bolus, 1.75 mg
per kg per h
infusion
No additional treatment or
continue infusion for up
to 4 h
alteparin 120 IU per kg SC every
12 h (maximum 10,000
IU twice daily)‡
IV GP IIb/IIIa planned:
target ACT 200 s
using UFH
IV GP IIb/IIIa
planned: 60 to 70
U per kg§ of UFH
No additional treatment
No IV GP IIb/IIIa
planned: target ACT
250 to 300 s for
HemoTec; 300 to
350 s for Hemochron
using UFH
No IV GP IIb/IIIa
planned: 100 to
140 U per kg of
UFH
noxaparin LD of 30 mg IV bolus may
be given
MD  1 mg per kg SC
every 12 h; extend
dosing interval to 1 mg
per kg every 24 h if
estimated creatinine
clearance less than
30 mL per min
Last SC dose less than
8 h: no additional
therapy
Last SC dose greater
than 8 h: 0.3 mg per
kg IV bolus
0.5 to 0.75 mg per
kg IV bolus
No additional treatment
ondaparinux 2.5 mg SC once daily.
Avoid for creatinine
clearance less than 30
mL per min
50 to 60 U per kg IV
bolus of UFH is
recommended by the
OASIS 5
Investigators¶
50 to 60 U per kg IV
bolus of UFH is
recommended by
the OASIS 5
Investigators¶
No additional treatment
nfractionated
eparin
LD of 60 U per kg (max
4,000 U) as IV bolus
MD of IV infusion of 12 U
per kg per h (max
1,000 U per h) to
maintain aPTT at 1.5 to
2.0 times control
(approximately 50 to
70 s)
IV GP IIb/IIIa planned:
target ACT 200 s
No IV GP IIb/IIIa
planned: target ACT
250 to 300 s for
HemoTec; 300 to
350 s for Hemochron
IV GP IIb/IIIa
planned: 60 to 70
U per kg§
No IV GP IIb/IIIa
planned: 100 to
140 U per kg
No additional treatmentContinued on next page
t
c
t
w
s
u
(
d
m
f
a
p
s
a
d
f
u
I
3
T
t
T
A
E
T
A
i
t
i
p
m
6
a
i
r
c ting ste
u
e38 Anderson et al. JACC Vol. 50, No. 7, 2007
ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:e1–157o invasive cardiovascular diagnosis and therapeutic pro-
edures. Ready access is defined as ensured, timely access
o a cardiac catheterization laboratory with personnel
ho have appropriate credentials and experience in inva-
ive coronary procedures, as well as to emergency or
rgent cardiovascular surgery and cardiac anesthesia
2,300).
The approach to the achievement of the twin goals
escribed here includes the initiation of pharmacological
anagement and planning of a definitive treatment strategy
or the underlying disease process. Most patients are stable
able 13. Continued
Drug* Initial Medical Treatment
During P
Patient Received
Initial Medical
Treatment
Intravenous A
bciximab Not applicable Not applicable
ptifibatide LD of IV bolus of 180 mcg
per kg
MD of IV infusion of 2.0
mcg per kg per min;
reduce infusion by 50%
in patients with
estimated creatinine
clearance less than 50
mL per min
Continue infusion
irofiban LD of IV infusion of 0.4
mcg per kg per min for
30 min
MD of IV infusion of 0.1
mcg per kg per min;
reduce rate of infusion
by 50% in patients with
estimated creatinine
clearance less than 30
mL per min
Continue infusion
dditional considerations include the possibility that a conservatively managed patient may dev
f fondaparinux was given for initial medical treatment; the safety of this drug combination is n
reatment, as noted in the table, additional intravenous enoxaparin is an acceptable option. *Th
n whom the physician is concerned about the risk of bleeding, a lower initial ASA dose after PC
atients with UA/NSTEMI in an era before the widespread use of important therapies such a
anagement era is not well established. §Some operators use less than 60 U per kg of UFH wi
0 U per kg in this setting. For patients managed by an initial conservative strategy, agents such
n intravenous infusion of UFH. They are also less likely to provoke heparin-induced thrombocyto
n conservatively managed patients using the regimens listed. ¶Personal communication, OASI
andomized trials.
ACT  activated clotting time; BMS  bare-metal stent; GP  glycoprotein; h  hour; IU  in
oronary intervention; PES  paclitaxel-eluting stent; SC  subcutaneous; SES  sirolimus-elu
nfractionated heparin.t presentation or stabilize after a brief period of intensive sharmacological management and, after appropriate coun-
eling, will be able to participate in the choice of an
pproach for definitive therapy (see Section 3.3 for a full
iscussion of conservative vs. invasive strategy selection). A
ew patients will require prompt triage to emergency or
rgent cardiac catheterization and/or the placement of an
ABP.
.1.1. General Care
he severity of symptoms dictates some of the general care
hat should be given during the initial treatment. Patients
After PCI At Hospital Discharge
tient Did Not
ceive Initial
ical Treatment
telet Therapy
0.25 mg per kg
bolus
f 0.125 mcg per
per min (max
mcg per min)
Continue MD infusion for
12 h
IV bolus of 180
g per kg
owed 10 min
er by second IV
us of 180 mcg
kg
f 2.0 mcg per
per min; reduce
usion by 50% in
ients with
imated
atinine
arance less
n 50 mL per
n
Continue MD infusion for
18 to 24 h
IV infusion of
mcg per kg
min for 30
n
f IV infusion of
mcg per kg
min; reduce
e of infusion by
% in patients
h estimated
atinine
arance less
n 30 mL per
n
Continue MD infusion for
18 to 24 h
eed for PCI, in which case an intravenous bolus of 50 to 60 U per kg of UFH is recommended
established. For conservatively managed patients in whom enoxaparin was the initial medical
in alphabetical order and is not meant to indicate a particular therapy preference. †In patients
to 162 mg/d is reasonable (Class IIa, LOE: C). ‡Dalteparin was evaluated for management of
ts, clopidogrel, and GP IIb/IIIa inhibitors. Its relative efficacy and safety in the contemporary
Ib/IIIa blockade, although no clinical trial data exist to demonstrate the efficacy of doses below
oxaparin and fondaparinux offer the convenience advantage of SC administration compared with
han UFH. Available data suggest fondaparinux is associated with less bleeding than enoxaparin
estigators, July 7, 2006. Note that this regimen has not been rigorously tested in prospective
nal unit; IV  intravenous; LD  loading dose; MD  maintenance dose; PCI  percutaneous
nt; U  units; UA/NSTEMI  unstable angina/non–ST-elevation myocardial infarction; UFH CI
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August 14, 2007:e1–157 ACC/AHA UA/NSTEMI Guideline Revisionan be mobilized to a chair and use a bedside commode
hen symptom free. Subsequent activity should not be
nappropriately restrictive; instead, it should be focused on
he prevention of recurrent symptoms and liberalized as
udged appropriate when response to treatment occurs.
atients with cyanosis, respiratory distress, or other high-
isk features should receive supplemental oxygen. Adequate
rterial oxygen saturation should be confirmed with direct
easurement (especially with respiratory distress or cyano-
is) or pulse oximetry. No evidence is available to support
he administration of oxygen to all patients with ACS in the
bsence of signs of respiratory distress or arterial hypoxemia.
ts use based on the evidence base can be limited to those
ith questionable respiratory status and documented hypox-
mia. Nevertheless, it is the opinion of the Writing Com-
ittee that a short period of initial routine oxygen supple-
entation is reasonable during initial stabilization of the
atient, given its safety and the potential for underrecogni-
ion of hypoxemia. Inhaled oxygen should be administered
f the arterial oxygen saturation (SaO2) declines to less than
0%. Finger pulse oximetry is useful for the continuous
onitoring of SaO2 but is not mandatory in patients who
o not appear to be at risk of hypoxemia. Patients should
ndergo continuous ECG monitoring during their ED
valuation and early hospital phase, because sudden, unex-
ected ventricular fibrillation is the major preventable cause
f death in this early period. Furthermore, monitoring for
he recurrence of ST-segment shifts provides useful diag-
ostic and prognostic information, although the system of
onitoring for ST-segment shifts must include specific
ethods intended to provide stable and accurate recordings.
.1.2. Use of Anti-Ischemic Therapies
.1.2.1. NITRATES
itroglycerin reduces myocardial oxygen demand while
nhancing myocardial oxygen delivery. Nitroglycerin, an
ndothelium-independent vasodilator, has both peripheral
nd coronary vascular effects. By dilating the capacitance
essels (i.e., the venous bed), it increases venous pooling to
ecrease myocardial preload, thereby reducing ventricular
able 14. NTG and Nitrates in Angina
Compound Route
TG Sublingual tablets 0
Spray 0
Transdermal 0
Intravenous 5
sosorbide dinitrate Oral 5
Oral, slow release 4
sosorbide mononitrate Oral 2
Oral, slow release 6
entaerythritol tetranitrate Sublingual 1
rythritol tetranitrate Sublingual 5
Oral 1dapted from Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the managem
NTG  nitroglycerin.all tension, a determinant of myocardial oxygen demand
MVO2). More modest effects on the arterial circulation
ecrease systolic wall stress (afterload), which contributes to
urther reductions in MVO2. This decrease in myocardial
xygen demand is in part offset by reflex increases in heart
ate and contractility, which counteract the reductions in
VO2 unless a beta blocker is concurrently administered.
itroglycerin dilates normal and atherosclerotic epicardial
oronary arteries and smaller arteries that constrict with
ertain stressors (e.g., cold, mental or physical exercise).
ith severe atherosclerotic coronary obstruction and with
ess severely obstructed vessels with endothelial dysfunction,
hysiological responses to changes in myocardial blood flow
re often impaired (i.e., loss of flow-mediated dilation), so
aximal dilation does not occur unless a direct-acting
asodilator like NTG is administered. Thus, NTG pro-
otes the dilation of large coronary arteries, as well as
ollateral flow and redistribution of coronary blood flow to
schemic regions. Inhibition of platelet aggregation also
ccurs with NTG (300), but the clinical significance of this
ction is not well defined.
Intravenous NTG can benefit patients whose symptoms
re not relieved in the hospital with three 0.4-mg sublingual
TG tablets taken 5 min apart (Tables 12 and 14) and with
he initiation of an oral or intravenous beta blocker (when
here are no contraindications), as well as those with HF or
ypertension. Note that NTG is contraindicated after the
se of sildenafil within the previous 24 h or tadalafil within
8 h or with hypotension (301–303). The suitable delay
efore nitrate administration after the use of vardenafil has
ot been determined, although blood pressure had generally
eturned to baseline by 24 h (304). These drugs inhibit the
hosphodiesterase that degrades cyclic guanosine mono-
hosphate, and cyclic guanosine monophosphate mediates
ascular smooth muscle relaxation by nitric oxide. Thus,
TG-mediated vasodilatation is markedly exaggerated and
rolonged in the presence of phosphodiesterase inhibitors.
itrate use within 24 h after sildenafil or the administration
f sildenafil in a patient who has received a nitrate within
4 h has been associated with profound hypotension, MI,
Dose/Dosage Duration of Effect
0.6 mg up to 1.5 mg 1 to 7 min
as needed Similar to sublingual tablets
0.8 mg per h every 12 h 8 to 12 h during intermittent therapy
0 mcg per min Tolerance in 7 to 8 h
mg, 2 or 3 times daily Up to 8 h
1 or 2 times daily Up to 8 h
twice daily 12 to 24 h
40 mg once daily
as needed Not known
mg as needed Not known
0 mg 3 times daily Not known.3 to
.4 mg
.2 to
to 20
to 80
0 mg
0 mg
0 to 2
0 mg
to 10
0 to 3ent of patients with chronic stable angina. Available at: http://www.acc.org/qualityandscience (4).
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ardenafil (301,304).
Intravenous NTG may be initiated at a rate of 10 mcg per
in through continuous infusion via nonabsorbing tubing
nd increased by 10 mcg per min every 3 to 5 min until
ome relief of symptoms or blood pressure response is noted.
f no response is seen at 20 mcg per min, increments of 10
nd, later, 20 mcg per min can be used. If symptoms and
igns of ischemia are relieved, there is no need to continue
o increase the dose to effect a blood pressure response. If
ymptoms and signs of ischemia are not relieved, the dose
hould be increased until a blood pressure response is
bserved. Once a partial blood pressure response is ob-
erved, the dosage increase should be reduced and the
nterval between increments lengthened. Side effects of
TG include headache and hypotension. Systolic blood
ressure generally should not be titrated to less than 110
m Hg in previously normotensive patients or to greater
han 25% below the starting mean arterial blood pressure if
ypertension was present. Nitroglycerin should be avoided
n patients with initial systolic blood pressure less than 90
m Hg or 30 mm Hg or more below baseline or with
arked bradycardia or tachycardia. Although recommenda-
ions for a maximal dose are not available, a ceiling of 200
cg per min is commonly used. Even prolonged (2 to 4
eeks) infusion at 300 to 400 mcg per min does not increase
ethemoglobin levels (306).
Topical or oral nitrates are acceptable alternatives for
atients who require antianginal therapy but who do not
ave ongoing refractory ischemic symptoms. Tolerance to
he hemodynamic effects of nitrates is dose and duration
ependent and typically becomes important after 24 h of
ontinuous therapy with any formulation. Patients who
equire continued intravenous NTG beyond 24 h may
equire periodic increases in infusion rate to maintain
fficacy. An effort must be made to use non–tolerance-
roducing nitrate regimens (lower doses and intermittent
osing). When patients have been free of ischemic discom-
ort and other manifestations of ischemia for 12 to 24 h, an
ttempt should be made to reduce the dose of intravenous
TG and to switch to oral or topical nitrates. It is not
ppropriate to continue intravenous NTG in patients who
emain free of signs and symptoms of ischemia. When
schemia recurs during continuous intravenous NTG ther-
py, responsiveness to nitrates can often be restored by
ncreasing the dose and, after symptoms have been con-
rolled for several hours, attempting to add a nitrate-free
nterval. This strategy should be pursued as long as symp-
oms are not adequately controlled. In stabilized patients,
ntravenous NTG should generally be converted within 24 h
o a nonparenteral alternative (Table 14) administered in a
on–tolerance-producing regimen to avoid the potential
eactivation of symptoms. A practical method for converting
ntravenous to topical NTG has been published (307).
Most studies of nitrate treatment in UA/NSTEMI have
een small and uncontrolled, and there are no randomized, placebo-controlled trials that address either symptom relief
r reduction in cardiac events. One small randomized trial
ompared intravenous NTG with buccal NTG and found
o significant difference in the control of ischemia (308). An
verview of small studies of NTG in MI from the prefi-
rinolytic era suggested a 35% reduction in mortality rates
309); in contrast, both the Fourth International Study of
nfarct Survival (ISIS-4) (310) and Gruppo Italiano per lo
tudio della Sopravvivenza nell’infarto Miocardico
GISSI-3) (311) trials formally tested this hypothesis in
atients with suspected MI in the reperfusion era and failed
o confirm this magnitude of benefit. However, these large
rials are confounded by frequent prehospital and hospital
se of NTG in the “control” groups. Nevertheless, a strategy
f routine as opposed to selective use of nitrates did not
educe mortality. The abrupt cessation of intravenous NTG
as been associated with exacerbation of ischemic changes
n the ECG (312), and a graded reduction in the dose of
ntravenous NTG is advisable. Thus, the rationale for NTG
se in UA/NSTEMI is extrapolated from pathophysiolog-
cal principles and extensive, although uncontrolled, clinical
bservations (300).
.1.2.2. MORPHINE SULFATE
orphine sulfate (1 to 5 mg IV) is reasonable for patients
hose symptoms are not relieved despite NTG (e.g., after
serial sublingual NTG tablets) or whose symptoms
ecur despite adequate anti-ischemic therapy. Unless
ontraindicated by hypotension or intolerance, morphine
ay be administered with intravenous NTG, with careful
lood pressure monitoring, and may be repeated every 5
o 30 min as needed to relieve symptoms and maintain
atient comfort.
Morphine sulfate has potent analgesic and anxiolytic
ffects, as well as hemodynamic effects, that are potentially
eneficial in UA/NSTEMI. No randomized trials have
efined the unique contribution of morphine to the initial
herapeutic regimen or its optimal administration schedule.
orphine causes venodilation and can produce modest
eductions in heart rate (through increased vagal tone) and
ystolic blood pressure to further reduce myocardial oxygen
emand. The major adverse reaction to morphine is an
xaggeration of its therapeutic effect, causing hypotension,
specially in the presence of volume depletion and/or
asodilator therapy. This reaction usually responds to supine
r Trendelenburg positioning or intravenous saline boluses
nd atropine when accompanied by bradycardia; it rarely
equires pressors or naloxone to restore blood pressure.
ausea and vomiting occur in approximately 20% of pa-
ients. Respiratory depression is the most serious complica-
ion of morphine; severe hypoventilation that requires in-
ubation occurs very rarely in patients with UA/NSTEMI
reated with morphine. Naloxone (0.4 to 2.0 mg IV) may be
dministered for morphine overdose with respiratory or
irculatory depression. Other narcotics may be considered in
atients allergic to morphine. A cautionary note on mor-
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August 14, 2007:e1–157 ACC/AHA UA/NSTEMI Guideline Revisionhine use has been raised by data from a large observational
egistry (n  443 hospitals) that enrolled patients with
A/NSTEMI (n  57,039) (313). Those receiving mor-
hine (30%) had a higher adjusted likelihood of death
propensity-adjusted OR  1.41, 95% CI 1.26 to 1.57),
hich persisted across all subgroups (313). Although subject
o uncontrolled selection biases, these results raise a safety
oncern and suggest the need for a randomized trial.
eanwhile, the Writing Committee has downgraded the
ecommendation for morphine use for uncontrolled isch-
mic chest discomfort from a Class I to a Class IIa
ecommendation.
.1.2.3. BETA-ADRENERGIC BLOCKERS
eta blockers competitively block the effects of cat-
cholamines on cell membrane beta receptors. Beta-1 ad-
energic receptors are located primarily in the myocardium;
nhibition of catecholamine action at these sites reduces
yocardial contractility, sinus node rate, and AV node
onduction velocity. Through these actions, they blunt the
eart rate and contractility responses to chest pain, exertion,
nd other stimuli. They also decrease systolic blood pres-
ure. All of these effects reduce MVO2. Beta-2 adrenergic
eceptors are located primarily in vascular and bronchial
mooth muscle; the inhibition of catecholamine action at
hese sites produces vasoconstriction and bronchoconstric-
ion (300). In UA/NSTEMI, the primary benefits of beta
lockers are due to inhibition of beta-1 adrenergic receptors,
hich results in a decrease in cardiac work and myocardial
xygen demand. Slowing of the heart rate also has a
avorable effect, acting not only to reduce MVO2 but also to
ncrease the duration of diastole and diastolic pressure-time,
determinant of forward coronary flow and collateral flow.
Beta blockers, administered orally, should be started early
n the absence of contraindications. Intravenous adminis-
ration may be warranted in patients with ongoing rest pain,
specially with tachycardia or hypertension, in the absence
f contraindications (see below) (Table 12).
able 15. Properties of Beta Blockers in Clinical Use
Drugs Selectivity Partial Agonist Act
ropranolol None No
etoprolol Beta1 No
tenolol Beta1 No
adolol None No
imolol None No
cebutolol Beta1 Yes
etaxolol Beta1 No
isoprolol Beta1 No
smolol (intravenous) Beta1 No
abetalol* None Yes
indolol None Yes
arvedilol None YesLabetalol and carvedilol are combined alpha and beta blockers. Adapted from Table 25, Gibbons RJ, A
ith chronic stable angina. Available at: http://www.acc.org/qualityandscience (4).The benefits of routine early intravenous use of beta
lockers in the fibrinolytic era have been challenged by 2
ater randomized trials of intravenous beta blockade
314,315) and by a post hoc analysis of the use of atenolol
n the GUSTO-I trial (316). A subsequent systematic
eview of early beta-blocker therapy in STEMI found no
ignificant reduction in mortality (27). Most recently, the
tility of early intravenous followed by oral beta blockade
metoprolol) was tested in 45,852 patients with MI (93%
ad STEMI, 7% had NSTEMI) in the COMMIT study
317). Neither the composite of death, reinfarction, or
ardiac arrest nor death alone was reduced for up to 28 d in
he hospital. Overall, a modest reduction in reinfarction and
entricular fibrillation (which was seen after day 1) was
ounterbalanced by an increase in cardiogenic shock, which
ccurred early (first day) and primarily in those who were
emodynamically compromised or in HF or who were
table but at high risk of development of shock. Thus, early
ggressive beta blockade poses a substantial net hazard in
emodynamically unstable patients and should be avoided.
isk factors for shock were older age, female sex, time delay,
igher Killip class, lower blood pressure, higher heart rate,
CG abnormality, and previous hypertension. There was a
oderate net benefit for those who were relatively stable
nd at low risk of shock. Whether to start beta blockade
ntravenously or orally in these latter stable patients is
nclear, and patterns of use vary. In an attempt to balance
he evidence base overall for UA/NSTEMI patients, beta
lockers are recommended in these guidelines to be initiated
rally, in the absence of contraindications (e.g., HF), within
he first 24 h. Greater caution is now suggested in the early
se of intravenous beta blockers, which should be targeted
o specific indications and should be avoided with HF,
ypotension, and hemodynamic instability.
The choice of beta blocker for an individual patient is
ased primarily on pharmacokinetic and side effect criteria,
s well as on physician familiarity (Table 15). There are no
omparative studies between members of this class in the
Usual Dose for Angina
20 to 80 mg twice daily
50 to 200 mg twice daily
50 to 200 mg per d
40 to 80 mg per d
10 mg twice daily
200 to 600 mg twice daily
10 to 20 mg per d
10 mg per d
50 to 300 mcg per kg per min
200 to 600 mg twice daily
2.5 to 7.5 mg 3 times daily
6.25 mg twice daily, uptitrated to a maximum of 25 mg twice dailyivitybrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients
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ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:e1–157cute setting. Beta blockers without intrinsic sympathomi-
etic activity are preferred, however. Agents studied in the
cute setting include metoprolol, propranolol, and atenolol.
arvedilol may be added to the list of agents studied for
ost-MI use. Comparative studies among different beta
lockers in the chronic setting after UA/NSTEMI also are
ot available to establish a preference among agents. In
atients with HF, 1 study suggested greater benefit with
arvedilol, with mixed beta-blocking and alpha-adrenergic-
locking effects, than metoprolol, a relatively selective
eta-1 blocker (318). In patients with hypertension, the
elative cardiovascular benefit of atenolol has been ques-
ioned on the basis of recent clinical trial analyses (319,320).
Patients with marked first-degree AV block (i.e., ECG
R interval greater than 0.24 s), any form of second- or
hird-degree AV block in the absence of a functioning
mplanted pacemaker, a history of asthma, severe LV
ysfunction or HF (e.g., rales or S3 gallop) or at high risk for
hock (see above) should not receive beta blockers on an
cute basis (4). Patients with evidence of a low-output state
e.g., oliguria) or sinus tachycardia, which often reflects low
troke volume, significant sinus bradycardia (heart rate less
han 50 beats per min), or hypotension (systolic blood
ressure less than 90 mm Hg) should not receive acute
eta-blocker therapy until these conditions have resolved.
atients at highest risk for cardiogenic shock due to intra-
enous beta blockade in the COMMIT trial were those
ith tachycardia or in Killip Class II or III (317). However,
eta blockers are strongly recommended before discharge in
hose with compensated HF or LV systolic dysfunction for
econdary prevention (321). Patients with significant
hronic obstructive pulmonary disease who may have a
omponent of reactive airway disease should be given beta
lockers very cautiously; initially, low doses of a beta-1–
elective agent should be used. If there are concerns about
ossible intolerance to beta blockers, initial selection should
avor a short-acting beta-1–specific drug such as metoprolol
r esmolol. Mild wheezing or a history of chronic obstruc-
ive pulmonary disease mandates a short-acting cardioselec-
ive agent at a reduced dose (e.g., 12.5 mg of metoprolol
rally) rather than the complete avoidance of a beta blocker.
In the absence of these concerns, previously studied
egimens may be used. Intravenous metoprolol may be given
n 5-mg increments by slow intravenous administration (5
g over 1 to 2 min), repeated every 5 min for a total initial
ose of 15 mg. In patients who tolerate the total 15-mg IV
ose, oral therapy can be initiated 15 min after the last
ntravenous dose at 25 to 50 mg every 6 h for 48 h.
hereafter, patients should receive a maintenance dose of up
o 100 mg twice daily. Alternatively, intravenous propran-
lol may be administered as an initial dose of 0.5 to 1.0 mg,
ollowed in 1 to 2 h by 40 to 80 mg by mouth every 6 to 8 h.
onitoring during intravenous beta-blocker therapy should
nclude frequent checks of heart rate and blood pressure and
ontinuous ECG monitoring, as well as auscultation for
ales and bronchospasm. Beta blockade also may be started Mrally, in smaller initial doses if appropriate, within the first
4 h, in cases in which a specific clinical indication for
ntravenous initiation is absent or the safety of aggressive
arly beta blockade is a concern. Carvedilol, 6.25 mg by
outh twice daily, uptitrated individually at 3- to 10-d
ntervals to a maximum of 25 mg twice daily, can reduce
ortality and reinfarction when given to patients with
ecent (3 to 21 d) MI and LV dysfunction (321). After the
nitial intravenous load, if given, patients without limiting
ide effects may be converted to an oral regimen. The target
esting heart rate is 50 to 60 beats per minute unless a
imiting side effect is reached. Selection of the oral agent
hould include the clinician’s familiarity with the agent.
aintenance doses are given in Table 15.
Initial studies of beta-blocker benefits in ACS were small
nd uncontrolled. An overview of double-blind, randomized
rials in patients with threatening or evolving MI suggests
n approximately 13% reduction in the risk of progression to
I (322). These trials were conducted prior to the routine
se of ASA, heparin, clopidogrel, GP IIb/IIIa inhibitors,
nd revascularization. These trials lack sufficient power to
ssess the effects of these drugs on mortality rates for UA.
ooled results from the Evaluation of c7E3 for the Preven-
ion of Ischemic Complications (EPIC), Evaluation of
TCA and Improve Long-term Outcome by c7E3 GP
Ib/IIIa receptor blockade (EPILOG), Evaluation of Plate-
et IIb/IIIa Inhibitor for STENTing (EPISTENT), CAP-
URE, and ReoPro in Acute myocardial infarction and
rimary PTCA Organization and Randomization Trial
RAPPORT) studies were used to evaluate the efficacy of
eta-blocker therapy in patients with ACS who were
ndergoing PCI (323). At 30 d, death occurred in 0.6% of
atients receiving beta-blocker therapy versus 2.0% of pa-
ients not receiving such therapy (p less than 0.001). At 6
onths, death occurred in 1.7% of patients receiving beta-
locker therapy versus 3.7% not receiving this therapy (p less
han 0.001). Thus, patients receiving beta-blocker therapy
ho undergo PCI for UA or MI have a lower short-term
ortality (323).
Overall, the rationale for beta-blocker use in all forms of
AD, including UA, is generally favorable, with the excep-
ion of initial HF. In the absence of contraindications, the
ew evidence appears sufficient to make beta blockers a
outine part of care. A related group shown to benefit are
igh- or intermediate-risk patients who are scheduled to
ndergo cardiac or noncardiac surgery (324). A recent
xception to beta-blocker benefit was COMMIT, a large
rial of mostly STEMI patients, which showed no overall
ortality effect. Subgroup analysis suggested this to be due
o an increased risk in those with initial HF or risk factors
or cardiogenic shock (317). In contrast to this adverse
xperience with early, aggressive beta blockade, carvedilol,
egun in low doses 3 to 10 d after MI in patients with LV
ysfunction (ejection fraction of 0.40 or less) and gradually
ptitrated, decreased subsequent death or nonfatal recurrent
I when given in conjunction with modern ACS therapies
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APRICORN (Carvedilol Post-Infarct Survival Control in
V Dysfunction) (321).
In conclusion, evidence for the beneficial effects of the use
f beta blockers in patients with UA is based on limited
andomized trial data along with pathophysiological con-
iderations and extrapolation from experience with CAD
atients who have other types of ischemic syndromes (stable
ngina or compensated chronic HF). The duration of
enefit with long-term oral therapy is uncertain and likely
aries with the extent of revascularization.
.1.2.4. CALCIUM CHANNEL BLOCKERS
alcium channel blockers (CCBs) reduce cell transmem-
rane inward calcium flux, which inhibits both myocardial
nd vascular smooth muscle contraction; some also slow AV
onduction and depress sinus node impulse formation.
gents in this class vary in the degree to which they produce
asodilation, decreased myocardial contractility, AV block,
nd sinus node slowing. Nifedipine and amlodipine have the
ost peripheral arterial dilatory effects but few or no AV or
inus node effects, whereas verapamil and diltiazem have
rominent AV and sinus node effects and some peripheral
rterial dilatory effects as well. All 4 of these agents, as well
s other approved agents, have coronary dilatory properties
hat appear to be similar. Although different CCBs are
tructurally and, potentially, therapeutically diverse, superi-
rity of 1 agent over another in UA/NSTEMI has not been
emonstrated, except for the increased risks posed by
apid-release, short-acting dihydropyridines such as nifedi-
ine (Table 16). Beneficial effects in UA/NSTEMI are
elieved to be due to variable combinations of decreased
yocardial oxygen demand (related to decreased afterload,
ontractility, and heart rate) and improved myocardial flow
able 16. Properties of Calcium Channel Blockers in Clinical U
Drug Usual Dose
ihydropyridines
Nifedipine* Immediate release: 30 to 90 mg daily orally
Slow release: 30 to 180 mg orally
Amlodipine 5 to 10 mg once daily
Felodipine 5 to 10 mg once daily
Isradipine 2.5 to 10 mg twice daily
Nicardipine 20 to 40 mg 3 times daily
Nisoldipine 20 to 40 mg once daily
Nitrendipine 20 mg once or twice daily
iscellaneous
Diltiazem Immediate release: 30 to 90 mg 4 times
daily
Slow release: 120 to 360 mg once daily
Verapamil Immediate release: 80 to 160 mg 3 times
daily
Slow release: 120 to 480 mg once dailyImmediate-release nifedipine not recommended for UA/NSTEMI except with concomitant beta blockade
pdate for the management of patients with chronic stable angina. Available at: http://www.acc.org/qrelated to coronary arterial and arteriolar dilation)
300,325). These agents also have theoretically beneficial
ffects on LV relaxation and arterial compliance. Major side
ffects include hypotension, worsening HF, bradycardia,
nd AV block.
Calcium channel blockers may be used to control ongoing
r recurring ischemia-related symptoms in patients who
lready are receiving adequate doses of nitrates and beta
lockers, in patients who are unable to tolerate adequate
oses of 1 or both of these agents, and in patients with
ariant angina (see Section 6.7). In addition, these drugs
ave been used for the management of hypertension in
atients with recurrent UA (325). Rapid-release, short-
cting dihydropyridines (e.g., nifedipine) must be avoided in
he absence of concomitant beta blockade because of in-
reased adverse potential (326,327,328). Verapamil and
iltiazem should be avoided in patients with pulmonary
dema or evidence of severe LV dysfunction (329–331).
mlodipine and felodipine are reasonably well tolerated by
atients with mild LV dysfunction (329–331,332–334),
lthough their use in UA/NSTEMI has not been studied.
he CCB evidence base in UA/NSTEMI is greatest for
erapamil and diltiazem (328,331).
Several randomized trials during the 1980s tested CCBs
n UA/NSTEMI and found that they relieve or prevent
igns and symptoms of ischemia to a degree similar to the
eta blockers. The Danish Study Group on Verapamil in
yocardial Infarction (DAVIT) (332,333) studied 3,447
atients with suspected UA/NSTEMI. A benefit was not
roved, but death or nonfatal MI tended to be reduced. The
iltiazem Reinfarction Study (DRS) studied 576 patients
ith UA/NSTEMI (329). Diltiazem reduced reinfarction
nd refractory angina at 14 d without an increase in
Duration of
Action Side Effects
Short Hypotension, dizziness, flushing, nausea, constipation,
edema
Long Headache, edema
Long Headache, edema
Medium Headache, fatigue
Short Headache, dizziness, flushing, edema
Short Similar to nifedipine
Medium Similar to nifedipine
Short Hypotension, dizziness, flushing, bradycardia, edema
Long
Short Hypotension, myocardial depression, heart failure,
edema, bradycardia
Longse. Modified from Table 27 in Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline
ualityandscience (4).
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I subset of patients in the Multicenter Diltiazem Postin-
arction Trial (MDPIT) suggested similar findings (334).
he Holland Interuniversity Nifedipine/metoprolol Trial
HINT), tested nifedipine and metoprolol in a 2  2
actorial design in 515 patients (327). The study was
topped early because of concern for harm with the use of
ifedipine alone. In contrast, patients already taking a beta
locker appeared to benefit from the addition of nifedipine
risk ratio [RR] 0.68) (335).
Meta-analyses combining UA/NSTEMI studies of all
CBs have suggested no overall benefit (322,336), whereas
hose excluding nifedipine (e.g., for verapamil alone) have
eported favorable effects on outcomes (332). Retrospective
nalyses of DAVIT and MDPIT suggested that verapamil
nd diltiazem can have a detrimental effect on mortality
ates in patients with LV dysfunction (329,330). In contrast,
erapamil reduced diuretic use in DAVIT-2, (333). Fur-
hermore, subsequent prospective trials with verapamil ad-
inistered to MI patients with HF who were receiving an
CE inhibitor suggested a benefit (330,337). The Dilti-
zem as Adjunctive Therapy to Activase (DATA) trial also
uggested that intravenous diltiazem in MI patients can be
afe; death, MI, and recurrent ischemia were decreased at 35
and 6 months (338).
In summary, definitive evidence for a benefit of CCBs in
A/NSTEMI is predominantly limited to symptom con-
rol. For immediate-release nifedipine, an increase in serious
vents is suggested when administered early without a beta
locker. The heart rate–slowing CCB drugs (verapamil and
iltiazem) can be administered early to patients with UA/
STEMI without HF without overall harm and with
rends toward a benefit. Therefore, when beta blockers
annot be used, and in the absence of clinically significant
V dysfunction, heart rate–slowing CCBs are preferred.
reater caution is indicated when combining a beta blocker
nd CCB for refractory ischemic symptoms, because they
ay act in synergy to depress LV function and sinus and AV
ode conduction. The risks and benefits in UA/NSTEMI
f newer CCBs, such as the dihydropyridines amlodipine
nd felodipine, relative to the older agents in this class that
ave been reviewed here, remain undefined, which suggests
cautious approach, especially in the absence of beta
lockade.
.1.2.5. INHIBITORS OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
ngiotensin-converting enzyme inhibitors have been shown
o reduce mortality rates in patients with MI or who
ecently had an MI and have LV systolic dysfunction
339–341), in patients with diabetes mellitus with LV
ysfunction (342), and in a broad spectrum of patients with
igh-risk chronic CAD, including patients with normal LV
unction (343). Follow-up of patients with LV dysfunction
fter MI in the TRACE (TRAndolapril Cardiac Evalua-
ion) trial showed that the beneficial effect of trandolapril on
ortality and hospitalization rate was maintained for at Feast 10 to 12 years (344). A systematic review assessing
otential ASA–ACE inhibitor interactions showed clini-
ally important benefits with ACE inhibitor therapy, irre-
pective of whether concomitant ASA was used, and only
eak evidence of a reduction in the benefit of ACE
nhibitor therapy added to ASA (345); these data did not
olely involve patients with MI. Accordingly, ACE inhibi-
ors should be used in patients receiving ASA and in those
ith hypertension that is not controlled with beta blockers.
ecent data on ACE inhibitor patients with stable CAD are
ummarized in the section on long-term medical therapy
see Section 5.2.3).
In patients with MI complicated by LV systolic dys-
unction, HF, or both, the angiotensin receptor blocker
alsartan was as effective as captopril in patients at high
isk for cardiovascular events after MI. The combination
f valsartan and captopril increased adverse events and
id not improve survival (346). Although not in the acute
are setting, treatment of patients with chronic HF with
andesartan (at least half of whom had an MI) in the
HARM (Candesartan in Heart failure Assessment in
eduction of Mortality)-Overall program showed a re-
uction in cardiovascular deaths and hospital admissions
or HF, independent of ejection fraction or baseline
reatment (347).
The selective aldosterone receptor blocker eplerenone,
sed in patients with MI complicated by LV dysfunction
nd either HF or diabetes mellitus, reduced morbidity and
ortality in the Eplerenone Post-acute myocardial infarc-
ion Heart failure Efficacy and SUrvival Study (EPHESUS)
348). This complements data from the earlier Randomized
Ldactone Evaluation Study (RALES), in which aldoste-
one receptor blockade with spironolactone decreased mor-
idity and death in patients with severe HF, half of whom
ad an ischemic origin (349). Indications for long-term use
f aldosterone receptor blockers are given in Section 5.2.3.
.1.2.6. OTHER ANTI-ISCHEMIC THERAPIES
ther less extensively studied therapies for the relief of
schemia, such as spinal cord stimulation (350) and pro-
onged external counterpulsation (351,352), are under eval-
ation. Most experience has been gathered with spinal cord
timulation in “intractable angina” (353), in which anginal
elief has been described. They have not been applied in the
cute setting for UA/NSTEMI.
The KATP channel openers have hemodynamic and
ardioprotective effects that could be useful in UA/
STEMI. Nicorandil is such an agent that has been
pproved in a number of countries but not in the United
tates. In a pilot double-blind, placebo-controlled study
f 245 patients with UA, the addition of this drug to
onventional treatment significantly reduced the number
f episodes of transient myocardial ischemia (mostly silent)
nd of ventricular and supraventricular tachycardia (354).
urther evaluation of this class of agents is underway.
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xerts antianginal effects without reducing heart rate or
lood pressure (355). Currently, ranolazine is indicated
lone or in combination with amlodipine, beta-blockers, or
itrates for the treatment of chronic angina that has failed to
espond to standard antianginal therapy. The recommended
nitial dose is 500 mg orally twice daily, which can be
scalated as needed to a maximum of 1000 mg twice daily.
he mechanism of action of ranolazine has not been fully
haracterized but appears to depend on membrane ion-
hannel effects (similar to those after chronic amiodarone)
356). It is contraindicated in patients with QT-prolonging
onditions. Preliminary results of a large (N  6,560)
atient trial of ranolazine, begun within 48 h of UA/
STEMI, suggested safety and symptom relief (reduction
n angina) but did not achieve the primary efficacy end point
f a reduction in the composite of cardiovascular death, MI,
r recurrent ischemia (hazard ratio [HR] 0.92, 95% CI 0.83
o 1.02) (357,357a). Thus, ranolazine may be safely admin-
stered for symptom relief after UA/NSTEMI, but it does
ot appear to significantly improve the underlying disease
ubstrate.
.1.2.7. INTRA-AORTIC BALLOON PUMP COUNTERPULSATION
xperience with IABP for refractory ischemia dates back
ore than 30 years. In a prospective registry of 22,663
ABP patients, 5,495 of whom had acute MI, placement
f an IABP in MI patients primarily was performed for
ardiogenic shock, for hemodynamic support during
atheterization and/or angioplasty, before high-risk sur-
ery, for mechanical complications of MI, or for refrac-
ory post-MI UA. Balloon insertions were successful in
7.7% of patients, and major complications occurred in
.7% of patients during a median use of 3 d (358). The
lacement of an IABP could be useful in patients with
ecurrent ischemia despite maximal medical management
nd in those with hemodynamic instability until coronary
ngiography and revascularization can be completed.
.1.2.8. ANALGESIC THERAPY
ecause of the known increased risk of cardiovascular events
mong patients taking COX-2 inhibitors and NSAIDs
359–361), patients who are taking them at the time of
A/NSTEMI should discontinue them immediately (see
ection 5.2.16 for additional discussion). A secondary anal-
sis of the Enoxaparin and Thrombolysis Reperfusion for
cute Myocardial Infarction Treatment (EXTRACT)-
IMI-25 data (362) demonstrated an increased risk of
eath, reinfarction, HF, or shock among patients who were
aking NSAIDs within 7 d of enrollment. Longer term
anagement is considered in Section 5.2.16.
.2. Recommendations for
ntiplatelet/Anticoagulant Therapy in Patients for
hom Diagnosis of UA/NSTEMI Is Likely or Definite
ecommendations are written as the reader follows the
lgorithms for antiplatelet/anticoagulant therapy and triage
a
ror angiography (Figs. 7, 8, and 9). Letters after recommen-
ations refer to the specific box in the algorithm. See Table
3 for dosing recommendations.
.2.1. Antiplatelet Therapy Recommendations
LASS I
1. Aspirin should be administered to UA/NSTEMI patients as soon as
possible after hospital presentation and continued indefinitely in
patients not known to be intolerant of that medication. (Level of
Evidence: A) (Figs. 7 and 8; Box A)
2. Clopidogrel (loading dose followed by daily maintenance dose)*
should be administered to UA/NSTEMI patients who are unable to
take ASA because of hypersensitivity or major gastrointestinal
intolerance. (Level of Evidence: A) (Figs. 7 and 8; Box A)
3. In UA/NSTEMI patients with a history of gastrointestinal bleeding,
when ASA and clopidogrel are administered alone or in combina-
tion, drugs to minimize the risk of recurrent gastrointestinal bleed-
ing (e.g., proton-pump inhibitors) should be prescribed concomi-
tantly. (Level of Evidence: B)
4. For UA/NSTEMI patients in whom an initial invasive strategy is
selected, antiplatelet therapy in addition to aspirin should be
initiated before diagnostic angiography (upstream) with either clo-
pidogrel (loading dose followed by daily maintenance dose)* or an
intravenous GP IIb/IIIa inhibitor. (Level of Evidence: A) Abciximab
as the choice for upstream GP IIb/IIIa therapy is indicated only if
there is no appreciable delay to angiography and PCI is likely to be
performed; otherwise, IV eptifibatide or tirofiban is the preferred
choice of GP IIb/IIIa inhibitor. (Level of Evidence: B)
5. For UA/NSTEMI patients in whom an initial conservative (i.e.,
noninvasive) strategy is selected (see Section 3.3), clopidogrel
(loading dose followed by daily maintenance dose)* should be
added to ASA and anticoagulant therapy as soon as possible after
admission and administered for at least 1 month (Level of Evi-
dence: A) and ideally up to 1 year. (Level of Evidence: B) (Fig. 8; Box C2)
6. For UA/NSTEMI patients in whom an initial conservative strategy is
selected, if recurrent symptoms/ischemia, HF, or serious arrhyth-
mias subsequently appear, then diagnostic angiography should be
performed. (Level of Evidence: A) (Fig. 8; Box D) Either an intrave-
nous GP IIb/IIIa inhibitor (eptifibatide or tirofiban; Level of Evi-
dence: A) or clopidogrel (loading dose followed by daily mainte-
nance dose; Level of Evidence: A)* should be added to ASA and
anticoagulant therapy before diagnostic angiography (upstream).
(Level of Evidence: C)
LASS IIa
. For UA/NSTEMI patients in whom an initial conservative strategy is
selected and who have recurrent ischemic discomfort with clopi-
dogrel, ASA, and anticoagulant therapy, it is reasonable to add a GP
IIb/IIIa antagonist before diagnostic angiography. (Level of Evi-
dence: C)
. For UA/NSTEMI patients in whom an initial invasive strategy is
selected, it is reasonable to initiate antiplatelet therapy with both
Some uncertainty exists about optimum dosing of clopidogrel. Randomized trials
stablishing its efficacy and providing data on bleeding risks used a loading dose of 300
g orally followed by a daily oral maintenance dose of 75 mg. Higher oral loading
oses such as 600 or 900 mg of clopidogrel more rapidly inhibit platelet aggregation
nd achieve a higher absolute level of inhibition of platelet aggregation, but the
dditive clinical efficacy and the safety of higher oral loading doses have not been
igorously established.
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an intravenous GP IIb/IIIa inhibitor. (Level of Evidence: B) Abciximab
as the choice for upstream GP IIb/IIIa therapy is indicated only if
there is no appreciable delay to angiography and PCI is likely to be
performed; otherwise, IV eptifibatide or tirofiban is the preferred
choice of GP IIb/IIIa inhibitor.† (Level of Evidence: B)
. For UA/NSTEMI patients in whom an initial invasive strategy is
selected, it is reasonable to omit upstream administration of an
intravenous GP IIb/IIIa antagonist before diagnostic angiography if
bivalirudin is selected as the anticoagulant and at least 300 mg of
clopidogrel was administered at least 6 h earlier than planned
catheterization or PCI. (Level of Evidence: B)
LASS IIb
or UA/NSTEMI patients in whom an initial conservative (i.e., noninva-
ive) strategy is selected, it may be reasonable to add eptifibatide or
irofiban to anticoagulant and oral antiplatelet therapy. (Level of Evi-
ence: B) (Fig. 8; Box C2)
Some uncertainty exists about optimum dosing of clopidogrel. Randomized trials
stablishing its efficacy and providing data on bleeding risks used a loading dose of 300 mg
rally followed by a daily oral maintenance dose of 75 mg. Higher oral loading doses such
s 600 or 900 mg of clopidogrel may more rapidly inhibit platelet aggregation and achieve
higher absolute level of inhibition of platelet aggregation, but the additive efficacy and
he safety of higher oral loading doses have not been rigorously established.
Factors favoring administration of both clopidogrel and GP IIb/IIIa inhibitor
igure 7. Algorithm for Patients With UA/NSTEMI Managed by an
hen multiple drugs are listed, they are in alphabetical order and not in order of pre
anagement strategy. ‡Evidence exists that GP IIb/IIIa inhibitors may not be necess
h earlier (Class I, Level of Evidence B for clopidogrel administration) and bivalirudi
lycoprotein; IV  intravenous; LOE  level of evidence; UA/NSTEMI  unstable angnclude: delay to angiography, high-risk features, and early recurrent ischemic
iscomfort.
‡
1LASS III
bciximab should not be administered to patients in whom PCI is not
lanned. (Level of Evidence: A)
.2.2. Anticoagulant Therapy Recommendations
LASS I
nticoagulant therapy should be added to antiplatelet therapy in
A/NSTEMI patients as soon as possible after presentation.
. For patients in whom an invasive strategy is selected, regimens with
established efficacy at a Level of Evidence: A include enoxaparin and
UFH (Fig. 7; Box B1), and those with established efficacy at a Level of
Evidence: B include bivalirudin and fondaparinux (Fig. 7; Box B1).
. For patients in whom a conservative strategy is selected, regimens
using either enoxaparin‡ or UFH (Level of Evidence: A) or fondapa-
rinux (Level of Evidence: B) have established efficacy. (Fig. 8; Box
C1) ‡See also Class IIa recommendation below.
. In patients in whom a conservative strategy is selected and who
have an increased risk of bleeding, fondaparinux is preferable.
(Level of Evidence: B) (Fig. 8; Box C1)
LASS IIa
or UA/NSTEMI patients in whom an initial conservative strategy is se-
ected, enoxaparin‡ or fondaparinux is preferable to UFH as anticoagulant
herapy, unless CABG is planned within 24 h. (Level of Evidence: B)
l Invasive Strategy
e (e.g., Boxes B1 and B2). *See dosing Table 13. †See Table 11 for selection of
the patient received a preloading dose of at least 300 mg of clopidogrel at least
lected as the anticoagulant (Class IIa, Level of Evidence B). ASA  aspirin; GP 
on–ST-elevation myocardial infarction; UFH  unfractionated heparin.Initia
ferenc
ary ifLimited data are available for the use of other LMWHs (e.g., dalteparin; see Tables
3 and 17) in UA/NSTEMI.
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ntiplatelet and Anticoagulant Therapy
LASS I
1. For UA/NSTEMI patients in whom an initial conservative strategy is
selected and no subsequent features appear that would necessi-
tate diagnostic angiography (recurrent symptoms/ischemia, HF, or
serious arrhythmias), a stress test should be performed. (Level of
Evidence: B) (Fig. 8; Box O)
a. If, after stress testing, the patient is classified as not at low risk,
diagnostic angiography should be performed. (Level of Evi-
dence: A) (Fig. 8; Box E1)
b. If, after stress testing, the patient is classified as being at low
igure 8. Algorithm for Patients With UA/NSTEMI Managed by an
hen multiple drugs are listed, they are in alphabetical order and not in order of pre
anagement strategy. ‡Recurrent symptoms/ischemia, heart failure, serious arrhyth
evel of evidence; LVEF  left ventricular ejection fraction; UA/NSTEMI  unstable arisk (Fig. 8; Box E2), the instructions noted below should befollowed in preparation for discharge (Fig. 8; Box K) (Level of
Evidence: A):
1. Continue ASA indefinitely. (Level of Evidence: A)
2. Continue clopidogrel for at least 1month (Level of Evidence:
A) and ideally up to 1 year. (Level of Evidence: B)
3. Discontinue intravenous GP IIb/IIIa inhibitor if started pre-
viously. (Level of Evidence: A)
4. Continue UFH for 48 h or administer enoxaparin or fondapa-
rinux for the duration of hospitalization, up to 8 d, and then
discontinue anticoagulant therapy. (Level of Evidence: A)
2. For UA/NSTEMI patients in whom CABG is selected as a postan-
giography management strategy, the instructions noted below
l Conservative Strategy
e (e.g., Boxes C1 and C2). *See dosing Table 13. †See Table 11 for selection of
SA  aspirin; EF  ejection fraction; GP  glycoprotein; IV  intravenous; LOE 
non–ST-elevation myocardial infarction; UFH  unfractionated heparin.Initia
ferencshould be followed (Fig. 9; Box G).
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b. Discontinue clopidogrel 5 to 7 d before elective CABG. (Level of
Evidence: B) More urgent surgery, if necessary, may be per-
formed by experienced surgeons if the incremental bleeding
risk is considered acceptable. (Level of Evidence: C)
c. Discontinue intravenous GP IIb/IIIa inhibitor (eptifibatide or
tirofiban) 4 h before CABG. (Level of Evidence: B)
d. Anticoagulant therapy should be managed as follows:
1. Continue UFH. (Level of Evidence: B)
2. Discontinue enoxaparin* 12 to 24 h before CABG and dose
with UFH per institutional practice. (Level of Evidence: B)
3. Discontinue fondaparinux 24 h before CABG and dose with
UFH per institutional practice. (Level of Evidence: B)
4. Discontinue bivalirudin 3 h before CABG and dose with UFH
per institutional practice. (Level of Evidence: B)
3. For UA/NSTEMI patients in whom PCI has been selected as a
postangiography management strategy, the instructions noted be-
low should be followed (Fig. 9; Box H):
a. Continue ASA. (Level of Evidence: A)
b. Administer a loading dose of clopidogrel† if not started before
diagnostic angiography. (Level of Evidence: A)
Limited data are available for the use of other LMWHs (e.g., dalteparin; see Tables
3 and 17) in UA/NSTEMI.
Some uncertainty exists about optimum dosing of clopidogrel. Randomized trials
stablishing its efficacy and providing data on bleeding risks used a loading dose of 300 mg
rally followed by a daily oral maintenance dose of 75 mg. Higher oral loading doses such
s 600 or 900 mg of clopidogrel more rapidly inhibit platelet aggregation and achieve a
igure 9. Management After Diagnostic Angiography in Patients W
See dosing Table 13. †Evidence exists that GP IIb/IIIa inhibitors may not be neces
h earlier (Class I, Level of Evidence B for clopidogrel administration) and bivalirudi
FH is recommended if fondaparinux is selected as the anticoagulant (see dosing T
resent, albeit without any significant, flow-limiting stenoses, long-term treatment wi
SA  aspirin; CABG  coronary artery bypass graft; CAD  coronary artery disease
ntervention; pre angio  before angiography; UA/NSTEMI  unstable angina/non–Sigher absolute level of inhibition of platelet aggregation, but the additive clinical efficacy
nd the safety of higher oral loading doses have not been rigorously established.c. Administer an intravenous GP IIb/IIIa inhibitor (abciximab,
eptifibatide, or tirofiban) if not started before diagnostic
angiography for troponin-positive and other high-risk pa-
tients (Level of Evidence: A). See Class IIa recommendation
below if bivalirudin was selected as the anticoagulant.
d. Discontinue anticoagulant therapy after PCI for uncomplicated
cases. (Level of Evidence: B)
4. For UA/NSTEMI patients in whom medical therapy is selected as a
postangiography management strategy and in whom no significant
obstructive CAD on angiography was found, antiplatelet and anticoag-
ulant therapy should be administered at the discretion of the clinician.
(Level of Evidence: C) For patients in whom evidence of coronary
atherosclerosis is present (e.g., luminal irregularities or intravascular
ultrasound-demonstrated lesions), albeit without flow-limiting steno-
ses, long-term treatment with ASA and other secondary prevention
measures should be prescribed. (Fig. 9; Box I) (Level of Evidence: C)
5. For UA/NSTEMI patients in whom medical therapy is selected as a
postangiography management strategy and in whom CAD was found
on angiography, the following approach is recommended (Fig. 9; Box J):
a. Continue ASA. (Level of Evidence: A)
b. Administer a loading dose of clopidogrel† if not given before
diagnostic angiography. (Level of Evidence: A)
c. Discontinue intravenous GP IIb/IIIa inhibitor if started previ-
ously. (Level of Evidence: B)
d. Anticoagulant therapy should be managed as follows:
1. Continue intravenous UFH for at least 48 h or until discharge if
A/NSTEMI
the patient received a preloading dose of at least 300 mg of clopidogrel at least
lected as the anticoagulant (Class IIa, Level of Evidence B). ‡Additional bolus of
3). §For patients in whom the clinician believes coronary atherosclerosis is
platelet agents and other secondary prevention measures should be considered.
glycoprotein; IV  intravenous; LD  loading dose; PCI  percutaneous coronary
tion myocardial infarction; UFH  unfractionated heparin.ith U
sary if
n is se
able 1
th anti
; GP given before diagnostic angiography. (Level of Evidence: A)
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August 14, 2007:e1–157 ACC/AHA UA/NSTEMI Guideline Revision2. Continue enoxaparin for duration of hospitalization, up to 8 d,
if given before diagnostic angiography. (Level of Evidence: A)
3. Continue fondaparinux for duration of hospitalization, up to 8
d, if given before diagnostic angiography. (Level of Evidence: B)
4. Either discontinue bivalirudin or continue at a dose of 0.25mg
per kg per h for up to 72 h at the physician’s discretion, if given
before diagnostic angiography. (Level of Evidence: B)
6. For UA/NSTEMI patients in whom a conservative strategy is se-
lected and who do not undergo angiography or stress testing, the
instructions noted below should be followed (Fig. 8; Box K):
a. Continue ASA indefinitely. (Level of Evidence: A)
b. Continue clopidogrel for at least 1 month (Level of Evidence: A)
and ideally up to 1 year. (Level of Evidence: B)
c. Discontinue IV GP IIb/IIIa inhibitor if started previously. (Level of
Evidence: A)
d. Continue UFH for 48 h or administer enoxaparin or fondapa-
rinux for the duration of hospitalization, up to 8 d, and then
discontinue anticoagulant therapy. (Level of Evidence: A)
7. For UA/NSTEMI patients in whom an initial conservative strategy is
selected and in whom no subsequent features appear that would
necessitate diagnostic angiography (recurrent symptoms/isch-
emia, HF, or serious arrhythmias), LVEF should be measured. (Level
of Evidence: B) (Fig. 8; Box L)
LASS IIa
1. For UA/NSTEMI patients in whom PCI is selected as a postangiog-
raphy management strategy, it is reasonable to omit administra-
tion of an intravenous GP IIb/IIIa antagonist if bivalirudin was
selected as the anticoagulant and at least 300 mg of clopidogrel
was administered at least 6 h earlier. (Level of Evidence: B) (Fig. 9)
2. If LVEF is less than or equal to 0.40, it is reasonable to perform
diagnostic angiography. (Level of Evidence: B) (Fig. 8; Box M)
3. If LVEF is greater than 0.40, it is reasonable to perform a stress test.
(Level of Evidence: B) (Fig. 8; Box N)
LASS IIb
or UA/NSTEMI patients in whom PCI is selected as a postangiography
anagement strategy, it may be reasonable to omit an intravenous GP
Ib/IIIa inhibitor if not started before diagnostic angiography for
roponin-negative patients without other clinical or angiographic high-
isk features. (Level of Evidence: C)
LASS III
ntravenous fibrinolytic therapy is not indicated in patients without
cute ST-segment elevation, a true posterior MI, or a presumed new left
undle-branch block. (Level of Evidence: A)
Antithrombotic therapy is essential to modify the disease
rocess and its progression to death, MI, or recurrent MI in
he majority of patients who have ACS due to thrombosis on
plaque. A combination of ASA, an anticoagulant, and
dditional antiplatelet therapy represents the most effective
herapy. The intensity of treatment is tailored to individual
isk, and triple-antithrombotic treatment is used in patients
ith continuing ischemia or with other high-risk features and
n patients oriented to an early invasive strategy (Table 11;
igs. 7, 8, and 9). Table 13 shows the recommended doses of
he various agents. A problematic group of patients are those
ho present with UA/NSTEMI but who are therapeuticallynticoagulated with warfarin. In such patients, clinical judg- dent is needed with respect to initiation of the antiplatelet and
nticoagulant therapy recommended in this section. A general
uide is not to initiate anticoagulant therapy until the interna-
ional normalized ratio (INR) is less than 2.0. However,
ntiplatelet therapy should be initiated even in patients thera-
eutically anticoagulated with warfarin, especially if an invasive
trategy is planned and implantation of a stent is anticipated. In
ituations where the INR is supratherapeutic, the bleeding risk
s unacceptably high, or urgent surgical treatment is necessary,
eversal of the anticoagulant effect of warfarin may be consid-
red with either vitamin K or fresh-frozen plasma as deemed
linically appropriate on the basis of physician judgment.
.2.4. Antiplatelet Agents and Trials (Aspirin,
iclopidine, Clopidogrel)
.2.4.1. ASPIRIN
ome of the strongest evidence available about the long-
erm prognostic effects of therapy in patients with coronary
isease pertains to ASA (363). By irreversibly inhibiting
OX-1 within platelets, ASA prevents the formation of
hromboxane A2, thereby diminishing platelet aggregation
romoted by this pathway but not by others. This platelet
nhibition is the plausible mechanism for the clinical benefit
f ASA, both because it is fully present with low doses of
SA and because platelets represent one of the principal
articipants in thrombus formation after plaque disruption.
lternative or additional mechanisms of action for ASA are
ossible, such as an anti-inflammatory effect (364), but they
re unlikely to be important at the low doses of ASA that
re effective in UA/NSTEMI. Among all clinical investi-
ations with ASA, trials in UA/NSTEMI have consistently
ocumented a striking benefit of ASA compared with
lacebo independent of the differences in study design, such
s time of entry after the acute phase, duration of follow-up,
nd dose used (365–368) (Fig. 10).
No trial has directly compared the efficacy of different
oses of ASA in patients who present with UA/NSTEMI;
owever, information can be gleaned from a collaborative
eta-analysis of randomized trials of antiplatelet therapy for
revention of death, MI, and stroke in high-risk patients
i.e., acute or previous vascular disease or other predisposing
onditions) (375). This collaborative meta-analysis pooled
ata from 195 trials involving more than 143,000 patients
nd demonstrated a 22% reduction in the odds of vascular
eath, MI, or stroke with antiplatelet therapy across a broad
pectrum of clinical presentations that included patients
resenting with UA/NSTEMI. Indirect comparisons of the
roportional effects of different doses of ASA ranging from
ess than 75 mg to up to 1500 mg daily showed similar
eductions in the odds of vascular events with doses between
5 and 1500 mg daily; when less than 75 mg was admin-
stered daily, the proportional benefit of ASA was reduced
y at least one half compared with the higher doses. An
nalysis from the CURE trial suggested that there was no
ifference in the rate of thrombotic events according to ASA
ose, but there was a dose-dependent increase in bleeding in
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ate was 2.0% in patients taking less than 100 mg of ASA,
.3% with 100 to 200 mg, and 4.0% with greater than 200
g per d (243,376). Therefore, maintenance doses of 75 to
62 mg of ASA are preferred.
The prompt action of ASA and its ability to reduce
ortality rates in patients with suspected MI enrolled in the
econd International Study of Infarct Survival (ISIS-2) trial
ed to the recommendation that ASA be initiated immediately
n the ED once the diagnosis of ACS is made or suspected.
spirin therapy also can be started in the prehospital setting
hen ACS is suspected. On the basis of prior randomized trial
rotocols and clinical experience, the initial dose of ASA
hould be between 162 and 325 mg. Although some trials have
sed enteric-coated ASA for initial dosing, more rapid buccal
bsorption occurs with non–enteric-coated formulations (377).
fter stenting, a higher initial maintenance dose of ASA of
25 mg per d has been recommended for 1 month after
are-metal stent implantation and 3 to 6 months after drug-
igure 10. Older Trials of Antiplatelet and Anticoagulant Therapy i
Best results group. †GPIIb/IIIa with no heparin. ‡All trials except PRISM compared
ave compared ASA with placebo, the combination of UFH and ASA with ASA alone,
P IIb/IIIa antagonist, UFH, and ASA with UFH plus ASA. The risk ratio values, 95%
I) varied. Results with the platelet GP IIb/IIIa antagonists are reported at the 30-d
ith ASA and UFH and to triple antithrombotic therapy with ASA, UFH, and a platelet
4 h per study design. Data are taken from PURSUIT (128), PRISM-PLUS (130), Lew
369), Gurfinkel et al. (370), FRISC group (371), CAPTURE (372), PARAGON (373), a
cute Coronary Syndromes; CAPTURE  c7E3 Fab AntiPlatelet Therapy in Unstable R
ary artery disease; GP  glycoprotein; hep.  heparin; LMWH  low-molecular-weig
ntagonism for the Reduction of Acute coronary syndrome events in a Global Organi
nhibition in ischemic Syndrome Management; PRISM-PLUS  Platelet Receptor Inhi
ymptoms; PURSUIT  Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Su
ase; UA/NSTEMI  unstable angina/non--ST-elevation myocardial infarction; UFH luting stent (DES) implantation (2). This was based Trimarily on clinical trials that led to approval of these
tents, which used the higher doses initially. However, a
osage change to a range of 162 to 325 mg per d initially has
een subsequently recommended, based on risk of excess
leeding and an update of current evidence for ASA dosing
Table 13; Fig. 11).
In patients who are already receiving ASA, it should be
ontinued. The protective effect of ASA has been sustained
or at least 1 to 2 years in clinical trials in UA/NSTEMI.
onger term follow-up data in this population are lacking.
ong-term efficacy can be extrapolated from other studies of
SA therapy in CAD. Studies in patients with prior MI,
troke, or transient ischemic attack have shown statistically
ignificant benefit during the first 2 years and some addi-
ional but not statistically significant benefit during the third
ear (363). In the absence of large comparison trials of
ifferent durations of antiplatelet treatment in patients with
VD or in primary prevention, it seems prudent to continue
SA indefinitely unless side effects are present (1,4,365).
/NSTEMI
-IIIa with UFH versus UFH. Meta-analysis of randomized trials in UA/NSTEMI that
mbination of an LMWH and ASA with ASA alone, and the combination of a platelet
d probability value for each trial are shown. The timing of the end point (death or
oint. Incremental gain is observed from single therapy with ASA to double therapy
/IIIa antagonist. In the CAPTURE trial, nearly all patients underwent PCI after 20 to
l. (365), Cairns et al. (366), Théroux et al. (367), RISC group (368), ATACS group
ISM (374). anta.  antagonist; ASA  aspirin; ATACS  Antithrombotic Therapy in
ory angina; CI  confidence interval; FRISC  FRagmin during InStability in Coro-
arin; MI  myocardial infarction; NA  not applicable; PARAGON  Platelet IIb/IIIa
Network; PCI  percutaneous coronary intervention; PRISM  Platelet Receptor
in ischemic Syndrome Management in Patients Limited by Unstable Signs and
ion Using Integrilin Therapy; RISC  Research on InStability in Coronary artery dis-
ctionated heparin; VA  Veterans Affairs.n UA
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eneral and instructed to continue the drug indefinitely,
nless a contraindication develops. It is important to em-
hasize to patients that there is a sound rationale for
oncomitant use of ASA even if other antithrombotic drugs,
uch as clopidogrel or warfarin, are administered concur-
ently (Fig. 11) and that withdrawal or discontinuation of
SA or clopidogrel has been associated with recurrent
pisodes of ACS, including stent thrombosis (378–380).
inally, because of a drug interaction between ibuprofen and
SA, patients should be advised to use an alternative
SAID or to take their ibuprofen dose at least 30 min after
ngestion of immediate-release ASA or at least 8 h before
SA ingestion to avoid any potential diminution of the
rotective effects of ASA. No recommendations about the
oncomitant use of ibuprofen and enteric-coated low-dose
SA can be made on the basis of available data (381).
Contraindications to ASA include intolerance and allergy
primarily manifested as asthma with nasal polyps), active
leeding, hemophilia, active retinal bleeding, severe un-
igure 11. Long-Term Anticoagulant Therapy at Hospital Discharge
For aspirin (ASA) allergic patients, use clopidogrel alone (indefinitely), or try aspirin
wice daily. ‡Continue ASA indefinitely and warfarin longer term as indicated for spec
mboli. §When warfarin is added to aspirin plus clopidogrel, an INR of 2.0 to 2.5 is
entricular; UA/NSTEMI  unstable angina/non–ST-elevated myocardial infarction.reated hypertension, an active peptic ulcer, or another cerious source of gastrointestinal or genitourinary bleeding.
astrointestinal side effects such as dyspepsia and nausea
re infrequent with the low doses. Primary prevention trials
ave reported a small excess in intracranial bleeding, which
s offset in secondary prevention trials by the prevention of
schemic stroke. It has been proposed that there is a negative
nteraction between ACE inhibitors and ASA, with a
eduction in the vasodilatory effects of ACE inhibitors,
resumably because ASA inhibits ACE inhibitor–induced
rostaglandin synthesis. This interaction does not appear to
nterfere importantly with the clinical benefits of therapy
ith either agent (382). Therefore, unless there are specific
ontraindications, ASA should be administered to all pa-
ients with UA/NSTEMI.
.2.4.2. ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS AND OTHER
NTIPLATELET AGENTS
wo thienopyridines—ticlopidine and clopidogrel—are ADP
eceptor (P2Y12) antagonists that are approved for anti-
latelet therapy (383). The platelet effects of ticlopidine and
r UA/NSTEMI
sitization. †For clopidogrel allergic patients, use ticlopidine, 250 mg by mouth
nditions such as atrial fibrillation; LV thrombus; cerebral, venous, or pulmonary
mended. INR  international normalized ratio; LOE  level of evidence; LV  leftAfte
desen
ific co
recomlopidogrel are irreversible but take several days to achieve
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dministration of a loading dose can shorten the time to
chievement of effective levels of antiplatelet therapy. Be-
ause the mechanisms of the antiplatelet effects of ASA and
DP antagonists differ, a potential exists for additive
enefit with the combination. In patients with a history of
astrointestinal bleeding, when ASA or a thienopyridine is
dministered alone or in combination, drugs to minimize the
isk of recurrent gastrointestinal bleeding (e.g., proton-pump
nhibitors) should be prescribed concomitantly (384–386).
Ticlopidine has been used successfully for the secondary
revention of stroke and MI and for the prevention of stent
losure and graft occlusion (387). The adverse effects of
iclopidine limit its usefulness: gastrointestinal problems
diarrhea, abdominal pain, nausea, and vomiting), neutro-
enia in approximately 2.4% of patients, severe neutropenia
n 0.8% of patients, and, rarely, thrombotic thrombocytopenia
urpura (388). Neutropenia usually resolves within 1 to 3
eeks of discontinuation of therapy but very rarely may be
atal. Thrombotic thrombocytopenia purpura, which is a very
ncommon, life-threatening complication, requires immediate
lasma exchange. Monitoring of ticlopidine therapy requires a
omplete blood count that includes a differential count every 2
eeks for the first 3 months of therapy.
Extensive clinical experience with clopidogrel is derived
n part from the Clopidogrel versus Aspirin in Patients at
isk of Ischaemic Events (CAPRIE) trial (389). A total of
9,185 patients were randomized to receive ASA 325 mg
er d or clopidogrel 75 mg per d. Entry criteria consisted of
therosclerotic vascular disease manifested as recent isch-
mic stroke, recent MI, or symptomatic peripheral arterial
isease. Follow-up extended for 1 to 3 years. The RR of
schemic stroke, MI, or vascular death was reduced by 8.7%
n favor of clopidogrel from 5.8% to 5.3% (p  0.04). The
enefit was greatest for patients with peripheral arterial
isease. This group had a 24% relative risk reduction (p 
.03). There was a slightly increased, but minimal, inci-
ence of rash and diarrhea with clopidogrel treatment and
lightly more bleeding with ASA. There was no excess
eutropenia with clopidogrel, which contrasts with ticlopi-
ine. The results provide evidence that clopidogrel is at least
s effective as ASA and appears to be modestly more
ffective. In 1 report, 11 severe cases of thrombotic throm-
ocytopenia purpura were described as occurring within 14
after the initiation of clopidogrel; plasma exchange was
equired in 10 of the patients, and 1 patient died (390).
hese cases occurred among more than 3 million patients
reated with clopidogrel.
Clopidogrel is reasonable antiplatelet therapy for second-
ry prevention, with an efficacy at least similar to that of
SA. Clopidogrel is indicated in patients with UA/
STEMI who are unable to tolerate ASA due to either
ypersensitivity or major gastrointestinal contraindications,
rincipally recent significant bleeding from a peptic ulcer or
astritis. In patients with a history of gastrointestinal bleed-
ng while taking ASA, when a thienopyridine is adminis- rered, drugs to minimize the risk of recurrent gastrointesti-
al bleeding (e.g., proton-pump inhibitors) should be
rescribed concomitantly (384–386). When treatment with
hienopyridines is considered during the acute phase, it
hould be recognized that there is a delay before attainment
f the full antiplatelet effect. Clopidogrel is preferred to
iclopidine because it more rapidly inhibits platelets and
ppears to have a more favorable safety profile.
An oral loading dose (300 mg) of clopidogrel is typically
sed to achieve more rapid platelet inhibition. The optimal
oading dose with clopidogrel has not been rigorously
stablished. The greatest amount of general clinical experi-
nce and randomized trial data exist for a clopidogrel
oading dose of 300 mg, which is the approved loading dose.
igher loading doses (600 to 900 mg) have been evaluated
391,392). They appear to be safe and more rapidly acting;
owever, it must be recognized that the database for such
igher loading doses is not sufficiently robust to formulate
efinitive recommendations. Most studies to date with
igher loading doses of clopidogrel have examined surro-
ates for clinical outcomes, such as measurements of 1 or
ore markers of platelet aggregation or function. When
roups of patients are studied, a general dose response is
bserved with increasing magnitude and speed of onset of
nhibition of platelet aggregation in response to agonists
uch as ADP as the loading dose increases. However,
onsiderable interindividual variation in antiplatelet effect
lso is observed with all loading doses of clopidogrel, which
akes it difficult to predict the impact of different loading
oses of clopidogrel in a specific patient. Small to moderate-
ized trials have reported favorable outcomes with a 600-mg
ersus a 300-mg loading dose in patients undergoing PCI
393); however, large-scale randomized trials are still
eeded to definitively compare the efficacy and safety of
ifferent loading regimens of clopidogrel. This is of partic-
lar importance because it is known that patients undergo-
ng CABG surgery shortly after receiving 300 mg of
lopidogrel have an increased risk of bleeding (394); the
elative risk of bleeding associated with higher loading doses
f clopidogrel remains to be established. The Writing
ommittee endorses the performance of appropriately de-
igned clinical trials to identify the optimal loading dose of
lopidogrel.
Two randomized trials compared clopidogrel with ticlo-
idine. In 1 study, 700 patients who successfully received a
tent were randomized to receive 500 mg of ticlopidine or
5 mg of clopidogrel, in addition to 100 mg of ASA, for 4
eeks (395). Cardiac death, urgent target-vessel revascular-
zation, angiographically documented thrombotic stent oc-
lusion, or nonfatal MI within 30 d occurred in 3.1% of
atients who received clopidogrel and 1.7% of patients who
eceived ticlopidine (p  0.24), and noncardiac death,
troke, severe peripheral vascular hemorrhagic events, or any
dverse event that resulted in the discontinuation of the
tudy medication occurred in 4.5% and 9.6% of patients,
espectively (p  0.01). The CLopidogrel ASpirin Stent
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onducted in 1,020 patients. A loading dose of 300 mg of
lopidogrel followed by 75 mg per d was compared to a daily
ose of 75 mg without a loading dose and with a loading
ose of 150 mg of ticlopidine followed by 150 mg twice per
ay (patients in each of the 3 arms also received ASA). The
rst dose was administered 1 to 6 h after stent implantation;
he treatment duration was 28 d. The trial showed better
olerance to clopidogrel with or without a loading dose than
o ticlopidine. Stent thrombosis or major complications
ccurred at the same frequency in the 3 groups.
The CURE trial randomized 12,562 patients with UA
nd NSTEMI presenting within 24 h to placebo or clopi-
ogrel (loading dose of 300 mg followed by 75 mg daily)
nd followed them for 3 to 12 months (243). All patients
eceived ASA. Cardiovascular death, MI, or stroke occurred
n 11.5% of patients assigned to placebo and 9.3% assigned
o clopidogrel (RR  0.80, p less than 0.001). In addition,
lopidogrel was associated with significant reductions in the
ate of in-hospital severe ischemia and revascularization, as well
s the need for fibrinolytic therapy or intravenous GP IIb/IIIa
eceptor antagonists. These results were observed across a wide
ariety of subgroups. A reduction in recurrent ischemia was
oted within the first few hours after randomization.
There was an excess of major bleeding (2.7% in the
lacebo group vs. 3.7% in the clopidogrel group, p  0.003)
nd of minor bleeding but not of life-threatening bleeding.
he risk of bleeding was increased in patients undergoing
ABG surgery within the first 5 d of stopping clopidogrel.
he CURE study was conducted at centers in which there
as no routine policy regarding early invasive procedures;
evascularization was performed during the initial admission in
nly 23% of the patients. Although the addition of a platelet
P IIb/IIIa inhibitor in patients receiving ASA, clopidogrel,
nd heparin in CURE was well tolerated, fewer than 10% of
atients received this combination. Therefore, additional in-
ormation on the safety of an anticoagulant and a GP IIb/IIIa
nhibitor in patients already receiving ASA and clopidogrel
hould be obtained. Accurate estimates of the treatment
enefit of clopidogrel in patients who received GP IIb/IIIa
ntagonists remain ill-defined.
The CURE trial also provides strong evidence for the
ddition of clopidogrel to ASA on admission in the man-
gement of patients with UA and NSTEMI in whom a
oninterventional approach is intended, an especially useful
pproach in hospitals that do not have a routine policy about
arly invasive procedures. The event curves for the 2 groups
eparate early. The optimal duration of therapy with clopi-
ogrel in patients who have been managed exclusively
edically has not been determined, but the favorable results
n CURE were observed over a period averaging 9 months
nd for up to 1 year.
The PCI-CURE study was an observational substudy of
he patients undergoing PCI within the larger CURE trial
397). In the PCI-CURE study, 2,658 patients had previ-
usly been randomly assigned to double-blind treatment iith clopidogrel (n  1313) as per the CURE protocol or
lacebo (n  1,345). Patients were pretreated with ASA
nd the study drug for a median of 10 d. After PCI, most
atients received open-label thienopyridine for approxi-
ately 4 weeks, after which the blinded study drug was
estarted for a mean of 8 months. Fifty-nine patients (4.5%)
n the clopidogrel group had the primary end point (a
omposite of cardiovascular death, MI, or urgent target-
essel revascularization) within 30 d of PCI compared with
6 (6.4%) in the placebo group (RR 0.70, 95% CI 0.50 to
.97, p  0.03). Overall, including events before and after
CI, there was a 31% reduction in cardiovascular death or
I (p  0.002). Thus, in patients with UA and NSTEMI
eceiving ASA and undergoing PCI, a strategy of clopi-
ogrel pretreatment followed by up to 1 year of clopidogrel
se (and probably at least 1 year in those with DES; see
elow) is beneficial in reducing major cardiovascular events
ompared with placebo and appears to be cost-effective (the
ncremental cost-effectiveness ratio for clopidogrel plus ASA
ompared with ASA alone was $15,400 per quality-adjusted
ife-year) (398). Therefore, clopidogrel should be used rou-
inely in patients who undergo PCI.
Pathological and clinical evidence particularly highlights
he need for longer-term ADP-receptor blockade in pa-
ients who receive DES (399). DESs consistently have been
hown to reduce stent restenosis. However, this same
ntiproliferative action can delay endothelialization, predis-
osing to stent thrombosis including late (beyond 3–6
onths) or very late (after 1 year) thrombosis after stent
lacement (399,399a,400). These concerns have raised
uestions about the ideal duration of dual antiplatelet
herapy (DAT) and the overall balance of benefit/risk of
ES compared with bare-metal stents (401). A number of
omparisons of outcomes up to 4 years after DES and
are-metal stent implantation, including the initial FDA
pproval trials, have been published (400,402–404,404a–
04f). These confirm a marked reduction in restenosis and
onsequent repeat revascularization procedures with DES
404c). However, although results have varied, they also
uggest a small incremental risk (of about 0.5%) of stent
hrombosis (404a– 404c). Reassuringly, they have not
hown an overall increase in death or MI after DES versus
are-metal stents, suggesting offsetting advantages of im-
roved revascularization versus increased stent thrombosis
isk. These observations also emphasize the need for a
ontinued search for more biocompatible stents that mini-
ize restenosis without increasing the risks of thrombosis.
In the ISAR-REACT-2 trial, patients undergoing PCI
ere assigned to receive either abciximab (bolus of 0.25 mg
er kg of body weight, followed by a 0.125-mg per kg per
in [maximum, 10 mg per min] infusion for 12 h, plus
eparin 70 U per kg of body weight) or placebo (placebo
olus and infusion of 12 h, plus heparin bolus, 140 U per kg)
244). All patients received 600 mg of clopidogrel at least
h before the procedure, as well as 500 mg of oral or
ntravenous ASA. Of 2,022 patients enrolled, 1,012 were
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ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:e1–157ssigned to abciximab and 1,010 to placebo. The primary
nd point was reached in 90 patients (8.9%) assigned to
bciximab versus 120 patients (11.9%) assigned to placebo,
25% reduction in risk with abciximab (RR 0.75, 95% CI
.58 to 0.97, p  0.03) (244). Among patients without an
levated cTn level, there was no difference in the incidence
f primary end-point events between the abciximab group
23 [4.6%] of 499 patients) and the placebo group (22
4.6%] of 474 patients; RR  0.99, 95% CI 0.56 to 1.76, p
0.98), whereas among patients with an elevated cTn level,
he incidence of events was significantly lower in the
bciximab group (67 [13.1%] of 513 patients) than in the
lacebo group (98 [18.3%] of 536 patients), which corre-
ponds to an RR of 0.71 (95% CI 0.54 to 0.95, p  0.02; p
0.07 for interaction). There were no significant differ-
nces between the 2 groups with regard to the risk of major
r minor bleeding or the need for transfusion. Thus, it
ppears beneficial to add an intravenous GP IIb/IIIa inhib-
tor to thienopyridine treatment if an invasive strategy is
lanned in patients with high-risk features (e.g., elevated
Tn level; Figs. 7, 8, and 9).
The optimal timing of administration of the loading dose
f clopidogrel for those who are managed with an early
nvasive strategy cannot be determined with certainty from
CI-CURE because there was no comparison of adminis-
ration of the loading dose before diagnostic angiography
“upstream treatment”) versus at the time of PCI (“in-lab
reatment”). However, based on the early separation of the
urves, when there is delay to coronary angiography, pa-
ients should receive clopidogrel as initial therapy (Figs. 7, 8,
nd 9). The Clopidogrel for the Reduction of Events
uring Observation (CREDO) trial (405), albeit not de-
igned specifically to study UA/NSTEMI patients, provides
artially relevant information on the question of timing of
he loading dose. Patients with symptomatic CAD and
vidence of ischemia who were referred for PCI and those
ho were thought to be highly likely to require PCI were
andomized to receive clopidogrel (300 mg) or matching
lacebo 3 to 24 h before PCI. All subjects received a
aintenance dose of clopidogrel (75 mg daily) for 28 d.
hus, CREDO is really a comparison of the administration
f a loading dose before PCI versus not administering a
oading dose at all. There is no explicit comparison within
REDO of a pre-PCI loading dose versus a loading dose in
he catheterization laboratory. In CREDO, the relative risk
or the composite end point of death/MI/urgent target-
essel revascularization was 0.82, in favor of the group who
eceived a loading dose before PCI compared with the
pposite arm that did not receive a loading dose, but this did
ot reach statistical significance (p  0.23). Subgroup
nalyses within CREDO suggest that if the loading dose is
iven at least 6 or preferably 15 h before PCI, fewer events
ccur compared with no loading dose being administered
406). One study from the Netherlands that compared
retreatment with clopidogrel before PCI versus adminis-
ration of a loading dose at the time of PCI in patients fndergoing elective PCI showed no difference in biomarker
elease or clinical end points (407).
Thus, there now appears to be an important role for
lopidogrel in patients with UA/NSTEMI, both in those
ho are managed conservatively and in those who undergo
CI, especially stenting, or who ultimately undergo CABG
urgery (408). However, it is not entirely clear how long
herapy should be maintained (409,410). Whereas increased
azard is clearly associated with premature discontinuation
f dual antiplatelet therapy after DES (405,411,412), the
enefit of extended therapy beyond 1 year is uncertain
401,403d,403e). Hence, the minimum requirements for
AT duration should be vigorously applied for each DES
ype. However, 1 year of DAT may be ideal for all
A/NSTEMI patients who are not at high risk of bleeding
iven the secondary preventive effects of DAT, perhaps
specially after DES. On the other hand, the limited
atabase at this point in time does not support a recom-
endation for DAT beyond 1 year for all DES-treated
atients (401,403d,403e). For patients with clinical features
ssociated with an increased risk of stent thrombosis, such
s diabetes or renal insufficiency or procedural characteristics
uch as multiple stents or a treated bifurcation lesion,
xtended DAT may be reasonable. Data on the relative
erits of DES versus bare-metal stents in “off-label” patients
such as multivessel disease or MI), who are at higher risk and
xperience higher event rates, and of the ideal duration of
AT in these patients, are limited and are currently insuffi-
ient to draw separate conclusions (401,403d,403e).
Because of the importance of dual-antiplatelet therapy
ith ASA and a thienopyridine after implantation of a
tent, especially if a DES is being considered, clinicians
hould ascertain whether the patient can comply with 1 year
f dual-antiplatelet therapy. Patients should also be in-
tructed to contact their treating cardiologist before stop-
ing any antiplatelet therapy, because abrupt discontinua-
ion of antiplatelet therapy can put the patient at risk of
tent thrombosis, an event that may result in MI or even
eath (411). Health care providers should postpone elective
urgical procedures until beyond 12 months after DES
mplantation (411). If a surgical procedure must be per-
ormed sooner than 12 months, an effort should be made to
aintain the patient on ASA and minimize the period of
ime of discontinuation of a thienopyridine (411).
In the CURE study, which predominantly involved
edical management of patients with UA/NSTEMI, the
elative risk reduction in events was of a similar magnitude
approximately 20%) during the first 30 d after randomiza-
ion as during the ensuing cumulative 8 months (413). In
ontrast, clopidogrel was not beneficial in a large trial of
igh-risk primary prevention patients (414).
Because clopidogrel, when added to ASA, increases the
isk of bleeding during major surgery, it has been recom-
ended that clopidogrel be withheld for at least 5 d (243)
nd up to 7 d before surgery in patients who are scheduled
or elective CABG (376,415). In many hospitals in which
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August 14, 2007:e1–157 ACC/AHA UA/NSTEMI Guideline Revisionatients with UA/NSTEMI undergo rapid diagnostic cath-
terization within 24 h of admission, clopidogrel is not
tarted until it is clear that CABG will not be scheduled
ithin the next several days. However, unstable patients
hould receive clopidogrel or be taken for immediate an-
iography (Figs. 7, 8, and 9). A loading dose of clopidogrel
an be given to a patient on the catheterization table if a
CI is to be performed immediately. If PCI is not per-
ormed, clopidogrel can be given after the catheterization.
owever, when clopidogrel is given before catheterization
nd urgent surgical intervention is indicated, some experi-
nce suggests that “early” bypass surgery may be undertaken
y experienced surgeons at acceptable incremental bleeding
isk. Among 2,858 UA/NSTEMI patients in the CRU-
ADE (Can Rapid Risk Stratification of Unstable Angina
atients Suppress Adverse Outcomes With Early Imple-
entation of the American College of Cardiology/
merican Heart Association Guidelines) Registry undergo-
ng CABG, 30% received acute clopidogrel therapy, the
ajority of these (87%) within 5 d of surgery. “Early”
ABG after clopidogrel was associated with a significant
ncrease in any blood transfusion (OR 1.36, 95% CI 1.10 to
.68) and the need for 4 or more units of blood (OR 1.70,
5% CI 1.32 to 2.1). In-hospital rates of death were low (3%
o 4%), and no difference was noted in rates of death,
einfarction, or stroke with “early” CABG in patients treated
ith versus without acute clopidogrel (394). The Writing
ommittee believes that more data on the overall relative
enefits versus risks of proceeding with early bypass surgery in
he presence of clopidogrel therapy are desirable and necessary
n order to formulate better-informed recommendations for
he timing of surgery in the UA/NSTEMI patient.
Sulfinpyrazone, dipyridamole, prostacyclin, and prostacy-
lin analogs have not been demonstrated to be of benefit in
A or NSTEMI and are not recommended. The throm-
oxane synthase blockers and thromboxane A2 receptor
ntagonists have been evaluated in ACS and have not
hown any advantage over ASA. A number of other
ntiplatelet drugs are currently available, and still others are
nder active investigation. Clopidogrel is currently the
referred thienopyridine because of its extensive evidence
ase, its more rapid onset of action, especially after a loading
ose (417,418), and its better safety profile than ticlopidine
396).
Evidence has emerged that there is considerable interpa-
ient variability in the response to clopidogrel, with a wide
ange of inhibition of platelet aggregation after a given dose
419). Patients with diminished responsiveness to clopi-
ogrel appear to be at increased risk of ischemic events
420,421). The reasons for the large interpatient variability
n responsiveness to clopidogrel are under investigation, but
ariation in absorption, generation of the active metabolite,
nd drug interactions are leading possibilities. Maneuvers to
vercome poor responsiveness to clopidogrel may involve an
ncrease in the dose (422). However, techniques for moni-
oring for poor response to clopidogrel and the appropriate posing strategy when it is uncovered remain to be
stablished.
.2.5. Anticoagulant Agents and Trials
number of drugs are available to clinicians for manage-
ent of patients with UA/NSTEMI. Although the medical
iterature sometimes refers to such drugs as “antithrombins,”
he Writing Committee has chosen to refer to them as
nticoagulants because they often inhibit 1 or more proteins
n the coagulation cascade before thrombin. Evaluation of
nticoagulant strategies is an active area of investigation. It
s difficult to draw conclusions that 1 anticoagulant strategy
s to be preferred over another given the uncertainty of
hether equipotent doses were administered, the different
urations of treatment studied across the trials, and the fact
hat many patients were already receiving 1 open-label
nticoagulant before they were randomized in a trial to
nother anticoagulant (which makes it uncertain what
esidual effect the open-label anticoagulant had in the trial).
ther aspects of the data set that confound interpretation of
he impact of specific anticoagulant strategies include a
ange of antiplatelet strategies administered concomitantly
ith the anticoagulant and the addition of a second anti-
oagulant, either because of clinician preference or as part of
rotocol design (423–425) as patients moved from the
edical management phase to the interventional manage-
ent phase of treatment for UA/NSTEMI.
The Writing Committee also wishes to draw attention to
he fact that active-control noninferiority trials are being
erformed with increasing frequency as it becomes ethically
ncreasingly difficult to perform placebo-controlled trials. In
his update, for example, noninferiority (“equivalence”)
omparisons on primary or major secondary end points were
mportant in the Acute Catheterization and Urgent Inter-
ention Triage strategy (ACUITY) (425), Organization to
ssess Strategies for Ischaemic Syndromes (OASIS-5)
424), and Randomized Evaluation of PCI Linking Angio-
ax to reduced Clinical Events (REPLACE-2) (426)
tudies. Although practically useful, noninferiority analyses
epend on assumptions not inherent in classic superiority
nalytical designs and thus present additional limitations
nd interpretative challenges (427–429). Noninferiority tri-
ls require an a priori choice of a “noninferiority margin,”
ypically defined in terms of a fraction of standard treatment
ffect to be preserved compared with a putative placebo
e.g., 0.5) and which rests on clinical judgment and statis-
ical issues (428). Because noninferiority trials do not have a
lacebo control, these assumptions cannot be easily verified.
hus, whether the new therapy indeed is therapeutically
equivalent” is less certain than in a superiority trial. Hence,
dditional caution in weighing and applying the results of
oninferiority trials is appropriate.
The Writing Committee believes that a number of
cceptable anticoagulant strategies can be recommended
ith a Class I status but emphasizes the fact that a
reference for a particular strategy is far from clear (Figs. 7,
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ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:e1–157, and 9). It is suggested that each institution agree on a
onsistent approach to minimize the chance of medication
rrors and double anticoagulation when personal prefer-
nces are superimposed on an already-initiated treatment
lan. Factors that should be weighed when one considers an
nticoagulant strategy (or set of strategies to cover the range
f patient scenarios) include established efficacy, risk of
leeding in a given patient, cost, local familiarity with
osing regimens (particularly if PCI is planned), anticipated
eed for surgery, and the desire to promptly reverse the
nticoagulant effect if bleeding occurs.
Unfractionated heparin exerts its anticoagulant effect by
ccelerating the action of circulating antithrombin, a pro-
eolytic enzyme that inactivates factor IIa (thrombin), factor
Xa, and factor Xa. It prevents thrombus propagation but
oes not lyse existing thrombi (430). Unfractionated hepa-
in is a heterogeneous mixture of polysaccharide chains of
olecular weights that range from 5,000 to 30,000 Daltons
nd have varying effects on anticoagulant activity. Unfrac-
ionated heparin binds to a number of plasma proteins,
lood cells, and endothelial cells. The LMWHs are ob-
ained through chemical or enzymatic depolymerization of
he polysaccharide chains of heparin to provide chains with
ifferent molecular weight distributions. Approximately
5% to 50% of the pentasaccharide-containing chains of
MWH preparations contain more than 18 saccharide
nits, and these are able to inactivate both thrombin and
actor Xa. Low-molecular-weight heparin chains that are
ewer than 18 saccharide units retain their ability to inacti-
ate factor Xa but not thrombin. Therefore, LMWHs are
elatively more potent in facilitating inhibition of factor Xa
han in the inactivation of thrombin. Distinct advantages of
MWH over UFH include decreased binding to plasma
roteins and endothelial cells and dose-independent clear-
nce, with a longer half-life that results in more predictable
nd sustained anticoagulation with once- or twice-a-day
ubcutaneous administration. An advantage of LMWHs is
hat they do not usually require laboratory monitoring of
ctivity. The pharmacodynamic and pharmacokinetic pro-
les of the different commercial preparations of LMWHs
ary, with their mean molecular weights ranging from 4,200
o 6,000 Daltons. Accordingly, their ratios of anti–factor Xa
o anti–factor IIa vary, ranging from 1.9 to 3.8 (431). By
ontrast, the direct thrombin inhibitors specifically block
hrombin without the need for a cofactor. Hirudin binds
irectly to the anion binding site and the catalytic sites of
hrombin to produce potent and predictable anticoagulation
432).
Bivalirudin is a synthetic analog of hirudin that binds
eversibly to thrombin and inhibits clot-bound thrombin.
ore upstream in the coagulation cascade are factor Xa
nhibitors, such as the synthetic pentasaccharide fondapa-
inux, that act proximally to inhibit the multiplier effects of
he downstream coagulation reactions and thereby reduce
he amount of thrombin that is generated. Advantages of
ondaparinux compared with UFH include decreased bind- sng to plasma proteins and endothelial cells and dose-
ndependent clearance, with a longer half-life that results in
ore predictable and sustained anticoagulation with fixed-
ose, once-a-day subcutaneous administration. An advan-
age of these agents over UFH is that like the LMWHs,
ondaparinux does not require laboratory monitoring of
ctivity. Fondaparinux is cleared renally, as is the anti–Xa
ctivity of enoxaparin. The factor Xa inhibitors do not have
ny action against thrombin that is already formed or that is
enerated despite their administration, which possibly con-
ributes to the observation of an increased rate of catheter
hrombosis when factor Xa inhibitors such as fondaparinux
re used alone to support PCI procedures. In the case of
oth the direct thrombin inhibitors and fondaparinux, it is
ot possible to reverse the effect with protamine because
hey lack a protamine-binding domain; reversal of their
ction in the event of bleeding requires discontinuation of
heir administration and, if needed, transfusion of coagula-
ion factors (e.g., fresh-frozen plasma).
In summary, whereas anticoagulant therapy forms a basic
lement of UA/NSTEMI therapy, recommendation of an
nticoagulant regimen has become more complicated by a
umber of new choices suggested by contemporary trials,
ome of which do not provide adequate comparative infor-
ation for common practice settings. The Writing Com-
ittee believes that inadequate unconfounded comparative
nformation is available to recommend a preferred regimen
hen an early, invasive strategy is used for UA/NSTEMI,
nd physician and health care system preference, together
ith individualized patient application, is advised. Addi-
ional experience may change this viewpoint in the future.
n the other hand, these available trials are less confounded
or the large number of patients treated with an initial
oninvasive or delayed invasive strategy: they suggest an
nticoagulant preference for these patients treated with a
oninvasive strategy in the order of fondaparinux, enoxapa-
in, and UFH (least preferred), using the specific regimens
ested in these trials. Bivalirudin has not been tested in a
oninvasive strategy and hence cannot be recommended
urrently. Even in this group, the order of preference often
epends on a single, albeit large, trial, so that additional
linical trial information will be welcomed.
The optimal duration of anticoagulation therapy remains
ndefined. Evidence for recurrence of events after cessation
f short-duration intravenous UFH and results of studies in
TEMI patients demonstrating superiority of anticoagulant
gents that are administered for the duration of the hospital
tay suggest that anticoagulation duration of more than 2 d
or those who are managed with a conservative strategy may
e beneficial, but this requires further study (433,434).
.2.5.1. UNFRACTIONATED HEPARIN
ix relatively small randomized, placebo-controlled trials
ith UFH have been reported (435–440). The results oftudies that compared the combination of ASA and heparin
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August 14, 2007:e1–157 ACC/AHA UA/NSTEMI Guideline Revisionith ASA alone are shown in Figure 10. In the trials that
sed UFH, the reduction in the rate of death or MI during
he first week was 54% (p  0.016), and in the trials that
sed either UFH or LMWH, the reduction was 63%. Two
ublished meta-analyses have included different studies. In
meta-analysis, which involved 3 randomized trials and an
arly end point (less than 5 d) (369), the risk of death or MI
ith the combination of ASA and heparin was reduced by
6% (p  0.03). In the second meta-analysis, which
nvolved 6 trials and end points that ranged from 2 to 12
eeks, the RR was reduced by 33% (p  0.06) (441). Most
f the benefits of the various anticoagulants are short term,
owever, and are not maintained on a long-term basis.
eactivation of the disease process after the discontinuation
f anticoagulants may contribute to this loss of early gain
mong medically treated patients that has been described
ith UFH (442), dalteparin (371), and hirudin (443,444).
he combination of UFH and ASA appears to mitigate this
eactivation in part (442,445), although there is hematologic
vidence of increased thrombin activity after the cessation of
ntravenous UFH (“rebound”) even in the presence of ASA
446). Uncontrolled observations suggested a reduction in
he “heparin rebound” by switching from intravenous to
ubcutaneous UFH for several days before the drug is
topped.
Unfractionated heparin has important pharmacokinetic
imitations that are related to its nonspecific binding to
roteins and cells. These pharmacokinetic limitations of
FH translate into poor bioavailability, especially at low
oses, and marked variability in anticoagulant response
mong patients (447). As a consequence of these pharma-
okinetic limitations, the anticoagulant effect of heparin
equires monitoring with the activated partial thromboplas-
in time (aPTT), a test that is sensitive to the inhibitory
ffects of UFH on thrombin (factor IIa), factor Xa, and
actor IXa. Many clinicians have traditionally prescribed a
xed initial dose of UFH (e.g., 5,000 U bolus, 1,000 U per
initial infusion); clinical trials have indicated that a
eight-adjusted dosing regimen can provide more predict-
ble anticoagulation than the fixed-dose regimen (448–
50). The weight-adjusted regimen recommended is an
nitial bolus of 60 U per kg (maximum 4,000 U) and an
nitial infusion of 12 U per kg per h (maximum 1,000 U per
). The therapeutic range of the various nomograms differs
ue to variation in the laboratory methods used to deter-
ine aPTT. The American College of Chest Physicians
onsensus conference (451) has therefore recommended
osage adjustments of the nomograms to correspond to a
herapeutic range equivalent to heparin levels of 0.3 to 0.7 U
er ml by anti–factor Xa determinations, which correlates
ith aPTT values between 60 and 80 s. In addition to body
eight, other clinical factors that affect the response to
FH include age and sex, which are associated with higher
PTT values, and smoking history and diabetes mellitus,
hich are associated with lower aPTT values (447,452). At
igh doses, heparin is cleared renally (451). wEven though weight-based UFH dosing regimens are
sed, the aPTT should be monitored for adjustment of
FH dosing. Because of variation among hospitals in the
ontrol aPTT values, nomograms should be established at
ach institution that are designed to achieve aPTT values in
he target range (e.g., for a control aPTT of 30 s, the target
ange [1.5 to 2.5 times control] would be 45 to 75 s). Delays
n laboratory turnaround time for aPPT results also can be
source of variability in care, resulting in over- or under-
nticoagulation for prolonged time periods, and should be
voided. Measurements should be made 6 h after any dosage
hange and used to adjust UFH infusion until the aPTT
xhibits a therapeutic level. When 2 consecutive aPTT
alues are therapeutic, the measurements may be made every
4 h and, if necessary, dose adjustment performed. In
ddition, a significant change in the patient’s clinical con-
ition (e.g., recurrent ischemia, bleeding, or hypotension)
hould prompt an immediate aPTT determination, fol-
owed by dose adjustment, if necessary.
Serial hemoglobin/hematocrit and platelet measurements
re recommended at least daily during UFH therapy. In
ddition, any clinically significant bleeding, recurrent symp-
oms, or hemodynamic instability should prompt their
mmediate determination. Serial platelet counts are neces-
ary to monitor for heparin-induced thrombocytopenia.
ild thrombocytopenia may occur in 10% to 20% of
atients who are receiving heparin, whereas significant
hrombocytopenia (platelet count less than 100,000) occurs
n 1% to 5% of patients and typically appears after 4 to 14
of therapy (453–457). A rare but dangerous complication
less than 0.2% incidence) is autoimmune UFH-induced
hrombocytopenia with thrombosis, which can occur both
hortly after initiation of UFH or, rarely, in a delayed (i.e.,
fter 5 to 19 d or more), often unrecognized form (458–
60). A high clinical suspicion mandates the immediate
essation of all heparin therapy (including that used to flush
ntravenous lines).
Most of the trials that evaluated the use of UFH in
A/NSTEMI have continued therapy for 2 to 5 d. The
ptimal duration of therapy remains undefined.
.2.5.2. LOW-MOLECULAR-WEIGHT HEPARIN
n a pilot open-label study, 219 patients with UA were
andomized to receive ASA (200 mg per d), ASA plus
FH, or ASA plus nadroparin (an LMWH) (370). The
ombination of ASA and LMWH significantly reduced the
otal ischemic event rate, the rate of recurrent angina, and
he number of patients requiring interventional procedures.
The FRISC study (371) randomized 1,506 patients with
A or non–Q-wave MI to receive subcutaneous adminis-
ration of the LMWH dalteparin (120 IU per kg twice
aily) or placebo for 6 d and then once a day for the next 35
o 45 d. Dalteparin was associated with a 63% risk reduction
n death or MI during the first 6 d (4.8% vs. 1.8%, p 
.001), which matched the favorable experience observed
ith UFH. Although an excess of events was observed after
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ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:e1–157he dose reduction to once daily after 6 d, a significant
ecrease was observed at 40 d with dalteparin in the
omposite outcome of death, MI, or revascularization
23.7% vs. 18.0%, p 0.005), and a trend was noted toward
reduction in rates of death or MI (10.7% vs. 8.0%, p 
.07).
Because the level of anticoagulant activity cannot be easily
easured in patients receiving LMWH (e.g., aPTT or
ctivated clotting time [ACT]), interventional cardiologists
ave expressed concern about the substitution of LMWH
or UFH in patients scheduled for catheterization with
ossible PCI. However, in a study involving 293 patients
ith UA/NSTEMI who received the usual dose of enox-
parin, Collett et al. (461) showed that PCI can be
erformed safely.
An alternative approach is to use LMWH during the
eriod of initial stabilization. The dose can be withheld on
he morning of the procedure, and if an intervention is
equired and more than 8 h has elapsed since the last dose
f LMWH, UFH can be used for PCI according to usual
ractice patterns. Because the anticoagulant effect of UFH
an be more readily reversed than that of LMWH, UFH is
referred in patients likely to undergo CABG within 24 h.
.2.5.3. LMWH VERSUS UFH
ine randomized trials have directly compared LMWH
ith UFH (Table 17). Two trials evaluated dalteparin,
nother evaluated nadroparin, and 6 evaluated enoxaparin.
eterogeneity of trial results has been observed. Trials with
alteparin and nadroparin reported similar rates of death or
onfatal MI compared with UFH, whereas 5 of 6 trials of
noxaparin found point estimates for death or nonfatal MI
hat favored enoxaparin over UFH; the pooled OR was 0.91
95% CI 0.83 to 0.99). The benefit of enoxaparin appeared
o be driven largely by a reduction in nonfatal MI, especially
n the cohort of patients who had not received any open-
abel anticoagulant therapy before randomization.
There are few data to assess whether the heterogeneous
esults are explained by different populations, study designs,
arious heparin dose regimens, properties of the various
MWHs (more specifically, different molecular weights
nd anti–factor Xa/anti–factor IIa ratios), concomitant ther-
pies, or other unrecognized influences. Although it is
empting to compare the relative treatment effects of the
ifferent LMWH compounds, the limitations of such indi-
ect comparisons must be recognized. The only reliable
ethod of comparing 2 treatments is through a direct
omparison in a well-designed clinical trial or series of trials.
he comparison of different therapies (e.g., different LM-
Hs) with a common therapy (e.g., UFH) in different
rials does not allow a conclusion to be made about the
elative effectiveness of the different LMWHs because of
he variability in both control group and experimental group
vent rates due to protocol differences, differences in con-
omitant therapies due to geographic and time variability, end the play of chance. Similar considerations apply to
omparisons among platelet GP IIb/IIIa inhibitors.
In the Enoxaparin Versus Tinzaparin (EVET) trial, 2
MWHs, enoxaparin and tinzaparin, administered for 7 d,
ere compared in 436 patients with UA/NSTEMI. Enox-
parin was associated with a lower rate of death/MI/
ecurrent angina at 7 and 30 d compared with tinzaparin
467,468). Bleeding rates were similar with the 2 LMWHs.
The advantages of LMWH preparations are the ease of
ubcutaneous administration and the absence of a need for
onitoring. Furthermore, the LMWHs stimulate platelets
ess than UFH (469) and are less frequently associated with
eparin-induced thrombocytopenia (456). In the ES-
ENCE trial, minor bleeding occurred in 11.9% of enox-
parin patients and 7.2% of UFH patients (p less than
.001), and major bleeding occurred in 6.5% and 7.0%,
espectively (169). In TIMI 11B, the rates of minor bleed-
ng in hospital were 9.1% and 2.5%, respectively (p less than
.001), and the rates of major bleeding were 1.5% and 1.0%
p  0.14) (180). In the FRISC study, major bleeding
ccurred in 0.8% of patients given dalteparin and in 0.5% of
atients given placebo, and minor bleeding occurred in 61
8.2%) of 746 patients and 2 (0.3%) of 760 patients,
espectively (371).
The anticoagulant effect of LMWH is less effectively
eversed with protamine than that of UFH. In addition,
MWH administered during PCI does not permit moni-
oring of the ACT to titrate the level of anticoagulation. In
he ESSENCE and TIMI 11B trials, special rules were set
o discontinue enoxaparin before PCI and CABG. Because
f limited experience with enoxaparin at the time the
SSENCE and TIMI 11B trials were conducted, UFH was
dministered during PCI to achieve ACT values of greater
han 350 s. In the Superior Yield of the New Strategy of
noxaparin, Revascularization and Glycoprotein IIb/IIIa
nhibitors (SYNERGY) trial, enoxaparin was compared to
FH during PCI in patients with high-risk UA/NSTEMI
423) (Fig. 12). More bleeding was observed with enoxaparin,
ith a statistically significant increase in TIMI-defined major
leeding (9.1% vs. 7.6%, p 0.008) but a nonsignificant excess
n GUSTO-defined severe bleeding (2.7% vs. 2.2%, p 0.08)
nd transfusions (17.0% vs. 16.0%, p  0.16). A post hoc
nalysis from SYNERGY suggested that some of the excess
leeding seen with enoxaparin could be explained by crossover
o UFH at the time of PCI (470). This remains to be validated
rospectively, but at the present time, it appears reasonable
o minimize the risk of excessive anticoagulation during
CI by avoiding crossover of anticoagulants (i.e., maintain
onsistent anticoagulant therapy from the pre-PCI phase
hroughout the procedure itself).
An economic analysis of the ESSENCE trial suggested
ost savings with enoxaparin (471). For patients who are
eceiving subcutaneous LMWH and in whom CABG is
lanned, it is recommended that LMWH be discontinued
nd UFH be used during the operation. Additional experi-
nce with regard to the safety and efficacy of the concom-
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Trial
(Reference) n LMWH/Dose UFH
End Point/
Drug Effect Analysis 95% CI p
Major Bleeding
(p)
RISC (371) 1,506 (a) 6 d*: dalteparin
120 IU per kg†
SC twice daily (max-
imum 10,000 IU)
(b) During first 40 d:
dalteparin 7,500 IU
SC once per day
(a) 6 d: placebo
(b) During first 40
d: placebo
(a) Death or new
MI (6 d):
LMWH 1.8%,
Placebo 4.8%
(b) Death or new
MI (during first
40 d‡): LMWH
8%, placebo
10.7%
(a) RR 0.37
ARR 3%
(b) RR 0.75
ARR 2.7%
(a) 0.20 to
0.68
(b) 0.54 to
1.03
(a) 0.001
(b) 0.07
(a) LMWH 0.8%,
placebo 0.5%;
ARR 0.3%
(p  NR)
(b) During first
40 d:
LMWH 0.3%,
placebo 0.3%;
ARR 0%
(p  NR)
SSENCE
(169)
3,171 Enoxaparin 1 mg per
kg SC twice daily
(minimum 48 h,
maximum 8 d)
UFH IV bolus
(usually 5,000
units) and
continued IV
infusion
(a) Death, MI, or
recurrent
angina at
14 d:
LMWH 16.6%,
UFH 19.8%
(b) Death, MI, or
recurrent
angina at
30 d:
LMWH 19.8%,
UFH 23.3%
(a) OR at 14 d 
0.80
ARR 3.2%
(b) OR at 30 d 
0.81
ARR 3.5%
(a) 0.67 to
0.96
(b) 0.68 to
0.96
(a) 0.019
(b) 0.016
At 30 d:
LMWH 6.5%,
UFH 7%;
ARR 0.5%
(p  0.57)
RIC (462) 1,482 (a) Days 1 to 6:
dalteparin 120 IU
per kg SC twice
daily
(b) Days 6 to 45§:
dalteparin 7,500 IU
SC once per day
(a) Days 1 to 6:
UFH 5,000 units
IV bolus and IV
infusion of
1,000 units per
h for 48 h
(b) Days 6 to 45:
placebo SC once
daily
(a) Death, MI, or
recurrence of
angina (Days
1 to 6):
LMWH 9.3%,
UFH 7.6%
(b) Death, MI, or
recurrence of
angina (Days
6 to 45):
12.3% in both
the LMWH and
UFH groups
(a) Death or MI
(Days 1 to 6):
LMWH 3.9%,
UFH 3.6%
(b) Death or MI
(Days 6 to 45):
LMWH 4.3%,
placebo 4.7%
(a) RR 1.18
ARR 1.7%
(b) RR 1.01
ARR 0%
(a) RR 1.07
ARR 0.3%
(b) RR 0.92
ARR 0.4%
(a) 0.84 to
1.66
(b) 0.74 to
1.38
(a) 0.63 to
1.80
(b) 0.54 to
1.57
(a) 0.33
(b) 0.96
(a) 0.80
(b) 0.76
(a) Days 1 to 6:
LMWH 1.1%,
UFH 1.0%;
ARR 0.1%
(p  NR)
(b) Days 6 to 45:
LMWH 0.5%,
placebo 0.4%;
ARR 0.1%
(p  NR)
RAX.I.S.
(463)
3,468 (a) Nadroparin 6 d:
nadroparin 86 anti-
Xa IU per kg IV
bolus, followed by
nadroparin 86 anti-
Xa IU per kg SC
twice daily for 6 d
(b) Nadroparin 14 d:
nadroparin 86 anti-
Xa IU per kg IV
bolus, followed by
nadroparin 86 anti-
Xa IU per kg SC
twice daily for 14 d
(a)  (b) UFH
5,000 units IV
bolus and UFH
infusion at
1,250 units per
h IV for 6 d (plus
or minus 2 d)
Cardiac death,
MI, refractory
angina,
recurrence of
UA at Day 14:
LMWH 6 d
17.8%,
LMWH 14 d
20.0%,
UFH 18.1%
(a) ARR 0.3%
(b) ARR 1.9%
(a) 2.8
to 3.4
(b) 5.1
to 1.3
(a) 0.85
(b) 0.24
At 6 d:
UFH 1.6%,
LMWH 1.5%,
ARR 0.1%
At 14 d:
UFH 1.6%,
LMWH 3.5%,
ARR 1.9%
(p  0.0035)
Continued on next page
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Trial
(Reference) n LMWH/Dose UFH
End Point/
Drug Effect Analysis 95% CI p
Major Bleeding
(p)
IMI 11B
(180)
3,910 (a) Inpatient:
enoxaparin 30mg IV
bolus immediately
followed by 1mg per
kg SC every 12 h
(b) Outpatient:
enoxaparin 40mg
SC twice per day
(patients weighing
less than 65 kg) or
60mg SC twice per
day (patients
weighing at least 65
kg)
(a) Inpatient: UFH
70 units per kg
bolus and
infusion at 15
units per h
titrated to aPTT
(treatment
maintained for a
minimum of 3
and maximum
of 8 d at
physician’s
discretion)
(b) Outpatient:
placebo SC
twice per day
Death, MI,
urgent
revascularization
(a) At 48 h:
LMWH 5.5%,
UFH 7.3%
(b) 8 d:
LMWH 12.4%,
UFH 14.5%
(c) 14 d:
LMWH 14.2%,
UFH 16.7%
(d) 43 d:
LMWH 17.3%,
UFH 19.7%
(a) OR 0.75
ARR 1.8%
(b) OR 0.83
ARR 2.1%
(c) OR 0.82
ARR 2.5%
(d) OR 0.85
ARR 2.4%
(a) 0.58 to
0.97
(b) 0.69 to
1.00
(c) 0.69 to
0.98
(d) 0.72 to
1.00
(a) 0.026
(b) 0.048
(c) 0.029
(d) 0.048
At 48 h:
LMWH 0.8%,
UFH 0.7%;
ARR 0.1%
(p  0.14)
End of initial
hospitalization
LMWH 1.5%,
UFH 1%;
ARR 0.5%
(p  0.143)
Between Day 8
and Day 43:
LMWH 2.9%,
placebo 2.9%;
ARR 0%
(p  0.021)
CUTE II
(464)
525 Enoxaparin 1 mg per
kg SC every 12 h
UFH 5,000 units IV
bolus and
maintenance
infusion at
1,000 units per
h IV adjusted to
aPTT
(a) Death or (b)
MI at 30 d
(a) LMWH 2.5%,
UFH 1.9%
(b) LMWH 6.7%,
UFH 7.1%
(a) RR 1.3
ARR 0.6%
(b) RR 0.94
ARR 0.4%
(a) 0.06 to
3.93
(b) 0.45 to
2.56
(a) 0.77
(b) 0.86
LMWH 0.3%;
UFH 1%;
ARR 0.7%
(p  0.57)
NTERACT¶
(465)
746 Enoxaparin 1 mg per
kg SC every 12 h
UFH 70 units per
kg IV bolus
followed by
continuous
infusion at 15
units per kg per h
Death or MI at
30 d:
LMWH 5.0%,
UFH 9.0%
RR 0.55
ARR 4%
0.30 to
0.96
0.031 At 96 h:
LMWH 1.8%;
UFH 4.6%;
ARR 2.8%
(p  0.03)
to Z
(466)
3,987 Enoxaparin 1 mg per
kg SC every 12 h
UFH 4,000 units IV
bolus followed
by 900 units per
h IV infusion for
patients
weighing equal
to or greater
than 70 kg
UFH 60 units per
kg (maximum
4,000 units) IV
bolus followed
by 12 units per
kg per h IV
infusion for
patients
weighing less
than 70 kg
All-cause death,
MI, or
refractory
ischemia
within 7 d of
tirofiban
initiation:
LMWH 8.4%,
UFH 9.4%
HR 0.88
ARR 1%
0.71 to
1.08
NR LMWH 0.9%;
UFH 0.4%;
ARR 0.5%
(p  0.05)Continued on next page
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ists and fibrinolytic agents is currently being acquired.
.2.5.3.1. EXTENDED THERAPY WITH LMWHs. The FRISC,
ragmin in unstable coronary artery disease study (FRIC),
IMI 11B, and Fast Revascularization during InStability in
oronary artery disease-II (FRISC-II) trials evaluated the
otential benefit of the prolonged administration of
MWH after hospital discharge (Table 17). In the FRISC
rial, doses of dalteparin were administered between 6 d and
5 to 45 d; in FRIC, patients were rerandomized after the
nitial 6-d treatment period to receive dalteparin for an
dditional 40 d, and the outpatient treatment period lasted
to 6 weeks in TIMI 11B and 1 week in the FRAXiparine
n Ischaemic Syndromes (FRAXIS) trial. The FRISC-II
rial used a different study design. Dalteparin was adminis-
ered to all patients for a minimum of 5 d (472). Patients
ere subsequently randomized to receive placebo or the
ontinued administration of dalteparin twice per day for up
o 90 d. Analysis of the results from the time of random-
zation showed a significant reduction with dalteparin in the
omposite end point of death or MI at 30 d (3.1% vs. 5.9%,
 0.002) but not at 3 months (6.7% vs. 8.0%, p  0.17).
he composite of death, MI, or revascularization during the
otal treatment period was reduced at 3 months (29.1% vs.
3.4%, p  0.031). The benefits of prolonged dalteparin
dministration were limited to patients who were managed
able 17. Continued
Trial
(Reference) n LMWH/Dose UFH
E
D
YNERGY††
(423)
9,978 Enoxaparin 1 mg per
kg SC every 12 h
UFH 60 units per
kg IV bolus
(maximum of
5,000 units) and
followed by IV
infusion of 12
units per kg per
h (maximum of
1,000 units per
h initially
Dea
n
d
d
r
LMW
U
or specific interventions and additional medications during the study, see individual study referen
han 5 mg per dL or intracranial or pericardial bleeding. ESSENCE: Major hemorrhage was defined
r more, or a retroperitoneal, intracranial, or intraocular hemorrhage. TIMI 11B: Overt bleed resultin
han or equal to 3 g per dL; or the requirement of transfusion of at least 2 U of blood. SYNERGY: TIM
ajor bleeding involved a hemoglobin drop greater than 5 g per dL (with or without an identified sit
NTERACT: Major bleeding included bleeding resulting in death, or retroperitoneal hemorrhage, or b
bleeding event was classified as major if it led to a fall in the hemoglobin level of at least 20 g per
tudy end point was first 6 d. †Initial trial dose of 150 IU per kg SC twice daily decreased to 120 IU
nd 9 patients or 14% minor episodes among 63 actively treated patients). ‡Follow-up incomplete
atients in ACUTE II received a tirofiban loading dose of 0.4 mcg per kg per min over 30 min, follow
80 mcg per kg bolus followed by a 2.0 mcg per kg per min infusion for 48 h. All patients enrolle
spirin, clopidogrel; patients eligible for enrollment even if LMWH or UFH given before enrollment
A to Z Aggrastat to Zocor study; ACUTE II Antithrombotic Combination Using Tirofiban and E
nterval; ESSENCE  Efficacy and Safety of Subcutaneous Enoxaparin in Unstable Angina and Non-Q-W
ntegrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment; IU intern
low-molecular-weight heparin; MI  myocardial infarction; NR  not reported; RR  relative risk;
lycoprotein IIb/IIIA Inhibitors; TIMI 11B  Thrombolysis In Myocardial Infarction 11B; U  unit; UA edically and to those with elevated TnT levels at baseline. Glthough these results make a case for the prolonged use of
n LMWH in selected patients who are managed medically
r in whom angiography is delayed, their relevance to
ontemporary practice is less clear now that clopidogrel is
sed more frequently and there is a much greater tendency
o proceed to an early invasive strategy.
.2.5.4. DIRECT THROMBIN INHIBITORS
irudin, the prototype of the direct thrombin inhibitors, has
een extensively studied but with mixed results. The GUSTO-
Ib trial randomly assigned 12,142 patients with suspected MI
o 72 h of therapy with either intravenous hirudin or UFH
473). Patients were stratified according to the presence of
T-segment elevation on the baseline ECG (4,131 patients) or
ts absence (8,011 patients). The primary end point of death,
onfatal MI, or reinfarction at 30 d occurred in 9.8% of the
FH group versus 8.9% of the hirudin group (OR 0.89, p 
.058). For patients without ST-segment elevation, the rates
ere 9.1% and 8.3%, respectively (OR 0.90, p  0.22). At
4 h, the risk of death or MI was significantly lower in the
atients who received hirudin than in those who received UFH
2.1% vs. 1.3%, p  0.001). However, the Thrombolysis and
hrombin Inhibition in Myocardial Infarction (TIMI) 9B trial
f hirudin as adjunctive therapy to thrombolytic therapy in
atients with STEMI showed no benefit of the drug over
FH either during study drug infusion or later (474). The
int/
ffect Analysis 95% CI p
Major Bleeding
(p)
al MI
first 30
ization
.0%,
.5%,
HR 0.96
ARR 0.5%
0.86 to
1.06
0.40 TIMI minor:
LMWH 12.5%,
UFH 12.3%;
ARR 0.2%
(p  0.80)
TIMI major:
LMWH 9.1%,
UFH 7.6%
ARR 1.5%
(p  0.008)
GUSTO severe:
LMWH 2.7%,
UFH 2.2%;
ARR 0.5%
(p  0.08)
jor bleeding was classified as follows in the various trials: A to Z: decrease in hemoglobin of more
eding resulting in death, transfusion of at least 2 U of blood, a fall in hemoglobin of 30 g per liter
ath; a bleed in a retroperitoneal, intracranial, or intraocular location; a hemoglobin drop of greater
USTO criteria. ACUTE II: Severity was recorded on the basis of the TIMI trial bleeding criteria. TIMI
ssociated with coronary artery bypass grafting) or intracranial hemorrhage or cardiac tamponade.
at a specific site accompanied by a drop in hemoglobin greater than or equal to 3 g per dL. FRIC:
quired transfusion, was intracranial, or caused death or cessation of the study treatment. *Primary
C twice daily due to increased bleeding during first 6 d (4 patients or 6% major bleeding episodes
atients (8 dalteparin, 5 placebo) at their request. §Primary study outcome was Days 6 to 45. All
maintenance infusion at 0.1 mcg per kg per min. ¶All patients in INTERACT received eptifibatide
A to Z Trial received aspirin and tirofiban. ††Patients also received glycoprotein IIb/IIIa inhibitors,
ments made to enoxaparin and UFH during percutaneous coronary intervention.
rin; aPTT activated partial thromboplastin time; ARR absolute risk reduction; CI confidence
yocardial Infarction; FRIC  FRagmin In unstable Coronary disease; HR  hazard ratio; INTERACT 
units; IV intravenous; LD loading dose; MDmaintenance dose; N number of patients; LMWH
ubcutaneous; SYNERGY  Superior Yield of the New strategy of Enoxaparin, Revascularization and
le angina; UFH  unfractionated heparin.nd Po
rug E
th or
onfat
uring
after
andom
H 14
FH 14
ces. Ma
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g in de
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ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:e1–157er kg bolus and 0.1 mg per kg per h infusion for 3 to 5 d after
he documentation of excess bleeding with higher doses used in
he GUSTO-IIA and TIMI 9A trials (0.6 mg per kg bolus
nd 0.2 mg per kg per h infusion) (473,475).
The OASIS program evaluated hirudin in patients with
A/NSTEMI. OASIS 1 (476) was a pilot trial of 909
atients that compared the low hirudin dose of 0.1 mg per
g per h infusion and the medium hirudin dose of 0.15 mg
er h infusion with UFH. The latter dose provided the best
esults, with a reduction in the rate of death, MI, or
efractory angina at 7 d (6.5% with UFH vs. 3.3% with
irudin, p  0.047). This medium dose was used in the
arge OASIS 2 (477) trial that consisted of 10,141 patients
ith UA/NSTEMI who were randomized to receive UFH
5,000 IU bolus plus 15 U per kg per h) or recombinant
irudin (0.4 mg per kg bolus and 0.15 mg per kg per h)
nfusion for 72 h. The primary end point of cardiovascular
eath or new MI at 7 d occurred in 4.2% in the UFH group
ersus 3.6% patients in the hirudin group (RR 0.84, p 
.064). A secondary end point of cardiovascular death, new
I, or refractory angina at 7 d was significantly reduced
ith hirudin (6.7% vs. 5.6%, RR 0.83, p  0.011). There
as an excess of major bleeding incidents that required
ransfusion with hirudin (1.2% vs. 0.7% with heparin, p 
.014) but no excess in life-threatening bleeding incidents
r strokes. A meta-analysis of the GUSTO-IIB, TIMI 9B,
ASIS 1, and OASIS 2 trials showed a relative risk of
eath or MI of 0.90 (p  0.015) with hirudin compared
ith UFH at 35 d after randomization; RR values were
imilar for patients receiving thrombolytic agents (0.88) and
igure 12. SYNERGY Primary Outcomes at 30 d
I  confidence interval; MI  myocardial infarction; SYNERGY  Superior Yield of t
423); UFH  unfractionated heparin.ot receiving thrombolytic agents (0.90) (477). hThe relative benefits of hirudin versus UFH in ACS
atients undergoing PCI were evaluated in the 1,410-
atient subset in GUSTO-IIb who underwent PCI during
he initial drug infusion. A reduction in nonfatal MI and the
omposite of death and MI was observed with hirudin that
as associated with a slightly higher bleeding rate (478).
Hirudin (lepirudin) is presently indicated by the US Food
nd Drug Administration only for anticoagulation in pa-
ients with heparin-induced thrombocytopenia (456) and
or the prophylaxis of deep vein thrombosis in patients
ndergoing hip replacement surgery. It should be adminis-
ered as a 0.4 mg per kg IV bolus over 15 to 20 s followed
y a continuous intravenous infusion of 0.15 mg per kg per
, with adjustment of the infusion to a target range of 1.5 to
.5 times the control aPTT values. Argatroban is another
irect thrombin inhibitor that is approved for the manage-
ent of patients with heparin-induced thrombocytopenia
479). However, in ACS, the monovalent direct thrombin
nhibitors (including argatroban) are ineffective antithrom-
otic agents compared with UFH, and thus, argatroban
hould generally not be used in management of ACS (480).
he recommended initial dose of argatroban is an intrave-
ous infusion of 2 mcg per kg per min, with subsequent
djustments to be guided by the aPTT (medical manage-
ent) or ACT (interventional management).
The REPLACE 2 investigators compared bivalirudin
bolus 0.75 mg per kg followed by infusion of 1.75 mg per
g per h with provisional GP IIb/IIIa inhibition) with UFH
5 U per kg bolus with planned GP IIb/IIIa inhibition in
atients undergoing urgent or elective PCI (426). Only 14%
w strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitorshe Nead been treated for UA within 48 h before enrollment.
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ivalirudin, with the benefits of a significantly lower bleed-
ng rate (481). Follow-up through 1 year also suggested
imilar mortality for the 2 approaches (482).
Bivalirudin was investigated further in the ACUITY trial
425) (Figs. 13 and 14). The ACUITY trial used a 2  2
actorial design to compare a heparin (UFH or enoxaparin)
igure 13. ACUITY Clinical Outcomes at 30 d
p for noninferiority. ACUITY  Acute Catheterization and Urgent Intervention Triage
igure 14. ACUITY Composite Ischemia and Bleeding OutcomesCUITY  Acute Catheterization and Urgent Intervention Triage strategY; CI  confidence i
nfractionated heparin.ith or without upstream GP IIb/IIIa inhibition versus
ivalirudin with or without upstream GP IIb/IIIa inhibi-
ion; a third arm tested bivalirudin alone and provisional GP
Ib/IIIa inhibition. The study was randomized but open-
abel (unblinded). The main comparisons in the ACUITY
rial were of heparin with GP IIb/IIIa inhibition versus
ivalirudin with GP IIb/IIIa inhibition versus bivalirudin
Y; CI  confidence interval; GP  glycoprotein; UFH  unfractionated heparin.nterval; GP  glycoprotein; PCI  percutaneous coronary intervention; UFH 
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0-d end points were prespecified: composite ischemia,
ajor bleeding, and net clinical outcomes (composite isch-
mia or major bleeding). Bivalirudin plus GP IIb/IIIa
nhibitors compared with heparin plus GP IIb/IIIa inhibi-
ors resulted in noninferior 30-d rates of composite ischemia
7.7% vs. 7.3%), major bleeding (5.3% vs. 5.7%), and net
linical outcomes (11.8% vs. 11.7%) (Fig. 13). Bivalirudin
lone compared with heparin plus GP IIb/IIIa inhibitors
esulted in noninferior rates of composite ischemia (7.8% vs.
.3%, p 0.32, RR 1.08, 95% CI 0.93 to 1.42), significantly
educed major bleeding (3.0% vs. 5.7%, p less than 0.001,
R 0.53, 95% CI 0.43 to 0.65), and superior 30-d net
linical outcomes (10.1% vs. 11.7% respectively, p  0.015,
R 0.86, 95% CI 0.77 to 0.97). For the subgroup of 5,753
atients who did receive a thienopyridine before angiogra-
hy or PCI, the composite ischemic end point occurred in
.0% in the bivalirudin-alone group versus 7.3% in the
roup that received heparin plus GP IIb/IIIa inhibition (RR
.97, 95% CI 0.80 to 1.17), whereas in the 3,304 patients
ho did not receive a thienopyridine before angiography or
CI, the composite ischemic event rate was 9.1% in the
ivalirudin-alone group versus 7.1% in the heparin plus GP
Ib/IIIa inhibition group (RR 1.29, 95% CI 1.03 to 1.63; p
or interaction 0.054) (Fig. 14) (425). The Writing Com-
ittee believes that this observation introduces a note of
aution about the use of bivalirudin alone, especially when
here is a delay to angiography when high-risk patients who
ay not be represented by the ACUITY trial population are
eing managed, or if early ischemic discomfort occurs after
he initial antithrombotic strategy has been implemented
Figs. 7, 8, and 9). The Writing Committee therefore
ecommends that patients meeting these criteria be treated
ith concomitant GP IIb/IIIa inhibitors or a thienopyri-
ine, administered before angiography to optimize out-
omes whether a bivalirudin-based or heparin-based anti-
oagulant strategy is used. This approach is also supported
y the findings of the ACUITY timing study that showed a
rend toward higher rates of ischemic events, which did not
eet inferiority criteria, in the deferred GP IIb/IIIa inhib-
tor group compared with the upstream GP IIb/IIIa inhib-
tor. Death/MI/unplanned revascularization for ischemia
ccurred in 7.1% of routine upstream GP IIb/IIIa inhibitor
roup versus 7.9% of deferred selective inhibitor group; RR
.12 (95% CI 0.97 to 1.29) (482a,482b). Similarly, in the
CUITY PCI substudy (482c,482d), subjects who did not
eceive a thienopyridine pre-PCI had higher rates of the
omposite ischemic end point in the bivalirudin-alone
roup compared with the heparin plus GP IIb/IIIa group.
n both the REPLACE 2 and ACUITY trials, bivalirudin
ith provisional GP IIb/IIIa blockade was associated with a
ower risk of bleeding, whereas this was not the case in
CUITY with the combination of bivalirudin and planned
P IIb/IIIa blockade, suggesting that dosing regimens and
oncomitant GP IIb/IIIa blockade plays an important role
n bleeding risk (483). The impact of switching anticoagu- iants after randomization, which has been associated with
xcess bleeding (423,484), is unclear for bivalirudin. It
hould be noted that the ACUITY protocol called for
ngiography within 24 to 48 h of randomization and that
he median time to catheterization (from the time the study
rug was started) was approximately 4 h; thus, the study
esults of this trial cannot be extrapolated beyond the group
f patients treated in an early invasive fashion.
.2.5.5. FACTOR XA INHIBITORS
he OASIS 5 investigators evaluated the use of fondapa-
inux in UA/NSTEMI (424) (Fig. 15). OASIS 5 compared
anticoagulant strategies given for a mean of 6 d; one of
hich was amended during the conduct of the trial. In
ASIS 5, patients with UA/NSTEMI were randomized to
control strategy of enoxaparin 1.0 mg per kg SC twice
aily (reduced to 1.0 mg per kg once daily for patients with
n estimated creatinine clearance less than 30 ml per min)
oupled with UFH when PCI was performed (no additional
FH if the last dose of enoxaparin was less than 6 h before).
f the last dose of enoxaparin was given more than 6 h
efore, the recommendation was that an intravenous bolus
f UFH 65 U per kg be administered if a GP IIb/IIIa
nhibitor was to be used and 100 U per kg if no GP IIb/IIIa
nhibitor was to be used. The opposite arm was a strategy of
ondaparinux 2.5 mg SC once daily to be supplemented as
ollows if PCI was performed: within 6 h of the last
ubcutaneous dose of fondaparinux, no additional study
rug was given if a GP IIb/IIIa inhibitor was used, and 2.5
g of fondaparinux was given intravenously if no GP
Ib/IIIa inhibitor was used; more than 6 h since the last dose
f fondaparinux, an additional intravenous dose of fondapa-
inux 2.5 mg was recommended if a GP IIb/IIIa inhibitor
as used or 5.0 mg IV if no GP IIb/IIIa inhibitor was used.
s explained by the OASIS 5 investigators, the rationale for
he recommendation to use UFH during PCI in the
noxaparin arm was based on lack of approval for enoxapa-
in for PCI in the US by the Food and Drug Administra-
ion, lack of available trial data on the use of enoxaparin
uring PCI when OASIS 5 was designed, and lack of any
ecommendations about the use of enoxaparin in the avail-
ble ACC/AHA or ESC PCI guidelines (personal commu-
ication, OASIS 5 Investigators, July 7, 2006). The UFH
osing recommendation in the enoxaparin arm was formu-
ated in consultation with the maker of enoxaparin and was
ot altered when the SYNERGY trial did not show
uperiority of enoxaparin over UFH (423). Of note, during
he conduct of the trial, catheter-associated thrombus was
eported 3 times more frequently with the fondaparinux
trategy (0.9% vs. 0.3%). After approximately 12,000 of the
0,078 patients ultimately enrolled in the trial had been
andomized, the protocol was amended to remind the
nvestigators to be certain that the intravenous dose of
ondaparinux was properly flushed in the line and to permit
he use of open-label UFH. As described by the OASIS 5
nvestigators (personal communication, OASIS 5 Investi-
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oth before and during PCI, with the dose being deter-
ined at their discretion.
The number of patients with primary outcome events at
d (death, MI, or refractory ischemia) was similar in the 2
roups (579 with fondaparinux [5.8%] vs. 573 with enox-
parin [5.7%]; HR in the fondaparinux group 1.01; 95% CI
.90 to 1.13), which satisfied prespecified noninferiority
riteria. The number of events that met this combined
rimary efficacy outcome showed a nonsignificant trend
oward a lower value in the fondaparinux group at 30 d (805
s. 864, p  0.13) and at the end of the study (180 d; 1,222
s. 1,308, p  0.06; Fig. 12). The rate of major bleeding at
d was lower with fondaparinux than with enoxaparin (217
vents [2.2%] vs. 412 events [4.1%]; HR 0.52; p less than
.001). The composite of the primary outcome and major
leeding at 9 d favored fondaparinux (737 events [7.3%] vs.
05 events [9.0%]; HR 0.81; p less than 0.001) (Fig. 15).
ondaparinux was associated with a significantly reduced
umber of deaths at 30 d (295 vs. 352, p 0.02) and at 180
(574 vs. 638, p  0.05). Fondaparinux also was associated
ith significant reductions in death, MI, and stroke (p 
.007) at 180 d.
Thus, fondaparinux is another anticoagulant that has
een given a Class I recommendation in the management of
A/NSTEMI, as noted in Figures 7, 8, and 9. As tested in
ASIS 5, the fondaparinux (plus UFH) strategy was
ssociated with lower bleeding rates, clearly an attractive
eature given the relationship between bleeding events and
ncreased risk of death and ischemic events (486). The excess
leeding in the enoxaparin arm may have been in part a result
igure 15. OASIS 5 Cumulative Risks of Death, MI, or Refractory
p for noninferiority. †p for superiority. CI  confidence interval; MI  myocardial infarctf the combination of enoxaparin and UFH during PCI. iAt present, based on experience in both OASIS 5 and
ASIS 6 (433), it appears that patients receiving fondapa-
inux before PCI should receive an additional anticoagulant
ith anti–IIa activity to support PCI (see Table 13). To
ate, the only anticoagulant that has been evaluated with
ondaparinux during PCI is UFH, and based on limited
xperience, the OASIS investigators recommend an UFH
ose of 50 to 60 U per kg IV when fondaparinux-treated
atients are taken to PCI (personal communication, OASIS
Investigators, July 7, 2006). However, a cautionary note is
hat this UFH recommendation is not fully evidence-based,
iven its inconsistent and uncontrolled use in OASIS 5.
ence, additional clinical trial information is needed to
stablish more rigorously the safety of intravenous UFH at
he time of PCI in patients receiving fondaparinux as initial
edical treatment (Table 13). Because the anticoagulant
ffect of UFH can be more readily reversed than that of
ondaparinux, UFH is preferred over fondaparinux in pa-
ients likely to undergo CABG within 24 h.
.2.5.6. LONG-TERM ANTICOAGULATION
he long-term administration of warfarin has been evalu-
ted in a few, mostly small studies. Williams et al. (436)
andomized 102 patients with UA to UFH for 48 h
ollowed by open-label warfarin for 6 months and reported
65% risk reduction in the rate of MI or recurrent UA. The
ntithrombotic Therapy in Acute Coronary Syndromes
ATACS) trial (369) randomized 214 patients with UA/
STEMI to ASA alone or to the combination of ASA plus
FH followed by warfarin. At 14 d, there was a reduction
n the composite end point of death, MI, and recurrent
mia
SIS 5  Fifth Organization to Assess Strategies for Ischemic Syndromes.Ischeschemia with the combination therapy (27.0% vs. 10.5%, p

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llocated to warfarin or placebo in addition to ASA, less
vidence was noted of angiographic progression in the
ulprit lesion after 10 weeks of treatment with warfarin
33% for placebo vs. 4% for warfarin) and more regression
as observed (487). The OASIS pilot study (488) compared
fixed dosage of warfarin 3 mg per d or a moderate dose
itrated to an INR of 2.0 to 2.5 in 197 patients and given for
months after the acute phase. Low-intensity warfarin had
o benefit, whereas the moderate-intensity regimen reduced
he risk of death, MI, or refractory angina by 58% and the
eed for rehospitalization for UA by 58%. However, these
esults were not reproduced in the larger OASIS 2 trial
477) of 3,712 patients randomized to the moderate-
ntensity regimen of warfarin or standard therapy, with all
atients receiving ASA. The rate of cardiovascular death,
I, or stroke after 5 months was 7.7% with the anticoag-
lant and 8.4% without (p  0.37) (489). Thus, the role, if
ny, of long-term warfarin in patients with UA/NSTEMI
emains to be defined.
The Coumadin Aspirin Reinfarction Study (CARS)
onducted in post-MI patients was discontinued prema-
urely owing to a lack of evidence of a benefit of reduced-
ose ASA (80 mg per d) combined with either 1 or 3 mg of
arfarin daily compared with 160 mg per d of ASA alone
490). The Combination Hemotherapy And Mortality Pre-
ention study found no benefit to the use of warfarin (to an
NR of 1.5 to 2.5) plus 81 mg per d of ASA versus 162 mg
er d of ASA alone with respect to total mortality (the
rimary end point), cardiovascular mortality, stroke, or
onfatal MI (mean follow-up of 2.7 years) after an index MI
491). Low- or moderate-intensity anticoagulation with
xed-dose warfarin thus is not recommended for routine use
fter hospitalization for UA/NSTEMI. Warfarin should be
rescribed, however, for UA/NSTEMI patients with estab-
ished indications for warfarin, such as atrial fibrillation, left
entricular thrombus, and mechanical prosthetic heart
alves.
The Antithrombotics in the Secondary Prevention of
vents in Coronary Thrombosis-2 (ASPECT-2) open-
abel trial randomized 999 patients after ACS to low-dose
SA, high-intensity oral anticoagulation (INR 3.0 to 4.0),
r combined low-dose ASA and moderate intensity oral
nticoagulation (INR 2.0 to 2.5) (492). After a median of 12
onths, the primary end point of MI, stroke, or death was
eached in 9% receiving ASA, 5% given anticoagulants (p
.048), and 5% receiving combination therapy (p  0.03).
ajor and minor bleeding events occurred in 1% and 5%,
% and 8%, and 2% and 15% of patients, respectively.
Similarly, a large (n  3,630) Norwegian open-label
tudy (WARIS-2) compared ASA (160 mg per d), high-
ntensity warfarin (INR target 2.8 to 4.2), or ASA (75 mg
er d) combined with moderate-intensity warfarin (INR 2.0
o 2.5) over a mean of 4 years after MI (41% with
on–Q-wave MI) (493). One third of patients underwent
n intervention over the study period. The primary outcome df death, nonfatal MI, or thromboembolic stroke occurred
n 20% of ASA patients, 16.7% of warfarin patients, and
5% of combination therapy patients (p  0.03). The
nnual major bleeding rate was 0.62% in both warfarin arms
nd 0.17% with ASA alone (p less than 0.001). Thus,
oderate-intensity warfarin with low-dose ASA appears to
e more effective than ASA alone when applied to MI
atients treated primarily with a noninterventional ap-
roach, but it is associated with a higher bleeding risk.
An indication for warfarin (e.g., for atrial fibrillation,
echanical prosthetic valve, or left ventricular thrombus) in
ddition to ASA and clopidogrel, which are indicated for
ost high-risk patients, arises occasionally after UA/
STEMI. There are no prospective trials and few observa-
ional data to establish the benefit and risk of such “triple
ntithrombotic” therapy (494,495). In the 2004 STEMI
uidelines (1), a Class IIb, Level of Evidence: C recom-
endation was given for the use of warfarin (INR 2.0 to
.0) in combination with ASA (75 to 162 mg) and clopi-
ogrel (75 mg per d) for patients with a stent implanted and
oncomitant indications for anticoagulation. Similarly, the
005 PCI guidelines (2) stated that warfarin in combination
ith clopidogrel and low-dose ASA should be used with
reat caution and only when INR is carefully regulated (2.0
o 3.0). Despite a limited amount of subsequent observa-
ional data (495), the evidence base remains small, which
eaves this recommendation at the Class IIb, Level of
vidence: C. When triple-combination therapy is selected
or clear indications and is based on clinical judgment that
enefit will outweigh the incremental risk of bleeding, then
herapy should be given for the minimum time and at the
inimally effective doses necessary to achieve protection.
n expanded evidence base on this issue is strongly needed.
igure 11 provides recommendations for long-term man-
gement of dual- and triple-antithrombotic therapy after
A/NSTEMI.
.2.6. Platelet GP IIb/IIIa Receptor Antagonists
he GP IIb/IIIa receptor is abundant on the platelet
urface. When platelets are activated, this receptor under-
oes a change in conformation that increases its affinity for
inding to fibrinogen and other ligands. The binding of
olecules of fibrinogen to receptors on different platelets
esults in platelet aggregation. This mechanism is indepen-
ent of the stimulus for platelet aggregation and represents
he final and obligatory pathway for platelet aggregation
496). The platelet GP IIb/IIIa receptor antagonists act by
ccupying the receptors, preventing fibrinogen from bind-
ng, and thereby preventing platelet aggregation. Experi-
ental and clinical studies have suggested that occupancy of
t least 80% of the receptor population and inhibition of
latelet aggregation to ADP (5 to 20 micromoles per liter)
y at least 80% results in potent antithrombotic effects
497). The various GP IIb/IIIa antagonists, however, pos-
ess significantly different pharmacokinetic and pharmaco-
ynamic properties (498).
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August 14, 2007:e1–157 ACC/AHA UA/NSTEMI Guideline RevisionAbciximab is a Fab fragment of a humanized murine
ntibody that has a short plasma half-life but strong affinity
or the receptor, which results in some receptor occupancy
hat persists in part for weeks. Platelet aggregation gradually
eturns to normal 24 to 48 h after discontinuation of the
rug. Abciximab also inhibits the vitronectin receptor (al-
havbeta3) on endothelial cells and the MAC-1 receptor on
eukocytes (499,500). The clinical relevance of occupancy of
hese receptors is unknown.
Eptifibatide is a cyclic heptapeptide that contains the
GD (Lys-Gly-Asp) sequence; tirofiban is a nonpeptide
imetic of the RGD (Arg-Gly-Asp) sequence of fibrinogen
498,501–503). Receptor occupancy with these 2 synthetic
ntagonists is, in general, in equilibrium with plasma levels.
hey have half-lives of 2 to 3 h and are highly specific for
he GP IIb/IIIa receptor. Platelet aggregation returns to
ormal in 4 to 8 h after discontinuation of these drugs, a
nding that is consistent with their relatively short half-lives
504). Glycoprotein IIb/IIIa antagonists can bind to differ-
nt sites on the receptor, which results in somewhat differ-
nt binding properties that can modify their platelet effects
nd, potentially and paradoxically, activate the receptor
505). Oral antagonists to the receptor, previously under
nvestigation, have been abandoned because of negative
esults of 5 large trials of 4 of these compounds (506–509).
The efficacy of GP IIb/IIIa antagonists in prevention of
he complications associated with percutaneous interven-
ions has been documented in numerous trials, many of
hem composed totally or largely of patients with UA
372,510–512) (Table 18). Two trials with tirofiban and 1
rial with eptifibatide have also documented their efficacy in
A/NSTEMI patients, only some of whom underwent
nterventions (128,130). Two trials were completed with the
xperimental drug lamifiban (373,513) and 1 with abcix-
mab (514). Few direct comparative data are available for
hese various antiplatelet agents. The TARGET study (Do
irofiban and ReoPro Give Similar Efficacy Trial) assessed
ifferences in safety and efficacy of tirofiban and abciximab
n 4,809 patients undergoing PCI with intended stenting
515). The composite of death, nonfatal MI, or urgent
arget-vessel revascularization at 30 d occurred more fre-
uently in the tirofiban group (7.6% vs. 6.0%). The advan-
age of abciximab was observed exclusively among patients
resenting with UA/NSTEMI (63% of the population)
515). A possible explanation for the inferior performance of
n-laboratory initiation of tirofiban for PCI in the setting of
CS was an insufficient loading dose of tirofiban to achieve
ptimal early (periprocedural) antiplatelet effect (516).
Abciximab has been studied primarily in PCI trials, in
hich its administration consistently resulted in reductions
n rates of MI and the need for urgent revascularization
Table 18). In subgroups of patients within those trials who
ad ACS, the risk of ischemic complications within the first
0 d after PCI was reduced by 60% to 80% with abciximab
herapy. Two trials with abciximab specifically studied
atients with acute ischemic syndromes. The CAPTURE trial enrolled patients with refractory UA (372). After
ngiographic identification of a culprit lesion suitable for
ngioplasty, patients were randomized to either abciximab
r placebo administered for 20 to 24 h before angioplasty
nd for 1 h thereafter. The rate of death, MI, or urgent
evascularization within 30 d (primary outcome) was re-
uced from 15.9% with placebo to 11.3% with abciximab
RR 0.71, p  0.012). At 6 months, death or MI had
ccurred in 10.6% of the placebo-treated patients versus
.0% of the abciximab-treated patients (p  0.19). Abcix-
mab is approved for the treatment of UA/NSTEMI as an
djunct to PCI or when PCI is planned within 24 h.
The GUSTO IV-ACS trial (514) enrolled 7,800 patients
ith UA/NSTEMI who were admitted to the hospital with
ore than 5 min of chest pain and either ST-segment
epression and/or elevated TnT or TnI concentration. All
eceived ASA and either UFH or LMWH. They were
andomized to an abciximab bolus and a 24-h infusion, an
bciximab bolus and a 48-h infusion, or placebo. In contrast
o other trials with GP IIb/IIIa antagonists, GUSTO
V-ACS enrolled patients in whom early (less than 48 h)
evascularization was not intended. At 30 d, death or MI
ccurred in 8.0% of patients taking placebo, 8.2% of patients
aking 24-h abciximab, and 9.1% of patients taking 48-h
bciximab, differences that were not statistically significant.
t 48 h, death occurred in 0.3%, 0.7%, and 0.9% of patients
n these groups, respectively (placebo vs. abciximab 48 h, p 
.008). The lack of benefit of abciximab was observed in most
ubgroups, including patients with elevated concentrations of
roponin who were at higher risk. Although the explanation for
hese results is not clear, they indicate that abciximab at the
osing regimen used in GUSTO IV-ACS is not indicated in
he management of patients with UA or NSTEMI in whom
n early invasive management strategy is not planned.
Tirofiban was studied in the Platelet Receptor Inhibition
n Ischemic Syndrome Management (PRISM) (374) and
latelet Receptor Inhibition in Ischemic Syndrome Man-
gement in Patients Limited by Unstable Signs and Symp-
oms (PRISM-PLUS) (130) trials. PRISM directly com-
ared tirofiban with heparin in 3,232 patients with
ccelerating angina or angina at rest and ST-segment or
-wave changes and with cardiac marker elevation, a
revious MI, or a positive stress test or angiographically
ocumented coronary disease (374). The primary composite
utcome (death, MI, or refractory ischemia at the end of a
8-h infusion period) was reduced from 5.6% with UFH to
.8% with tirofiban (RR 0.67, p  0.01). At 30 d, the
requency of the composite outcome was similar in the 2
roups (17.1% for UFH vs. 15.9% for tirofiban, p  0.34),
ut a trend toward reduction in the rate of death or MI was
resent with tirofiban (7.1% vs. 5.8%, p  0.11), and a
ignificant reduction in mortality rates was observed (3.6%
s. 2.3%, p  0.02). The benefit of tirofiban was mainly
resent in patients with an elevated TnI or TnT concen-
ration at baseline.
Table 18. UA/NSTEMI Outcome of Death or Myocardial Infarction in Clinical Trials of GP IIb/IIIa Antagonists Involving More Than 1,000 Patients
Trial (Year) Study Population Drugs
Results
ARR, % RR 95% CI p
Placebo GP IIb/IIIa
n % n %
PCI trials
EPIC (1994) (510) High-risk PTCA Abciximab 72/696 10.3 49/708 6.9* 3.4 0.68 0.47 to 0.95 0.022
EPILOG (1997) (511) All PTCA Abciximab 85/939 9.1 35/935 3.7* 5.4 0.41 0.28 to 0.61 Less than
0.001
CAPTURE (1997) (372) UA Abciximab 57/635 9.0 30/630 4.8 4.2 0.53 0.35 to 0.81 0.003
IMPACT II (1997) (517) All PTCA Eptifibatide 112/1328 8.4 93/1349 6.9* 1.5 0.83 0.63 to 1.06 0.134
RESTORE (1997) (518) UA Tirofiban 69/1070 6.4 54/1071 5.0 1.4 0.78 0.55 to 1.10 0.162
EPISTENT (1998) (512) Elective stenting Abciximab 83/809 10.2 38/794 4.8* 5.4 0.46 0.32 to 0.68 Less than
0.001
ESPRIT (2000) (519) Elective stenting Eptifibatide 104/1024 10.2 66/1040 6.3 3.9 0.62 0.46 to 0.84 0.0016
ISAR-REACT (2004) (520) Elective stenting with clopidogrel
pretreatment
Abciximab 42/1080 3.9 43/1079 4.0 0.1 1.02 0.68 to 1.55 0.91
ACS trials
PRISM-PLUS (1998)
(130)
UA/NQWMI Tirofiban 95/797 11.9 67/733* 9.1* 2.8 0.70 0.51 to 0.96 0.03
PRISM (1998) (374) UA/NQWMI Tirofiban 115/1616 7.1 94/1616 5.8† 1.3 0.82 0.61 to 1.05 0.11
PURSUIT (1998) (128) UA/NQWMI Eptifibatide 744/4739 15.7 670/4722 14.2* 1.5 0.90 0.82 to 1.00 0.04
PARAGON A (1998) (373) UA/NQWMI Lamifiban 89/758 11.7 80/755 10.6*† 1.1 0.90 0.68 to 1.20 0.48
GUSTO IV ACS (2001)
(514)
UA/NQWMI Abciximab 209/2598 8.0 450/5202‡ 8.7 0.7 1.08 0.92 to 1.26 0.36
PARAGON B (2002) (521) UA/NQWMI Lamifiban 296/2597 11.4 278/2628 10.6 0.8 0.94 0.77 to 1.09 0.32
ISAR-REACT (2006) (244) UA/NSTEMI§ Abciximab 116/1010 11.5 87/1012 8.6 2.9 0.75 0.57 to 0.97 0.03
All PCI trials 624/7581 8.2 408/7606 5.4 2.8 0.65 0.58 to 0.74 Less than
0.0001
All ACS trials 1664/14 115 11.7 1726/16 668 10.4 1.3 0.86 0.81 to 0.93 Less than
0.0001
All PCI and ACS trials 2288/21 696 10.5 2134/24 274 8.8 1.7 0.83 0.83 to 0.84 Less than
0.0001
*Best treatment group selected for analysis. †Platelet GP IIb/IIIa antagonist without heparin. ‡Pooled results for 24- and 48-h infusion arms. §Used an invasive (PCI) strategy; all patients received clopidogrel.
ACS acute coronary syndrome; CAPTURE c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina; CI confidence interval; EPIC Evaluation of c7E3 for the Prevention of Ischemic Complications; EPILOG Evaluation of PTCA and Improve Long-term Outcome
by c7E3 GP IIb/IIIa receptor blockade; EPISTENT  Evaluation of Platelet IIb/IIIa Inhibitor for STENTing; ESPRIT  Enhanced Suppression of Platelet Receptor GP IIb/IIIa using Integrilin Therapy; GUSTO IV ACS  Global Use of Strategies to Open Occluded Coronary
Arteries IV; IMPACT II Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis II; ISAR-REACT Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment; NQWMI non–Q-wave myocardial infarction; PARAGON Platelet
IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network; PCI  percutaneous coronary intervention; PRISM  Platelet Receptor Inhibition in Ischemic Syndrome Management; PRISM-PLUS  Platelet Receptor Inhibition
in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms; PTCA percutaneous transluminal coronary angioplasty; PURSUIT Platelet Glycoprotein IIb/IIIa in Unstable 16 Angina: Receptor Suppression Using Integrilin Therapy; RESTORE
 Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis; RR  risk ratio; UA  unstable angina; UA/NSTEMI  unstable angina/non–ST-elevation myocardial infarction.
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August 14, 2007:e1–157 ACC/AHA UA/NSTEMI Guideline RevisionThe PRISM-PLUS trial enrolled 1,915 patients with
linical features of UA/NSTEMI within the previous 12 h
nd the presence of ischemic ST-T changes or CK and
K-MB elevation (130). Patients were randomized to
irofiban alone, UFH alone, or the combination for a period
arying from 48 to 108 h. The tirofiban-alone arm was
ropped during the trial because of an excess mortality rate.
he combination of tirofiban and UFH compared with
FH alone reduced the primary composite end point of
eath, MI, or refractory ischemia at 7 d from 17.9% to
2.9% (RR 0.68, p  0.004). This composite outcome also
as significantly reduced at 30 d (22%, p  0.03) and at 6
onths (19%, p 0.02). The end point of death or nonfatal
I was reduced at 7 d (43%, p  0.006), at 30 d (30%, p 
.03), and at 6 months (22%, p  0.06). A high rate of
ngiography in this trial could have contributed to the
mportant reduction in event rates. Computer-assisted anal-
sis of coronary angiograms obtained after 48 h of treatment
n PRISM-PLUS also showed a reduction in the thrombus
oad at the site of the culprit lesion and improved coronary
ow in patients who received the combination of tirofiban
nd UFH (134). Tirofiban, in combination with heparin,
as been approved for the treatment of patients with ACS,
ncluding patients who are managed medically and those
ndergoing PCI.
Eptifibatide was studied in the PURSUIT trial, which
nrolled 10,948 patients who had chest pain at rest within
he previous 24 h and ST-T changes or CK-MB elevation
128). The study drug was added to standard management
ntil hospital discharge or for 72 h, although patients with
ormal coronary arteries or other mitigating circumstances
ad shorter infusions. The infusion could be continued for
n additional 24 h if an intervention was performed near the
nd of the 72-h infusion period. The primary outcome rate
f death or nonfatal MI at 30 d was reduced from 15.7% to
4.2% with eptifibatide (RR 0.91, p  0.042). Within the
rst 96 h, a substantial treatment effect was seen (9.1% vs.
.6%, p  0.01). The benefits were maintained at 6-month
ollow-up. Eptifibatide has been approved for the treatment of
atients with ACS (UA/NSTEMI) who are treated medically
r with PCI. It is usually administered with ASA and heparin.
The cumulative event rates observed during the phase of
edical management and at the time of PCI in the
APTURE, PRISM-PLUS, and PURSUIT trials are
hown in Figure 16 (523). By protocol design, almost all
atients underwent PCI in CAPTURE. In PRISM-PLUS,
ngiography was recommended. A percutaneous revascular-
zation was performed in 31% of patients in PRISM-PLUS
nd in 13% of patients in PURSUIT. Each trial showed a
tatistically significant reduction in the rate of death or MI
uring the phase of medical management; the reduction in
vent rates was magnified at the time of the intervention.
Although it is tempting to evaluate the drug effect by
omparing patients who had intervention with those who
id not, such an analysis is inappropriate. Patients who do
ot undergo intervention include many low-risk patients, 0atients who died before having the opportunity for inter-
ention, patients with contraindications, and patients with
ncomplicated courses in countries and practices that use
he ischemia-guided approach; there is no way to adjust for
hese imbalances. Accordingly, the analysis in Figure 16
ncludes the event rates for all patients during the time when
hey were treated medically. It then begins the analysis anew
n patients who underwent PCI at the time of angiography
hile taking drug or placebo. In the PRISM-PLUS trial,
,069 patients did not undergo early PCI. Although tirofi-
an treatment was associated with a lower incidence of
eath, MI or death, or MI or refractory ischemia at 30 d,
hese reductions were not statistically significant (130). In a
igh-risk subgroup of these patients not undergoing PCI
TIMI risk score greater than or equal to 4) (159), tirofiban
ppeared to be beneficial whether patients underwent PCI
OR 0.60, 95% CI 0.35 to 1.01) or not (OR 0.69, 95% CI
.49 to 0.99); however, no benefit was observed in patients
t lower risk (181,525). In the PURSUIT trial, the impact
f eptifibatide on the incidence of death or MI in the
ubgroup of patients who did not undergo revascularization
ithin the first 72 h was modest and consistent with the
verall trial result, although not individually significant
15.6% vs. 14.5%, p  0.23) (128).
Boersma et al. performed a meta-analysis of GP IIb/IIIa
ntagonists of all 6 large, randomized, placebo-controlled
rials (including GUSTO IV; [514]) involving 31,402 pa-
ients with UA/NSTEMI not routinely scheduled to un-
ergo coronary revascularization (526). In the overall pop-
lation, the risk of death or MI by 30 d was modestly
educed in the active treatment arms (11.8% vs. 10.8%, OR
.91, 95% CI 0.84 to 0.98, p  0.015). Treatment effect
ppeared to be greater among higher-risk patients with
roponin elevations or ECG ST-segment depressions. Un-
xpectedly, no benefit was observed in women, but there
as no evidence of a sex difference in treatment effect once
atients were stratified by troponin concentrations (a risk
eduction was seen in both men and women with elevated
Tn levels). These and other data have elevated troponin
evel to a major factor in decision making for the use of these
gents in UA/NSTEMI. Major bleeding complications
ere increased in the GP IIb/IIIa antagonist-treated group
ompared with those who received placebo (2.4% vs. 1.4%,
less than 0.0001). For special considerations about the use
f GP IIb/IIIa antagonists in women, see Section 6.1.2.1.
A relationship was observed between revascularization
rocedures and the apparent treatment effect of GP IIb/IIIa
lockade in the meta-analysis by Boersma et al. (526).
evascularization strategies were not specified by trial pro-
ocols or randomized, but 5,847 (19%) of the 31,402
atients underwent PCI or CABG within 5 d, and 11,965
atients (38%) did so within 30 d. Significant reductions in
he risk of death or MI with GP IIb/IIIa blockade were
bserved in these subgroups (OR 0.79, 95% CI 0.68 to 0.91
or patients revascularized within 5 d; OR  0.89, 95% CI
.80 to 0.98 for patients revascularized within 30 d),
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ther 19,416 patients who did not undergo coronary revas-
ularization within 30 d (OR for death or MI 0.95, 95% CI
.86 to 1.05). The authors concluded that the benefit of GP
Ib/IIIa blockade in patients with UA/NSTEMI was “clin-
cally most meaningful in patients at high risk of thrombotic
omplications” (526). The findings of this meta-analysis in
he context of other trials of GP IIb/IIIa blockade during
CI suggest that GP IIb/IIIa inhibitors are of substantial
igure 16. Kaplan-Meier Curves Showing Cumulative Incidence of
ncidence is shown in patients randomly assigned to platelet GP IIb/IIIa receptor antago
rials. Left: events during the initial period of medical treatment until the moment of PCI
as performed in almost all patients as per study design; abciximab was discontinued 1
eriod of medical therapy with eptifibatide that lasted 72 h and for 24 h after the interve
eriod of medical therapy with tirofiban, and the drug infusion was maintained for 12 to
he event rates reset to 0% before the intervention. Creatine kinase or creatine kinase-M
ng medical management and exceeding 3 times the upper limit of normal for PCI-related
IIa receptor inhibition in non–ST-elevation acute coronary syndromes. Circulation 1999;1
illiams & Wilkins. CABG  coronary artery bypass graft; CAPTURE  c7E3 Fab AntiPlat
number of patients; OR  odds ratio; PCI  percutaneous coronary intervention; PRIS
ted by Unstable Signs and symptoms; PURSUIT  Platelet glycoprotein IIb/IIIa in Unstaenefit in patients with UA/NSTEMI who undergo PCI, fre of modest benefit in patients who are not routinely
cheduled to undergo revascularization (but who may do
o), and are of questionable benefit in patients who do not
ndergo revascularization.
Although there is a temptation to use the comparison of
ach of these GP IIb/IIIa inhibitors with placebo to draw
onclusions about relative efficacy, such an exercise could be
isleading. Each trial had different entry criteria, different
pproaches to angiographic evaluation, and different criteria
h or MI
ld line) or placebo. Data are derived from the CAPTURE, PURSUIT, and PRISM-PLUS
G. In the CAPTURE trial, abciximab was administered for 18 to 24 h before the PCI
r the intervention. In PURSUIT, a PCI was performed in 11.2% of patients during a
In PRISM-PLUS, an intervention was performed in 30.2% of patients after a 48-h
fter an intervention. Right: events occurring at the time of PCI and the next 48 h, with
ations exceeding 2 times the upper limit of normal were considered as infarction dur-
ts. Adapted from Boersma E, Akkerhuis KM, Théroux P, et al. Platelet glycoprotein IIb/
45–8 (523), CAPTURE (240), PURSUIT (172), and PRISM-PLUS (134). © Lippincott,
erapy in Unstable REfractory angina; GP  glycoprotein; MI  myocardial infarction; N
S  Platelet Receptor Inhibition in ischemic Syndrome Management in Patients Lim-
ina: Receptor Suppression Using Integrilin Therapy.Deat
nist (bo
or CAB
h afte
ntion.
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ifferences cannot be accounted for in an indirect compar-
son. Head-to-head (direct) comparisons are required to
raw reliable conclusions about the relative efficacy of these
ifferent molecules. As noted earlier, 1 trial (TARGET)
emonstrated an advantage to in-laboratory initiation of
bciximab over tirofiban for UA/NSTEMI patients under-
oing PCI with stenting (515). An explanation offered for
his difference was an insufficient loading dose of tirofiban to
chieve optimal periprocedural antiplatelet effect (516).
Treatment with a GP IIb/IIIa antagonist increases the risk
f bleeding, which is typically mucocutaneous or involves the
ccess site of vascular intervention. Unfortunately, each trial
lso used a different definition of bleeding and reported
leeding related to CABG differently. In the PRISM trial,
ith no interventions (including CABG) on treatment, major
leeding (excluding CABG) occurred in 0.4% of patients who
eceived tirofiban and 0.4% of patients who received UFH
374). In the PRISM-PLUS trial, major bleeding according to
he TIMI criteria was reported in 1.4% of patients who
eceived tirofiban and 0.8% of patients who received placebo (p
0.23), whereas PURSUIT reported major bleeding in 10.6%
f patients who received eptifibatide and 9.1% of patients who
eceived placebo (p 0.02) (134,172). In the PURSUIT trial,
ith the exclusion of patients who underwent CABG, the
ates were 3.0% with eptifibatide and 1.3% with placebo (p less
han 0.001). No trials have shown an excess of intracranial
leeding with a GP IIb/IIIa inhibitor. As with the efficacy
ata, the temptation to make indirect comparisons should be
empered by the variability in protocol, circumstances, and
efinitions of the trial.
Aspirin has been used with the intravenous GP IIb/IIIa
eceptor blockers in all trials. A strong case also can be made
or the concomitant use of heparin with GP IIb/IIIa
eceptor blockers. The tirofiban arm without UFH in the
RISM-PLUS trial was discontinued early because of an
xcess of deaths. In addition, the PURSUIT trial reported a
igher event rate in the 11% of patients who were not
reated with concomitant heparin (128). In a randomized
omparison, a lower-dose regimen of the GP IIb/IIIa
nhibitor lamifiban gave a more favorable outcome trend
hen combined with heparin than when administered
ithout heparin (373). Current recommendations call for
he concomitant use of heparin with GP IIb/IIIa inhibitors.
lycoprotein IIb/IIIa inhibitors can increase the ACT
hen combined with heparin, which means that lower doses
f heparin are required to achieve a target level of antico-
gulation. Moreover, trial data indicate that lower heparin
oses diminish the bleeding risk associated with GP IIb/
IIa blockade in the setting of PCI, findings that likely can
e extrapolated to the medical phase of management in
atients with UA/NSTEMI.
Blood hemoglobin and platelet counts should be monitored
nd patient surveillance for bleeding should be performed daily
uring the administration of GP IIb/IIIa receptor blockers.
hrombocytopenia is an unusual complication of this class of Ngents. Severe thrombocytopenia, defined by nadir platelet
ounts of less than 50,000 per ml, is observed in 0.5% of
atients, and profound thrombocytopenia, defined by nadir
latelet counts of less than 20,000 per ml, is observed in 0.2%
f patients. Although reversible, thrombocytopenia is associ-
ted with an increased risk of bleeding (527,528).
Several trials have demonstrated that GP IIb/IIIa inhib-
tors can be used with LMWH among patients with
nstable ischemic syndromes. In the Antithrombotic Com-
ination Using Tirofiban and Enoxaparin (ACUTE II)
tudy (529), UFH and enoxaparin were compared in pa-
ients with UA/NSTEMI receiving tirofiban. The inci-
ence of major and minor bleeding was similar, and there
as a trend to fewer adverse events in patients receiving
noxaparin. More recently, 2 large-scale, randomized trials
ave examined the relative efficacy of enoxaparin versus
FH among patients with ACS. One of these, the A to Z
rial (Aggrastat to Zocor), randomized 3,987 patients who
ere treated with concomitant ASA and tirofiban (466).
oronary angiography was performed in 60% of patients.
onsignificant trends toward fewer ischemic end points but
ore frequent bleeding events were observed with enoxapa-
in than with UFH therapy (466). In the larger SYNERGY
rial, 10,027 patients with high-risk ACS were randomized
o receive either UFH or enoxaparin (423) (Fig. 12).
lycoprotein IIb/IIIa antagonists were administered to 57% of
atients, and 92% underwent coronary angiography. No ad-
antage of enoxaparin over heparin was observed for the
rimary end point of death or myocardial infarction by 30 d
14.0% vs. 14.5%), but the 2 randomized therapies offered
imilar protection against ischemic events during PCI. Enox-
parin was associated, however, with an excess risk of TIMI
ajor bleeding (9.1% vs. 7.6%, p  0.008) (423).
The ACUITY trial investigated the combination of a GP
Ib/IIIa inhibitor with bivalirudin, a direct thrombin inhib-
tor (see Section 3.2.2.4 and Fig. 13) (425). Glycoprotein
Ib/IIIa inhibition with bivalirudin resulted in similar (non-
nferior) clinical outcomes compared with GP IIb/IIIa
nhibition with UFH or enoxaparin.
A challenge for the current guidelines is integrating the GP
Ib/IIIa studies from the 1990s with more recent studies using
reangiography clopidogrel loading, newer anticoagulants, and
arying degrees of patient acuity and risk/benefit. The current
vidence base and expert opinion suggest that for UA/
STEMI patients in whom an initial invasive strategy is
elected, either an intravenous GP IIb/IIIa inhibitor or clopi-
ogrel should be added to ASA and anticoagulant therapy
efore diagnostic angiography (upstream) for lower-risk,
roponin-negative patients and that both should be given
efore angiography for high-risk, troponin-positive patients
Class I recommendations). For UA/NSTEMI patients in
hom an initial conservative (i.e., noninvasive) strategy is
elected, the evidence for benefit is less; for this strategy, the
ddition of eptifibatide or tirofiban to anticoagulant and oral
ntiplatelet therapy may be reasonable for high-risk UA/
STEMI patients (Class IIb recommendation).
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he failure of intravenous fibrinolytic therapy to improve
linical outcomes in the absence of MI with ST-segment
levation or bundle-branch block was clearly demonstrated in
he TIMI 11B, ISIS-2, and GISSI 1 trials (129,530,531). A
eta-analysis of fibrinolytic therapy in UA/NSTEMI patients
howed no benefit of fibrinolysis versus standard therapy
531a). Fibrinolytic agents had no significant beneficial effect
nd actually increased the risk of MI (531a). Consequently,
uch therapy is not recommended for the management of
atients with an ACS without ST-segment elevation, a
osterior-wall MI, or a presumably new left bundle-branch
lock (see ACC/AHA Guidelines for the Management of
atients With ST-Elevation Myocardial Infarction [1]).
.3. Initial Conservative Versus Initial Invasive
trategies
RECOMMENDATIONS
LASS I
. An early invasive strategy (i.e., diagnostic angiography with intent to
perform revascularization) is indicated in UA/NSTEMI patients who
have refractory angina or hemodynamic or electrical instability
(without serious comorbidities or contraindications to such proce-
dures). (Level of Evidence: B)
. An early invasive strategy (i.e., diagnostic angiography with intent to
perform revascularization) is indicated in initially stabilized UA/
NSTEMI patients (without serious comorbidities or contraindications
to such procedures) who have an elevated risk for clinical events
(see Table 11 and Sections 2.2.6 and 3.4.3). (Level of Evidence: A)
LASS IIb
. In initially stabilized patients, an initially conservative (i.e., a selectively
invasive) strategy may be considered as a treatment strategy for UA/
NSTEMI patients (without serious comorbidities or contraindications to
such procedures) who have an elevated risk for clinical events (see Table
11 and Sections 2.2.6 and 3.4.3) including those who are troponin posi-
tive. (Level of Evidence: B) The decision to implement an initial conserva-
tive (vs. initial invasive) strategy in these patients may be made by
considering physician and patient preference. (Level of Evidence: C)
. An invasive strategy may be reasonable in patients with chronic
renal insufficiency. (Level of Evidence: C)
LASS III
. An early invasive strategy (i.e., diagnostic angiography with intent to
perform revascularization) is not recommended in patients with exten-
sive comorbidities (e.g., liver or pulmonary failure, cancer), in whom the
risks of revascularization and comorbid conditions are likely to out-
weigh the benefits of revascularization. (Level of Evidence: C)
. An early invasive strategy (i.e., diagnostic angiography with intent to
perform revascularization) is not recommended in patients with
acute chest pain and a low likelihood of ACS. (Level of Evidence: C)
. An early invasive strategy (i.e., diagnostic angiography with intent to
perform revascularization) should not be performed in patients who
will not consent to revascularization regardless of the findings. (Level of
Evidence: C)
.3.1. General Principles
n addition to aggressive medical therapy, 2 treatment
athways have emerged for treating ACS patients. The ainitial” or “early” invasive strategy, now known simply as
he “invasive” strategy, triages patients to undergo an inva-
ive diagnostic evaluation without first getting a noninvasive
tress test or without failing medical treatment (i.e., an
nitial conservative diagnostic strategy, or sometimes now
nown as the “selective invasive strategy”; see below and de
inter et al. [532]). Patients treated with an invasive
trategy generally will undergo coronary angiography within
to 24 h of admission; however, these patients also are
reated with the usual UA/NSTEMI medications, includ-
ng appropriate anti-ischemic, antiplatelet, and anticoagu-
ant therapy, as outlined in Sections 3.1 and 3.2. These
rugs generally are not withheld until after angiography.
ithin the invasive strategy, there is a subgroup of patients
resenting to the ED who require urgent catheterization
nd revascularization in the absence of ST deviation because
f ongoing ischemic symptoms or hemodynamic or rhythm
nstability. These patients are often rushed off to the
atheterization laboratory within minutes to a few hours of
rrival and are not considered appropriate candidates for a
onservative strategy. Even here, appropriate medical ther-
py is considered; however, with these patients, the admin-
stration of GP IIb/IIIa inhibitors or clopidogrel may be
elayed until the time of angiography, at a physician’s
iscretion (Figs. 7, 8, and 9). On the other hand, the longer
he interval between presentation and angiography in pa-
ients, the greater the incremental benefit of “upstream”
ntiplatelet therapy. In summary, the invasive strategy can
e subdivided into: 1) those patients requiring urgent
ngiography/revascularization very soon after arrival at the
D, and 2) those with a UA/NSTEMI presentation who
re designated either by patient/physician discretion or after
isk assessment to benefit from “early” but nonurgent
ngiography/intervention.
In contrast, the “initial conservative strategy” (also referred
o as “selective invasive management”) calls for proceeding with
n invasive evaluation only for those patients who fail medical
herapy (refractory angina or angina at rest or with minimal
ctivity despite vigorous medical therapy) or in whom objective
vidence of ischemia (dynamic ECG changes, high-risk stress
est) is identified. Estimating the risk for an adverse outcome is
aramount for determining which strategy is best applied to an
ndividual ACS patient. Several risk tools have been validated
hat are useful in guiding the type and intensity of therapy by
dentifying patients most likely to benefit from aggressive
reatment.
One such valuable tool for risk determination is based on
ata from the TIMI 11B and ESSENCE trials (159) and is
iscussed in Section 2.2.6 and Table 8. The TIMI risk
alculator is available at http://www.timi.org/.
Another simple risk-prediction tool has been validated by
ata from GRACE (168) (Fig. 4; Section 2.2.6). The
RACE calculator can estimate short and intermediate
ortality and is useful when making diagnostic and treat-
ent decisions for ACS patients. The GRACE clinicalpplication tool can be downloaded to a handheld PDA to
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ww.outcomes-umassmed.org/grace.
The PURSUIT, TIMI, and GRACE risk scores dem-
nstrate good predictive accuracy for death and MI. They
rovide valuable information that can be used to identify
atients likely to benefit from early, aggressive therapy,
ncluding intravenous GP platelet inhibitors and early cor-
nary revascularization (174).
.3.2. Rationale for the Initial Conservative Strategy
few multicenter trials have shown similar outcomes with
nitial conservative and invasive therapeutic strategies
129,533,534). Some trials (534,535) have emphasized the
arly risk associated with revascularization procedures. The
onservative strategy seeks to avoid the routine early use of
nvasive procedures unless patients experience refractory or
ecurrent ischemic symptoms or develop hemodynamic
nstability. When the conservative strategy is chosen, a plan
or noninvasive evaluation is required to detect severe
schemia that occurs spontaneously or at a low threshold of
tress and to promptly refer these patients for coronary
ngiography and revascularization when possible. In addi-
ion, as in STEMI (536), an early echocardiogram should be
onsidered to identify patients with significant LV dysfunc-
ion (e.g., LVEF less than 0.40). Such a finding prompts
onsideration for angiography to identify left main or
ultivessel CAD, because patients with multivessel disease
nd LV dysfunction are at high risk and could accrue a
urvival benefit from CABG (537,538). In addition, a stress
est (e.g., exercise or pharmacological stress) for the assess-
ent of ischemia is recommended before discharge or
hortly thereafter to identify patients who may also benefit
rom revascularization. The use of aggressive anticoagulant
nd antiplatelet agents has reduced the incidence of adverse
utcomes in patients managed conservatively (see Section
.3) (128,134,169,180,372,374,523,539). An advantage of-
ered by the conservative strategy is that many patients
tabilize on medical therapy and will not require coronary
ngiography. Consequently, the conservative strategy limits
he use of in-hospital cardiac catheterization and may avoid
ostly and possibly unnecessary invasive procedures.
.3.3. Rationale for the Invasive Strategy
or patients with UA/NSTEMI without recurrent ischemia
n the first 24 h, the use of angiography provides an invasive
pproach to risk stratification. It can identify the 10% to
0% of patients with no significant coronary stenoses and
he approximately 20% with 3-vessel disease with LV
ysfunction or left main CAD. This latter group can derive
survival benefit from CABG (see Section 4). In addition,
CI of the culprit lesion has the potential to reduce the risk
or subsequent hospitalization and the need for multiple
ntianginal drugs compared with the early conservative
trategy (TIMI IIIB) (129). Just as the use of improved
nticoagulant therapy and/or a platelet GP IIb/IIIa receptor
locker has improved the outcome in patients managed hccording to the conservative strategy, the availability of
hese agents also makes the invasive approach more attrac-
ive, particularly because the early hazard of PCI is lessened.
he availability of GP IIb/IIIa receptor blockers also has led
o 2 alternatives for the routine invasive approach: imme-
iate angiography or deferred angiography.
.3.4. Immediate Angiography
xcluding those in need of urgent intervention, 2 alterna-
ives for the invasive approach have emerged: early (“imme-
iate”) or deferred angiography (i.e., with respect to a 12- to
8-h window). Some believe that proceeding immediately
o angiography is an efficient approach for the ACS patient.
atients found not to have CAD may be discharged rapidly
r shifted to a different management strategy. Patients with
bvious culprit lesions amenable to PCI can have a proce-
ure performed immediately, hastening discharge. Patients
ith left main CAD and those with multivessel disease and
V dysfunction can be sent expeditiously to undergo bypass
urgery, thereby avoiding a risky waiting period. Support for
mmediate angiography comes from the Intracoronary
tenting with Antithrombotic Regimen Cooling-off Study
ISAR-COOL) (540). All ACS patients were treated with
ntensive medical therapy (including oral and intravenous
ntiplatelet therapy). They were randomized to immediate
ngiography (median time 2.4 h) or a prolonged “cooling
ff” period for a median of 86 h before undergoing cathe-
erization. Patients randomized to immediate angiography
ad significantly fewer deaths or MIs at 30 d. Importantly,
his difference in outcome was attributed to events that
ccurred before catheterization in the “cooling off” group,
hich supports the rationale for intensive medical therapy
nd very early angiography. Data supporting this approach
re limited, but additional clinical trial results are expected
n the future.
.3.5. Deferred Angiography
n most reports that involve use of the invasive strategy,
ngiography has been deferred for 12 to 48 h while antithrom-
otic and anti-ischemic therapies are intensified. Several ob-
ervational studies, as summarized in Smith et al (541) have
ound a lower rate of complications in patients undergoing PCI
ore than 48 h after admission, during which heparin and
SA were administered, than with early intervention; how-
ver, the value of medical stabilization before angiography has
ever been assessed formally or proven.
.3.6. Comparison of Early Invasive and Initial
onservative Strategies
rior meta-analyses have concluded that routine invasive
herapy is better than an initial conservative or selectively
nvasive approach (542–544). Mehta et al. (543) concluded
hat the routine invasive strategy resulted in an 18% relative
eduction in death or MI, including a significant reduction
n MI alone. The routine invasive arm was associated with
igher in-hospital mortality (1.8% vs. 1.1%), but this
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ant reduction in mortality between discharge and the end
f follow-up (3.8% vs. 4.9%). The invasive strategy also was
ssociated with less angina and fewer rehospitalizations than
ith the conservative pathway. Patients undergoing routine
nvasive treatment also had improved quality of life.
In contrast to these finding, other studies, most recently
CTUS (Invasive versus Conservative Treatment in Unsta-
le coronary Syndromes) (532), have favorably highlighted a
trategy of selective invasive therapy (532). In ICTUS,
,200 high-risk ACS patients were randomized to routine
nvasive versus selective invasive management and followed
p for 1 year with respect to the combined incidence of
eath, MI, and ischemic rehospitalization. All patients were
reated with optimal medical therapy that included ASA,
lopidogrel, LMWH, and lipid-lowering therapy; abcix-
mab was given to those undergoing revascularization. At
he end of 1 year, there was no significant difference in the
omposite end point between groups. This study suggests
hat a selective invasive strategy could be reasonable in ACS
atients. A possible explanation for the lack of benefit of the
nvasive approach in this trial (and other trials) (545) could
e related to the relatively high rate of revascularization
ctually performed in patients treated in the selective inva-
ive arm (47%), thereby reducing observed differences be-
ween treatment strategies (174), and to the lower event rate
lower-risk population) than in other studies. Results were
nchanged during longer term follow-up (545a,545b). Nev-
rtheless, ICTUS required troponin positivity for entry. Thus
roponin alone might no longer be an adequate criterion for
trategy selection, especially with increasingly sensitive tropo-
in assays. The degree of troponin elevation and other high-
isk clinical factors taken together should be considered in
electing a treatment strategy.
Other criticisms of ICTUS have included that it was
elatively underpowered for hard end points and that it used a
ontroversial definition for post-procedural MI (i.e., even
inimal, asymptomatic CK-MB elevation) (532,545a,545b).
Additionally, 1-year follow-up may be inadequate to fully
ealize the long-term impact and benefit of the routine
nvasive strategy. In the RITA-3 trial (Third Randomized
ntervention Treatment of Angina), 5-year but not 1-year
vent rates favored the early invasive arm (see Fig. 17 and
ext below) (546). In ICTUS, however, results were main-
ained during a 3-year follow-up (546a).
Thus, these guidelines recommend that in initially stabi-
ized UA/NSTEMI patients, an initial conservative (selec-
ive invasive) strategy may be considered as a treatment
ption. The Writing Committee also believes that addi-
ional comparative trials of the selective invasive with the
outine initial invasive strategies are indicated using aggres-
ive contemporary medical therapies in both arms, including
outine dual antiplatelet therapy in medically treated pa-
ients (as recommended in Section 5.2.1) as well as aggres-
ive lipid lowering and other updated secondary prevention
easures (as summarized in Section 5.2). Further study would provide a stronger evidence base for an initial conser-
ative/selective invasive strategy in initially stabilized pa-
ients, as it has for stable angina patients (546a).
Nevertheless, a meta-analysis of contemporary random-
zed trials in NSTEMI, including ICTUS, currently sup-
orts a long-term mortality and morbidity benefit of an
arly invasive as compared with an initial conservative
trategy (547). Nonfatal MI at 2 years (7.6% vs. 9.1%,
espectively; RR 0.83, 95% CI 0.72 to 0.96, p  0.012) and
ospitalization (at 13 months; RR  0.69, 95% CI 0.65 to
.74, p less than 0.0001) also were reduced by an early
nvasive strategy (Fig. 18). A separate review of contempo-
ary randomized trials in the stent era using the Cochrane
atabase arrived at similar conclusions (548). Details of
elected contemporary trials of invasive versus conservative
trategies follow.
In the FRISC-II study, 3,048 ACS patients were treated
ith dalteparin for 5 to 7 d (245). Of these patients, 2,457
igure 17. Cumulative Risk of Death or Myocardial Infarction or
eath in RITA-3
umulative risk of death or myocardial infarction (top) or of death (bottom) in the
ITA 3 trial of patients with non-ST acute coronary syndromes. Reprinted from The
ancet, 366, Fox KAA, Poole-Wilson P, Clayton TC, et al. 5-year outcome of an
nterventional strategy in non-ST-elevation acute coronary syndrome: the British
eart Foundation RITA 3 randomised trial, 914–20. Copyright 2005, with permis-
ion from Elsevier (546). RITA-3  Third Randomized Intervention Treatment of
ngina trial.ho qualified were then randomized (2 2 factorial design)
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August 14, 2007:e1–157 ACC/AHA UA/NSTEMI Guideline Revisionigure 18. Relative Risk of Outcomes With Early Invasive Versus Conservative Therapy in UA/NSTEMI
: Relative risk of all-cause mortality for early invasive therapy compared with conservative therapy at a mean follow-up of 2 years. B: Relative risk of recurrent nonfatal myocardial
nfarction for early invasive therapy compared with conservative therapy at a mean follow-up of 2 years. C: Relative risk of recurrent unstable angina resulting in rehospitalization for
arly invasive therapy compared with conservative therapy at a mean follow-up of 13 months. Modified from the Journal of the American College of Cardiology, 48, Bavry AA, Kumb-
ani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes a meta-analysis of contemporary randomized clinical trials, 1319–25. Copyright
006, with permission from Elsevier (547). CI  confidence interval; FRISC-II  FRagmin and fast Revascularization during InStability in Coronary artery disease; ICTUS  Invasive
ersus Conservative Treatment in Unstable coronary Syndromes; ISAR-COOL  Intracoronary Stenting with Antithrombotic Regimen COOLing-off study; RITA-3  Third Randomized
ntervention Treatment of Angina trial; RR  relative risk; TIMI-18  Thrombolysis In Myocardial Infarction-18; TRUCS  Treatment of Refractory Unstable angina in geographically
solated areas without Cardiac Surgery; UA/NSTEMI  unstable angina/non–ST-elevation myocardial infarction; VINO  Value of first day angiography/angioplasty In evolving Non-ST
egment elevation myocardial infarction: Open multicenter randomized trial.
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ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:e1–157o continue to receive dalteparin or placebo (double blind)
nd to receive either a noninvasive or an invasive treatment
trategy, with coronary angiography and revascularization, if
ppropriate, performed within 7 d of admission. At 6
onths, there were no differences between continued dalte-
arin compared with placebo. However, death or MI
ccurred in 9.4% of patients assigned to the invasive strategy
ersus 12.1% of those assigned to the noninvasive strategy (p
ess than 0.03). At 1 year, the mortality rate in the invasive
trategy group was 2.2% compared with 3.9% in the
oninvasive strategy group (p  0.016) (549). It may be
oncluded from FRISC-II that patients with UA/NSTEMI
ho are not at very high risk for revascularization and who
rst receive an average of 6 d of treatment with LMWH,
SA, nitrates, and beta blockers have a better outcome at 6
onths with a (delayed) routine invasive approach than
ith a routine conservative approach, with very low revas-
ularization rates. Long-term outcomes of the FRISC-II
rial have been published recently (550). At 5 years, the
nvasive strategy was favored for the primary end point of
eath or nonfatal MI (HR 0.81, p  0.009). Benefit was
onfined to men, nonsmokers, and patients with 2 or more
isk factors.
In the TACTICS-TIMI 18 trial (182), 2,220 patients
ith UA or NSTEMI were treated with ASA, heparin, and
he GP IIb/IIIa inhibitor tirofiban. They were randomized
o an early invasive strategy with routine coronary angiog-
aphy within 48 h followed by revascularization if the
oronary anatomy was deemed suitable or to a more
onservative strategy. In the latter group, catheterization
as performed only if the patient had recurrent ischemia or
positive stress test. Death, MI, or rehospitalization for
CS at 6 months occurred in 15.9% of patients assigned to
he invasive strategy versus 19.4% assigned to the more
onservative strategy (p  0.025). Death or MI (182) was
lso reduced at 6 months (7.3% vs. 9.5%, p less than 0.05).
he beneficial effects on outcome were observed in
edium- and high-risk patients, as defined by an elevation
f TnT greater than 0.01 ng per ml, the presence of
T-segment deviation, or a TIMI risk score greater than 3
159). In the absence of these high-risk features, outcomes
n patients assigned to the 2 strategies were similar, which
mphasizes the critical importance of appropriate risk strat-
fication. Rates of major bleeding were similar, and lengths
f hospital stay were reduced in patients assigned to the
nvasive strategy. The benefits of the invasive strategy were
chieved at no significant increase in the costs of care over
he 6-month follow-up period.
Thus, both the FRISC-II (245) and TACTICS-TIMI
8 (182) trials showed a benefit in patients assigned to the
nvasive strategy. In contrast to earlier trials, a large majority
f patients undergoing PCI in these 2 trials received
oronary stenting as opposed to balloon angioplasty alone.
lso, there was a differential rate of thienopyridine use
etween the 2 arms; only stented patients were treated. In
RISC-II, the invasive strategy involved treatment for an average of 6 d in the hospital with LMWH, ASA, nitrates,
nd beta blockers before coronary angiography, an approach
hat would be difficult to adopt in US hospitals. In
ACTICS-TIMI 18, treatment included the GP IIb/IIIa
ntagonist tirofiban, which was administered for an average
f 22 h before coronary angiography. The routine use of the
P IIb/IIIa inhibitor in this trial may have eliminated the
xcess risk of early (within 7 d) MI in the invasive arm, an
xcess risk that was observed in FRISC-II and other trials in
hich there was no routine “upstream” use of a GP IIb/IIIa
locker. Therefore, an invasive strategy is associated with a
etter outcome in UA/NSTEMI patients at high risk as
efined in Table 11 and as demonstrated in TACTICS-
IMI 18 when a GP IIb/IIIa inhibitor is used (182).
lthough the benefit of intravenous GP IIb/IIIa inhibitors
s established for UA/NSTEMI patients undergoing PCI,
he optimal time to commence these drugs before the
rocedure has not been established. In the PURSUIT trial
128), in patients with UA/NSTEMI who were admitted to
ommunity hospitals, the administration of eptifibatide was
ssociated with a reduced need for transfer to tertiary
eferral centers and improved outcomes (551).
The RITA-3 trial (546) compared early and conservative
herapy in 1,810 moderate-risk patients with ACS. Patients
ith positive cardiac biomarkers (CK-MB greater than 2 times
he upper limit of normal at randomization) were excluded
rom randomization, as were those with new Q waves, MI
ithin 1 month, PCI within 1 year, and any prior CABG. The
ombined end point of death, nonfatal MI, and refractory
ngina was reduced from 14.5% to 9.6% by early invasive
reatment. The benefit was driven primarily by a reduction in
efractory angina. There was a late divergence of the curves,
ith reduced 5-year death and MI in the early invasive arm
Fig. 17).
In the VINO trial (Value of first day angiography/
ngioplasty In evolving Non-ST segment elevation myocar-
ial infarction: Open multicenter randomized trial) (522),
31 patients with NSTEMI were randomized to cardiac
atheterization on the day of admission versus conservative
herapy. Despite the fact that 40% of the conservatively
reated patients crossed over to revascularization by the time
f the 6-month follow-up, there was a significant reduction
n death or reinfarction for patients assigned to early
ngiography and revascularization (6% vs. 22%).
The ISAR-COOL trial (540) randomized 410 intermediate-
o high-risk patients to very early angiography and revascular-
zation versus a delayed invasive strategy. All patients were
reated with intensive medical therapy that included ASA,
eparin, clopidogrel (600-mg loading dose), and the intrave-
ous GP IIb/IIIa receptor inhibitor tirofiban. In the very early
rm, patients underwent cardiac catheterization at a mean time
f 2.4 h versus 86 h in the delayed invasive arm. The very early
nvasive strategy was associated with significantly better out-
ome at 30 d, measured by reduction in death and large MI
5.9% vs. 11.6%). More importantly, the benefit seen was
ttributable to a reduction in events before cardiac catheteriza-
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ted with a ”cooling-down” period.
.3.7. Subgroups
ACTICS-TIMI 18 demonstrated a reduction in the
-month end point of death or MI in older adult ACS
atients. With respect to gender, controversy exists over
evascularization treatment differences between men and
omen with ACS. The FRISC-II trial showed a benefit of
arly revascularization in men for death or MI that was not
bserved for women (552). In contrast, death, MI, or
ehospitalization rates were reduced for both men and
omen in TACTICS-TIMI 18 (182). Furthermore, an
bservational study reported that women actually did better
han men with early interventional therapy for UA/
STEMI (553). Finally, RITA-3 (546) showed that the
outine strategy of invasive evaluation resulted in a beneficial
ffect in men that was not seen in women. Additional
esearch is required to further clarify these diverse observa-
ions (554).
.3.8. Care Objectives
he objective is to provide a strategy that has the most
otential to yield the best clinical outcome and improve
ong-term prognosis. The purpose of coronary angiography
s to provide detailed information about the size and
istribution of coronary vessels, the location and extent of
therosclerotic obstruction, and the suitability for revascu-
arization. The LV angiogram, which is usually performed
long with coronary angiography, provides an assessment of
he extent of focal and global LV dysfunction and of the
resence and severity of coexisting disorders (e.g., valvular
r congenital lesions). A detailed discussion of revascular-
zation is presented in Section 4 of these guidelines, as well
s in the ACC/AHA Guidelines for Percutaneous Coro-
ary Intervention (2) and the ACC/AHA Guideline Up-
ate for Coronary Artery Bypass Graft Surgery (555).
lthough general guidelines can be offered, the selection of
ppropriate procedures and the decision to refer patients for
evascularization require both clinical judgment and coun-
eling with the patient and the patient’s family regarding
xpected risks and benefits.
Although not conducted in patients with UA/NSTEMI,
he following studies have addressed the value of stress
esting in guiding therapy. The DANish trial in Acute
yocardial Infarction (DANAMI) studied 503 patients
ith inducible ischemia (i.e., a positive exercise stress test)
fter fibrinolytic therapy for first MI and compared an
schemia-guided invasive strategy with a conservative strat-
gy (556). The invasive strategy in the post-MI patients
ith inducible ischemia resulted in a reduction in the
ncidence of reinfarction, hospitalizations for UA, and stable
ngina. Similarly, in the Asymptomatic Cardiac Ischemia
ilot (ACIP) study (557,558), 558 clinically stable patients
ith ischemia on stress testing and during daily life (ST-egment depression on exercise treadmill testing or perfu- Nion abnormality on radionuclide pharmacological stress test
f unable to exercise, in addition to ST-segment depression
n ambulatory ECG monitoring), most of whom had
ngina in the previous 6 weeks, were randomized to 1 of 3
nitial treatment strategies: symptom-guided medical care,
schemia-guided medical care, or revascularization. More
han one third of these patients had “complex” stenoses on
ngiography. Those randomized to early revascularization
xperienced less ambulatory ischemia at 12 weeks than did
hose randomized to initial medical care in whom revascu-
arization was delayed and symptom driven.
After either STEMI or NSTEMI, the SWISSI II (Swiss
nterventional Study of Silent Ischemia Type II) study,
hich randomized 201 patients with silent ischemia, dem-
nstrated by stress imaging, to either revascularization with
CI or anti-ischemic drug therapy and followed them for an
verage of 10 years. Survival free of cardiac death, nonfatal
I, or symptom-driven revascularization was significantly
educed in the PCI group. Though relatively small, the
tudy supports the use of stress testing after UA/NSTEMI
or guiding the selection of invasive evaluation in UA/
STEMI patients treated with an initial conservative strat-
gy (558a).
In ACS patients with UA/NSTEMI, the purpose of
oninvasive testing is both to identify ischemia and to
dentify candidates at high risk for adverse outcomes and to
irect them to coronary angiography and revascularization
hen possible. However, neither randomized trials
129,245,533,534) nor observational data (559) uniformly
upport an inherent superiority for the routine use of
oronary angiography and revascularization (see Section 4).
ccordingly, the decision regarding which strategy to pur-
ue for a given patient should be based on the patient’s
stimated outcome risk assisted by clinical and noninvasive
est results, available facilities, previous outcome of revas-
ularization by the team available in the institution in which
he patient is hospitalized, and patient preference.
Coronary angiography can enhance prognostic stratifica-
ion. This information can be used to guide medical therapy
nd to plan revascularization therapy, but it is important to
mphasize that an adverse outcome in ACS is very time
ependent and that after 1 to 2 months, the risk for adverse
utcome is essentially the same as that for low-risk chronic
table angina (Fig. 17). Several older studies in patients with
table angina, including the Second Randomized Interven-
ion Treatment of Angina (RITA-2) trial (535), have found
higher early risk of death or MI with an interventional
trategy than with medical management alone. Thus, the
iming of coronary angiography and revascularization is
ritically important if patients at high risk are to benefit.
nfortunately, the total number of operative complications
s increased when revascularization procedures are per-
ormed routinely, because some patients who are not in need
f revascularization will be exposed to its hazards. However,
ontemporary use of aggressive medical therapy in UA/
STEMI, including oral and intravenous antiplatelet
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azard and risk for ischemic complications in patients
ndergoing early invasive procedures.
Patients with UA/NSTEMI often can be divided into
ifferent risk groups on the basis of their initial clinical
resentation. The TIMI, PURSUIT, and GRACE scores
re useful clinical tools for assigning risk to patients pre-
enting with UA/NSTEMI (Table 8; Fig. 4; see Section
.2.6.).
Risk stratification in turn identifies patients who are most
ikely to benefit from subsequent revascularization. For
xample, patients with left main disease or multivessel CAD
ith reduced LV function are at high risk for adverse
utcomes and are likely to benefit from surgical bypass.
linical evaluation and noninvasive testing will aid in the
dentification of most patients in the high-risk subset,
ecause they often have 1 or more of the following high-risk
eatures: advanced age (greater than 70 years), prior MI,
evascularization, ST-segment deviation, HF or depressed
esting LV function (i.e., LVEF less than or equal to 0.40)
n noninvasive study, or noninvasive stress test findings.
he presence of any of these risk factors or of diabetes
ellitus aids in the identification of high-risk patients who
ould benefit from an invasive strategy.
The majority of patients presenting with UA/NSTEMI,
owever, do not fall into the very high-risk group and do
ot have findings that typically portend a high risk for
dverse outcomes. Accordingly, they are not likely to receive
he same degree of benefit from routine revascularization
fforded to high-risk patients, and an invasive study is
ptional for those at lower risk and can be safely deferred
ending further clinical developments. Decisions regarding
oronary angiography in patients who are not high risk
ccording to findings on clinical examination and noninva-
ive testing can be individualized on the basis of patient
references and the degree to which they are affected by
linical symptoms.
The data on which recommendations for invasive or
onservative strategy recommendations are based come from
everal randomized trials. Older trials included TIMI IIIB
129,561), Veterans Affairs Non-Q-Wave Infarction Strat-
gies in Hospital (VANQWISH) (534), and Medicine
ersus Angiography in Thrombolytic Exclusion (MATE)
533). More recent trials, relevant to contemporary practice,
nclude FRISC-II (245), TACTICS-TIMI 18 (182),
INO (522), RITA-3 (546), ISAR-COOL (540), and
CTUS (532); a large, prospective, multinational registry,
he OASIS registry (559); and several meta-analyses (542–
44). See Section 3.3.1.5 for a detailed description of these
rials and the more recent meta-analyses (543,547).
Some selected areas require additional comment. In a
atient with UA, a history of prior PCI within the past 6
onths suggests the presence of restenosis, which often can
e treated effectively with repeat PCI. Coronary angiogra-
hy without preceding functional testing is generally indi-
ated. Patients with prior CABG represent another sub- proup for whom a strategy of early coronary angiography is
sually indicated. The complex interplay between the pro-
ression of native coronary disease and the development of
raft atherosclerosis with ulceration and embolization is
ifficult to untangle noninvasively; these considerations
rgue for early coronary angiography. In addition, patients
ith known or suspected reduced LV systolic function,
ncluding patients with prior anterior Q-wave MIs, those
ith known depressed LV function, and those who present
ith HF, have sufficient risk that the possibility of benefit
rom revascularization procedures merits early coronary
ngiography without preceding functional testing.
In patients with UA/NSTEMI, coronary angiography
ypically shows the following profile: 1) no severe epicardial
tenosis in 10% to 20% with a sex differential, 2) 1-vessel
tenosis in 30% to 35%, 3) multivessel stenosis in 40% to
0%, and 4) significant (greater than 50%) left main stenosis
n 4% to 10%. In the early invasive strategy in TIMI IIIB,
o critical obstruction (less than 60% diameter stenosis) was
ound in 19% of patients, 1-vessel stenosis in 38%, 2-vessel
tenosis in 29%, 3-vessel stenosis in 15%, and left main
tenosis (greater than 50%) in 4% (564). Complex plaques
re usually believed to be responsible for the culprit lesions.
hese usually are eccentric and sometimes have irregular
orders and correlate with intracoronary thrombi and an
ncreased risk of recurrent ischemia at rest, MI, and cardiac
eath (563). Similar findings were noted in more than 80%
f the patients in the VANQWISH trial, and more than 1
omplex lesion was found in most patients (534). Interest-
ngly, in TIMI IIIB, many of the patients without severe
tenosis had reduced contrast clearance, which suggests
icrovascular dysfunction (564), which can contribute to
mpaired myocardial perfusion.
Appropriate treatment for women presenting with ACS
ight be different from that in men (see also Section 6.1).
n FRISC-II and RITA-3, an improved outcome in the
arly invasive arm was seen only in men, whereas the benefit
f early revascularization was equivalent in men and women
n the TACTICS-TIMI 18 (182) trial provided that the
roponin level was elevated. In contrast, low-risk women
ended to have worse outcomes, including a higher risk of
ajor bleeding, with early revascularization therapy,
hereas low-risk men were neither harmed nor benefited by
his strategy (565). Most studies showed that women were
ore likely than men to have either normal vessels or
oncritical stenoses. High-risk women also were more likely
o have elevation of CRP and BNP and less often had
levated troponin (182,565). Women with any positive
iomarker benefited from invasive therapy, whereas those
ithout elevated CRP, BNP, or troponin did better with a
onservative approach (see Section 6.1).
Patients with severe 3-vessel stenosis and reduced LV
unction and those with left main stenosis should be
onsidered for early CABG (see Section 4). In low-risk
atients, quality of life and patient preferences should be
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trategy. Low-risk patients whose symptoms do not respond
ell to maximal medical therapy and who experience poor
uality of life and functional status and are prepared to
ccept the risks of revascularization should be considered for
evascularization.
The discovery that a patient does not have significant
bstructive CAD should prompt consideration of whether
he symptoms represent another cause of cardiac ischemia
e.g., syndrome X, coronary spasm, coronary embolism, or
oronary artery dissection; see Section 6) or pericarditis/
yocarditis or are noncardiac in origin. There is a distinc-
ion between normal coronaries and vessels with less than
0% stenoses but with atherosclerotic plaque present, which
ight be demonstrated to be extensive on coronary intra-
ascular ultrasound. The latter can include visualization of a
ulprit ulcerated plaque. Noncardiac syndromes should
rompt a search for the true cause of symptoms. Unfortu-
ately, many such patients continue to have recurrent
ymptoms, are readmitted to the hospital, can become
isabled, and continue to consume health care resources
ven with repeated coronary angiography (566,567).
It is not presently possible to define the extent of
omorbidity that would, in every case, make referral for
oronary angiography and revascularization inappropriate.
he high-risk patient with significant comorbidities re-
uires thoughtful discussion among the physician, patient,
nd family and/or patient advocate. A decision for or against
evascularization must be made on a case-by-case basis.
Examples of extensive comorbidity that usually preclude
evascularization include 1) advanced or metastatic malig-
ancy with a projected life expectancy of 1 year or less, 2)
ntracranial pathology that contraindicates the use of sys-
emic anticoagulation or causes severe cognitive disturbance
e.g., Alzheimer’s disease) or advanced physical limitations,
) end-stage cirrhosis with symptomatic portal hypertension
e.g., encephalopathy, visceral bleeding), and 4) CAD that
s known from previous angiography not to be amenable to
evascularization. This list is not meant to be all-inclusive.
ore difficult decisions involve patients with significant
omorbidities that are not as serious as those listed here;
xamples include patients who have moderate or severe
enal failure but are stable with dialysis.
Consultation with an interventional cardiologist and a
ardiac surgeon before coronary angiography is advised to
efine technical options and likely risks and benefits. The
perators who perform coronary angiography and revascu-
arization and the facility in which these procedures are
erformed are important considerations, because the avail-
bility of interventional cardiologists and cardiac surgeons
ho are experienced in high-risk and complex patients is
ssential. As a general principle, the potential benefits of
oronary angiography and revascularization must be care-
ully weighed against the risks and the conflicting results of fhe clinical trials and registries. The Writing Committee
ndorses further research into techniques that could reduce
leeding (e.g., radial access and smaller sheath sizes) (568)
nd the proper selection and dosing of drugs to minimize
leeding in patients with UA/NSTEMI.
.4. Risk Stratification Before Discharge
RECOMMENDATIONS
LASS I
. Noninvasive stress testing is recommended in low-risk patients
(Table 7) who have been free of ischemia at rest or with low-level
activity and of HF for a minimum of 12 to 24 h. (Level of Evidence: C)
. Noninvasive stress testing is recommended in patients at interme-
diate risk (Table 7) who have been free of ischemia at rest or with
low-level activity and of HF for a minimum of 12 to 24 h. (Level of
Evidence: C)
. Choice of stress test is based on the resting ECG, ability to perform
exercise, local expertise, and technologies available. Treadmill ex-
ercise is useful in patients able to exercise in whom the ECG is free
of baseline ST-segment abnormalities, bundle-branch block, LV
hypertrophy, intraventricular conduction defect, paced rhythm, pre-
excitation, and digoxin effect. (Level of Evidence: C)
. An imaging modality should be added in patients with resting
ST-segment depression (greater than or equal to 0.10 mV), LV
hypertrophy, bundle-branch block, intraventricular conduction de-
fect, preexcitation, or digoxin who are able to exercise. In patients
undergoing a low-level exercise test, an imaging modality can add
sensitivity. (Level of Evidence: B)
. Pharmacological stress testing with imaging is recommended when
physical limitations (e.g., arthritis, amputation, severe peripheral vas-
cular disease, severe chronic obstructive pulmonary disease, or gen-
eral debility) preclude adequate exercise stress. (Level of Evidence: B)
. Prompt angiography without noninvasive risk stratification should
be performed for failure of stabilization with intensive medical
treatment. (Level of Evidence: B)
. A noninvasive test (echocardiogram or radionuclide angiogram) is
recommended to evaluate LV function in patients with definite ACS
who are not scheduled for coronary angiography and left ventricu-
lography. (Level of Evidence: B)
The management of ACS patients requires continuous
isk stratification. Important prognostic information is de-
ived from careful initial assessment, the patient’s course
uring the first few days of management, and the patient’s
esponse to anti-ischemic and antithrombotic therapy. The
raunwald classification (14,260) has been validated pro-
pectively and represents an appropriate clinical instrument
o help predict outcome (569). Angina at rest, within 48 h
n the absence of an extracardiac condition (primary UA;
raunwald Class III), and UA in the early postinfarction
eriod (Braunwald class C), along with age, male sex,
ypertension, and maximal intravenous antianginal/anti-
schemic therapy, were independent predictors for death or
onfatal MI. The baseline ECG on presentation was also
ound to be extremely useful for risk stratification in the
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ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:e1–157IMI III registry (199), as discussed in Section 2.2.6.2, and
n the RISC (Research on InStability in Coronary artery
isease) study group (570). In a more recent database of
2,142 patients presenting within 12 h of the onset of
schemic symptoms, the ECG at presentation allowed
ndividualized risk stratification across the spectrum of ACS
127) (Fig. 19). In many cases, noninvasive stress testing
rovides a very useful supplement to such clinically based
isk assessment. In addition, as pointed out previously,
roponins are very helpful in risk assessment. Some patients,
owever, are at such high risk for an adverse outcome that
oninvasive risk stratification would not be likely to identify
subgroup with sufficiently low risk to avoid coronary
ngiography to determine whether revascularization is pos-
ible. These patients include those who, despite intensive
edical therapy, manifest recurrent rest angina, hemody-
amic compromise, or severe LV dysfunction. Such patients
hould be considered directly for early coronary angiography
ithout noninvasive stress testing; however, referral for
oronary angiography is not reasonable if they are unwilling
o consider revascularization or have severe complicating
llnesses that preclude revascularization. Other patients may
ave such a low likelihood of CAD after initial clinical
valuation that even an abnormal test finding is unlikely to
rompt additional therapy that would further reduce risk
e.g., a 35-year-old woman without CAD risk factors). Such
atients would ordinarily not be considered for coronary
ngiography and revascularization unless the diagnosis of
A/NSTEMI is unclear. The majority of patients present-
ng with UA/NSTEMI do not fall into these categories and
re accordingly reasonable candidates for risk stratification
ith noninvasive testing.
Determination of patient risk on the basis of a validated
coring algorithm (e.g., from the TIMI, GRACE, or
URSUIT trial data) can be valuable for identifying high-
isk patients (see Section 2.2.6 and Table 8). They also can
ssist in selecting those who can benefit most from more
ggressive therapies, such as LMWH or an invasive treat-
ent strategy (see Section 3.4.1).
.4.1. Care Objectives
he goals of noninvasive testing are to 1) determine the
resence or absence of ischemia in patients with a low or
ntermediate likelihood of CAD and 2) estimate prognosis.
his information is key for the development of further
iagnostic steps and therapeutic measures.
A detailed discussion of noninvasive stress testing in
AD is presented in the ACC/AHA Guidelines for Exer-
ise Testing, ACC/AHA Guidelines for the Clinical Use of
ardiac Radionuclide Imaging, and ACC/AHA Guidelines
or the Clinical Application of Echocardiography (4,571–
73) (Tables 19, 20, and 21). Briefly, the provocation of
schemia at a low workload (574) or a high-risk treadmill
core (i.e., greater than or equal to 11) (575) implies severe (imitation in the ability to increase coronary blood flow.
his is usually the result of severe coronary artery obstruction
nd is associated with a high risk for an adverse outcome
nd/or severe angina after discharge. Unless there are contra-
ndications to revascularization, such patients generally merit
eferral for early coronary angiography to direct a revascular-
zation procedure, if appropriate. On the other hand, the
ttainment of a higher workload (e.g., greater than 6.5 meta-
olic equivalents [METS]) without evidence of ischemia
igure 19. Kaplan-Meier Estimates of Probability of Death Based
n Admission Electrocardiogram
odified with permission from Savonitto S, Ardissino D, Granger CB, et al. Prognos-
ic value of the admission electrocardiogram in acute coronary syndromes. JAMA
999;281:707–13 (127). Copyright © 1999 American Medical Association.low-risk treadmill score greater than or equal to 5) (575) is
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August 14, 2007:e1–157 ACC/AHA UA/NSTEMI Guideline Revisionssociated with functionally less severe coronary artery obstruc-
ion. Such patients have a better prognosis and can often be
afely managed conservatively. Ischemia that develops at
reater than 6.5 METS can be associated with severe coronary
rtery obstruction, but unless other high-risk markers are
resent (greater than 0.2-mV ST-segment depression or ele-
ation, fall in blood pressure, ST-segment shifts in multiple
eads reflecting multiple coronary regions, or prolonged ST-
able 19. Noninvasive Risk Stratification
igh risk (greater than 3% annual mortality rate)
Severe resting LV dysfunction (LVEF less than 0.35)
High-risk treadmill score (score 11 or less)
Severe exercise LV dysfunction (exercise LVEF less than 0.35)
Stress-induced large perfusion defect (particularly if anterior)
Stress-induced multiple perfusion defects of moderate size
Large, fixed perfusion defect with LV dilation or increased lung uptake
(thallium-201)
Stress-induced moderate perfusion defect with LV dilation or increased lung
uptake (thallium-201)
Echocardiographic wall-motion abnormality (involving more than 2
segments) developing at low dose of dobutamine (10 mcg per kg per min
or less) or at a low heart rate (less than 120 beats per min)
Stress echocardiographic evidence of extensive ischemia
ntermediate risk (1% to 3% annual mortality rate)
Mild/moderate resting LV dysfunction (LVEF  0.35 to 0.49)
Intermediate-risk treadmill score (11 to 5)
Stress-induced moderate perfusion defect without LV dilation or increased
lung intake (thallium-201)
Limited stress echocardiographic ischemia with a wall-motion abnormality
only at higher doses of dobutamine involving less than or equal to 2
segments
ow risk (less than 1% annual mortality rate)
Low-risk treadmill score (score 5 or greater)
Normal or small myocardial perfusion defect at rest or with stress*
Normal stress echocardiographic wall motion or no change of limited resting
wall-motion abnormalities during stress*
Although the published data are limited, patients with these findings will probably not be at low
isk in the presence of either a high-risk treadmill score or severe resting LV dysfunction (LVEF
ess than 0.35). Reproduced from Table 23 in Gibbons RJ, Abrams J, Chatterjee K, et al.
CC/AHA 2002 guideline update for the management of patients with chronic stable angina: a
eport of the American College of Cardiology/American Heart Association Task Force on Practice
uidelines (Committee to Update the 1999 Guidelines for the Management of Patients With
hronic Stable Angina). 2002. Available at: www.acc.org/qualityandscience/clinical/
tatements.htm (4).
LV  left ventricular; LVEF  left ventricular ejection fraction.
able 20. Noninvasive Test Results That Predict
igh Risk for Adverse Outcome (Left Ventricular Imaging)
Stress Radionuclide
Ventriculography Stress Echocardiography
xercise EF 0.50 or less Rest EF 0.35 or less
est EF 0.35 or less Wall-motion score index greater than 1
all in EF 0.10 or greater
dapted from O’Rourke RA, Chatterjee K, Dodge HT, et al. Guidelines for clinical use of cardiac
adionuclide imaging, December 1986: a report of the American College of Cardiology/American
eart Association Task Force on Assessment of Cardiovascular Procedures (Subcommittee on
uclear Imaging). J Am Coll Cardiol 1986;8:1471–83 (576); and Cheitlin MD, Alpert JS,
rmstrong WF, et al. ACC/AHA guidelines for the clinical application of echocardiography.2
irculation 1997;95:1686–744 (577).
EF  ejection fraction.egment shifts [greater than 6 min] in recovery), these patients
lso may be safely managed conservatively (Table 20).
Stress radionuclide ventriculography or stress echocardi-
graphy (Table 20) provides an important alternative to
xercise electrocardiography testing. Myocardial perfusion
maging with pharmacological stress (Table 21) is particu-
arly useful in patients who are unable to exercise. The
rognostic value of pharmacological stress testing appears
imilar to that of exercise testing with imaging, although
here are few direct comparisons.
As noted earlier (Section 2.3.2.), CMR is a newer
maging modality that can effectively assess cardiac function,
erfusion (e.g., with adenosine stress), and viability at the
ame study. The combination of these features has been
eported to yield excellent predictive information in sus-
ected CAD/ACS patients (296).
.4.2. Noninvasive Test Selection
here are no conclusive data that either LV function or
yocardial perfusion at rest and during exercise or pharmaco-
ogical stress is superior in the assessment of prognosis. Both
he extent of CAD and the degree of LV dysfunction are
mportant in the selection of the appropriate therapy. Studies
hat directly compare prognostic information from multiple
oninvasive tests for ischemia in patients after the stabilization
f UA/NSTEMI are hampered by small sample size. Dobut-
mine stress echocardiography measures both resting LV
unction and the functional consequences of a coronary steno-
is (571). An ischemic response is characterized by initially
mproved LV function at low-stress doses, followed by dete-
ioration with increasing dobutamine doses (571). However,
A and MI are listed as contraindications for dobutamine
tress echocardiography (578).
The RISC study evaluated predischarge symptom-limited
icycle exercise testing in 740 men with UA/NSTEMI (579).
ultivariate analysis showed that the extent of ST-segment
epression, expressed as the number of leads with ischemic
hanges at a low maximal workload, was negatively correlated
ndependently with infarct-free survival rates at 1 year. This
nd other smaller studies permit a comparison of the effective-
ess of exercise ECG with exercise or dipyridamole thallium-
able 21. Noninvasive Test Results That Predict High Risk for
dverse Outcome on Stress Radionuclide Myocardial
erfusion Imaging
bnormal myocardial tracer distribution in more than 1 coronary artery region
at rest or with stress or a large anterior defect that reperfuses
bnormal myocardial distribution with increased lung uptake
ardiac enlargement
dapted from O’Rourke RA, Chatterjee K, Dodge HT, et al. Guidelines for clinical use of cardiac
adionuclide imaging, December 1986: a report of the American College of Cardiology/American
eart Association Task Force on Assessment of Cardiovascular Procedures (Subcommittee on
uclear Imaging). J Am Coll Cardiol 1986;8:1471–83 (576).01 study for risk stratification. All of these noninvasive tests
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ion into low- and high-risk subgroups.
Selection of the noninvasive stress test should be based
rimarily on patient characteristics, local availability, and ex-
ertise in interpretation (580). Because of simplicity, lower
ost, and widespread familiarity with performance and inter-
retation, the standard low-level exercise ECG stress test
emains the most reasonable test in patients who are able to
xercise and who have a resting ECG that is interpretable for
T-segment shifts. Patients with an ECG pattern that would
nterfere with interpretation of the ST segment should have an
xercise test with imaging. Patients who are unable to exercise
hould have a pharmacological stress test with imaging. Low-
nd intermediate-risk patients admitted with ACS may un-
ergo symptom-limited stress testing provided they have been
symptomatic and clinically stable for 12 to 24 h.
The optimal testing strategy in women is less well defined
han in men (see Section 6.1), but there is evidence that
maging studies are superior to exercise ECG evaluation in
omen (580,581). Exercise testing has been reported to be less
ccurate for diagnosis in women. At least a portion of the lower
eported accuracy derives from a lower pretest likelihood of
AD in women than in men; the higher prevalence of
schemia secondary to vascular dysfunction (coronary endothe-
ial and/or microvascular dysfunction) in the absence of ob-
tructive CAD also is a likely contributor to this.
Results of a symptom-limited exercise test performed 3
o 7 d after UA/NSTEMI were compared with results of
test conducted 1 month later in 189 patients (534,582).
he diagnostic and prognostic values of the tests were
imilar, but the earlier test identified patients who developed
dverse events during the first month, and this represented
pproximately one half of all events that occurred during the
rst year. These data illustrate the importance of early nonin-
asive testing for risk stratification.
The VANQWISH trial used symptom-limited thallium
xercise treadmill testing at 3 to 5 d to direct the need for
ngiography in the 442 non–Q-wave MI patients randomized
o an early conservative strategy (534). Among subjects in the
onservative arm meeting VANQWISH stress test criteria to
ross over to coronary angiography, 51% were found to have
urgical CAD and showed favorable outcomes after revascu-
arization (583). These findings support the concept that
oninvasive stress testing can be used successfully to identify a
igh-risk subset of patients who can be directed to coronary
ngiography. It is unlikely that any angiographically directed
arly revascularization strategy could alter the very low early
vent rates observed in patients without a high-risk stress test.
Noninvasive tests are most useful for management decisions
hen risk can be stated in terms of events over time. A large
opulation of patients must be studied to derive and test the
quations needed to accurately predict individual patient risk.
o noninvasive study has been reported in a sufficient numberf patients after the stabilization of UA/NSTEMI to develop fnd test the accuracy of a multivariable equation to report test
esults in terms of absolute risk. Therefore, data from studies of
table angina patients must be used for risk, reported as events
ver time. Although the pathological process that evokes
schemia may be different in the 2 forms of angina, it is likely
hat the use of prognostic nomograms derived from patients
ith stable angina also are predictive of risk in patients with
ecent UA/NSTEMI after stabilization. With this untested
ssumption, the much larger literature derived from popula-
ions that include patients with both stable angina and UA/
STEMI provides equations for risk stratification that convert
hysiological changes observed during noninvasive testing into
tatements of risk expressed as events over time.
.4.3. Selection for Coronary Angiography
n contrast to the noninvasive tests, coronary angiography
rovides detailed structural information to allow an assessment
f prognosis and to provide direction for appropriate manage-
ent. When combined with LV angiography, it also allows an
ssessment of global and regional LV function. Indications for
oronary angiography are interwoven with indications for
ossible therapeutic plans, such as PCI or CABG.
Coronary angiography is usually indicated in patients with
A/NSTEMI who either have recurrent symptoms or isch-
mia despite adequate medical therapy or are at high risk as
ategorized by clinical findings (HF, serious ventricular ar-
hythmias) or noninvasive test findings (significant LV dys-
unction: ejection fraction less than 0.35, large anterior or
ultiple perfusion defects; Tables 19, 20, and 21), as discussed
n Section 3.4.2. Patients with UA/NSTEMI who have had
revious PCI or CABG also should generally be considered for
arly coronary angiography, unless prior coronary angiography
ata indicate that no further revascularization is likely to be
ossible. The placement of an IABP may allow coronary
ngiography and revascularization in those with hemodynamic
nstability (see Section 3.1.2.7). Patients with suspected Prinz-
etal’s variant angina also are candidates for coronary angiog-
aphy (see Section 6.7).
In all cases, the general indications for coronary angiog-
aphy and revascularization are tempered by individual
atient characteristics and preferences. Patient and physi-
ian judgments regarding risks and benefits are particularly
mportant for patients who might not be candidates for
oronary revascularization, such as very frail older adults and
hose with serious comorbid conditions (i.e., severe hepatic,
ulmonary, or renal failure; active or inoperable cancer).
.4.4. Patient Counseling
esults of testing should be discussed with the patient, the
atient’s family, and/or the patient’s advocate in a language
hat is understood by them. Test results should be used to
elp determine the advisability of coronary angiography, the
eed for adjustments in the medical regimen, and the need
or secondary prevention measures (see Section 5).
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.1. Recommendations for Revascularization With
CI and CABG in Patients With UA/NSTEMI
See Fig. 20 for details of the decision tree.)
.1.1. Recommendations for PCI
LASS I
. An early invasive PCI strategy is indicated for patients with UA/
NSTEMI who have no serious comorbidity and who have coronary
lesions amenable to PCI and any of the high-risk features listed in
Section 3.3. (See Section 3.3 for specific recommendations and
their Level of Evidence.)
. Percutaneous coronary intervention (or CABG) is recommended for
UA/NSTEMI patients with 1- or 2-vessel CAD with or without signif-
icant proximal left anterior descending CAD but with a large area of
viable myocardium and high-risk criteria on noninvasive testing.
(Level of Evidence: B)
. Percutaneous coronary intervention (or CABG) is recommended for
UA/NSTEMI patients with multivessel coronary disease with suit-
able coronary anatomy, with normal LV function, and without dia-
betes mellitus. (Level of Evidence: A)
. An intravenous platelet GP IIb/IIIa inhibitor is generally recom-
mended in UA/NSTEMI patients undergoing PCI. (Level of Evidence:
A) See Section 3.2.3 and Figures 7, 8, and 9 for details on timing
and dosing recommendations (see Table 13).
LASS IIa
. Percutaneous coronary intervention is reasonable for focal saphe-
nous vein graft (SVG) lesions or multiple stenoses in UA/NSTEMI
patients who are undergoing medical therapy and who are poor
candidates for reoperative surgery. (Level of Evidence: C)
. Percutaneous coronary intervention (or CABG) is reasonable for
UA/NSTEMI patients with 1- or 2-vessel CAD with or without signif-
icant proximal left anterior descending CAD but with a moderate
area of viable myocardium and ischemia on noninvasive testing.
(Level of Evidence: B)
. Percutaneous coronary intervention (or CABG) can be beneficial
compared with medical therapy for UA/NSTEMI patients with
1-vessel disease with significant proximal left anterior descending
CAD. (Level of Evidence: B)
. Use of PCI is reasonable in patients with UA/NSTEMI with significant
left main CAD (greater than 50% diameter stenosis) who are
candidates for revascularization but are not eligible for CABG or who
require emergent intervention at angiography for hemodynamic
instability. (Level of Evidence: B)
LASS IIb
. In the absence of high-risk features associated with UA/NSTEMI, PCI
may be considered in patients with single-vessel or multivessel CAD
who are undergoing medical therapy and who have 1 or more lesions
to be dilatedwith a reduced likelihood of success. (Level of Evidence: B)
. Percutaneous coronary intervention may be considered for UA/
NSTEMI patients who are undergoing medical therapy who have 2-
or 3-vessel disease, significant proximal left anterior descending
CAD, and treated diabetes or abnormal LV function, with anatomysuitable for catheter-based therapy. (Level of Evidence: B)LASS III
. Percutaneous coronary intervention (or CABG) is not recommended
for patients with 1- or 2-vessel CAD without significant proximal left
anterior descending CAD with no current symptoms or symptoms
that are unlikely to be due to myocardial ischemia and who have no
ischemia on noninvasive testing. (Level of Evidence: C)
. In the absence of high-risk features associated with UA/NSTEMI, PCI
is not recommended for patients with UA/NSTEMI who have single-
vessel or multivessel CAD and no trial of medical therapy, or who
have 1 or more of the following:
a. Only a small area of myocardium at risk. (Level of Evidence: C)
b. All lesions or the culprit lesion to be dilated with morphology that
conveys a low likelihood of success. (Level of Evidence: C)
c. A high risk of procedure-related morbidity or mortality. (Level of
Evidence: C)
d. Insignificant disease (less than 50% coronary stenosis). (Level of
Evidence: C)
e. Significant left main CAD and candidacy for CABG. (Level of
Evidence: B)
. A PCI strategy in stable patients with persistently occluded infarct-
related coronary arteries after NSTEMI is not indicated. (Level of
Evidence: B)
.1.2. Recommendations for CABG
LASS I
. Coronary artery bypass graft surgery is recommended for UA/NSTEMI
patients with significant left main CAD (greater than 50% stenosis).
(Level of Evidence: A)
. Coronary artery bypass graft surgery is recommended for UA/
NSTEMI patients with 3-vessel disease; the survival benefit is
greater in patients with abnormal LV function (LVEF less than 0.50).
(Level of Evidence: A)
. Coronary artery bypass graft surgery is recommended for UA/
NSTEMI patients with 2-vessel disease with significant proximal
left anterior descending CAD and either abnormal LV function
(LVEF less than 0.50) or ischemia on noninvasive testing. (Level
of Evidence: A)
. Coronary artery bypass graft surgery is recommended for UA/
NSTEMI patients in whom percutaneous revascularization is not
optimal or possible and who have ongoing ischemia not responsive
to maximal nonsurgical therapy. (Level of Evidence: B)
. Coronary artery bypass graft surgery (or PCI) is recommended for
UA/NSTEMI patients with 1- or 2-vessel CAD with or without signif-
icant proximal left anterior descending CAD but with a large area of
viable myocardium and high-risk criteria on noninvasive testing.
(Level of Evidence: B)
. Coronary artery bypass graft surgery (or PCI) is recommended for
UA/NSTEMI patients with multivessel coronary disease with suit-
able coronary anatomy, with normal LV function, and without dia-
betes mellitus. (Level of Evidence: A)
LASS IIa
. For patients with UA/NSTEMI and multivessel disease, CABG with
use of the internal mammary arteries can be beneficial over PCI in
patients being treated for diabetes. (Level of Evidence: B)
. It is reasonable to perform CABG with the internal mammary artery
for UA/NSTEMI patients with multivessel disease and treated dia-betes mellitus. (Level of Evidence: B)
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SVG stenoses, especially when there is significant stenosis of a graft
that supplies the LAD. (Level of Evidence: C)
. Coronary artery bypass graft surgery (or PCI) is reasonable for
UA/NSTEMI patients with 1- or 2-vessel CAD with or without signif-
icant proximal left anterior descending CAD but with a moderate
area of viable myocardium and ischemia on noninvasive testing.
(Level of Evidence: B)
. Coronary artery bypass graft surgery (or PCI) can be beneficial
compared with medical therapy for UA/NSTEMI patients with
1-vessel disease with significant proximal left anterior descending
CAD. (Level of Evidence: B)
. Coronary artery bypass surgery (or PCI with stenting) is reasonable
for patients with multivessel disease and symptomatic myocardial
ischemia. (Level of Evidence: B)
LASS IIb
oronary artery bypass graft surgery may be considered in patients
ith UA/NSTEMI who have 1- or 2-vessel disease not involving the
roximal LAD with a modest area of ischemic myocardium when
ercutaneous revascularization is not optimal or possible. (If there is a
arge area of viable myocardium and high-risk criteria on noninvasive
esting, this recommendation becomes a Class I recommendation.)
igure 20. Revascularization Strategy in UA/NSTEMI
There is conflicting information about these patients. Most consider CABG to be pr
nary artery; PCI  percutaneous coronary intervention UA/NSTEMI  unstable angiLevel of Evidence: B) mLASS III
oronary artery bypass graft surgery (or PCI) is not recommended for
atients with 1- or 2-vessel CAD without significant proximal left
nterior descending CAD with no current symptoms or symptoms that
re unlikely to be due to myocardial ischemia and who have no
schemia on noninvasive testing. (Level of Evidence: C)
.2. General Principles
s discussed in Section 3.4.3, coronary angiography is
seful for defining the coronary artery anatomy in patients
ith UA/NSTEMI and for identifying subsets of high-risk
atients who can benefit from early revascularization. Cor-
nary revascularization (PCI or CABG) is performed to
mprove prognosis, relieve symptoms, prevent ischemic
omplications, and improve functional capacity. The deci-
ion to proceed from diagnostic angiography to revascular-
zation is influenced not only by the coronary anatomy but
lso by a number of additional factors, including anticipated
ife expectancy, ventricular function, comorbidity, func-
ional capacity, severity of symptoms, and quantity of viable
yocardium at risk. These are all important variables that
ust be considered before revascularization is recom-
le to PCI. CABG  coronary artery bypass graft; LAD  left anterior descending cor-
n–ST-elevation myocardial infarction.ended. For example, patients with distal obstructive cor-
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August 14, 2007:e1–157 ACC/AHA UA/NSTEMI Guideline Revisionnary lesions or those who have large quantities of irrevers-
bly damaged myocardium are unlikely to benefit from
evascularization, particularly if they can be stabilized with
edical therapy. Patients with high-risk coronary anatomy
re likely to benefit from revascularization in terms of both
ymptom improvement and long-term survival (Fig. 20).
he indications for coronary revascularization in patients
ith UA/NSTEMI are similar to those for patients with
hronic stable angina and are presented in greater detail in
he ACC/AHA Guidelines for the Management of Patients
ith Chronic Stable Angina (4), the ACC/AHA Guide-
ines for Coronary Artery Bypass Graft Surgery (555), and
he 2005 ACC/AHA/SCAI Guidelines Update for Percu-
aneous Coronary Intervention (2).
Plaque rupture with subsequent platelet aggregation and
hrombus formation is most often the underlying patho-
hysiological cause of UA/NSTEMI (124,126). The man-
gement of many patients with UA/NSTEMI often in-
olves revascularization of the underlying CAD with either
CI or CABG. Selection of the appropriate revasculariza-
ion strategy depends on clinical factors, operator experi-
nce, and extent of the underlying CAD. Many patients
ith UA/NSTEMI have coronary disease that is amenable
o either form of therapy; however, some patients have
igh-risk features, such as reduced LV function, that place
hem in a group of patients who experience improved
ong-term survival rates with CABG. In other patients,
dequate revascularization with PCI might not be optimal
r even possible, and CABG would be the better revascu-
arization choice. In still other patients who are poor
urgical candidates, PCI is preferred.
Findings in large registries of patients with CAD suggest
hat the mode of clinical presentation should have little
earing on the subsequent revascularization strategy
7,9,13,124,126). In a series of 9,263 patients with CAD, an
dmission diagnosis of UA (vs. chronic stable angina) had
o influence on 5-year survival rates after CABG, percuta-
eous transluminal coronary angioplasty (PTCA), or med-
cal treatment (584). An initial diagnosis of UA also did not
nfluence survival 3 years after either CABG or PTCA in
9,576 patients treated in the state of New York (585).
oreover, long-term survival rates after CABG are similar
or UA patients who present with rest angina, increasing
ngina, new-onset angina, or post-MI angina (586). These
bservations suggest that published data that compare
efinitive treatments for patients who initially present with
ultiple clinical manifestations of CAD can be used to
uide management decisions for patients who present with
A/NSTEMI. Consequently, the indications for coronary
evascularization in patients with UA/NSTEMI are, in
eneral, similar to those for patients with stable angina. The
rincipal difference is that the impetus for some form of
evascularization is stronger in patients with UA/NSTEMI
y the very nature of the presenting symptoms (586).
oreover, revascularization in patients with UA/NSTEMI,articularly those with high-risk characteristics, appears to 2e of most benefit if performed early in the hospital course
see Section 3.3).
.3. Percutaneous Coronary Intervention
n recent years, technological advances coupled with high
cute success rates and low complication rates have in-
reased the use of percutaneous catheterization in patients
ith UA/NSTEMI. Stenting and the use of adjunctive
latelet GP IIb/IIIa inhibitors have further broadened the
se of PCI by improving both the safety and durability of
hese procedures. Percutaneous coronary revascularization
intervention) strategies are referred to in these guidelines as
PCI.” This term refers to a family of percutaneous tech-
iques, including standard balloon angioplasty (PTCA),
ntracoronary stenting, and atheroablative technologies
e.g., atherectomy, thrombectomy, or laser angioplasty).
Percutaneous transluminal coronary angioplasty” some-
imes is used to refer to studies in which this was the
ominant form of PCI, before the widespread use of
tenting. The majority of current PCIs involve balloon
ilation and coronary stenting. Stenting has contributed
reatly to catheter-based revascularization by reducing the
isks of both acute vessel closure and late restenosis. Drug-
luting stents have been demonstrated to markedly reduce
he risk of restenosis compared with bare-metal stents.
lthough stenting has become the most widely used percu-
aneous technique, with most laboratories in the United
tates employing stents in 80% to 85% of their PCI
rocedures, other devices continue to be used for specific
esions and patient subsets. Although the technical safety
nd efficacy of atheroablative and thrombectomy devices
ave been described, few data exist to demonstrate incre-
ental benefit with regard to clinical outcomes, and even
ess information is available that describes the use of these
trategies specifically in patients with UA/NSTEMI (587).
he need to continue with the development of safer, more
ffective PCI techniques is emphasized by recently raised
oncerns about delayed endothelialization over DES and
onsequent increases in late coronary thrombotic events,
otentially leading to death or MI (399,400,402,403,411).
Other techniques and devices, such as the AngioJet
hrombectomy catheter, have been tested for the treatment
f thrombi that are visible within a coronary artery (588).
xperience with these devices has indicated that the angio-
raphic appearance of a coronary stenosis can be improved,
ut few comparative data exist to substantiate improvements
n clinical outcome.
The reported clinical efficacy of PCI in UA/NSTEMI
as varied. This is likely attributable to differences in study
esign, treatment strategies, patient selection, and operator
xperience. Nevertheless, the success rate of PCI in patients
ith UA/NSTEMI overall is quite high. In TIMI IIIB, for
xample, angiographic success was achieved in 96% of
atients with UA/NSTEMI who underwent balloon angio-
lasty. With clinical criteria, periprocedural MI occurred in
.7% of patients, emergency CABG surgery was required in
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as 0.5% (129,589).
The use of balloon angioplasty has been evaluated in
everal other trials of patients with UA versus stable angina
590–595). A large retrospective study compared the results
f angioplasty in patients with stable angina to that in
atients with UA (591). After an effort to manage patients
ith UA with medical therapy, PTCA was performed an
verage of 15 d after hospital admission. Compared with
atients with stable angina, UA patients showed no signif-
cant differences with respect to primary clinical success
92% for UA vs. 94% for stable angina), in-hospital mor-
ality rates (0.3% vs. 0.1%), or the number of adverse events
t 6-month follow-up (591). These findings suggest that
esults in immediate and 6-month outcomes are comparable
n patients with stable angina and UA. In addition, in a
etrospective analysis, the results in UA patients were
imilar regardless of whether the procedure was performed
arly (less than 48 h) or late (greater than 48 h) after hospital
resentation (590).
Although other earlier studies (predominantly from the
980s) had suggested that patients with UA who undergo
alloon PTCA have higher rates of MI and restenosis than
atients with stable angina (592–596), contemporary cath-
ter revascularization differs by often involving coronary
tenting, DES, and adjunctive use of platelet GP IIb/IIIa
eceptor inhibitors, which are likely to affect not only
mmediate- but also long-term outcomes (512). Histori-
ally, PTCA had been limited by acute vessel closure, which
ccurs in approximately 5% of patients, and by coronary
estenosis, which occurred in approximately 35% to 45% of
reated lesions during a 6-month period. Coronary stenting
as offered an important alternative to PTCA because of its
ssociation with both a marked reduction in acute closure
nd lower rates of restenosis. By preventing acute or
hreatened closure, stenting reduces the incidence of
rocedure-related STEMI and need for emergency CABG
urgery and can also prevent other ischemic complications.
In a comparison of the use of the Palmaz-Schatz coronary
tent in patients with stable angina and patients with UA,
o significant differences were found with respect to in-
ospital outcome or restenosis rates (597). Another study
ound similar rates of initial angiographic success and
n-hospital major complications in stented patients with UA
ompared with those with stable angina (598). Major
dverse cardiac events at 6 months were also similar between
he 2 groups, whereas the need for repeat PCI and target-
essel revascularization was actually less in the UA group.
n the other hand, other data have suggested that UA
ncreases the incidence of adverse ischemic outcomes in
atients undergoing coronary stent deployment despite
herapy with ticlopidine and ASA, which suggests the need
or more potent antiplatelet therapy in this patient popula-
ion (599).
Drug-eluting stent use for UA/NSTEMI has increased
ramatically in recent years. Kandzari et al. evaluated eatterns of DES utilization in 8,852 high-risk UA/
STEMI patients who underwent PCI between 2003 and
004 in 262 hospitals in the CRUSADE Quality Improve-
ent Initiative (601). During a 9-month period, DES use
ncreased from 52.6% to 78.5% of cases. Differences in
election of DES compared with bare bare-metal stents
ere noted, but adjusted rates of death and recurrent
nfarction were favorable for DES.
The open artery hypothesis suggested that late patency of
n infarct artery is associated with improved LV function,
ncreased electrical stability, and the provision of collateral
essels to other coronary beds for protection against future
vents. The Occluded Artery Trial (OAT) (602, 603) tested
he hypothesis that routine PCI for total occlusion 3 to 28
after MI would reduce the composite of death, reinfarc-
ion, or Class IV heart failure. Stable patients (n  2166)
ith an occluded infarct artery after MI were randomized to
ptimal medical therapy and PCI with stenting or optimal
edical therapy alone. The qualifying period of 3 to 28 d
as based on calendar days, thus the minimal time from
ymptom onset to angiography was just over 24 h. Inclusion
riteria included absence of angina or heart failure at rest
nd LVEF less than 50% or proximal occlusion of a major
picardial artery with a large risk region. Exclusion criteria
ncluded NYHA Class III or IV heart failure, serum creatinine
reater than 2.5 mg/dL, left main or 3-vessel disease, clinical
nstability, or severe inducible ischemia on stress testing if the
nfarct zone was not akinetic or dyskinetic.
Percutaneous coronary intervention did not reduce death,
einfarction, or HF, and there was a trend toward excess
einfarction during 4 years of follow-up. Findings in the
95-patient NSTEMI subgroup were similar to those in the
verall group (n  2,166) and the larger STEMI groups.
hus, a routine PCI strategy in OAT-type patients with
ersistently occluded infarct-related coronary arteries after
STEMI is not indicated.
.3.1. Platelet Inhibitors and Percutaneous
evascularization
n important advance in the treatment of patients with
A/NSTEMI who are undergoing PCI was the introduc-
ion of platelet GP IIb/IIIa receptor inhibitors in the 1990s
see Section 3.2) (126,128,130,510–512,604–606). This
herapy takes advantage of the fact that platelets play an
mportant role in the development of ischemic complica-
ions that can occur in patients with UA/NSTEMI or
uring coronary revascularization procedures. Currently, 3
latelet GP IIb/IIIa inhibitors are approved by the Food
nd Drug Administration on the basis of the outcomes of a
ariety of placebo-controlled clinical trials: abciximab, tiro-
ban, and eptifibatide. The EPIC (510), EPILOG (511),
APTURE (372), and EPISTENT (512) trials investi-
ated the use of abciximab; the PRISM (374), PRISM-
LUS (130), and Randomized Efficacy Study of Tirofiban
or Outcomes and REstenosis (RESTORE) (518) trials
valuated tirofiban; and the Integrilin to Minimize Platelet
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URSUIT (128), and Enhanced Suppression of Platelet
eceptor GP IIb/IIIa using Integrilin Therapy (ESPRIT)
519) trials studied the use of eptifibatide (Table 18). All 3
f these agents interfere with the final common pathway for
latelet aggregation. All have shown efficacy in reducing the
ncidence of ischemic complications in patients with UA/
STEMI (Fig. 16).
In the only head-to-head comparison of 2 GP IIb/IIIa
nhibitors, the TARGET trial randomized 5,308 patients to
irofiban or abciximab before undergoing PCI with the
ntent to perform stenting (515). The primary end point, a
omposite of death, nonfatal MI, or urgent target-vessel
evascularization at 30 d, occurred less frequently in those
eceiving abciximab than in those given tirofiban (6.0% vs.
.6%, p  0.038). There was a similar direction and
agnitude for each component of the end point. Differ-
nces in outcome between the 2 randomized treatment
roups were particularly marked among patients with UA/
STEMI (63% of patients), in whom 30-d composite end
oint event rates were 9.3% with tirofiban versus 6.3% with
bciximab (p  0.002). Although this finding is subject to
he limitations of subgroup analysis, it suggests that any
ifferences in efficacy between GP IIb/IIIa inhibitors might
e most apparent among patients undergoing PCI in the
etting of UA/NSTEMI. Inferior efficacy observed with
irofiban in this trial might have been related to inadequate
nitial (loading) dosing, which was subsequently demon-
trated to result in platelet inhibition that was inadequate
only 28% to 33% early platelet inhibition) and less than
hat achieved with abciximab (65% to 81%) (516). A
ubsequent study evaluating a higher bolus dose of tirofiban
25 mcg per kg) during PCI was unfortunately discontinued
rematurely because of funding issues. Eptifibatide has not
een compared directly to either abciximab or tirofiban.
The question of whether GP IIb/IIIa inhibition is still
seful in UA/NSTEMI patients undergoing PCI who have
eceived a high loading dose (600 mg) of clopidogrel was
aised by a study in CAD patients treated in an elective
etting (607). To address this, 2,022 patients with UA/
STEMI undergoing PCI were loaded with clopidogrel,
00 mg, at least 2 h before the procedure and then
andomized to receive either abciximab or placebo (ISAR-
EACT 2) (244). The primary end point of death, nonfatal
einfarction, or urgent target-vessel revascularization within
0 d was reached in 8.9% of patients assigned to abciximab
ersus 11.9% assigned to placebo, a 25% difference, and was
imited entirely to patients with an elevated troponin level,
n whom the incidence of a primary event was 13.1% in the
bciximab group compared with 18.3% in the placebo group
p  0.02). Bleeding risks were similar in the 2 groups.
hus, GP IIb/IIIa inhibition provides incremental benefit
eyond high-oral-dose clopidogrel loading for NSTEMI
atients with elevated cardiac biomarker levels but not for
A patients with normal levels who are undergoing PCI. 2In summary, data from both retrospective observations
nd randomized clinical trials indicate that PCI can lead to
ngiographic success in most patients with UA/NSTEMI
Table 18). The safety of these procedures in these patients
s enhanced by the addition of intravenous platelet GP
Ib/IIIa receptor inhibitors to the standard regimen of ASA,
nticoagulants, clopidogrel, and anti-ischemic medications.
.4. Surgical Revascularization
meta-analysis of 6 trials conducted during the early years
f CABG (between 1972 and 1978) documented a clear
urvival advantage for CABG over medical therapy in
ymptomatic patients with left main and 3-vessel coronary
isease that was independent of LV function (322). No
urvival difference was documented between the 2 therapies
or patients with 1- or 2-vessel coronary disease. However,
ramatic changes in both surgical technique (including
nternal thoracic artery grafting to the LAD) and in medical
herapy (e.g., potent anticoagulant and antiplatelet thera-
ies) have subsequently occurred. Pocock et al. (608) per-
ormed a meta-analysis on the results of 8 randomized trials
ompleted between 1986 and 1993 and compared the
utcomes of CABG and PTCA in 3,371 patients with
ultivessel CAD before widespread stent use. Many of
hese patients presented with UA. At 1-year follow-up, no
ifference was documented between the 2 therapies in
ardiac death or MI, but a lower incidence of angina and
eed for revascularization was associated with CABG.
The Bypass Angioplasty Revascularization Investigation
BARI) trial, the largest randomized comparison of CABG
nd PTCA, was performed in 1,829 patients with 2- or
-vessel CAD (609,610). Unstable angina was the admit-
ing diagnosis in 64% of these patients, and 19% had treated
iabetes mellitus. A statistically significant advantage in
urvival without MI independent of the severity of present-
ng symptoms was observed for CABG over PCI at 7 years
84.4% vs. 80.9%, p  0.04) (611). Subgroup analysis
emonstrated that the survival benefit was confined to
atients with treated diabetes mellitus (76.4% with CABG
ompared with 55.7% for patients treated with PTCA, p 
.001). The Coronary Angioplasty versus Bypass Revascu-
arization Investigation (CABRI) trial also showed a sur-
ival benefit for CABG in patients with diabetes mellitus
ith multivessel CAD (612). A confirmatory study from
mory University showed that with correction for baseline
ifferences, patients requiring insulin with multivessel dis-
ase had improved survival with CABG versus PTCA (613)
see Section 6.2).
A large patient registry of consecutive CAD compared
he 5-year survival rates for medical treatment, PTCA, and
ABG between 1984 and 1990 (584). Patients with 3- or
-vessel disease with a proximal severe (greater than or equal
o 95%) LAD stenosis treated with CABG had significantly
etter 5-year survival rates than did those who received
edical treatment or PTCA. In patients with less severe-vessel CAD or with 1-vessel CAD, either form of
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py. The 2 revascularization treatments were equivalent for
atients with nonsevere 2-vessel disease. Percutaneous
ransluminal coronary angioplasty provided better survival
ates than CABG in patients with 1-vessel disease, except
or those with severe proximal LAD stenosis, for whom the
revascularization strategies were equivalent. However, in
atients with single-vessel disease, all therapies were asso-
iated with high 5-year survival rates, and the differences
mong the treatment groups were very small.
Hannan et al. (585) compared 3-year risk-adjusted sur-
ival rates in 29,646 CABG patients and 29,930 PTCA
atients undergoing revascularization in the state of New
ork in 1993, adjusted for differences in baseline and
ngiographic characteristics. The anatomic extent of disease
as the only variable that interacted with the specific
evascularization therapy that influenced long-term survival.
nstable angina or diabetes mellitus did not result in
reatment-related differences in long-term survival rates.
atients with single-vessel disease not involving the LAD or
ith less than 70% LAD stenosis had higher adjusted
-year survival rates with PTCA (95.3%) than with CABG
92.4%). Patients with proximal LAD stenosis of at least
0% had higher adjusted 3-year survival rates with CABG
han with PTCA regardless of the number of diseased
oronary vessels. Patients with 3-vessel disease had higher
djusted 3-year survival rates with CABG regardless of
roximal LAD disease. Patients with other 1- or 2-vessel
isease had no treatment-related difference in survival rates.
he 3-year reintervention rate was significantly higher in
he PCI group than in the CABG group both for subse-
uent CABG (10.4% vs. 0.5%) and for subsequent PCI
26.6% vs. 2.8%).
Hannan et al. performed a follow-up study using the
ame New York State cardiac registries to compare the
utcomes of 37,212 patients who underwent CABG with
2,102 patients who underwent PCI using stents (614). The
aximum follow-up was more than 3 years in each group.
atients were divided into 5 anatomic groups; 2-vessel
isease without LAD disease; 2-vessel disease with proximal
AD disease; 2-vessel disease with nonproximal LAD
isease; 3-vessel disease with proximal LAD disease; and
-vessel disease with nonproximal LAD disease. Patients
ith single-vessel disease were generally treated with PCI.
he unanticipated finding was that the risk-adjusted long-
erm mortality of patients in all 5 subsets was lower in the
ABG group. The HR for death after CABG compared
ith stent implantation ranged from a low of 0.64 (95% CI
.56 to 0.74) for patients with 3-vessel disease and proximal
AD disease to a high of 0.76 (95% CI 0.60 to 0.96) for
atients with 2-vessel disease with involvement of the
onproximal LAD. The risk of long-term mortality also
as lower with CABG for patients with diabetes in each of
hese anatomic subsets, with HRs ranging from 0.59 to
.69. In all but the subset of patients with 2-vessel disease
ithout LAD disease, the increase in mortality associated tith PCI compared with CABG was significant for patients
ith diabetes. The lack of significance in this subset likely
eflected smaller numbers of patients (CABG plus PCI
ombined). In this study (614), as in the earlier study by
annan et al. (585), the 3-year reintervention rate was
ignificantly higher in the PCI group than in the CABG
roup for both subsequent CABG (7.8% vs. 0.3%) and
ubsequent PCI (27.3% vs. 4.6%). In contrast, the random-
zed trials of multivessel disease have shown no differences
n patients without diabetes. These disparate results could
e due to adverse selection biases for PCI. On the other
and, the registry is very large and included a broad range of
ngiographic characteristics not included in the randomized
rials. Consistently, however, the location of a coronary
tenosis in the LAD, especially if severe and proximal, is a
haracteristic associated with higher mortality rates and
ith a favorable outcome with CABG.
The BARI and CABRI randomized trials appeared to
dentify a subset of diabetic patients who had a better
utcome with CABG than with PTCA, a finding not
bserved in earlier cohort studies (609,610,612) but con-
rmed in a more recent cohort study that exclusively used
tents in the PCI group (614). Analysis of the subgroup
ith diabetes was retrospective in both the BARI and
ABRI trials. Moreover, the treatment-related effect was
ot reproduced in the BARI registry population (615). A
easonable explanation for these inconsistent results is that
hysicians might be able to recognize characteristics of
AD in diabetic patients that permit patients to more safely
ndergo one or the other revascularization therapy. How-
ver, when all patients with diabetes are randomly assigned
o therapies without the added insight of clinical judgment,
treatment advantage is apparent for CABG. Given the
ombination of data derived from randomized trials and
ore recent cohort studies comparing PCI using stents with
ABG, it is reasonable to consider CABG as the preferred
evascularization strategy for most patients with 3-vessel
isease, especially if it involves the proximal LAD, and for
atients with multivessel disease and treated diabetes mel-
itus or LV dysfunction. Alternatively, it would be unwise to
eny the advantages of PCI to a patient with diabetes and
ess severe coronary disease on the basis of the current
nformation. In addition, the use of GP IIb/IIIa inhibitors
ogether with PCI for UA/NSTEMI in recent years appears
o have resulted in more favorable outcomes (133,616).
An important consideration in a comparison of different
evascularization strategies is that none of the large random-
zed trials reflect the current practice of interventional
ardiology that includes the routine use of stents, with an
ncreasing use of DES, and the increasing use of platelet
eceptor inhibitors. Coronary stenting improves procedural
afety, and DES reduce restenosis compared with PTCA or
are-metal stents. The adjuvant use of platelet inhibitors,
articularly in high-risk patients, is also associated with
mproved short- and intermediate-term outcomes. Al-
hough the effects of DES and platelet GP IIb/IIIa inhib-
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dded benefit relative to CABG cannot be assumed or
ssessed on the basis of the previously reported randomized
rials or large registries. Meanwhile, refinement of surgical
anagement with right internal mammary artery grafts,
adial artery grafts, improved myocardial protection strate-
ies, and less invasive methodology could have reduced the
orbidity and mortality rates for CABG. In fact, the
isk-adjusted mortality for CABG has declined progres-
ively during the last decade based on data derived from the
TS National Adult Cardiac Database (617).
The most recent comparisons of PCI and CABG surgery,
elevant to current medical practice, can be summarized as
ollows: In a randomized study of patients with medically
efractory myocardial ischemia at high risk of adverse
utcomes of CABG surgery (the Angina With Extremely
erious Operative Mortality Evaluation [AWESOME]
rial), there was comparable survival with traditional CABG
urgery and PCI, which included stenting or atherectomy
618). A meta-analysis of CABG versus stenting for the
reatment of multivessel disease (619) included patients in
he randomized trials Arterial Revascularization Therapy
tudy (ARTS), Stent or Surgery (SoS), Estudio Random-
zado Argentino de Angioplastia vs. CIrugia-II (ERACI-
I), and Multicenter Anti Atherosclerotic Study-II (MASS-
I) (620–624). ERACI-II included a cohort in which 92%
f the patients had UA; patients in the SoS study did not
ave apparent recent acute events; patients in MASS-II had
table angina and preserved ventricular function; and those
n ARTS (with 5-year follow-up data) were not specifically
escribed. However, these trials, which enrolled patients
etween 1995 and 2000 and primarily used traditional
n-pump CABG surgery and PCI with bare-metal stents,
howed no difference in the primary composite end point of
eath, MI, and stroke and no difference in mortality
etween the CABG and the stent groups. The ARTS trial,
hich included but was not limited to patients with UA,
andomized patients with multivessel disease to coronary
tenting versus CABG. Three-year survival rates without
troke and MI were identical in both groups.
Nevertheless, evolutionary changes in revascularization
herapy require randomized trials that incorporate the most
ontemporary therapies. Off-pump CABG and PCI with
ES are 2 examples. Indeed, not all evolutionary changes in
herapy have shown net incremental clinical benefits. Ran-
omized trial data suggest that coronary graft patency rates
re somewhat lower with off-pump CABG (625). The use
f DES has not decreased the occurrence of death or MI
ompared with bare-metal stents, and DES are subject to a
mall increase in the rate of late (greater than 6-month,
ff-dual-platelet antagonism) stent thrombotic complica-
ions and thrombosis-related clinical events (399,400,402,
03,411,626). Further complicating the picture, ASA and
lopidogrel and other medical therapies are increasingly
tilized in patients after CABG (627), which makes com-
arisons of medical, PCI, and surgical therapy challenging. uhe requirement for long-term follow-up and the need for
dequate statistical power add to the difficulty in defining
he unique benefits of each of the available forms of therapy
eparately. In summary, it cannot be assumed that all
volutionary changes in these therapies will have a beneficial
mpact on long-term outcomes, and clinical judgment in
reatment selection for individual patients and a conserva-
ive approach to new therapies are indicated.
.5. Conclusions
n general, the indications for PCI and CABG in UA/
STEMI are similar to those for stable angina (628–633).
igh-risk patients with LV systolic dysfunction, patients with
iabetes mellitus, and those with 2-vessel disease with severe
roximal LAD involvement or severe 3-vessel or left main
isease should be considered for CABG (Fig. 20). Many other
atients will have less severe CAD that does not put them at
igh risk for cardiac death. However, even less severe disease
an have a substantial negative impact on the quality of life.
ompared with high-risk patients, low-risk patients will have
egligibly increased chances of long-term survival with CABG
or PCI) and therefore should be managed medically. How-
ver, in low-risk patients, quality of life and patient preferences
ay be considered in addition to strict clinical outcomes in the
election of a treatment strategy. Low-risk patients whose
ymptoms do not respond well to maximal medical therapy
nd who experience a significant negative impact on their
uality of life and functional status should be considered for
evascularization. Patients in this group who are unwilling to
ccept the increased short-term procedural risks to gain long-
erm benefits or who are satisfied with their existing capabilities
hould be managed medically at first and followed up carefully
s outpatients. Other patients who are willing to accept the
isks of revascularization and who want to improve their
unctional status or to decrease symptoms may be considered
ppropriate candidates for early revascularization.
. Late Hospital Care, Hospital Discharge,
nd Post-Hospital Discharge Care
he acute phase of UA/NSTEMI is usually over within 2
onths. The risk of progression to MI or the development
f recurrent MI or death is highest during that period. At 1
o 3 months after the acute phase, most patients resume a
linical course similar to that in patients with chronic stable
oronary disease.
The broad goals during the hospital discharge phase
re 2-fold: 1) to prepare the patient for normal activities
o the extent possible and 2) to use the acute event as an
pportunity to reevaluate the plan of care, particularly
ifestyle and risk factor modification. Aggressive risk
actor modifications that can prolong survival should be
he main goals of long-term management of stable CAD.
atients who have undergone successful PCI with an
ncomplicated course are usually discharged the next day,
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enerally discharged 4 to 7 d after CABG. Medical
anagement of low-risk patients after noninvasive stress
esting and coronary angiography can typically be accom-
lished rapidly, with discharge soon after testing. Med-
cal management of a high-risk group of patients who are
nsuitable for or unwilling to undergo revascularization
ould require vigilant inpatient monitoring in order to
chieve adequate ischemic symptom control with medical
herapy that will minimize future morbidity and mortality
nd improve quality of life.
.1. Medical Regimen and Use of Medications
RECOMMENDATIONS
LASS I
. Medications required in the hospital to control ischemia should be
continued after hospital discharge in patients with UA/NSTEMI who
do not undergo coronary revascularization, patients with unsuccess-
ful revascularization, and patients with recurrent symptoms after
revascularization. Upward or downward titration of the doses may
be required. (Level of Evidence: C)
. All post-UA/NSTEMI patients should be given sublingual or spray
NTG and instructed in its use. (Level of Evidence: C)
. Before hospital discharge, patients with UA/NSTEMI should be
informed about symptoms of worsening myocardial ischemia and
MI and should be instructed in how and when to seek emergency
care and assistance if such symptoms occur. (Level of Evidence: C)
. Before hospital discharge, post-UA/NSTEMI patients and/or desig-
nated responsible caregivers should be provided with supportable,
easily understood, and culturally sensitive instructions with respect
to medication type, purpose, dose, frequency, and pertinent side
effects. (Level of Evidence: C)
. In post-UA/NSTEMI patients, anginal discomfort lasting more than 2
or 3 min should prompt the patient to discontinue physical activity
or remove himself or herself from any stressful event. If pain does
not subside immediately, the patient should be instructed to take 1
dose of NTG sublingually. If the chest discomfort/pain is unim-
proved or worsening 5 min after 1 NTG dose has been taken, it is
recommended that the patient or a family member/friend call 9-1-1
immediately to access EMS. While activating EMS access, addi-
tional NTG (at 5-min intervals 2 times) may be taken while lying
down or sitting. (Level of Evidence: C)
. If the pattern or severity of anginal symptoms changes, which suggests
worsening myocardial ischemia (e.g., pain is more frequent or severe
or is precipitated by less effort or now occurs at rest), the patient should
contact his or her physician without delay to assess the need for
additional treatment or testing. (Level of Evidence: C)
In most cases, the inpatient anti-ischemic medical regi-
en used in the nonintensive phase (other than intravenous
TG) should be continued after discharge, and the anti-
latelet/anticoagulant medications should be changed to an
utpatient regimen. The goals for continued medical ther-
py after discharge relate to potential prognostic benefits
primarily shown for antiplatelet agents, beta blockers,
ow-density cholesterol (LDL-C)-lowering agents, and in-
ibitors of the renin-angiotensin aldosterone system, espe- hially for ejection fraction of 0.40 or less), control of
schemic symptoms (nitrates, beta blockers, and CCBs), and
reatment of major risk factors such as hypertension, smok-
ng, dyslipidemia, physical inactivity, and diabetes mellitus
see Section 5.2). Thus, the selection of a medical regimen
s individualized to the specific needs of each patient based
n the in-hospital findings and events, the risk factors for
AD, drug tolerability, and recent procedural interventions.
he mnemonic ABCDE (Aspirin, antianginals, and ACE
nhibitors; Beta blockers and blood pressure; Cholesterol
nd cigarettes; Diet and diabetes; Education and exercise)
as been found to be useful in guiding treatment (4,634).
An effort by the entire multidisciplinary team with special
kills (physicians, nurses, dietitians, pharmacists, rehabilita-
ion specialists, care managers, and physical and occupa-
ional therapists) is often necessary to prepare the patient for
ischarge. Both the patient and family should receive
nstructions about what to do if ischemic symptoms occur in
he future (74). Face-to-face patient instruction is important
nd should be reinforced and documented with written
nstruction sheets. Enrollment in a cardiac rehabilitation
rogram after discharge can enhance patient education and
ompliance with the medical regimen (see Section 5.4).
Telephone follow-up can serve to reinforce in-hospital
nstruction, provide reassurance, and answer the patient’s
uestions (635). If personnel and budget resources are
vailable, the health care team should establish a follow-up
ystem in which personnel specially trained to support and
ssist clinicians in CAD management call patients on the
elephone. For example, calls might occur weekly for the
rst 4 weeks after discharge. This structured program can
auge the progress of the patient’s recovery, reinforce the
AD education taught in the hospital, address patient
uestions and concerns, and monitor progress in meeting
isk factor modification goals.
.2. Long-Term Medical Therapy and Secondary
revention
atients with UA/NSTEMI require secondary prevention
or CAD at discharge. The management of the patient with
table CAD is of relevance, as detailed in the ACC/AHA/
CP Guidelines for the Management of Patients With
hronic Stable Angina (4), as are the secondary prevention
uidelines (3) outlined in the more recent ACC/AHA
uidelines for the Management of Patients With ST-
levation MI (1) and Secondary Prevention (3,38).
A health care team with expertise in aggressively
anaging CAD risk factors should work with patients
nd their families to educate them in detail regarding
pecific targets for LDL-C and high-density lipoprotein
holesterol (HDL-C), blood pressure, body mass index
BMI), physical activity, and other appropriate lifestyle
odifications (44). These health care teams can beospital-, office-, or community-based and may include
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econdary prevention programs. The family should be
nstructed on how best to further support the patient by
ncouraging reasonable changes in risk behavior (e.g.,
ooking AHA, Mediterranean, or DASH [Dietary Ap-
roach to Stop Hypertension] diet meals for the entire
amily; exercising together). This is particularly impor-
ant when screening of family members reveals common
isk factors, such as dyslipidemia, hypertension, second-
and smoke, and obesity. Of recent concern is the
ational trend to obesity, which has increased over the
ast decade in all 50 states, and its risk consequences
636). The combination of evidence-based therapies
rovides complementary, added morbidity and mortality
eductions (637,638); prescription of and compliance
ith these combination therapies should be stressed.
.2.1. Antiplatelet Therapy
ee Figure 11 for antiplatelet therapy recommendations in
lgorithm format.
LASS I
. For UA/NSTEMI patients treated medically without stenting, aspi-
rin* (75 to 162 mg per day) should be prescribed indefinitely (Level
of Evidence: A); clopidogrel† (75 mg per day) should be prescribed
for at least 1 month (Level of Evidence: A) and ideally for up to 1
year. (Level of Evidence: B)
. For UA/NSTEMI patients treated with bare-metal stents, aspirin*
162 to 325 mg per day should be prescribed for at least 1 month
(Level of Evidence: B), then continued indefinitely at a dose of 75 to
162 mg per day (Level of Evidence: A); clopidogrel should be
prescribed at a dose of 75 mg per day for a minimum of 1 month
and ideally for up to 1 year (unless the patient is at increased risk of
bleeding; then it should be given for a minimum of 2 weeks). (Level
of Evidence: B)
. For UA/NSTEMI patients treated with DES, aspirin* 162 to 325 mg
per day should be prescribed for at least 3 months after sirolimus-
eluting stent implantation and 6 months after paclitaxel-eluting
stent implantation then continued indefinitely at a dose of 75 to
162 mg per day. (Level of Evidence: B) Clopidogrel 75 mg daily
should be given for at least 12 months to all post-PCI patients
receiving DES. (Level of Evidence: B)
. Clopidogrel 75 mg daily (preferred) or ticlopidine (in the absence of
contraindications) should be given to patients recovering from
UA/NSTEMI when ASA is contraindicated or not tolerated because
of hypersensitivity or gastrointestinal intolerance (but with gastro-
protective agents such as proton-pump inhibitors). (Level of Evi-
dence: A)
LASS IIa
or UA/NSTEMI patients in whom the physician is concerned about the
isk of bleeding, a lower initial aspirin dose after PCI of 75 to 162 mg
er day is reasonable. (Level of Evidence: C)
For ASA-allergic patients, use clopidogrel alone (indefinitely), or try aspirin
esensitization.
For clopidogrel-allergic patients, use ticlopidine 250 mg by mouth twice daily.
§
iLASS IIb
or UA/NSTEMI patients who have an indication for anticoagulation,
dd warfarin‡ to maintain an international normalization ratio of 2.0 to
.0.§ (Level of Evidence: B)
LASS III
ipyridamole is not recommended as an antiplatelet agent in post-UA/
STEMI patients because it has not been shown to be effective. (Level
f Evidence: A)
.2.2. Beta Blockers
LASS I
. Beta blockers are indicated for all patients recovering from UA/
NSTEMI unless contraindicated. (For those at low risk, see Class IIa
recommendation below). Treatment should begin within a few days
of the event, if not initiated acutely, and should be continued
indefinitely. (Level of Evidence: B)
. Patients recovering from UA/NSTEMI with moderate or severe LV
failure should receive beta-blocker therapy with a gradual titration
scheme. (Level of Evidence: B)
LASS IIa
t is reasonable to prescribe beta blockers to low-risk patients (i.e.,
ormal LV function, revascularized, no high-risk features) recovering
rom UA/NSTEMI in the absence of absolute contraindications. (Level
f Evidence: B)
.2.3. Inhibition of the Renin-Angiotensin-Aldosterone
ystem
LASS I
. Angiotensin-converting enzyme inhibitors should be given and con-
tinued indefinitely for patients recovering from UA/NSTEMI with HF,
LV dysfunction (LVEF less than 0.40), hypertension, or diabetes
mellitus, unless contraindicated. (Level of Evidence: A)
. An angiotensin receptor blocker should be prescribed at discharge
to those UA/NSTEMI patients who are intolerant of an ACE inhibitor
and who have either clinical or radiological signs of HF and LVEF less
than 0.40. (Level of Evidence: A)
. Long-term aldosterone receptor blockade should be prescribed for
UA/NSTEMI patients without significant renal dysfunction (esti-
mated creatinine clearance should be greater than 30 mL per min)
or hyperkalemia (potassium should be less than or equal to 5 mEq
per liter) who are already receiving therapeutic doses of an ACE
inhibitor, have an LVEF less than or equal to 0.40, and have either
symptomatic HF or diabetes mellitus. (Level of Evidence: A)
LASS IIa
. Angiotensin-converting enzyme inhibitors are reasonable for pa-
tients recovering from UA/NSTEMI in the absence of LV dysfunction,
hypertension, or diabetes mellitus unless contraindicated. (Level of
Evidence: A)
Continue ASA indefinitely and warfarin longer term as indicated for specific
onditions such as atrial fibrillation; LV thrombus; or cerebral, venous, or pulmonary
mboli.
An INR of 2.0 to 2.5 is preferable while given with ASA and clopidogrel, especially
n older patients and those with other risk factors for bleeding.
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tients with HF and LVEF greater than 0.40. (Level of Evidence: A)
. In UA/NSTEMI patients who do not tolerate ACE inhibitors, an
angiotensin receptor blocker can be useful as an alternative to ACE
inhibitors in long-term management provided there are either clin-
ical or radiological signs of HF and LVEF less than 0.40. (Level of
Evidence: B)
LASS IIb
he combination of an ACE inhibitor and an angiotensin receptor
locker may be considered in the long-term management of patients
ecovering from UA/NSTEMI with persistent symptomatic HF and LVEF
ess than 0.40* despite conventional therapy including an ACE inhibitor
r an angiotensin receptor blocker alone. (Level of Evidence: B)
Data on the utility of ACE inhibitors in stable CAD in the
resence of HF and LV dysfunction have been compelling,
hereas data in their absence have been conflicting. A reduc-
ion in the rates of mortality and vascular events was reported
n the Heart Outcomes Prevention Evaluation (HOPE) Study
343) with the long-term use of an ACE inhibitor (ramipril) in
oderate-risk patients with CAD, many of whom had pre-
erved LV function, as well as patients at high risk of
eveloping CAD. Similar but smaller benefits were reported in
he EUROPA study (EUropean trial on Reduction Of cardiac
vents with Perindopril in patients with stable coronary Artery
isease), which observed a significant reduction in incidence of
ardiovascular death, MI, or cardiac arrest among moderate-
isk patients with known coronary disease without apparent
F randomized to perindopril versus placebo (639). Conflict-
ng results, however, were observed in the Prevention of Events
ith Angiotensin Converting Enzyme Inhibition (PEACE)
rial, which found no significant difference in the risk of
ardiovascular death, MI, or coronary revascularization among
ow-risk patients with stable CAD and preserved LV function
hen an ACE inhibitor (trandolapril) was added to modern
onventional therapy (640); however, a subsequent meta-
nalysis of these 3 major trials supported benefit across the risk
pectrum studied (641). These and other data may be harmo-
ized by postulating that ACE inhibitors provide general
enefit in stable CAD but that the absolute benefit is propor-
ional to disease-related risk, with those at lowest risk benefit-
ng least (641,642). These and other agents that may be used
n patients with chronic CAD are listed in Table 22 and are
iscussed in detail in the ACC/AHA Guidelines for the
anagement of Patients With Chronic Stable Angina (4).
.2.4. Nitroglycerin
LASS I
. Nitroglycerin to treat ischemic symptoms is recommended. (Level of
Evidence: C)
.2.5. Calcium Channel Blockers
LASS IThe safety of this combination has not been proven in patients also on aldosterone
ntagonist and is not recommended.
†
‡. Calcium channel blockers† are recommended for ischemic symp-
toms when beta blockers are not successful. (Level of Evidence: B)
. Calcium channel blockers† are recommended for ischemic symp-
toms when beta blockers are contraindicated or cause unaccept-
able side effects. (Level of Evidence: C)
.2.6. Warfarin Therapy
LASS I
se of warfarin in conjunction with ASA and/or clopidogrel is associ-
ted with an increased risk of bleeding and should be monitored
losely. (Level of Evidence: A)
LASS IIb
arfarin either without (INR 2.5 to 3.5) or with low-dose ASA (75 to 81
g per d; INR 2.0 to 2.5) may be reasonable for patients at high CAD
isk and low bleeding risk who do not require or are intolerant of
lopidogrel. (Level of Evidence: B)
.2.7. Lipid Management
LASS I
1. The following lipid recommendations are beneficial:
a. Lipid management should include assessment of a fasting lipid
profile for all patients, within 24 h of hospitalization. (Level of
Evidence: C)
b. Hydroxymethyl glutaryl-coenzyme A reductase inhibitors (st-
atins), in the absence of contraindications, regardless of base-
line LDL-C and diet modification, should be given to post-UA/
NSTEMI patients, including postrevascularization patients.
(Level of Evidence: A)
c. For hospitalized patients, lipid-lowering medications should be
initiated before discharge. (Level of Evidence: A)
d. For UA/NSTEMI patients with elevated LDL-C (greater than or
equal to 100 mg per dL), cholesterol-lowering therapy should
be initiated or intensified to achieve an LDL-C of less than
100 mg per dL. (Level of Evidence: A) Further titration to less than
70 mg per dL is reasonable. (Class IIa, Level of Evidence: A)
e. Therapeuticoptions to reducenon–HDL-C‡are recommended, includ-
ing more intense LDL-C–lowering therapy. (Level of Evidence: B)
f. Dietary therapy for all patients should include reduced intake of
saturated fats (to less than 7% of total calories), cholesterol (to
less than 200 mg per d), and trans fat (to less than 1% of
energy). (Level of Evidence: B)
g. Promoting daily physical activity and weight management
are recommended. (Level of Evidence: B)
2. Treatment of triglycerides and non-HDL-C is useful, including the
following:
a. If triglycerides are 200 to 499 mg per dL, non-HDL-C‡ should be
less than 130 mg per dL. (Level of Evidence: B)Short-acting dihydropyridine calcium channel antagonists should be avoided.
Non-HDL-C  total cholesterol minus HDL-C.
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August 14, 2007:e1–157 ACC/AHA UA/NSTEMI Guideline Revisionb. If triglycerides are greater than or equal to 500 mg per dL*,
therapeutic options to prevent pancreatitis are fibrate† or nia-
cin† before LDL-lowering therapy is recommended. It is also
recommended that LDL-C be treated to goal after triglyceride-
lowering therapy. Achievement of a non-HDL-C‡ less than 130
mg per dL (i.e., 30 mg per dL greater than LDL-C target) if
possible is recommended. (Level of Evidence: C)
LASS IIa
1. The following lipid management strategies can be beneficial:
a. Further reduction of LDL-C to less than 70 mg per dL is reason-
able. (Level of Evidence: A)
b. If baseline LDL cholesterol is 70 to 100 mg per dL, it is
reasonable to treat LDL-C to less than 70 mg per dL. (Level of
Evidence: B)
c. Further reduction of non-HDL-C‡ to less than 100 mg per dL is
reasonable; if triglycerides are 200 to 499 mg per dL, non-
HDL-C target is less than 130 mg per dL. (Level of Evidence: B)
Patients with very high triglycerides should not consume alcohol. The use of bile acid
equestrants is relatively contraindicated when triglycerides are greater than 200 mg
er dL.
The combination of high-dose statin plus fibrate can increase risk for severe
yopathy. Statin doses should be kept relatively low with this combination. Dietary
able 22. Medications Used for Stabilized UA/NSTEMI Patient
Anti-Ischemic and Antithrombotic/Antiplatelet
Agents Dru
spirin Antiplatelet
lopidogrel* or ticlopidine Antiplatelet when as
eta blockers Anti-ischemic
CEI EF less than 0.40 or
itrates Antianginal
alcium channel blockers (short-acting
dihydropyridine antagonists should be avoided)
Antianginal
ipyridamole Antiplatelet
Agents for Secondary Prevention and Other
Indications
Ris
MG-CoA reductase inhibitors LDL cholesterol grea
ibrates HDL cholesterol less
iacin HDL cholesterol less
iacin or fibrate Triglycerides 200 mg
ntidepressant Treatment of depres
reatment of hypertension Blood pressure great
or greater than 13
disease or diabete
ormone therapy (initiation)† Postmenopausal sta
reatment of diabetes HbA1C greater than 7
ormone therapy (continuation)† Postmenopausal sta
OX-2 inhibitor or NSAID Chronic pain
itamins C, E, beta-carotene; folic acid, B6, B12 Antioxidant effect; h
Preferred to ticlopidine.†For risk reduction of coronary artery disease.
ACEI  angiotensin-converting enzyme inhibitor; CHF  congestive heart failure; COX-2  cyclo
oenzyme A; INR international normalized ratio; LDL low-density lipoprotein; NSAID nonster
ngina.upplement niacin must not be used as a substitute for prescription niacin.
Non-HDL-C  total cholesterol minus HDL-C.
§
td. Therapeutic options to reduce non-HDL-C‡ (after LDL-C lower-
ing) include niacin† or fibrate* therapy.
e. Nicotinic acid (niacin)† and fibric acid derivatives (fenofibrate,
gemfibrozil)* can be useful as therapeutic options (after LDL-
C–lowering therapy) for HDL-C less than 40 mg per dL. (Level of
Evidence: B)
f. Nicotinic acid (niacin)† and fibric acid derivatives (fenofibrate,
gemfibrozil)* can be useful as therapeutic options (after LDL-
C–lowering therapy) for triglycerides greater than 200 mg per
dL. (Level of Evidence: B)
g. The addition of plant stanol/sterols (2 g per d) and/or viscous
fiber (more than 10 g per d) is reasonable to further lower LDL-C.
(Level of Evidence: A)
LASS IIb
ncouraging consumption of omega-3 fatty acids in the form of fish§ or
n capsule form (1 g per d) for risk reduction may be reasonable. For
reatment of elevated triglycerides, higher doses (2 to 4 g per d) may be
sed for risk reduction. (Level of Evidence: B)
There is a wealth of evidence that cholesterol-lowering
herapy for patients with CAD and hypercholesterolemia
643) or with mild cholesterol elevation (mean 209 to 218
g per dL) after MI and UA reduces vascular events and
eath (644,645). Moreover, recent trials have provided
ion Class/Level of Evidence
I/A
s contraindicated I/A
I/B
greater than 0.40 I/A IIa/A
I/C for ischemic symptoms
I for ischemic symptoms; when beta blockers are
not successful (B) or contraindicated, or cause
unacceptable side effects (C)
III/A
tor Class/Level of Evidence
n 70 mg per dL Ia
40 mg per dL IIa/B
40 mg per dL IIa/B
L IIa/B
IIb/B
n 140/90 mm Hg
mm Hg if kidney
sent
I/A
III/A
I/B
III/B
IIa/C, IIb/C or III/C
steine lowering III/A
ase 2; EF  ejection fraction; HDL  high-density lipoprotein; HMG-CoA  hydroxymethyl glutaryl
nti-inflammatory drug; NSTEMI non–ST-segment elevation myocardial infarction; UA unstables
g Act
pirin i
HF EF
k Fac
ter tha
than
than
per d
sion
er tha
0/80
s pre
te
%
te
omocy
oxygenPregnant and lactating women should limit their intake of fish to minimize exposure
o methylmercury.
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ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:e1–157ounting evidence that statin therapy is beneficial regard-
ess of whether the baseline LDL-C level is elevated
646–648). More aggressive therapy has resulted in sup-
ression or reversal of coronary atherosclerosis progression
nd lower cardiovascular event rates, although the impact on
otal mortality remains to be clearly established (649). These
ata are discussed more fully elsewhere (3,17,39).
For patients with CHD or CHD equivalents (i.e., ath-
rosclerosis in other vascular territories, diabetes mellitus, or
0-year estimated cardiovascular risk greater than 20%), the
CEP Adult Treatment Panel III recommended a target
DL-C level less than 100 mg per dL (17). Therapeutic
ifestyle changes are recommended as well. Therapeutic
ifestyle changes include diet, weight management, and
ncreased physical activity. Specific diet recommendations
nclude restriction of calories from saturated fat to less than
% of total caloric intake and of cholesterol to less than 200
g per d. Additionally, increased soluble fiber (10 to 25 g
er d) and plant stanols/sterols (2 g per d) are noted as
herapeutic lifestyle change dietary options to enhance
DL-C lowering. Reduction in trans fat (to less than 1% of
aloric intake) subsequently has been added to prevention
uidelines (3,38). These guidelines also recommend consid-
ration of drug therapy if LDL-C is above goal range, either
imultaneously with therapeutic lifestyle changes or sequen-
ially, after 3 months of therapeutic lifestyle changes.
An update to the Adult Treatment Panel III guidelines
as published in mid 2004 (16). The major change recom-
ended in this update is an LDL-C treatment goal of less
han 70 mg per dL as a reasonable option in very-high-risk
atients (such as after UA/NSTEMI). Furthermore, if a
igh-risk patient has high triglycerides (greater than 200 mg
er dL) or low HDL-C (less than 40 mg per dL),
onsideration can be given to combining a fibrate or
icotinic acid with an LDL-lowering drug. For moderately
igh-risk patients (2 or more risk factors and 10-year risk of
0% to 20%), the recommended LDL-C goal is less than
30 mg per dL, but an LDL-C goal of less than 100 mg per
L is a reasonable option. When drug therapy is utilized in
oderate- to high-risk patients, it is advised that the
ntensity of the treatment be sufficient to achieve a reduction
n LDL-C levels of at least 30% to 40%. Therapeutic
ifestyle changes to modify existing lifestyle-based risk
actors are strongly urged regardless of LDL-C levels.
Two trials further support early intensive lipid lowering
fter ACS. In the PROVE-IT TIMI 22 study (PRavastatin
r atorVastatin Evaluation and Infection Therapy–
hrombolysis In Myocardial Infarction 22), 4,162 patients
ithin 10 d of ACS were randomized to 40 mg of
ravastatin or 80 mg of atorvastatin daily (648). The median
DL-C achieved in the moderately intensive (standard-
ose) pravastatin group was 95 mg per dL compared with a
edian of 62 mg per dL in the aggressive, high-dose
torvastatin group. A 16% reduction in the HR for the
rimary composite end point of all-cause death, MI, UA
equiring rehospitalization, revascularization (performed at
N
Beast 30 d after randomization), and stroke was observed in
avor of the high-dose regimen. The second trial, phase Z of
he A to Z Trial (647), compared early initiation of an
ntensive statin regimen (simvastatin 40 mg per d for 1
onth followed by 80 mg per d thereafter) with a delayed
nitiation of a less-intensive regimen (placebo for 4 months
ollowed by simvastatin 20 mg per d) in patients with ACS.
o difference was observed between the groups during the
rst 4 months of follow-up for the primary end point
composite of cardiovascular death, nonfatal MI, readmis-
ion for ACS, and stroke). However, from 4 months
hrough the end of the study, the primary end point was
ignificantly reduced in the aggressive treatment arm, which
epresented a favorable trend toward a reduction of major
ardiovascular events with the early, aggressive statin regi-
en. The incidence of myopathy (CK greater than 10 times
he upper limit of normal, with muscle symptoms) occurred
ore frequently in the early/aggressive treatment group,
hich reinforces the need for careful monitoring and
ollow-up with aggressive treatment.
Observational studies have generally supported initiation
f lipid-lowering therapy before discharge after ACS both
or safety and for early efficacy (event reduction) (650). In
ontrast, a meta-analysis of randomized trials of early (less
han 14 d) initiation of lipid lowering after ACS, although
upporting its safety, suggests that efficacy is generally
elayed beyond 4 months (651).
Short- and long-term compliance is a clear benefit of
n-hospital initiation of lipid lowering (652). In a demon-
tration project, the Cardiovascular Hospitalization Athero-
clerosis Management Program, the in-hospital initiation of
ipid-lowering therapy increased the percentage of patients
reated with statins 1 year later from 10% to 91%, and for
hose with an LDL-C less than 100 mg per dL, the
ercentage increased from 6% to 58% (653), which suggests
hat predischarge initiation of lipid-lowering therapy en-
ances long-term compliance. Thus, there appear to be no
dverse effects and substantial advantages to the initiation of
ipid-lowering therapy before hospital discharge (652,654).
uch early initiation of therapy also has been recommended
n the update of the third report of the NCEP (16).
dherence to statin therapy was shown to be associated
ith improved survival in a large, population-based longi-
udinal observational study (655).
.2.8. Blood Pressure Control
LASS I
lood pressure control according to JNC 7 guidelines* is recommended
i.e., blood pressure less than 140/90mmHg or less than 130/80mm
g if the patient has diabetes mellitus or chronic kidney disease).
Level of Evidence: A) Additional measures recommended to treat and
ontrol blood pressure include the following:
Chobanian AV, Bakris GL, Black HR, et al., for the National High Blood Pressure
ducation Program Coordinating Committee. The seventh report of the Joint
ational Committee on Prevention, Detection, Evaluation, and Treatment of High
lood Pressure: the JNC 7 report. JAMA 2003;289:2560–72 (656).
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August 14, 2007:e1–157 ACC/AHA UA/NSTEMI Guideline Revision. Patients should initiate and/or maintain lifestyle modifications,
including weight control, increased physical activity, alcohol moder-
ation, sodium reduction, and emphasis on increased consumption
of fresh fruits, vegetables, and low-fat dairy products. (Level of
Evidence: B)
. For patients with blood pressure greater than or equal to 140/90
mm Hg (or greater than or equal to 130/80 mm Hg for individuals
with chronic kidney disease or diabetes mellitus), it is useful to add
blood pressure medication as tolerated, treating initially with beta
blockers and/or ACE inhibitors, with addition of other drugs such as
thiazides as needed to achieve target blood pressure. (Level of
Evidence: A)
All patients with elevated systolic or diastolic blood pressures
hould be educated and motivated to achieve targeted hyper-
ensive control according to JNC 7 guidelines (656) adapted to
atients with ischemic heart disease (656a). Systolic and
iastolic blood pressures should be in the normal range (i.e.,
ess than 140/90 mm Hg; 130/80 mm Hg if the patient has
iabetes mellitus or chronic kidney disease).
.2.9. Diabetes Mellitus
LASS I
iabetes management should include lifestyle and pharmacotherapy
easures to achieve a near-normal HbA1c level of less than 7%. (Level
f Evidence: B) Diabetes management should also include the
ollowing:
. Vigorous modification of other risk factors (e.g., physical activity,
weight management, blood pressure control, and cholesterol man-
agement) as recommended should be initiated and maintained.
(Level of Evidence: B)
. It is useful to coordinate the patient’s diabetic care with the patient’s
primary care physician or endocrinologist. (Level of Evidence: C)
Glycemic control during and after ACS is discussed in
ection 6.2.1.
Overweight patients should be instructed in a weight loss
egimen, with emphasis on the importance of regular
xercise and a lifelong prudent diet to maintain ideal body
ass index. Patients should be informed and encouraged
hat even small reductions in weight can have positive
enefits. This can be reassuring to severely obese patients. In
he Diabetes Prevention Program study, 3,234 overweight
ubjects with elevated fasting and postload plasma glucose
oncentrations were randomized to treatment with met-
ormin or a lifestyle modification program (657). The goals of
he lifestyle modification program were targeted to at least a
% weight loss and at least 150 min of physical activity per
eek. The incidence of diabetes mellitus was reduced by 58%
n the lifestyle modification group and 31% in the metformin
roup compared with placebo. The study supports the sub-
tantial positive effects of even modest changes in weight and
hysical activity on the development of diabetes, a major risk
actor for cardiovascular events (657–659).
.2.10. Smoking Cessation
LASS I
moking cessation and avoidance of exposure to environmental to-
acco smoke at work and home are recommended. Follow-up, referralo special programs, or pharmacotherapy (including nicotine replace-
ent) is useful, as is adopting a stepwise strategy aimed at smoking
essation (the 5 As are: Ask, Advise, Assess, Assist, and Arrange).
Level of Evidence: B)
For patients who smoke, persistent smoking cessation
ounseling is often successful and has substantial potential
o improve survival. Daly et al. (660) quantified the long-
erm effects of smoking on patients with ACS. Men less
han 60 years old who continued to smoke had a risk of
eath due to all causes that was 5.4 times that of men who
topped smoking (p less than 0.05). Referral to a smoking
essation program and the use of pharmacological agents
ncluding nicotine patches or gum are recommended (661).
Bupropion, an anxiolytic agent and weak inhibitor of
euronal uptake of neurotransmitters, has been effective
hen added to brief regular counseling sessions in helping
atients to quit smoking. The treatment of 615 study
ubjects for 7 weeks resulted in smoking cessation rates of
8.8% for the 100 mg per d dosage and 44.2% for 300 mg
er d compared with 19.6% for placebo-assigned patients (p
ess than 0.001) (661). The abstinence rate at 1 year was
3.0% for those treated with bupropion 300 mg per d versus
2.4% for those receiving placebo (661).
Recently, another nonnicotine replacement therapy,
arenicline, was approved to assist in smoking cessation.
arenicline is a first-in-class nicotine acetylcholine receptor
artial agonist, designed to provide some nicotine effects
easing withdrawal symptoms) and to block the effects of
icotine from cigarettes, discouraging smoking. Approval
as based on demonstrated effectiveness in 6 clinical trials
nvolving a total of 3,659 chronic cigarette smokers (32–34).
n 2 of the 5 placebo-controlled trials, varenicline also was
ompared to buproprion and found to be more effective.
arenicline is given for an initial 12-week course. Success-
ully treated patients may continue treatment for an addi-
ional 12 weeks to improve the chances of long-term
bstinence. Family members who live in the same house-
old should also be encouraged to quit smoking to help
einforce the patient’s effort and to decrease the risk of
econdhand smoke for everyone.
.2.11. Weight Management
LASS I
eight management, as measured by body mass index and/or waist
ircumference, should be assessed on each visit. A body mass index of
8.5 to 24.9 kg per m2 and a waist circumference (measured horizon-
ally at the iliac crest) of less than 40 inches for men and less than 35
nches for women is recommended. (Level of Evidence: B) Additional
eight management practices recommended include the following:
. On each patient visit, it is useful to consistently encourage weight
maintenance/reduction through an appropriate balance of physical
activity, caloric intake, and formal behavioral programs when indi-
cated to maintain/achieve a body mass index between 18.5 and
24.9 kg per m2. (Level of Evidence: B)
. If waist circumference is 35 inches ormore inwomenor 40 inches ormore
in men, it is beneficial to initiate lifestyle changes and consider treatment
strategies for metabolic syndrome as indicated. (Level of Evidence: B)
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weight by approximately 10% from baseline. With success, further
weight loss can be attempted if indicated through further assess-
ment. (Level of Evidence: B)
.2.12. Physical Activity
LASS I
. The patient’s risk after UA/NSTEMI should be assessed on the basis
of an in-hospital determination of risk. A physical activity history or
an exercise test to guide initial prescription is beneficial. (Level of
Evidence: B)
. Guided/modified by an individualized exercise prescription, patients
recovering from UA/NSTEMI generally should be encouraged to
achieve physical activity duration of 30 to 60 min per d, preferably
7 (but at least 5) d per week of moderate aerobic activity, such as
brisk walking, supplemented by an increase in daily lifestyle activi-
ties (e.g., walking breaks at work, gardening, and household work).
(Level of Evidence: B)
. Cardiac rehabilitation/secondary prevention programs are recom-
mended for patients with UA/NSTEMI, particularly those with mul-
tiple modifiable risk factors and/or those moderate- to high-risk
patients in whom supervised exercise training is particularly war-
ranted. (Level of Evidence: B)
LASS IIb
he expansion of physical activity to include resistance training on 2 d
er week may be reasonable. (Level of Evidence: C)
Federal and ACC/AHA guidelines recommend that all
mericans strive for at least 30 to 60 min of moderate
hysical activity most days of the week, preferably daily
662). The 30 to 60 min can be spread out over 2 or 3
egments during the day. For post-UA/NSTEMI patients,
aily walking can be encouraged immediately after dis-
harge. Excellent resource publications on exercise prescrip-
ion in cardiovascular patients are available (45,663). Phys-
cal activity is important in efforts to lose weight because it
ncreases energy expenditure and plays an integral role in
eight maintenance. Regular physical activity reduces
ymptoms in patients with CVD, improves functional
apacity, and improves other cardiovascular risk factors such
s insulin resistance and glucose intolerance (45). Beyond
he instructions for daily exercise, patients require specific
nstruction on those strenuous activities (e.g., heavy lifting,
limbing stairs, yard work, and household activities) that are
ermissible and those they should avoid. Several activity
uestionnaires or nomograms, specific to the cardiac popu-
ation and general population, have been developed to help
uide the patient’s exercise prescription if an exercise test is
ot available (664–667). As emphasized by the US Public
ealth Service, comprehensive cardiac rehabilitation ser-
ices include long-term programs involving medical evalu-
tion, prescribed exercise, cardiac risk factor modification,
ducation, and counseling (668). These programs are de-
igned to limit the physiological and psychological effects of
ardiac illness, reduce the risk for sudden death or reinfarc-
ion, control cardiac symptoms, and enhance the psychos-
cial and vocational status of selected patients. Enrollment
n a cardiac rehabilitation program after discharge can lnhance patient education and compliance with the medical
egimen and assist with the implementation of a regular
xercise program (45,47,573,669,670). In addition to aero-
ic training, mild- to moderate-resistance training may be
onsidered. This can be started 2 to 4 weeks after aerobic
raining has begun (671). Expanded physical activity is an
mportant treatment component for the metabolic syn-
rome, which is becoming increasingly prevalent.
Exercise training can generally begin within 1 to 2 weeks
fter UA/NSTEMI treated with PCI or CABG to relieve
schemia (663). Unsupervised exercise may target a heart rate
ange of 60% to 75% of maximum predicted; supervised
raining (see Section 5.4) may target a somewhat higher heart
ate (70% to 85% of maximum predicted) (663). Additional
estrictions apply when residual ischemia is present.
.2.13. Patient Education
LASS I
eyond the detailed instructions for daily exercise, patients should be
iven specific instruction on activities (e.g., heavy lifting, climbing
tairs, yard work, and household activities) that are permissible and
hose that should be avoided. Specific mention should be made
egarding resumption of driving, return to work, and sexual activity.
Level of Evidence: C) Specific recommendations for physical activity
ollow in Section 5.4.
Patients should be educated and motivated to achieve
ppropriate target LDL-C and HDL-C goals. Patients who
ave undergone PCI or CABG derive benefit from choles-
erol lowering (672) and deserve special counseling lest they
istakenly believe that revascularization obviates the need
or significant lifestyle changes. The NHLBI “Your Guide
o Better Health” series provides useful educational tools for
atients (http://hp2010.nhlbihin.net/yourguide/).
.2.14. Influenza
LASS I
n annual influenza vaccination is recommended for patients with
ardiovascular disease. (Level of Evidence: B)
.2.15. Depression
LASS IIa
t is reasonable to consider screening UA/NSTEMI patients for depres-
ion and refer/treat when indicated. (Level of Evidence: B)
.2.16. Nonsteroidal Anti-Inflammatory Drugs
LASS I
t the time of preparation for hospital discharge, the patient’s need for
reatment of chronic musculoskeletal discomfort should be assessed,
nd a stepped-care approach to treatment should be used for selection
f treatments (Fig. 21). Pain relief should begin with acetaminophen,
mall doses of narcotics, or nonacetylated salicylates. (Level of Evi-
ence: C)
LASS IIa
t is reasonable to use nonselective NSAIDs, such as naproxen, if initial
herapy with acetaminophen, small doses of narcotics, or nonacety-
ated salicylates is insufficient. (Level of Evidence: C)
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onsteroidal anti-inflammatory drugs with increasing degrees of rela-
ive COX-2 selectivity may be considered for pain relief only for situa-
ions in which intolerable discomfort persists despite attempts at
tepped-care therapy with acetaminophen, small doses of narcotics,
onacetylated salicylates, or nonselective NSAIDs. In all cases, the
owest effective doses should be used for the shortest possible time.
Level of Evidence: C)
LASS III
onsteroidal anti-inflammatory drugs with increasing degrees of rela-
ive COX-2 selectivity should not be administered to UA/NSTEMI pa-
ients with chronic musculoskeletal discomfort when therapy with
cetaminophen, small doses of narcotics, nonacetylated salicylates, or
onselective NSAIDs provides acceptable levels of pain relief. (Level of
vidence: C)
The selective COX-2 inhibitors and other nonselective
SAIDs have been associated with increased cardiovascular
isk. The risk appears to be amplified in patients with
stablished CVD (1,359–362). In a large Danish observa-
ional study of first-time MI patients (n 58,432), the HRs
nd 95% CIs for death were 2.80 (2.41 to 3.25) for
ofecoxib, 2.57 (2.15 to 3.08) for celecoxib, 1.50 (1.36 to
.67) for ibuprofen, 2.40 (2.09 to 2.80) for diclofenac, and
.29 (1.16 to 1.43) for other NSAIDS (361). There were
ose-related increases in risk of death and non–dose-
ependent trends for rehospitalization for MI for all drugs
360,361). An AHA scientific statement on the use of
SAIDS concluded that the risk of cardiovascular events is
roportional to COX-2 selectivity and the underlying risk in
he patient (673). Nonpharmacological approaches were
igure 21. Stepped-Care Approach to Pharmacological Therapy for
ith Known Cardiovascular Disease or Risk Factors for Ischemic H
Addition of ASA may not be sufficient protection against thrombotic events. Reprod
onsteroidal Anti-Inflammatory Drugs (NSAIDS)-An Update for Clinicians © 2007, Am
nonsteroidal anti-inflammatory drugs; PPI  proton-pump inhibitor.ecommended as the first line of treatment, followed by the ttepped-care approach to pharmacological therapy, as
hown in Figure 21.
.2.17. Hormone Therapy
LASS III
. Hormone therapy with estrogen plus progestin, or estrogen alone,
should not be given de novo to postmenopausal women after
UA/NSTEMI for secondary prevention of coronary events. (Level of
Evidence: A)
. Postmenopausal women who are already taking estrogen plus
progestin, or estrogen alone, at the time of UA/NSTEMI in general
should not continue hormone therapy. However, women who are
more than 1 to 2 years past the initiation of hormone therapy who
wish to continue such therapy for another compelling indication
should weigh the risks and benefits, recognizing the greater risk of
cardiovascular events and breast cancer (combination therapy) or
stroke (estrogen). Hormone therapy should not be continued while
patients are on bedrest in the hospital. (Level of Evidence: B)
Although prior observational data suggested a protective
ffect of hormone therapy for coronary events, a randomized
rial of hormone therapy for secondary prevention of death
nd MI (Heart and Estrogen/progestin Replacement Study
HERS]) failed to demonstrate a beneficial effect (674).
isturbingly, there was an excess risk for death and MI early
fter hormone therapy initiation. The Women’s Health
nitiative included randomized primary prevention trials of
strogen plus progestin and estrogen alone. Both trials were
topped early owing to an observed increased risk related to
ormone therapy that was believed to outweigh the poten-
ial benefits of further study (675–677). It is recommended
culoskeletal Symptoms
Disease
ith permission. American Heart Association Scientific Statement on the Use of
Heart Association, Inc. (673). ASA  aspirin; COX-2  cyclooxygenase-1; NSAIDsMus
eart
uced w
ericanhat postmenopausal women receiving hormone therapy at
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ikewise, hormone therapy should not be initiated for
econdary prevention of coronary events. However, there
ay be other permissible indications for hormone therapy in
ostmenopausal women (e.g., prevention of perimenopausal
ymptoms such as flushing, or prevention of osteoporosis) if
he benefits are believed to outweigh the increased cardio-
ascular risk).
.2.18. Antioxidant Vitamins and Folic Acid
LASS III
. Antioxidant vitamin supplements (e.g., vitamins E, C, or beta caro-
tene) should not be used for secondary prevention in UA/NSTEMI
patients. (Level of Evidence: A)
. Folic acid, with or without B6 and B12, should not be used for
secondary prevention in UA/NSTEMI patients. (Level of Evidence: A)
Although there is an association of elevated homocysteine
lood levels and CAD, a reduction in homocysteine levels
ith routine folate supplementation was not demonstrated
o reduce the risk of CAD events in 2 trials (Norwegian
itamin Trial [NORVIT] and HOPE) that included
ost-MI or high risk, stable patients (678–681). Similarly,
large clinical trials experience with antioxidant vitamins
as failed to demonstrate benefit for primary or secondary
revention (38,681a).
.3. Postdischarge Follow-Up
RECOMMENDATIONS
LASS I
. Detailed discharge instructions for post-UA/NSTEMI patients should
include education on medications, diet, exercise, and smoking
cessation counseling (if appropriate), referral to a cardiac rehabili-
tation/secondary prevention program (when appropriate), and the
scheduling of a timely follow-up appointment. Low-risk medically
treated patients and revascularized patients should return in 2 to 6
weeks, and higher risk patients should return within 14 d. (Level of
Evidence: C)
. Patients with UA/NSTEMI managed initially with a conservative strat-
egy who experience recurrent signs or symptoms of UA or severe
(Canadian Cardiovascular Society class III) chronic stable angina de-
spite medical management who are suitable for revascularization
should undergo timely coronary angiography. (Level of Evidence: B)
. Patients with UA/NSTEMI who have tolerable stable angina or no
anginal symptoms at follow-up visits should be managed with
long-term medical therapy for stable CAD. (Level of Evidence: B)
. Care should be taken to establish effective communication between
the post-UA/NSTEMI patient and health care team members to
enhance long-term compliance with prescribed therapies and rec-
ommended lifestyle changes. (Level of Evidence: B)
The risk of death within 1 year can be predicted on the
asis of clinical information and the ECG (see also Section
.3). In a study of 515 survivors of hospitalization for
STEMI, risk factors included persistent ST-segment
epression, HF, advanced age, and ST-segment elevation at
ischarge (682). Patients with all high-risk markers present
ad a 14-fold greater mortality rate than did patients with sll markers absent. Elevated cardiac TnT levels have also
een demonstrated to provide independent prognostic in-
ormation for cardiac events at 1 to 2 years. For patients
ith ACS in a GUSTO-IIa substudy, age, ST-segment
levation on admission, prior CABG, TnT, renal insuffi-
iency, and severe chronic obstructive pulmonary disease
ere independently associated with risk of death at 1 year
683,684). For UA/NSTEMI patients, prior MI, TnT
ositivity, accelerated angina before admission, and recur-
ent pain or ECG changes were independently associated
ith risk of death at 2 years. Patients managed with an
nitial conservative strategy (see Section 3) should be reas-
essed at the time of return visits for the need for cardiac
atheterization and revascularization. Specifically, the pres-
nce and severity of angina should be ascertained. Rates of
evascularization during the first year have been reported to
e high (685). Long-term (7 years) follow-up of 282
atients with UA demonstrated high event rates during the
rst year (MI 11%, death 6%, PTCA 30%, and CABG
7%); however, after the first year, event rates were low
685). Independent risk factors for death/MI were age
reater than 70 years, diabetes, and male sex. A predictive
odel for the risk of death from discharge to 6 months after
n ACS has been developed and validated using the
7,142-patient GRACE registry database (168). Mortality
veraged 4.8%. Nine predictive variables were identified:
lder age, history of MI, history of HF, increased pulse rate
t presentation, lower systolic blood pressure at presenta-
ion, elevated initial serum creatinine level, elevated initial
erum cardiac biomarker levels, ST-segment depression on
resenting ECG, and not having a PCI performed in the
ospital. The C statistic for the validation cohort was 0.75.
he GRACE tool was suggested to be a simple, robust tool
or clinical use.
Certain patients at high risk of ventricular tachyarrhyth-
ia after UA/NSTEMI may be candidates for an implant-
ble cardioverter defibrillator. Indications and timing of an
mplantable cardioverter defibrillator in this setting are
resented in the STEMI guidelines (1) and more recently
he Ventricular Arrhythmias and Sudden Cardiac Death
uidelines (686). Indications for testing for atherosclerotic
isease in other vascular beds (i.e., carotid, peripheral
rterial) are also covered elsewhere in recent guidelines
687).
Major depression has also been reported to be an inde-
endent risk factor for cardiac events after MI and occurs in
p to 25% of such patients (688). Antidepressant therapy
with sertraline) was safe and effective for relief of depressive
ymptoms in a controlled trial in 369 depressed patients
ith ACS, but it did not conclusively demonstrate a
eneficial effect on cardiovascular end points, perhaps be-
ause of limited sample size (689). Cognitive therapy and, in
ome cases, sertraline did not affect late survival after MI in
nother randomized study (Enhancing Recovery in Coro-
ary Heart Disease [ENRICHD]), but those whose depres-
ion did not improve were at higher risk of late mortality
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August 14, 2007:e1–157 ACC/AHA UA/NSTEMI Guideline Revision690). The CREATE trial evaluated interpersonal psycho-
herapy (IPT) compared with clinical management and the
elective serotonin reuptake inhibitor citalopram compared
ith placebo in a 2 2 factorial design among patients with
AD and major depression (691). The primary end point of
amilton Depression Rating Scale score was improved in
he citalopram group versus placebo (mean reduction 14.9
s. 11.6, p 0.005) but did not differ for IPT versus clinical
anagement (mean reduction 12.1 vs. 14.4, p  0.06).
ikewise, the secondary end point of reduction in mean
eck Depression Inventory score was improved in the
italopram group but did not differ for IPT.
Patients recognized to be at high risk for a cardiac event
fter discharge for any of the above reasons should be seen
or follow-up earlier and more frequently than lower-risk
atients.
The overall long-term risk for death or MI 2 months after
n episode of UA/NSTEMI is similar to that of other CAD
atients with similar characteristics. Van Domburg et al.
685) reported a good long-term outcome even after a
omplicated early course. Based on a median follow-up of
lmost 8 years, mortality in the first year was 6%, then 2%
o 3% annually in the following years (685). When the
atient has returned to the baseline level, typically 6 to 8
eeks after hospitalization, arrangements should be made
or long-term regular follow-up visits, as for stable CAD.
ardiac catheterization with coronary angiography is rec-
mmended for any of the following situations: 1) significant
ncrease in anginal symptoms, including recurrent UA; 2)
igh-risk pattern (e.g., at least 2 mm of ST-segment
epression, systolic blood pressure decline of at least 10 mm
g) on exercise test (see Section 3.4); 3) HF; 4) angina with
ild exertion (inability to complete stage 2 of the Bruce
rotocol for angina); and 5) survivors of sudden cardiac
eath. Revascularization is recommended based on the
oronary anatomy and ventricular function (see Section 4,
CC/AHA Guidelines for the Management of Patients
ith Chronic Stable Angina [4], and ACC/AHA 2004
uideline Update for Coronary Artery Bypass Graft Sur-
ery [555]).
Minimizing the risk of recurrent cardiovascular events
equires optimizing patients’ compliance with prescribed
herapies and recommended lifestyle modifications. Many
tudies exploring predictors of compliance have failed to
nd predictive value in simple demographic or socioeco-
omic variables. More reliable predictors are the patients’
eliefs and perceptions about their vulnerability to disease
nd the efficacy of the prescribed treatments and, impor-
antly, various aspects of the relationship with their health
are provider (692–694). Development of a therapeutic
elationship with the patient and family is likely to enhance
ompliance. Care should be taken to ensure that there is
dequate time spent with the family focused on explanation
f the disease and proposed treatments, the importance of
dhering to the prescribed treatment plan, and exploration
f patient-specific barriers to compliance. Participation in cardiac rehabilitation/secondary prevention programs can
elp reinforce patient-specific secondary prevention issues
nd can address barriers to compliance. Close communica-
ion between the treating physician and the cardiac rehabil-
tation team is important to maximize effectiveness
3,47,695,696).
.4. Cardiac Rehabilitation
LASS I
ardiac rehabilitation/secondary prevention programs, when avail-
ble, are recommended for patients with UA/NSTEMI, particularly
hose with multiple modifiable risk factors and those moderate- to
igh-risk patients in whom supervised or monitored exercise training is
arranted. (Level of Evidence: B)
Cardiac rehabilitation programs are designed to limit the
hysiological and psychological effects of cardiac illness,
educe the risk for sudden death or reinfarction, control
ardiac symptoms, stabilize or reverse the atherosclerotic
rocess, and enhance the psychosocial and vocational status
f selected patients (668,695,697). Cardiac rehabilitation is
comprehensive long-term program that involves medical
valuation, prescribed exercise, cardiac risk factor modifica-
ion, education, and counseling (668,698). Cardiac rehabil-
tation may occur in a variety of settings, including medi-
ally supervised groups in a hospital, physician’s office, or
ommunity facility (696). Exercise may involve a stationary
icycle, treadmill, calisthenics, walking, or jogging, and
onitoring may include ECG telemetry, depending on a
atient’s risk status and the intensity of exercise training.
ducation and counseling concerning risk factor modifica-
ion are individualized, and close communication between
he treating physician and cardiac rehabilitation team may
romote long-term behavioral change (695,696). Alterna-
ive delivery approaches, including home exercise, internet-
ased, and transtelephonic monitoring/supervision, can be
mplemented effectively and safely for carefully selected
linically stable patients (668,699).
Witt et al. (700) examined the association of participation
n cardiac rehabilitation with survival in Olmstead County,
innesota, and found that participants had a lower risk of
eath and recurrent MI at 3 years (p less than 0.001 and p
0.049, respectively). The survival benefit associated with
articipation was stronger in more recent years (700). In this
tudy, half of the eligible patients participated in cardiac
ehabilitation after MI, although women and older adult
atients were less likely to participate, independent of other
haracteristics.
A pooled-effect estimate for total mortality for the
xercise-only intervention demonstrated a reduction in all-
ause mortality (random effects model OR 0.73 [95% CI
.54 to 0.98]) compared with usual care. Comprehensive
ardiac rehabilitation reduced all-cause mortality, although
o a lesser degree (OR 0.87 [95% CI 0.71 to 1.05]). Neither
f the interventions had an effect on the occurrence of
onfatal MI. The authors concluded that exercise-based
ardiac rehabilitation appeared to be effective in reducing
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ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:e1–157ardiac deaths but that it was still unclear whether an
xercise-only or a comprehensive cardiac rehabilitation in-
ervention was more beneficial. The population studied was
redominantly male, middle-aged, and low risk. The au-
hors suggested that those who could have benefited from
he intervention might have been excluded owing to age,
ender, or comorbidity. The authors cautioned that the
esults were of limited reliability because the quality of
eporting in the studies was generally poor, and there were
igh losses to follow-up (698).
Cardiac rehabilitation comprising exercise training and
ducation, counseling, and behavioral interventions yielded
mprovements in exercise tolerance with no significant
ardiovascular complications, improvements in symptoms
decreased anginal pain and improved symptoms of HF
uch as shortness of breath and fatigue), and improvements
n blood lipid levels; reduced cigarette smoking in conjunc-
ion with a smoking cessation program; decreased stress;
nd improved psychosocial well-being (668). In addition to
eductions in total cholesterol and LDL-C, increases in
DL-C levels occur (701).
Cardiac rehabilitation has been reported to improve
rognosis after MI in a cost-effective manner (702,703). In
urrent practice, referrals for cardiac rehabilitation are more
requent after bypass surgery and less frequent after PCI for
A/NSTEMI (704). Benefits of rehabilitation after un-
omplicated UA/NSTEMI with revascularization and
odern medical therapy are less clear in comparison with
TEMI or complicated NSTEMI.
Existing community studies reveal that fewer than one
hird of patients with MI receive information or counseling
bout cardiac rehabilitation before being discharged from
he hospital (668,705). Only 16% of patients in a study of 5
ospitals in 2 Michigan communities were referred to a
ardiac rehabilitation program at discharge, and only 26% of
he patients later interviewed in the community reported
ctual participation in such a program; however, 54% of the
atients referred at discharge did participate at the time of
heir follow-up interview (705). Physician referral was the
ost powerful predictor of patient participation in a cardiac
ehabilitation program. In a longitudinal study of the use of
npatient cardiac rehabilitation in 5,204 Worcester, Mass,
esidents hospitalized with MI in seven 1-year periods
etween 1986 and 1997, patients not referred to inpatient
ardiac rehabilitation were less likely to be prescribed
ffective cardiac medications and to undergo risk factor
odification counseling before discharge (706).
Patient reasons for nonparticipation and noncompliance
nclude affordability of service, insurance coverage/
oncoverage, social support from a spouse or other care-
iver, gender-specific attitudes, patient-specific internal fac-
ors such as anxiety or poor motivation, and logistical and
nancial constraints, or a combination of these factors
688,705). Women and the elderly are referred less fre-
uently to cardiac rehabilitation programs, even though they
erive benefit from them (38,707–710). Health care systems phould consider instituting processes that encourage referral
f appropriate patients to cardiac rehabilitation/secondary
revention programs (for example, the use of standardized
rder sets that facilitate this, such as the AHA “Get with the
uidelines” tools). In addition, it is important that referring
ealth care practitioners and cardiac rehabilitation teams
ommunicate in ways that promote patient participation. Of
ote, Medicare coverage for rehabilitation recently was
xpanded beyond post-MI, post-CABG, and stable angina
o include PCI (711).
.5. Return to Work and Disability
eturn-to-work rates after MI, which currently range from
3% (712) to 94% (713), are difficult to influence because
hey are confounded by factors such as job satisfaction,
nancial stability, and company policies (714). In PAMI
Primary Angioplasty in Myocardial Infarction)-II, a study
f primary PTCA in low-risk patients with MI (i.e., age less
han 70 years, ejection fraction greater than 0.45, 1- or
-vessel disease, and good PTCA result), patients were
ncouraged to return to work at 2 weeks (715). The actual
iming of return to work was not reported, but no adverse
vents occurred as a result of this strategy.
Cardiac rehabilitation programs after MI can contribute
o reductions of mortality and improved physical and
motional well-being (see Section 5.4). Patients whose
xpectations for return to work were addressed in rehabili-
ation returned to work at a significantly faster rate than the
ontrol group in a prospective study (716).
Lower or absent levels of depressive symptoms before MI
ncreases the odds of recovery of functional status (717).
atients with high pre-event functional independence mea-
urement have a shorter length of stay and a greater
ikelihood of discharge to home (718). Pre-event peak
erobic capacity and depression score are the best indepen-
ent predictors of postevent physical function. Women tend
o have lower physical function scores than men of similar
ge, depression score, and comorbidity. Resting LVEF is
ot a predictor of physical function score.
Patients’ cardiac functional states are not a strong predic-
or of their probability of returning to work. Diabetes, older
ge, Q-wave MI, and preinfarction angina are associated
ith failure to resume full employment (719). However,
sychological variables such as trust, job security, patient
eelings about disability, expectations of recovery by both
hysician and patient, and degree of somatizing are more
redictive (720,721). Physical requirements of the job play a
ole as well (719,721).
To aid occupational physicians in making return-to-work
ecisions, Froom et al. (719) studied the incidence of post- MI
vents at 1, 2, 4, 6, 9, and 12 months. Events included cardiac
eath, recurrent infarction, CHF, and UA. They found that
he incidence of events reached a low steady state at 10 weeks.
Return to work can be determined by employer regulations
ather than by the patient’s medical condition. It behooves the
hysician to provide data to prove that the patient’s job does
n
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August 14, 2007:e1–157 ACC/AHA UA/NSTEMI Guideline Revisionot impose a prohibitive risk for a cardiac event. An example is
he case of Canadian bus drivers reported by Kavanagh et al.
722). These patients were evaluated with a stress test. The
hysician and technologist studied the drivers at work and
howed that the cardiac stress values during driving were only
alf of the average values obtained in the stress laboratory. The
alculated risk of sudden cardiovascular incidents causing injury
r death to passengers, other road users, and the drivers
hemselves in the first year after recovery from an MI was 1 in
0,000 driving-years. The bus drivers were allowed to return to
ork after they satisfied the Canadian Cardiovascular Society
uidelines.
Covinsky et al. (723) performed a mail survey study of
atients with MIs. Three months after discharge, women
eported worse physical and mental health and were more
ikely to work less than before the MI. Similarly, women
ere less likely to return to work than men. Contemporary
nformation specific to UA/NSTEMI on return to work by
ender is needed.
The current aggressive interventional treatment of ACS
ill have an impact on mortality, morbidity, and hospital
ength of stay (724). It remains to be determined whether
arlier improvement in cardiac condition after ACS will
able 23. Energy Levels Required to Perform Some Common A
Less Than 3 METS 3–5 METS 5–7
Se
ashing
having
ressing
esk work
ashing dishes
riving auto
ight housekeeping
Cleaning windows
Raking
Power lawn mowing
Bed making/stripping
Carrying objects (15 to 30 lb)
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Climbing stair
Carrying objec
Occ
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Badminton (co
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Basketball
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Stream Fishin
Physical
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Level walking
Bicycling (9–1
Swimming, br
dapted with permission from Haskell WL. Design and implementation of cardiac conditioning p
hurchill Livingstone, 1978 (725).
METS  metabolic equivalents; mph  miles per hour.ave an effect on the rate of return to work because of the multiple noncardiac factors that influence disability and
eturn to work.
.6. Other Activities
n patients who desire to return to physically demanding
ctivities early, the safety of the activity can be deter-
ined by comparing performance on a graded exercise
est with the MET level required for the desired activity.
able 23 presents energy levels, expressed in METS,
equired to perform a variety of common activities (725).
his and similar tables can be helpful in translating a
atient’s performance on a graded exercise test into daily
ctivities that can be undertaken with reasonable safety.
The health care provider should provide explicit advice
bout when to return to previous levels of physical activity,
exual activity, and employment. Daily walking can be
ncouraged immediately (726). In stable patients without
omplications (Class I), sexual activity with the usual
artner can be resumed within 1 week to 10 d. Driving can
egin 1 week after discharge if the patient is judged to be in
ompliance with individual state laws. Each state’s Depart-
ent of Motor Vehicles or its equivalent has mandated
ertain criteria, which vary from state to state and must be
ies
7–9 METS More Than 9 METS
e
en
wing
ly)
to 60 lb)
Sawing wood
Heavy shoveling
Climbing stairs (moderate
speed)
Carrying objects (60 to 90 lb)
Digging vigorously
Carrying loads upstairs
(objects more than
90 lb)
Climbing stairs
(quickly)
Shoveling heavy snow
nal
c tools
Digging ditches (pick and
shovel)
Forestry
Farming
Lumber jack
Heavy laborer
Shoveling (heavy)
nal
itive)
ill)
Canoeing
Mountain climbing
Paddle ball
Walking (5 mph)
Running (12 min. mile)
Mountain or rock climbing
Soccer
Handball
Football (competitive)
Squash
Ski touring
Vigorous basketball
(game)
itioning
.0 mph)
)
troke
Level jogging (5 mph)
Swimming (crawl stroke)
Rowing machine
Heavy calisthenics
Bicycling (12 mph)
Running (more than 6
mph)
Bicycling (more than
13 mph)
Rope jumping
Walking uphill (5 mph)
. In: Wenger NL, Hellerstein HK, editors. Rehabilitation of the Coronary Patient. New York, NY:ctivit
METS
lf-Car
n gard
n mo
s (slow
ts (30
upatio
erior)
umati
reatio
mpet
s)
ownh
king
g
Cond
(4.5–5
0 mph
east s
rogramet before operation of a motor vehicle after serious illness
(
a
r
a
c
n
b
s
8
r
p
A
t
o
f
c
r
e
h
t
l
r
w
w
5
S
E
c
h
i
d
m
i
u
“
W
e
t
s
s
T
d
t
r
f
o
s
m
o
c
p
t
e
d
t
i
i
I
e
s
h
t
w
w
w
6
6
C
1
2
3
4
C
o
a
o
t
c
W
t
t
d
t
w
l
m
i
p
6
C
w
r
C
e102 Anderson et al. JACC Vol. 50, No. 7, 2007
ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:e1–157727). These include such caveats as the need to be
ccompanied and to avoid stressful circumstances such as
ush hour, inclement weather, night driving, heavy traffic,
nd high speeds. For patients who have experienced a
omplicated MI (one that required CPR or was accompa-
ied by hypotension, serious arrhythmias, high-degree
lock, or CHF), driving should be delayed 2 to 3 weeks after
ymptoms have resolved.
Most commercial aircraft are pressurized to 7,500 to
,000 feet and therefore could cause hypoxia due to the
educed alveolar oxygen tension. The maximum level of
ressurization is limited to 8,000 feet (2440 m) by Federal
viation Administration regulation (728). Therefore, air
ravel within the first 2 weeks of MI should be undertaken
nly if there is no angina, dyspnea, or hypoxemia at rest or
ear of flying. The individual must have a companion, must
arry NTG, and must request airport transportation to avoid
ushing and increased cardiac demands. Availability of an
mergency medical kit and automated external defibrillator
as been mandated as of April 12, 2004 (729), in all aircraft
hat carry at least approximately 30 passengers and have at
east 1 flight attendant.
Patients with UA (i.e., without infarction) who are
evascularized and otherwise stable may accelerate return to
ork, driving, flying, and other normal activities (often,
ithin a few days).
.7. Patient Records and Other Information
ystems
ffective medical record systems that document the
ourse and plan of care should be established or en-
anced. Both paper-based and electronic systems that
ncorporate evidence-based guidelines of care, tools for
eveloping customized patient care plans and educational
aterials, and capture of data for appropriate standard-
zed quality measurements should be implemented and
sed routinely. Examples of such tools are the ACC’s
Guidelines Applied in Practice” and the AHA’s “Get
ith the Guidelines.” All computerized provider order
ntry (CPOE) systems should incorporate these at-
ributes as well. In some settings, the regular and con-
istent use of such systems and tools has been shown to
ignificantly improve quality of care and patient safety.
he patient’s medical record from the time of hospital
ischarge should indicate the discharge medical regimen,
he major instructions about postdischarge activities and
ehabilitation, and the patient’s understanding and plan
or adherence to the recommendations. After resolution
f the acute phase of UA/NSTEMI, the medical record
hould summarize cardiac events, current symptoms, and
edication changes since hospital discharge or the last
utpatient visit and should document the plan for future
are. Processes for effective and timely transfer of relevant
rehospital and postdischarge patient information be-
ween all participating caregivers should be continuously
nhanced in accordance with existing regulatory stan- (ards. This should include providing all patients with the
ools to facilitate access to and understanding of the nature and
mportance of their most current plan of care. With the
ncreasing numbers of patients who have regular access to the
nternet, awareness of online information reflecting current
vidence-based and professionally developed standards of care
hould be encouraged and promoted. Several sites with reliable
ealth care information relevant to UA/NSTEMI are available
o patients (http://www.heartauthority.com; http://
ww.nhlbi.nih.gov/health/dci/index.html; http://
ww.nlm.nih.gov/medlineplus/tutorial.html; and http://
ww.fda.gov/hearthealth/index.html).
. Special Groups
.1. Women
RECOMMENDATIONS
LASS I
. Women with UA/NSTEMI should be managed with the same phar-
macological therapy as men both in the hospital and for secondary
prevention, with attention to antiplatelet and anticoagulant doses
based on weight and renal function; doses of renally cleared medi-
cations should be based on estimated creatinine clearance. (Level
of Evidence: B)
. Recommended indications for noninvasive testing in women with
UA/NSTEMI are similar to those for men. (Level of Evidence: B)
. For women with high-risk features, recommendations for invasive
strategy are similar to those of men. See Section 3.3. (Level of
Evidence: B)
. In women with low-risk features, a conservative strategy is recom-
mended. (Level of Evidence: B)
Although at any age, women have a lower incidence of
AD than men, they account for a considerable proportion
f UA/NSTEMI patients, and UA/NSTEMI is a serious
nd common condition among women. It is important to
vercome long-held notions that severe coronary manifes-
ations are uncommon in this population; however, women
an manifest CAD somewhat differently than men (679).
omen who present with chest discomfort are more likely
han men to have noncardiac causes and cardiac causes other
han fixed obstructive coronary artery stenosis. Other car-
iac causes include coronary vasospasm, abnormal vasodila-
or reserve, and other mechanisms (679,731–733). Women
ith CAD are, on average, older than men and are more
ikely to have comorbidities such as hypertension, diabetes
ellitus, and HF with preserved systolic function; to man-
fest angina rather than MI; and, among angina and MI
atients, to have atypical symptoms (150,734–736).
.1.1. Profile of UA/NSTEMI in Women
onsiderable clinical information about UA/NSTEMI in
omen has emerged from many randomized trials and
egistries (150,552,554,734,737). As in other forms of
AD, women are older and have more comorbiditiesdiabetes mellitus and hypertension) and stronger family
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ave had a previous MI or cardiac procedures (734), more
ikely to have a history of HF, but less likely to have LV
ystolic dysfunction. Women present with symptoms of
imilar frequency, duration, and pattern, but more often
han men, they have anginal-equivalent symptoms such as
yspnea or atypical symptoms (72,141,738). The frequency
f ST-segment changes is similar to that for men, but
omen more often have T-wave inversion. There are
otable differences in the profiles of cardiac biomarkers for
omen and men, with a consistent finding in trials and
egistries that women less often have elevated levels of
roponin (552,554,565,737). In an analysis of TACTICS-
IMI 18, women also less often had elevation of CK-MB;
owever, women more often had increased levels of high-
ensitivity CRP or BNP than men. Importantly, the prog-
ostic value of elevated biomarkers is similar in men and
omen (739). Coronary angiograms in both trials and
egistries revealed less extensive CAD in women, as well as
higher proportion with nonobstructive CAD. The rate of
onobstructive CAD can be as high as 37% despite selection
f women according to strict inclusion criteria in clinical
rials (150,554).
A differing symptom pattern in women than men, the
ower frequency of positive cardiac biomarkers despite high
ates of ST-T abnormalities on the ECG, and the higher
requency of nonobstructive CAD in women make it
hallenging to confirm the diagnosis of UA/NSTEMI. This
s a likely cause of underutilization of several therapies in
omen compared with men (737). There are important
echanisms of ischemic chest pain other than platelet/
hrombus aggregates on plaque erosion or ulceration in
omen (see Section 6.8). Although some studies report that
emale sex is a risk factor for poor outcome in UA/
STEMI on the basis of unadjusted event rates, (72,737),
ultivariate models have not found female sex to be an
ndependent risk factor for death, reinfarction, or recurrent
schemia. This is in contrast to an apparent independent risk
f death for women compared with men with STEMI,
articularly for younger women.
.1.2. Management
.1.2.1. PHARMACOLOGICAL THERAPY
n studies that span the spectrum of CAD, women tend to
eceive less intensive pharmacological treatment than men
734,737,740), perhaps in part because of a general percep-
ion of lower frequency and severity of CAD in women.
lthough the specifics vary regarding beta blockers and
ther drugs (150,734,741), a consistent (and disturbing)
attern is that women are prescribed ASA and other
ntithrombotic agents less frequently than men (150,737,740).
omen derive the same treatment benefit as men from ASA,
lopidogrel (54), anticoagulants, beta blockers, ACE inhibi-
ors, and statins (54,742). A meta-analysis of GP IIb/IIIa
ntagonists in ACS demonstrated an interaction between sex
nd treatment effect, with an apparent lack of efficacy in women (526); however, women with elevated troponin levels
eceived the same beneficial effect as men treated with GP
Ib/IIIa antagonists. The findings of a beneficial effect of a
irect invasive strategy in women treated with a GP IIb/IIIa
ntagonist in TACTICS-TIMI 18 (see Section 6.1.2.3) fur-
her supports the similar efficacy of these agents in this cohort
f women and men.
Despite the clear benefit of antiplatelet and anticoagulant
herapy for women with ACS, women are at increased risk
f bleeding. A low maintenance dose of ASA (75 to 162
g) should be used to reduce the excess bleeding risk,
specially in combination with clopidogrel (54). Estimated
reatinine clearance instead of serum creatinine levels
hould guide decisions about dosing and the use of agents
hat are renally cleared, e.g., LMWHs and the small-
olecule GP IIb/IIIa antagonists. In a large community-
ased registry study, 42% of patients with UA/NSTEMI
eceived excessive initial dosing of at least 1 antiplatelet or
nticoagulant agent (UFH, LMWH, or GP IIb/IIIa inhib-
tor) (743). Female sex, older age, renal insufficiency, low
ody weight, and diabetes were predictors of excessive
osing. Dosing errors predicted an increased risk of major
leeding (743). The formula used to estimate creatinine
learance for dose adjustment in clinical studies and labeling
hat defines adjustments for several medications have been
ased on the Cockroft-Gault formula for estimating creat-
nine clearance, which is not identical to the Modification of
iet and Renal Disease (MDRD) formula recently recom-
ended for screening for renal disease (744), either in units
r cutpoints for adjustment. Weight-based adjustment of
edication doses also should be applied carefully where
ecommended.
The use of hormone therapy in postmenopausal women is
iscussed in Section 5.2.17.
.1.2.2. CORONARY ARTERY REVASCULARIZATION
ontemporary studies have cast doubt on the widely held
elief that women fare worse with PCI and CABG than do
en because of technical factors (e.g., smaller artery size,
reater age, and more comorbidities) (150,735,742,745–
49). In the case of PCI, it has been suggested that
ngiographic success and late outcomes are similar in
omen and men, although in some series, early complica-
ions occurred more frequently in women (745,746,750–
53). However, the outlook for women undergoing PCI
ppears to have improved, as evidenced by the NHLBI
TCA registry (754). Earlier studies of women undergoing
ABG showed that women were less likely to receive
nternal mammary arteries or complete revascularization
nd had a higher mortality rate (RR 1.4 to 4.4) than men
748,749,755). However, more recent studies of CABG in
atients with ACS show a more favorable outlook for
omen than previously thought (see Section 6.3)
756,757,757a).
A Mayo Clinic review of 3,014 patients (941 women)ith UA who underwent PCI reported that women had
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ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:e1–157imilar early and late results as men (735). The BARI trial
f 1,829 patients compared PTCA and CABG, primarily in
atients with UA, and showed that the results of revascu-
arization were, if anything, better in women than men
hen corrected for other factors. At an average 5.4-year
ollow-up, mortality rates for men and women were 12%
nd 13%, respectively, but when adjusted for baseline
ifferences (e.g., age, diabetes, and other comorbidities),
here was a lower risk of death (RR 0.60, 95% CI 0.43 to
.84, p 0.003) but a similar risk of death or MI (RR 0.84,
5% CI 0.66 to 1.07, p  0.16) in women compared with
en (755). The NHLBI Dynamic Registry has reported
mproved outcomes for women who underwent PCI in
997 to 1998 compared with 1985 to 1986. Compared with
en, women had similar procedural success, in-hospital
eath, MI, and CABG (754). Although the 1-year event
ate was higher for women, female sex was not indepen-
ently associated with death or MI because women tended
o be older and had more comorbidities. A prospective study
f 1,450 patients with UA/NSTEMI who underwent an
ndirect or direct invasive strategy with coronary stenting
eported that female sex was independently associated with
lower rate of death and MI (HR 0.51, 95% CI 0.28 to
.95) (553).
.1.2.3. INITIAL INVASIVE VERSUS INITIAL CONSERVATIVE STRATEGY
n the modern era, clinical trials assessing a direct invasive
trategy compared with an initial conservative strategy for
he management of UA/NSTEMI have consistently dem-
nstrated a benefit for men (552,554,565). Approximately
ne third of the cohorts in these trials were women (n 
,179), and the results on the efficacy and safety of a direct
nvasive strategy in women have been conflicting. Each trial
as underpowered to evaluate the subgroup of women, and
here were substantial differences among the trials (Table
4). A meta-analysis of trials in the era of stents and GP
Ib/IIIa antagonists has failed to show a survival benefit of
direct invasive strategy in women at 6 to 12 months (OR
or women 1.07, 95% CI 0.82 to 1.41; OR for men 0.68,
5% CI 0.57 to 0.81) (542).
In TACTICS-TIMI 18, there was a significant reduction
n the primary end point of death, nonfatal MI, or rehos-
italization for an ACS with a direct invasive strategy (OR
.45, 95% CI 0.24 to 0.88, p  0.02) (182). All subjects in
his trial (n  754) were treated with an early GP IIb/IIIa
ntagonist (tirofiban). A similar overall reduction in the
rimary composite end point of death, MI, or rehospital-
zation for ACS at 6 months was observed for women and
en (adjusted OR 0.72, 95% CI 0.47 to 1.11 and adjusted
R 0.64, 95% CI 0.47 to 0.88, respectively). Women were
lder, more frequently had hypertension, and less frequently
ad previous MI, CABG, and elevated cardiac biomarkers
p less than 0.001 for all), but there was no significant
ifference in TIMI risk score distribution by sex (p  0.76)
565). A similar reduction in composite risk was observed in
omen with intermediate (3 to 4) or high (5 to 7) TIMI risk fcores as in men. However, in contrast to men with a low
IMI risk score who had similar outcomes with an invasive
nd conservative strategy, low-risk women had an OR for
vents of 1.59 (95% CI 0.69 to 3.67) for the invasive
ompared with the conservative strategy (565). However,
he number of events was small (n  26 events), and the p
alue for interaction between strategy, TIMI risk score, and
ex on outcome did not achieve significance (p  0.09). An
levated biomarker, including BNP, CRP, CK-MB, and
roponin, also identified women (and men) who benefited
ifferentially from a direct invasive strategy. The reduction
n risk was enhanced in women with elevated TnT levels
adjusted OR 0.47, 95% CI 0.26 to 0.83), with a similar
eduction in the primary end point noted for women and
en with elevated troponin. However, in contrast to the
imilar outcome for the invasive versus conservative strategy
n men with a negative TnT marker (OR 1.02, 95% CI 0.64
o 1.62, p  0.04), the primary end point of death, MI, and
ehospitalization occurred significantly more frequently in
omen with negative troponin randomized to an invasive
trategy (OR 1.46, 95% CI 0.78 to 2.72) (565).
The RITA-3 trial enrolled 682 women (38% of 1,810
atients) (758). There was a significant interaction between
ex and treatment strategy (invasive versus conservative) on
utcome in RITA-3 (p  0.042). In contrast to a reduction
n death or MI for men assigned to an invasive strategy, the
R for women was 1.09. Women assigned to an initial
onservative strategy had a lower rate of death and MI
5.1%) at 1 year than the women enrolled in TACTICS-
IMI 18 (9.7% at 6 months). Consistent with this differ-
nce, 37% of women in RITA-3 had no significant obstruc-
ive CAD, compared with 17% of women in TACTICS-
IMI 18 (759). Other notable differences between RITA-3
nd TACTICS-TIMI 18 include routine use of GP IIb/
IIa antagonist in TACTICS-TIMI 18 and different crite-
ia for the MI end point in both the conservative and the
nvasive treatment groups. The RITA-3 investigators have
eported that the rates of death and MI for women are
1.1% and 12.7% in the conservative versus invasive strat-
gy, respectively, that is, not significantly different, when
here was a lower threshold for cardiac marker diagnosis of
I among the conservatively treated group (554).
In the only trial that showed an overall survival benefit for
n invasive strategy, FRISC-II, there was a significant
nteraction in outcome between treatment strategy, which
ncluded a systematic but delayed interventional approach
ithin 7 d of symptom onset, and sex (549,552). Thirty
ercent of the 2,457 enrolled patients were women, and the
eath and MI rate at 1 year was nonsignificantly higher for
nvasively treated versus conservatively treated women, in
ontrast to a large reduction in death and MI for men.
emale sex was independently associated with events in the
nvasively assigned patients. However, the poor outcome of
omen was largely driven by a 9.9% death rate at 1 year in
omen who underwent CABG. In contrast, the death rateor women who underwent PCI in the invasive strategy
Table 24. Invasive Versus Conservative Strategy Results for UA/NSTEMI by Gender
Study (Reference) Timing End Point Overall Result Results in Men Results in Women Comment
TACTICS-TIMI 18 (182,565)
2002
n  2220
34% female
Angiography 4 to 48 h Death, MI 30 d
Inv: 4.7%
Cons: 7.0%,
p  0.02
ARR  2.3%
6 months
Inv: 7.3%
Cons: 9.5%
OR  0.74 (95% CI
0.54 to 1.00)
ARR  2.2%
6 months
Inv: 7.6%
Cons: 9.4%
OR  0.68 (95% CI 0.43 to 1.05)
ARR  1.8%
6 months
Inv: 6.6%
Cons: 9.7%
OR  0.45 (95% CI 0.24 to 0.88)
ARR  3.1%
Benefit greater in women with
high cTnT; OR  0.47 (95%
CI 0.26 to 0.83) for death,
MI, and rehospitalization
RITA-3 (758) 2002
n  1810
38% female
Angiography within 48 h Death, MI, refractory
angina
Death, MI
4 months
Inv: 9.6%
Cons: 14.5%,
p  0.001
RR  0.66 (95% CI
0.51 to 0.85)
ARR  4.9%
1 year
Inv: 7.0%
Cons: 8.3%, p  0.58
RR  0.91 (95% CI
0.67 to 1.25)
ARR  0.7%
4 months
Inv: 8.8%
Cons: 17.3%
ARR  8.5%
1 year
Inv: 7.0%
Cons: 10.1%
Arr  3.1%
4 months
Inv: 10.9%
Cons: 9.6%, p  NS
ARR  1.3%
1 year
Inv: 8.6%
Cons: 5.1%
ARR  3.5%
Angina reduced with invasive
strategy
FRISC II (245,549,552) 1999
n  2457
30% female
Revascularization within
7 d
Death, MI 6 months
Inv: 9.4%
Cons: 12.1%,
p  0.3
ARR  2.7%
1 year
Inv: 10.4%
Cons: 14.1%,
p  0.005
ARR  3.7%
1 year
Inv: 9.6%
Cons: 15.8% p less than 0.001
ARR  6.2%
6 months
Inv: 10.5%
Cons: 8.3%, RR  1.26
(95% CI 0.80 to 1.97)
ARR  1.9%
1 year
Inv: 12.4%
Cons: 10.5%, p  NS
ARR  1.9%
Mortality benefit at 1 year
(2.2% vs. 3.9%)
ARR  1.7% p  0.02,
not seen in women
(4% vs. 3.3%)
ARR  0.7%
TIMI-IIIB (150) 1997
n  1423
34% female
Angiography 1 to 48 h Death, MI 1 year
Inv: 10.8%
Cons: 12.2%,
p  0.42
ARR  1.4%
Death at 6 weeks
Inv: 2.6%
Cons: 1.4%
ARR  1.2%
MI at 6 weeks
Inv: 5.5%
Cons: 6.0%
ARR  0.5%
Death at 6 weeks
Inv: 2%
Cons: 4.4%
ARR  2.4%
MI at 6 weeks
Inv: 4.4%
Cons: 5.2%
ARR  0.8%
Invasively treated patients
had less angina and fewer
rehospitalizations for
ischemia
Reproduced with permission from Percutaneous Coronary Intervention and Adjunctive Pharmacotherapy in Women: A Statement for Healthcare professionals from the American Heart Association © 2005, American Heart Association, Inc. (742).
ACS  acute coronary syndrome; ARR  absolute risk reduction; CI  confidence interval; Cons  conservative; cTnT  cardiac troponin T; FRISC II  Fast Revascularization during InStability in Coronary artery disease-II; Inv  invasive; MI  myocardial infarction;
n  number of patients; NS  nonsignificant; NSTEMI  non–ST-segment elevation MI; OR  odds ratio; PTCA  percutaneous transluminal coronary angioplasty; RITA-3  Third Randomized Intervention Treatment of Angina; RR  risk ratio; TACTICS-TIMI 18  Treat
Angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy–Thrombolysis In Myocardial Infarction 18; TIMI IIIB  Thrombolysis In Myocardial Infarction III; UA  unstable angina.
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5% CI 0.27 to 8.28; p  nonsignificant [NS]).
In summary, women with UA/NSTEMI and high-risk
eatures, including elevated cardiac biomarkers, appear to
enefit from an invasive strategy with early intervention and
djunctive GP IIb/IIIa antagonist use. There is no benefit of
direct invasive strategy for low-risk women, and the
eight of evidence from the recent randomized clinical trials
uggests that there may be excess risk associated with a
irect invasive strategy in this group. The challenges in the
iagnosis of UA/NSTEMI and the varied pathophysiology
f ischemic pain in women who present with rest discomfort
uggest that perhaps the excess risk of a direct invasive
trategy observed in low-risk women could be due to
ntervention on a stable incidental coronary lesion in a
oman with another mechanism for rest pain.
.1.3. Stress Testing
n general, ECG exercise testing is less predictive in women
han in men, primarily because of the lower pretest proba-
ility of CAD (581,760–762). Perfusion studies using
estamibi have good sensitivity and specificity in women
763). Breast attenuation is less of a problem than previously
ith thallium-201 stress testing with new tissue software.
tress echocardiography (dobutamine or exercise) is there-
ore an accurate and cost-effective technique for CAD
etection in women (581). Newer perfusion methods such
s adenosine-stress CMR also appear to be promising in
omen. Cardiac magnetic resonance imaging (for function,
erfusion, and viability) and multislice CCTA are 2 new
iagnostic modalities that could prove particularly useful in
omen because of their promise of both greater sensitivity
nd specificity (improved diagnostic accuracy). Evidence of
schemia by objective measures without obstructive CAD
arries an adverse prognosis (4,764) and is suggestive of
ascular dysfunction (coronary endothelial or microvascular
ysfunction) as an etiological mechanism.
Recommendations for noninvasive testing in women are
he same as in men (see Section 3.4) (733,764). A report of
76 women who underwent treadmill exercise suggests that
he Duke Treadmill Score provides accurate diagnostic and
rognostic estimates in both women and men (765). The
uke Treadmill Score actually performed better for women
han for men in the exclusion of CAD. There were fewer
ow-risk women than men with any significant CAD (at
east 1 vessel with greater than 75% stenosis; 20% in women
s. 47% in men, p less than 0.001).
Regarding dobutamine stress echocardiography, pilot
hase data from the Women’s Ischemia Syndrome Evalu-
tion (WISE) indicated that in women, the test reliably
etects multivessel disease (sensitivity 81.8%, similar to that
n men) but not 1-vessel disease (766). Several studies have
ndicated that women with positive stress tests tend not to
e evaluated as aggressively as men (741), which is inappro-
riate given the adverse prognosis of ischemia as demon-
trated in WISE and other studies (733,767–774). sIn the TIMI IIIB registry, women underwent exercise
esting in a similar proportion as men (150,734). The
requencies of stress test positivity were also similar, al-
hough women were less likely to have a high-risk stress test
esult. Moreover, women were less likely to undergo an-
iography (RR 0.71, p less than 0.001), perhaps because of
he lower percentage with high-risk test results on nonin-
asive testing.
.1.4. Conclusions
omen with UA/NSTEMI are older and more frequently
ave comorbidities compared with men but have more
typical presentations and appear to have less severe and less
xtensive obstructive CAD. Women receive ASA less fre-
uently than do men, but patients with UA/NSTEMI of
ither sex benefit from and should receive this agent, as well
s other Class I recommended agents. Doses should be
djusted on the basis of weight and estimated creatinine
learance for renally cleared drugs for all recommended
gents when appropriate. Image-enhanced stress testing has
imilar prognostic value in women as in men.
.2. Diabetes Mellitus
RECOMMENDATIONS
LASS I
. Medical treatment in the acute phase of UA/NSTEMI and decisions
on whether to perform stress testing, angiography, and revascular-
ization should be similar in patients with and without diabetes
mellitus. (Level of Evidence: A)
. In all patients with diabetes mellitus and UA/NSTEMI, attention
should be directed toward aggressive glycemic management in
accordance with current standards of diabetes care endorsed by the
American Diabetes Association and the American College of Endo-
crinology. Goals of therapy should include a preprandial glucose
target of less than 110 mg per dL and a maximum daily target of
less than 180 mg per dL. The postdischarge goal of therapy should
be HbA1C less than 7%, which should be addressed by primary care
and cardiac caregivers at every visit. (Level of Evidence: B)
. An intravenous platelet GP IIb/IIIa inhibitor should be administered
for patients with diabetes mellitus as recommended for all UA/
NSTEMI patients (Section 3.2). (Level of Evidence: A) The benefit
may be enhanced in patients with diabetes mellitus. (Level of
Evidence: B)
LASS IIa
. For patients with UA/NSTEMI and multivessel disease, CABG with
use of the internal mammary arteries can be beneficial over PCI in
patients being treated for diabetes mellitus. (Level of Evidence: B)
. Percutaneous coronary intervention is reasonable for UA/NSTEMI
patients with diabetesmellitus with single-vessel disease and induc-
ible ischemia. (Level of Evidence: B)
. In patients with UA/NSTEMI and diabetes mellitus, it is reasonable
to administer aggressive insulin therapy to achieve a glucose less
than 150 mg per dL during the first 3 hospital (intensive care unit)
days and between 80 and 110 mg per dL thereafter whenever
possible. (Level of Evidence: B)
lease see Section 4 for further explanation of revascularization
trategies.
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yperglycemic Patients With UA/NSTEMI
oronary artery disease accounts for 75% of all deaths in
atients with diabetes mellitus (50,51), and approximately
0% to 25% of all patients with UA/NSTEMI have
iabetes (610,734,775–778). Patients with UA/NSTEMI
nd diabetes have more severe CAD (776,779,780), and
iabetes is an important independent predictor for adverse
utcomes (death, MI, or readmission with UA at 1 year; RR
.9) (781–784). In addition, many patients with diabetes
ho present with UA/NSTEMI have already undergone
ABG (785).
Patients with diabetes tend to have more extensive
oncoronary vascular comorbidities, hypertension, LV hy-
ertrophy, cardiomyopathy, and HF. In addition, auto-
omic dysfunction, which occurs in approximately one third
f patients with diabetes, influences heart rate and blood
ressure, raises the threshold for the perception of angina,
nd may be accompanied by LV dysfunction (786–788). On
oronary angiography, patients with diabetes and UA have
greater proportion of ulcerated plaques (94% vs. 60%, p 
.01) and intracoronary thrombi (94% vs. 55%, p  0.004)
han patients without diabetes (789). These findings suggest
higher risk of plaque instability.
According to American Diabetes Association standards
f care (790), the relationship of controlled blood glucose
evels and reduced mortality in the setting of MI has been
emonstrated. The American College of Endocrinology has
lso emphasized the importance of careful control of blood
lucose targets in the range of 110 mg per dL preprandially
o a maximum of 180 mg per dL. In 1 study (791),
dmission blood glucose values were analyzed in consecutive
atients with MI. Analysis revealed an independent associ-
tion of admission blood glucose and mortality. The 1-year
ortality rate was significantly lower in subjects with
dmission plasma glucose less than 101 mg per dL (5.6
mol per liter) than in those with plasma glucose 200 mg
er dL (11 mmol per liter). In the first Diabetes and
nsulin-Glucose Infusion in Acute Myocardial Infarction
DIGAMI) study (792,793) insulin-glucose infusion fol-
owed by subcutaneous insulin treatment in diabetic patients
ith MI was examined. Mean blood glucose in the intensive
nsulin intervention arm was 172.8 mg per dL (9.5 mmol
er liter) compared with 211 mg per dL (11.6 mmol per
iter) in the “conventional” group. Overall, the intensive
pproach reduced long-term relative mortality (at 3.4 years
f follow-up) by 25% in the insulin-treated group. The
road range of blood glucose levels within each arm limits
he ability to define specific blood glucose target thresholds.
In the second DIGAMI study (794), 3 treatment strat-
gies were compared in a randomized trial among 1,253
atients with type 2 diabetes mellitus and suspected MI:
cute insulin-glucose infusion followed by insulin-based
ong-term glucose control, insulin-glucose infusion followed
y standard glucose control, and routine metabolic manage- gent according to local practice. Blood glucose was reduced
ore at 24 h in those receiving insulin-glucose infusions,
ut long-term glucose control, assessed by HbA1C, did not
iffer between the groups, and the fasting glucose in group
(8.0 mmol per liter) did not reach target (5 to 7 mmol per
iter). The primary end point of all-cause mortality between
roups 1 and 2 did not differ significantly (23.4% vs. 22.6%)
t a median of 2.1 years of follow-up. Morbidity also did not
iffer among the 3 groups. Although the DIGAMI-2
egimen of acutely introduced, long-term insulin treatment
n the setting of suspected acute MI was not demonstrated
o incrementally reduce morbidity and mortality, epidemi-
logical analyses still support a strong, independent rela-
ionship between glucose levels and long-term mortality in
atients with ischemic heart disease (794).
Attainment of targeted glucose control in the setting of
ardiac surgery is associated with reduced mortality and risk
f deep sternal wound infections in cardiac surgery patients
ith diabetes (795,796). This supports the concept that
erioperative hyperglycemia is an independent predictor of
nfection in patients with diabetes mellitus, with the lowest
ortality in patients with blood glucose less than or equal to
50 mg per dL (8.3 mmol per liter) (797).
A mixed group of patients with and without diabetes
dmitted to a surgical intensive care unit (ICU) were
andomized to receive intensive insulin therapy (target
lood glucose 80 to 110 mg per dL [4.4 to 6.1 mmol per
iter]). Achievement of a mean blood glucose of 103 mg per
L (5.7 mmol per liter) reduced mortality during the ICU
tay and decreased overall in-hospital mortality (798). Sub-
equent analysis demonstrated that for each 20-mg per dL
1.1-mmol per liter) glucose elevation above 100 mg per dL
5.5 mmol per liter), the risk of death during the ICU stay
ncreased. Hospital and ICU survival were linearly associ-
ted with ICU glucose levels, with the highest survival rates
ccurring in patients achieving an average blood glucose less
han or equal to 110 mg per dL (6.1 mmol per liter).
Although beta blockers can mask the symptoms of
ypoglycemia or lead to it by blunting the hyperglycemic
esponse, they nevertheless should be used with appropriate
aution in patients with diabetes mellitus and UA/
STEMI. Diuretics that cause hypokalemia can inhibit
nsulin release and thereby worsen glucose intolerance.
Elevated blood glucose among critically ill patients even
n the absence of clinical diabetes mellitus has received
ecent attention as an important risk factor for mortality
799). A randomized trial in the surgical ICU setting (800)
ound that strict glycemic control with insulin reduced both
orbidity and in-hospital mortality (800). More recently,
he role of intensive insulin therapy in the medical ICU
etting has been studied (801) in 1,200 medical ICU
atients (some with CVD) randomized to conventional
herapy (insulin administered when glucose exceeded 215
g per dL, tapering infusion when glucose fell below 180
g per dL) or to intensive insulin therapy (targeting alucose of 80 to 110 mg per dL). Overall, intensive insulin
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ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:e1–157id not significantly reduce in-hospital mortality, the pri-
ary end point (37.3% in the intensive therapy arm, 40% in
he conventional arm, p 0.33), but secondary outcomes of
cquired kidney injury, time to ventilator weaning, and ICU
nd hospital discharge stays were reduced. Hypoglycemia
as more common but often consisted of a single, asymp-
omatic episode. However, when analysis was restricted to
he intended population of 767 patients whose ICU stay was
t least 3 d, in-hospital death was reduced from 52.5% to
3% (p  0.009) and ICU death from 38.1% to 31.3% (p 
.005). In addition, secondary outcomes of time to ventila-
or weaning, days to ICU discharge and to hospital dis-
harge, acquired kidney injury, hyperbilirubinemia, and
RP levels were reduced. Pending results of additional
andomized clinical trials (802), a reasonable approach is to
pply a less aggressive glucose control strategy during the
rst 3 ICU days (e.g., goal of less than 150 mg per dL) in
ery ill patients (e.g., with ventilators or on parenteral
eeding) (803). Thereafter, and in less ill patients, a more
ntensive insulin regimen could be instituted, with a goal of
ormoglycemia (80 to 110 mg per dL).
.2.2. Coronary Revascularization
pproximately 20% of all patients who undergo CABG
804) and PCI (746,747,750,751,779,780) have diabetes
ellitus. Data regarding outcomes are complex. In the
oronary Artery Surgery Study (CASS) of CABG, patients
ith diabetes had a 57% higher mortality rate than patients
ithout diabetes. A striking advantage for CABG over PCI
as found in treated patients with diabetes in the BARI trial
776), a randomized trial of PCI versus CABG in 1,829
table patients with multivessel disease, of whom 19% were
atients with diabetes (see Section 4). As in other studies,
atients with diabetes mellitus had increased comorbidity
ates. Five years after randomization, patients who required
reatment for diabetes had a lower survival rate than patients
ithout diabetes (73.1% vs. 91.3%, p less than 0.0001),
hereas survival rates in patients without and with diabetes
ho did not require hypoglycemic treatment were similar
93.3% vs. 91.1%, pNS). Outcomes for CABG in treated
atients with diabetes were far better than those for PCI
80.6% vs. 65.5% survival, p  0.0003). An interesting
nding was that the mortality rate during the 5.4 years of
he study in patients with diabetes who received SVGs
18.2%) was similar to that of patients who underwent PCI
20.6%); whereas the mortality rate in patients who received
nternal mammary arteries was much lower (2.9%). Results
f the Emory Angioplasty versus Surgery Trial (EAST) at 8
ears showed a similar trend but were less conclusive (805).
he increased mortality rate noted in randomized trials in
atients with diabetes treated with PTCA has been con-
rmed in a registry study from Emory University (613).
ncorrected, there was little difference in long-term mor-
ality rates. The CABG patients had more severe disease,
nd with correction for baseline differences, there was an
mproved survival rate in insulin-requiring patients with dultivessel disease who were revascularized with CABG
ather than with PCI. That the more severely diseased
atients, in a nonrandomized registry, were selectively sent
ore often for CABG than for PCI probably represents
ood clinical decision making.
A 9-year follow-up of the NHLBI registry showed a similar
isturbing pattern for patients with diabetes undergoing PCI
779). Immediate angiographic success and completeness of
evascularization were similar, but compared with patients
ithout diabetes, patients with diabetes (who, again, had more
evere CAD and comorbidities) had increased rates of hospital
ortality (3.2% vs. 0.5%), nonfatal MI (7.0% vs. 4.1%), death
nd MI (10.0% vs. 4.5%), and the combined end point of
eath, MI, and CABG (11% vs. 6.7%; p less than 0.01 for all).
t 9 years, rates of mortality (35.9% vs. 17.9%), MI (29% vs.
8.5%), repeat PCI (43.0% vs. 36.5%), and CABG (37.6% vs.
7.4%) were all higher in patients with diabetes than in those
ithout (779).
However, as discussed in Section 4, other data point to a
esser differential effect of PCI in patients with diabetes. For
xample, data from the BARI registry varied from those of
he BARI trial. In the registry, there was no significant
ifference in cardiac survival for patients with diabetes
ndergoing PCI (92.5%) and CABG (94%; p  NS)
615,806). In the Duke University registry, patients with
iabetes and PCI or CABG were matched with the BARI
opulation (807). The outcome in patients with diabetes
as worse than that without diabetes with either CABG or
CI, but there was no differential effect by therapy. The
-year survival rate for PCI and CABG adjusted for
aseline characteristics was 86% and 89% in patients with
iabetes and 92% and 93% without diabetes, respectively
807).
Stents could improve the outcome of patients with
iabetes who undergo PCI. In a study with historical
ontrols, the outcome after coronary stenting was superior
o that after PTCA in patients with diabetes, and the
estenosis rate after stenting was reduced (63% vs. 36%,
iabetes vs. no diabetes with balloon PTCA at 6 months, p
0.0002, compared with 25% and 27% with stents, p 
S) (805). On the other hand, patients with diabetes who
nderwent atherectomy had a substantial restenosis rate
60% over 6 months) (808). Using data derived from the
orthern New England registries, a contemporary BARI-
ike comparison of long-term survival after PCI (64% with
t least 1 stent) versus CABG found significantly better
isk-adjusted long-term survival in CABG patients with
-vessel disease (HR 0.60, p less than 0.01) (809). Similar
enefits of CABG over PCI were demonstrated for patients
ith diabetes.
Three trials have shown that abciximab considerably
mproved the outcome of PCI in patients with diabetes. In
he EPILOG trial, abciximab resulted in a greater decline in
eath/MI over 6 months after PCI in patients with diabetes
HR 0.36, 95% CI 0.21 to 0.61) than in those without
iabetes (HR 0.60, 95% CI 0.44 to 0.83) (810). Similar
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LUS trial (133,811). EPISTENT was a randomized trial
hat compared stent plus placebo with stent plus abciximab
nd balloon plus abciximab in 2,399 patients, of whom
0.5% had diabetes and 20.3% had UA (512). The 30-d
vent rate (death, MI, and urgent revascularization) in
atients with diabetes declined from 12.1% (stent plus
lacebo) to 5.6% (stent plus abciximab; p  0.040). At 6
onths, the drug reduced revascularization of target arteries
n patients with diabetes (16.6% vs. 8.1%, p  0.02). Death
r MI was reduced to a similar degree in patients with
iabetes as that in patients without diabetes (812). These
enefits were maintained at 1 year (813). Thus, in the
-month data, initial GP IIb/IIIa therapy, as well as
tenting, considerably improved the safety of PCI in pa-
ients with diabetes. In a comparative trial of abciximab and
irofiban (TARGET), both agents were associated with
omparable event rates, including similar rates of 6-month
arget-vessel revascularization and 1-year mortality (814).
.2.3. Conclusions
iabetes occurs in approximately one fifth of patients with
A/NSTEMI and is an independent predictor of adverse
utcomes. It is associated with more extensive CAD,
nstable lesions, frequent comorbidities, and less favorable
ong-term outcomes with coronary revascularization, espe-
ially with PTCA. It is unclear whether these differences are
ue to more frequent restenosis and/or severe progression of
he underlying disease (779). The use of stents, particularly
ith abciximab, appears to provide more favorable results in
atients with diabetes, although more data are needed,
ncluding with DES. Coronary artery bypass grafting, espe-
ially with 1 or both internal mammary arteries, leads to
ore complete revascularization and a decreased need for
eintervention than PCI, even when bare-metal stents are
sed in diabetic patients with multivessel disease. Given the
iffuse nature of diabetic coronary disease, the relative
enefits of CABG over PCI may well persist for diabetic
atients, even in the era of DES.
.3. Post-CABG Patients
RECOMMENDATIONS
LASS I
. Medical treatment for UA/NSTEMI patients after CABG should fol-
low the same guidelines as for non–post-CABG patients with UA/
NSTEMI. (Level of Evidence: C)
. Because of the many anatomic possibilities that might be respon-
sible for recurrent ischemia, there should be a low threshold for
angiography in post-CABG patients with UA/NSTEMI. (Level of Evi-
dence: C)
LASS IIa
. Repeat CABG is reasonable for UA/NSTEMI patients with multiple
SVG stenoses, especially when there is significant stenosis of a graft
that supplies the LAD. Percutaneous coronary intervention is rea-
sonable for focal saphenous vein stenosis. (Level of Evidence: C) ((Note that an intervention on a native vessel is generally preferable
to that on a vein graft that supplies the same territory, if possible.)
. Stress testing with imaging in UA/NSTEMI post-CABG patients is
reasonable. (Level of Evidence: C)
Overall, up to 20% of patients presenting with UA/
STEMI have previously undergone CABG (785). Con-
ersely, approximately 20% of post-CABG patients develop
A/NSTEMI during an interval of 7.5 years (815), with a
ighly variable postoperative time of occurrence (816).
ost-CABG patients who present with UA/NSTEMI are
t higher risk, with more extensive CAD and LV dysfunc-
ion than those patients who have not previously undergone
urgery.
.3.1. Pathological Findings
athologically, intimal hyperplasia or atherosclerosis may
evelop in SVGs, and there is a particular tendency for
hrombotic lesions to develop in these vessels (in 72% of
rafts resected in 1 study) (817–820). In addition, post-
ABG patients may develop atherosclerosis in their native
essels, and this can lead to UA/NSTEMI (820,821).
owever, obstructive lesions are more likely to occur in
VGs (53% within 5 years, 76% at 5 to 10 years, and 92%
t greater than 10 years) (822), and there is a high rate of
arly graft failure in current practice (occlusion in up to one
hird at 1 year). Spasm in grafts or native vessels (823,824)
nd technical complications may also play a role in the
evelopment of UA/NSTEMI during the early postopera-
ive period (815,825). Both angioscopic and angiographic
ndings indicate that SVG disease is a serious and unstable
rocess. Angioscopically, friable plaques occur uniquely in
VGs (44% vs. 0% in native coronary arteries), whereas
ough and white plaques occur in both SVGs and native
oronary arteries (826). Angiographically, the SVGs more
requently have complex lesions (i.e., overhanging edges,
rregular borders, ulcerations, or thrombosis), thrombi (37%
s. 12%, p  0.04), and total occlusions (49% vs. 24%, p 
.02) (822).
.3.2. Clinical Findings and Approach
ompared with UA/NSTEMI patients without prior
ABG, post-CABG patients are more often male (presum-
bly because more men than women have undergone
ABG), older, and more likely to have diabetes. They have
ore extensive native-vessel CAD and more previous MIs
nd LV dysfunction. Symptomatically, these patients have
ore prolonged chest pain than ACS patients without prior
ABG. More than 30% of post-CABG patients have
esting ECG abnormalities, and ECG stress tests are
herefore less conclusive (827); however, a test that becomes
ositive after having been negative is helpful in the diagnosis
f ischemia. Myocardial stress perfusion imaging and do-
utamine echocardiography are often helpful diagnostically
828). Furthermore, a positive imaging test can help to
d
c
t
n
z
t
m
c
o
p
M
a
w
c
u
d
w
e
e
M
p
h
i
U
p
s
6
4
h
M

6
P
a
o
e
a
c
t
r
u
6
C
1
2
3
4
5
b
c
e
y
p
m
r
a
s
N
m
a
p
p
T
L
4
5
6
7
8
*
h
o
C
e110 Anderson et al. JACC Vol. 50, No. 7, 2007
ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:e1–157efine the area of ischemia in post-CABG patients with
omplex disease.
The outcomes of UA/NSTEMI in post-CABG pa-
ients are less favorable than those in patients who have
ot undergone CABG. There is a high rate of emboli-
ation of atherosclerotic material from friable grafts at
he time of intervention, which makes these procedures
ore difficult and which is associated with higher rates of
omplications (829). In one matched case-control study
f UA, the initial course was similar, but post-CABG
atients had twice the incidence of adverse events (death,
I, or recurrent UA) during the first year. This was
ttributed to a lower rate of complete revascularization,
hich was possible in only 9 of 42 post-CABG patients
ompared with 39 of 52 patients who had not previously
ndergone CABG (p  0.001) (815). Results were
irectionally similar in the TIMI III registry of ACS, in
hich 16% of patients were post-CABG. Here again,
arly outcomes in post-CABG patients and others were
quivalent, but at 1 year, the rate of adverse events (death,
I, or recurrent ischemia) was 39.3% for those who had
reviously undergone CABG versus 30.2% for those who
ad not (p  0.002) (830).
Revascularization with either PCI or reoperation often is
ndicated and is possible in post-CABG patients with
A/NSTEMI. In a randomized controlled trial that com-
ared stents with PTCA of obstructed SVGs, there was no
tatistically significant difference in restenosis during a
-month period, although a trend favored stents (34% vs.
6%) (831). Although hemorrhagic complications were
igher in the stent group, clinical outcomes (freedom from
I or repeat revascularization) were better (73% vs. 58%, p
0.03) (831).
.3.3. Conclusions
ost-CABG patients, especially those with only SVGs, are
t high risk of UA/NSTEMI. There is a higher likelihood
f disease in SVGs than in native arteries, and this differ-
nce increases with postoperative time. Pathologically and
ngiographically, disease in SVGs has characteristics asso-
iated with instability. There also are difficulties with
readmill ECG testing and less favorable outcomes with
able 25. Impact of Age on Outcomes of Acute Coronary Synd
Age Group
No. of Deaths
(Hospital Mortality Rate)*
ess than 45 y 20 (1.3)
5 to 54 y 79 (2.0)
5 to 64 y 171 (3.1)
5 to 74 y 373 (5.5)
5 to 84 y 439 (9.3)
5 y or more 260 (18.4)
All p less than 0.0001. The GRACE risk model includes systolic blood pressure, initial serum
ospital arrival. Modified with permission from Avezum A, Makdisse M, Spencer F, et al. Impact o
f Acute Coronary Events (GRACE). Am Heart J 2005; 149:67–73 (835).
I  confidence interval; GRACE  Global Registry of Acute Coronary Events; OR  odds ratio.epeat revascularization than in patients who have not
ndergone previous CABG.
.4. Older Adults
RECOMMENDATIONS
LASS I
. Older patients with UA/NSTEMI should be evaluated for appropriate
acute and long-term therapeutic interventions in a similar manner
as younger patients with UA/NSTEMI. (Level of Evidence: A)
. Decisions onmanagement of older patients with UA/NSTEMI should
not be based solely on chronologic age but should be patient-
centered, with consideration given to general health, functional and
cognitive status, comorbidities, life expectancy, and patient prefer-
ences and goals. (Level of Evidence: B)
. Attention should be given to appropriate dosing (i.e., adjusted by
weight and estimated creatinine clearance) of pharmacological
agents in older patients with UA/NSTEMI, because they often have
altered pharmacokinetics (due to reduced muscle mass, renal
and/or hepatic dysfunction, and reduced volume of distribution)
and pharmacodynamics (increased risks of hypotension and bleed-
ing). (Level of Evidence: B)
. Older UA/NSTEMI patients face increased early procedural risks
with revascularization relative to younger patients, yet the overall
benefits from invasive strategies are equal to or perhaps greater in
older adults and are recommended. (Level of Evidence: B)
. Consideration should be given to patient and family preferences,
quality-of-life issues, end-of-life preferences, and sociocultural dif-
ferences in older patients with UA/NSTEMI. (Level of Evidence: C)
Older adults represent a group of patients in whom
aseline risk is higher (Table 25) and who have more
omorbidities but who derive equivalent or greater ben-
fit (e.g., invasive vs. conservative strategy) compared to
ounger patients. Although a precise definition of “older
atients” or “elderly” has not been established in the
edical literature, many studies have used this term to
efer to those who are 75 years and older. On the basis of
large national ACS registry, older patients make up a
ubstantial portion of those presenting with UA/
STEMI, with 35% older than 75 years and 11% aged
ore than 85 years (832). Older persons also present with
number of special and complex challenges. First, older
ersons who develop UA/NSTEMI are more likely to
resent with atypical symptoms, including dyspnea and
: GRACE Risk Model
Crude OR (95% CI) Adjusted OR (95% CI)
Reference Reference
1.47 (0.90 to 2.41) 1.95 (1.06 to 3.61)
2.35 (1.47 to 3.74) 2.77 (1.53 to 4.99)
4.34 (2.76 to 6.83) 4.95 (2.78 to 8.79)
7.54 (4.80 to 11.8) 8.04 (4.53 to 14.3)
16.7 (10.5 to 26.4) 15.7 (8.77 to 28.3)
ne, heart rate, initial cardiac enzyme, Killip class, ST- segment deviation, and cardiac arrest at
n management and outcome of acute coronary syndrome: observations from the Global Registryrome
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August 14, 2007:e1–157 ACC/AHA UA/NSTEMI Guideline Revisiononfusion, rather than with the chest pain typically
xperienced by younger patients with acute myocardial
schemia (833). Conversely, noncardiac comorbidities
uch as chronic obstructive lung disease, gastroesophageal
eflux disease, upper-body musculoskeletal symptoms,
ulmonary embolism, and pneumonia also are more
requent and may be associated with chest pain at rest
hat can mimic classic symptoms of UA/NSTEMI.
ence, successful recognition of true myocardial isch-
mia in the elderly is often more difficult than in younger
atients. Second, they are more likely than younger
atients to have altered or abnormal cardiovascular anat-
my and physiology, including a diminished beta-
ympathetic response, increased cardiac afterload due to
ecreased arterial compliance and arterial hypertension,
rthostatic hypotension, cardiac hypertrophy, and ven-
ricular dysfunction, especially diastolic dysfunction
834). Third, older patients typically have developed
ignificant cardiac comorbidities and risk factors, such as
ypertension, prior MI, HF, cardiac conduction abnor-
alities, prior CABG, peripheral and cerebrovascular
isease, diabetes mellitus, renal insufficiency, and stroke.
ourth, because of this larger burden of comorbid dis-
ase, older patients tend to be treated with a greater
umber of medications and are at higher risk for drug
nteractions and polypharmacy. Hence, among an already
igh-risk population, older age is associated with higher
isease severity and higher disease and treatment risk at
resentation (832).
.4.1. Pharmacological Management
verall, although the elderly have been generally underrep-
esented in randomized controlled trials, when examined,
lder subgroups appear to have relatively similar relative risk
eductions and similar or greater absolute risk reductions in
any end points as younger patients for commonly used
reatments in the management of UA/NSTEMI. In spite of
n increasing number of possible relative contraindications
ssociated with older age, the rates of serious adverse events
or most older patients generally remain low when evidence-
ased treatment for UA/NSTEMI is provided. Despite
enerally similar benefits, recent studies such as CRUSADE
832), TACTICS-TIMI 18 (182), and GRACE (835) have
ocumented significantly lower use of evidence-based ther-
pies in the elderly, including less use of an aggressive, early
nvasive strategy and of key pharmacotherapies, including
nticoagulants, beta blockers, clopidogrel, and GP IIb/IIIa
nhibitors.
With this said, precautions need to be taken to person-
lize these therapies (i.e., beginning with lower doses than
n younger patients, whenever appropriate, and providing
areful observation for toxicity). Older persons are particu-
arly vulnerable to adverse events from cardiovascular drugs
ue to altered drug metabolism and distribution, as well as
o exaggerated drug effects. Reductions in cardiac output
nd in renal and hepatic perfusion and function decrease the
ate of elimination of drugs in the elderly. Additionally, slder patients typically have lower drug distribution volumes
due to a lower body mass). As a result, drugs need to be
arefully selected and individually adjusted. Current evi-
ence demonstrates that older adults are frequently exces-
ively dosed. In a community-based registry, among treated
atients aged 75 years or older, 38% received an excessive
ose of UFH, 17% received excessive LMWH, and 65%
eceived an excessive dose of a GP IIb/IIIa antagonist (832).
subsequent study from the same registry found that 15%
f major bleeding in UA/NSTEMI patients could be
ttributed to excessive dosing (743). Mortality and length of
tay also were higher in patients receiving excessive dosing.
In the elderly, drugs such as beta blockers that undergo
rst-pass hepatic metabolism exhibit increased bioavailabil-
ty (836). Exaggerated pharmacodynamic responses to drugs
ften resulted from lower cardiac output, plasma volume,
nd vasomotor tone, as well as blunted baroreceptor and
eta-adrenergic responses.
.4.2. Functional Studies
lder persons can have difficulty performing standardized
xercise tolerance tests because of age-related medical prob-
ems, such as general deconditioning, decreased lung capac-
ty, chronic pain, sensory neuropathy, osteoarthritis, and
uscle weakness. Furthermore, the higher prevalence of
reexisting resting ECG abnormalities (782), arrhythmias
140,837), and cardiac hypertrophy often make the inter-
retation of a standard stress ECG inconclusive or impos-
ible. In such patients, alternative methods for evoking
vidence of acute myocardial ischemia, such as pharmaco-
ogical stress testing with dynamic cardiac imaging, may be
ubstituted (see also Section 3.4).
.4.3. Percutaneous Coronary Intervention in Older
atients
ecent evidence from several major interventional trials has
emonstrated a clear benefit for older patients. A collabo-
ative meta-analysis of several more recently published PCI
rials (FRISC-II, TACTICS, RITA-3, VINO, and
ATE) have suggested that the majority of the benefit
rom an invasive strategy in the elderly has accrued from
ontemporary strategies used in trials published after 1999
nd in patients with positive troponins or their cardiac
iomarkers (543). These trials indicated that compared with
ounger patients, the elderly gain important absolute ben-
fits from an early invasive strategy but at a cost of increased
leeding. Specifically, a significant benefit was seen in
eduction of the combined end point of death and recurrent
I, but only a trend to reduction in death was noted. A
ecent observational analysis in a community population
ailed to show an early benefit on in-hospital survival with
n invasive strategy in the older subgroup (75 years or
lder), which highlights the need for continued caution in
pplying trial results uniformly in older patients (837a).
hus, selection of older patients for an early invasivetrategy is complex, including risk from disease and risk
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n these trials, age should not preclude consideration.
Despite these potential benefits, older patients are also far
ess likely to undergo angiography (RR 0.65, p less than 0.001
t 6 weeks) and coronary revascularization (RR 0.79, p 0.002
t 6 weeks) after a UA/NSTEMI episode than younger
atients. This apparent underuse of potentially beneficial in-
erventions might be due in part to practitioner concerns about
he increased risk of complications. Finding the appropriate
alance between benefit and risk of aggressive therapies to
aximize net clinical outcome remains a challenge in the elderly.
.4.4. Contemporary Revascularization Strategies in
lder Patients
everal studies of PCI in patients aged 65 to 75 years have
hown that success rates with experienced medical profes-
ionals are similar to those in younger patients, but with
ven older patients, success rates decline and complication
ates rise. On the other hand, a Mayo Clinic review of PCI
n patients greater than 65 years old (of whom 75% had UA)
evealed an overall success rate of 93.5%, an immediate
n-hospital mortality rate of 1.4%, and a need for emergency
ABG rate of only 0.7% (838). Angiographic outcome
hanged little between the 65-to-69-year-old group and the
reater than 75-year-old group, and the 1-year event rate
death, MI, CABG, repeat PCI, or severe angina) was
5.1% in all patients greater than 65 years old (838).
redictors of outcomes (i.e., extent and severity of CAD
nd comorbidities) after PCI in older patients were the same
s those in younger patients (839). Similarly, a review of
oronary stenting in the elderly reported that procedural
uccess rates were high (95% to 98%) and periprocedural
omplication rates were low (MI 1.2% to 2.8%, urgent
ABG 0.9% to 1.8%, repeat PCI 0% to 0.6%) in the
lderly, with little difference between those greater than 75
ears old and those less than 65 years old (840). Subgroup
nalyses in both TIMI IIIB (129) and FRISC-II (245)
howed a greater advantage of the invasive strategy in
atients older than 65 years of age. More contemporary
tudies have confirmed this advantage, including
ACTICS-TIMI 18 (841). Among patients older than 75
ears of age, the early invasive strategy conferred an absolute
eduction of 10.8 percentage points (to 10.8% from 21.6%;
 0.016) and a relative reduction of 56% in death or MI
t 6 months; however, benefits came with an increased risk
f major bleeding events (16.6% vs. 6.5%; p  0.009).
A review of 15,679 CABG procedures performed in
atients greater than 70 years old from the Toronto Hos-
ital (842) reported encouraging results. Operative mortal-
ty rates declined from 7.2% in 1982 to 1986, to 4.4% in
987 to 1991 (and from 17.2% to 9.1% for high-risk
atients) but showed little further change in the period of
992 to 1996. Predictors of operative death (LV dysfunc-
ion, previous CABG, peripheral vascular disease, and
iabetes) were similar to those in younger patients. COperative morbidity and mortality rates increase for CABG
ith advanced age, but outcomes have been favorable com-
ared with medical therapy, and quality of life improves
843–847). A recent retrospective review of 662,033 patients
ho underwent cardiac surgical procedures performed using
he STS National Cardiac Database (848) found a CABG
perative mortality of 2.8% for patients 50 to 79 years of age,
.1% for patients 80 to 89 years of age, and 11.8% for patients
ged 90 years or more. This study included more than 1,000
atients over 90 years of age and 5 centenarians and docu-
ented that the 57% of nonagenarians without certain risk
actors (renal failure, IABP, emergency surgery, or peripheral
r cerebrovascular disease) constituted a relatively low-risk
roup with an operative mortality of only 7.2%, similar to the
verall risk in octogenarians. Thus, with appropriate selection,
ABG surgery can be an appropriate revascularization strategy
n even the oldest patient subgroups.
.4.5. Conclusions
lder patients with UA/NSTEMI tend to have atypical
resentations of disease, substantial comorbidity, ECG stress
ests that are more difficult to interpret, and different physio-
ogical responses to pharmacological agents compared with
ounger patients. Although they are at highest risk, guideline-
ecommended therapies are used less frequently. Even though
heir outcomes with interventions and surgery are not as
avorable as those of younger patients, coronary revasculariza-
ion should be recommended when the same group of prog-
ostic risk factors that play a role in the younger age group are
aken into account. The approach to these patients also must
onsider general medical and cognitive status, bleeding risk and
ther risk of interventions, anticipated life expectancy, and
atient or family preferences.
.5. Chronic Kidney Disease
RECOMMENDATIONS
LASS I
. Creatinine clearance should be estimated in UA/NSTEMI patients,
and the doses of renally cleared drugs should be adjusted appropri-
ately. (Level of Evidence: B)
. In chronic kidney disease patients undergoing angiography, isosmo-
lar contrast agents are indicated and are preferred. (Level of Evi-
dence: A)
Chronic kidney disease (CKD) is not only a coronary risk
quivalent for ascertainment of coronary risk but also a risk
actor for the development and progression of CVD (744).
hronic kidney disease constitutes a risk factor for adverse
utcomes after MI (849), including NSTEMI and other
oronary patient subsets. In the highly validated GRACE
isk score, serum creatinine is 1 of the 8 independent
redictors of death (168,835). In recent study, even early
KD constituted a significant risk factor for cardiovascular
vents and death (849,850). Chronic kidney disease also
redicts an increase in recurrent cardiovascular events (851).
ardiovascular death is 10 to 30 times higher in dialysis
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August 14, 2007:e1–157 ACC/AHA UA/NSTEMI Guideline Revisionatients than in the general population. The underrepresen-
ation of patients with renal disease in randomized con-
rolled trials of CVD is of concern (179). Most of the
imited evidence available and current opinion suggest that
hen appropriately monitored, cardiovascular medications
nd interventional strategies can be applied safely in those
ith renal impairment and provide therapeutic benefit
849). However, not all recent evidence is consistent with
his premise: atorvastatin did not significantly reduce the
rimary end point of cardiovascular death, nonfatal MI, or
troke in a prospective randomized trial of patients with
iabetes and end-stage CKD who were undergoing hemo-
ialysis (234). The preference for primary PCI has also been
uestioned (235).
Particularly in the setting of ACS, bleeding complications
re higher in this patient subgroup because of platelet
ysfunction and dosing errors; benefits of fibrinolytic ther-
py, antiplatelet agents, and anticoagulants can be negated
r outweighed by bleeding complications; and renin-
ngiotensin-aldosterone inhibitors can impose a greater risk
ecause of the complications of hyperkalemia and worsen-
ng renal function in the CKD patient. Angiography carries
n increased risk of contrast-induced nephropathy; the usual
enefits of percutaneous interventions can be lessened or
bolished; and PCI in patients with CKD is associated with
higher rate of early and late complications of bleeding,
estenosis, and death (179). Thus, the identification of
KD is important in that it represents an ACS subgroup
ith a far more adverse prognosis but for whom interven-
ions have less certain benefit.
Coronary arteriography is a frequent component of the care
f ACS patients. As such, contrast-induced nephropathy can
onstitute a serious complication of diagnostic and interven-
ional procedures. In patients with CKD or CKD and diabe-
es, isosmolar contrast material lessens the rise in creatinine and
s associated with lower rates of contrast-induced nephropathy
han low-osmolar contrast media. This has been documented
n a randomized clinical trial (RECOVER [Renal Toxicity
valuation and Comparison Between Visipaque (Iodixanol)
nd Hexabrix (Ioxaglate) in Patients With Renal Insufficiency
ndergoing Coronary Angiography]) comparing iodixanol
ith ioxaglate (852) and in a meta-analysis of 2,727 patients
rom 16 randomized clinical trials (853). Identification of
KD patients as recommended in the AHA science advisory
n detection of chronic kidney disease in patients with or at
ncreased risk of cardiovascular disease should guide the use of
sosmolar contrast agents (744).
To increase awareness of CKD, an AHA science advisory
or the detection of CKD in patients with or at increased risk
or CVD recently was developed in collaboration with the
ational Kidney Foundation (744). The advisory recommen-
ations are that all patients with CVD be screened for evidence
f kidney disease by estimating glomerular filtration rate,
esting for microalbuminuria, and measuring the albumin-to-
reatinine ratio (Class IIa, Level of Evidence: C). A glomerular
ltration rate less than 60 ml per min per 1.73 square meters ofody surface should be regarded as abnormal (Class I, Level of
vidence: B). Furthermore, the albumin-to-creatinine ratio
hould be used to screen for the presence of kidney damage in
dult patients with CVD, with values greater than 30 mg of
lbumin per 1 g of creatinine regarded as abnormal (Class IIa,
evel of Evidence: B).
A diagnosis of renal dysfunction is critical to proper medical
herapy of UA/NSTEMI. Many cardiovascular drugs used in
A/NSTEMI patients are renally cleared; their doses should
e adjusted for estimated creatinine clearance (see also Section
). In a large community-based registry study, 42% of patients
ith UA/NSTEMI received excessive initial dosing of at least
antiplatelet or antithrombin agent (UFH, LMWH, or GP
Ib/IIIa inhibitor) (743). Renal insufficiency was an indepen-
ent predictor of excessive dosing. Dosing errors predicted an
ncreased risk of major bleeding. Clinical studies and labeling
hat defines adjustments for several of these drugs have been
ased on the Cockroft-Gault formula for estimating creatinine
learance, which is not identical to the MDRD formula. Use of
he Cockroft-Gault formula to generate dose adjustments is
ecommended. The impact of renal dysfunction on biomarkers
f necrosis (i.e., troponin) is discussed in Section 2.2.8.2.1.
To increase the meager evidence base and to optimize care for
his growing high-risk population, the recognition of CKD
atients with or at risk of CVD and the inclusion and reporting of
enal disease in large CVD trials must be increased in the future.
.6. Cocaine and Methamphetamine Users
RECOMMENDATIONS
LASS I
. Administration of sublingual or intravenous NTG and intravenous or
oral calcium channel blockers is recommended for patients with
ST-segment elevation or depression that accompanies ischemic
chest discomfort after cocaine use. (Level of Evidence: C)
. Immediate coronary angiography, if possible, should be performed in
patients with ischemic chest discomfort after cocaine use whose ST
segments remain elevated after NTG and calcium channel blockers;
PCI is recommended if occlusive thrombus is detected. (Level of
Evidence: C)
. Fibrinolytic therapy is useful in patients with ischemic chest discom-
fort after cocaine use if ST segments remain elevated despite NTG
and calcium channel blockers, if there are no contraindications, and
if coronary angiography is not possible. (Level of Evidence: C)
LASS IIa
. Administration of NTG or oral calcium channel blockers can be
beneficial for patients with normal ECGs or minimal ST-segment
deviation suggestive of ischemia after cocaine use. (Level of Evi-
dence: C)
. Coronary angiography, if available, is probably recommended for
patients with ischemic chest discomfort after cocaine use with
ST-segment depression or isolated T-wave changes not known to be
previously present and who are unresponsive to NTG and calcium
channel blockers. (Level of Evidence: C)
. Management of UA/NSTEMI patients with methamphetamine use
similar to that of patients with cocaine use is reasonable. (Level of
Evidence: C)
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dministration of combined alpha- and beta-blocking agents (e.g.,
abetalol) may be reasonable for patients after cocaine use with
ypertension (systolic blood pressure greater than 150 mm Hg) or
hose with sinus tachycardia (pulse greater than 100 beats per min)
rovided that the patient has received a vasodilator, such as NTG or a
alcium channel blocker, within close temporal proximity (i.e., within
he previous hour). (Level of Evidence: C)
LASS III
oronary angiography is not recommended in patients with chest pain
fter cocaine use without ST-segment or T-wave changes and with a
egative stress test and cardiac biomarkers. (Level of Evidence: C)
The use of cocaine can produce myocardial ischemia,
hereby leading to UA/NSTEMI (854–857). The wide-
pread use of cocaine makes it mandatory to consider this
ause, because its recognition mandates special manage-
ent. Specifically, initial management recommendations
or cocaine-induced ACS include NTG and calcium chan-
el antagonists. Assessment for resolution of chest discom-
ort and ECG changes is then undertaken before fibrinolytic
herapy is initiated or angiography is considered. The use of
eta blockers in close proximity (i.e., within 4 to 6 h) of
ocaine exposure is controversial, with some evidence for
arm; thus, when used, the guidelines recommend combi-
ation alpha and beta blockade in addition to a vasodilator.
here are no data to guide recommendations for beta
lockade later after exposure, after cocaine elimination.
The action of cocaine is to block presynaptic reuptake of
eurotransmitters such as norepinephrine and dopamine,
hich produces excess concentrations at the postsynaptic
eceptors that lead to sympathetic activation and the stim-
lation of dopaminergic neurons (858). There may also be a
irect contractile effect on vascular smooth muscle (855).
etoxification is accomplished with plasma and liver cho-
inesterases, which form metabolic products that are ex-
reted in the urine. Infants, elderly patients, and patients
ith hepatic dysfunction lack sufficient plasma cholinester-
se to metabolize the drug (859) and therefore are at high
isk of adverse effects with cocaine use.
.6.1. Coronary Artery Spasm With Cocaine Use
he basis for coronary spasm has been demonstrated in both
n vitro (859) and in vivo (855,860–864) experiments in
nimals and humans. Reversible vasoconstriction of rabbit
ortic rings has been demonstrated with cocaine in concen-
rations of 103 to 108 mol per liter. Pretreatment with
alcium channel blockers markedly inhibits cocaine-induced
asoconstriction. Coronary injection of cocaine produces
asoconstriction in miniswine with experimentally induced
onocclusive atherosclerotic lesions (865).
Nademanee et al. (866) performed 24-h ECG monitor-
ng in 21 male cocaine users after admission to a substance
buse treatment center and found that 8 had frequent
pisodes of ST-segment elevation, most during the first 2
eeks of withdrawal. In cocaine users with prolonged
L
myocardial ischemia, coronary arteriography can reveal cor-
nary artery spasm with otherwise normal-appearing coro-
ary arteries or with underlying minimally obstructive cor-
nary atherosclerosis (855,857,860). The cocaine-induced
ncrease in coronary vascular resistance is reversed with
alcium channel blockers (861,867). Cocaine increases the
esponse of platelets to arachidonic acid, thus increasing
hromboxane A2 production and platelet aggregation (868).
n addition, reversible combined reduction in protein C and
ntithrombin III has been observed in patients with
ocaine-related arterial thrombosis (869). All of these effects
avor coronary thrombosis (855,862,870). Coronary throm-
osis can also develop as a consequence of coronary spasm.
Cocaine users can develop ischemic chest discomfort that
s indistinguishable from the UA/NSTEMI secondary to
oronary atherosclerosis. The patient who presents with
rolonged myocardial ischemia should be questioned about
he use of cocaine. In a study by Hollander et al. (871), the
resence or absence of cocaine use was assessed in only 13%
f patients who presented to the ED with chest pain. Table
6 lists the clinical characteristics of a typical patient with
ocaine-related chest pain or MI (857).
Most patients who present to the ED with cocaine-
ssociated chest pain do not develop MI (872). MI development
as been reported to occur only in 6% of such patients (857).
Accelerated coronary atherosclerosis has been reported in
hronic users of cocaine (873,874); coronary artery spasm is
ore readily precipitated at sites of atherosclerotic plaques
860). Cocaine causes sinus tachycardia, as well as an
ncrease in blood pressure and myocardial contractility,
hereby increasing myocardial oxygen demand (861). These
ncreases can precipitate myocardial ischemia and UA/
STEMI in both the presence and absence of obstructive
oronary atherosclerosis and coronary spasm.
Aortic dissection (875) and coronary artery dissection
855,875) have been reported as consequences of cocaine
se. Other reported cardiac complications are myocarditis
874) and cardiomyopathy (876,877).
able 26. Clinical Characteristics in the Typical Patient With
ocaine-Related Chest Pain, Unstable Angina, or Myocardial
nfarction
oung age, usually less than 40 years
ale gender
igarette smoker, but no other risk factors for atherosclerosis
hronic or first-time cocaine user
ymptom onset minutes or even several hours after cocaine use
ssociated with all routes of administration
ay occur with small or large doses
ften associated with concomitant use of cigarettes and/or alcohol
eprinted from Progressive Cardiovascular Disease, 40, Pitts WF, Lange RA, Cigarroa JE, Hillis
D. Cocaine-induced myocardial ischemia and infarction: pathophysiology, recognition, and
anagement, 65–76. Copyright 1997, with permission from Elsevier (857).
6W
E
S
b
(
r
b
u
t
s
i
i
w
i
a
m
o
b
a
a
i
n
a
p
c
c
a
g
A
i
C
T
p
m
S
n
m
2
t
d
w
p
d
e
c
c
O
s
s
h
c
a
a
u
a
t
s
t
6
G
o
e
t
s
c
a
p
C
A
t
c
f
6
C
1
2
3
C
1
2
C
P
a
E
f
t
r
(
e115JACC Vol. 50, No. 7, 2007 Anderson et al.
August 14, 2007:e1–157 ACC/AHA UA/NSTEMI Guideline Revision.6.2. Treatment
hen a patient with or suspected of cocaine use is seen in the
D with chest pain compatible with myocardial ischemia and
T-segment elevation, sublingual NTG or a calcium channel
lockers (e.g., diltiazem 20 mg IV) should be administered
855,864). If there is no response, immediate coronary angiog-
aphy should be performed, if possible. Fibrinolytic therapy has
een successfully employed in patients with MI after cocaine
se, although these patients frequently have contraindications
o fibrinolysis, including hypertension, seizures, or aortic dis-
ection. Thus, PCI may be a preferred method of revascular-
zation in this setting. However, even this therapeutic strategy
s problematic in subjects with cocaine-related MI; those in
hom stents are deployed are at substantial risk of subsequent
n-stent thrombosis unless double-antiplatelet therapy (ASA
nd clopidogrel) is ingested regularly and predictably for several
onths afterward, and those who partake in substance abuse
ften are unreliable in adhering to such a regimen. Thus,
are-metal stents, which require a shorter duration of dual-
ntiplatelet therapy, generally are preferred to DES in cocaine
busers. If thrombus is present and PCI is unavailable or
neffective, fibrinolytic agents may be administered if there are
o contraindications (878,879). If catheterization is not avail-
ble, intravenous fibrinolytic therapy may be considered in
atients with ST-segment elevation and clinical symptoms
onsistent with MI.
If the ECG is normal or shows only minimal T-wave
hanges and there is a history of chest pain compatible with
cute myocardial ischemia, the patient should receive sublin-
ual NTG or an oral calcium channel blocker and be observed.
fter cocaine use, increased motor activity, skeletal muscle
njury, and rhabdomyolysis can occur, causing CK and even
K-MB elevation in the absence of MI (880). Troponin I and
nT are more specific for myocardial injury and therefore are
referred. Blood should be drawn twice for serum markers of
yocardial necrosis at 6-h intervals. If the ECG shows
T-segment changes and the cardiac biochemical markers are
ormal, the patient should be observed in the hospital in a
onitored bed for 24 h; most complications will occur within
4 h (881). If the patient’s clinical condition is unchanged and
he ECG remains unchanged after 24 h, the patient can be
ischarged (879). A shorter observation period of 9 to 12 h,
ith measurement of troponin levels at 3, 6, and 9 h after
resentation, also has been validated (882).
Many observers believe that beta blockers are contrain-
icated in cocaine-induced coronary spasm because there is
vidence from a single double-blind, randomized, placebo-
ontrolled trial that beta-adrenergic blockade augments
ocaine-induced coronary artery vasoconstriction (883).
thers believe that if the patient has a high sympathetic
tate with sinus tachycardia and hypertension, beta blockers
hould be used (855). Labetalol, an alpha and beta blocker,
as been advocated, because it has been shown not to induce
oronary artery vasoconstriction (884) even though its beta-
drenergic–blocking action predominates over its alpha- cdrenergic–blocking activity in the doses that are commonly
sed (884). Therefore, in cocaine-induced myocardial ischemia
nd vasoconstriction, NTG and calcium channel blockers are
he preferred drugs. Both NTG and verapamil have been
hown to reverse cocaine-induced hypertension, coronary ar-
erial vasoconstriction (864,883), and tachycardia (verapamil).
.6.3. Methamphetamine Use and UA/NSTEMI
iven the rapid increase in methamphetamine abuse, recognition
f its cardiovascular risk is of mounting importance. Currently, the
vidence base for UA/NSTEMI after methamphetamine and its
reatment is limited to a few publications of case reports and small
eries (885–888). These suggest that ACS is increasingly
ommon in patients evaluated in the ED for chest discomfort
fter methamphetamine use and that the frequency of other
otentially life-threatening arrhythmias is not negligible (886).
linical presentation resembles that of cocaine-associated
CS. On the basis of the similarities in pathophysiology and
hese few clinical observations, therapy similar to that of
ocaine-induced UA/NSTEMI is recommended pending in-
ormation more specific to methamphetamine.
.7. Variant (Prinzmetal’s) Angina
RECOMMENDATIONS
LASS I
. Diagnostic investigation is indicated in patients with a clinical
picture suggestive of coronary spasm, with investigation for the
presence of transient myocardial ischemia and ST-segment eleva-
tion during chest pain. (Level of Evidence: A)
. Coronary angiography is recommended in patients with episodic
chest pain accompanied by transient ST-segment elevation. (Level
of Evidence: B)
. Treatment with nitrates and calcium channel blockers is recom-
mended in patients with variant angina whose coronary angiogram
shows no or nonobstructive coronary artery lesions. Risk factor
modification is recommended, with patients with atherosclerotic
lesions considered to be at higher risk. (Level of Evidence: B)
LASS IIb
. Percutaneous coronary intervention may be considered in patients
with chest pain and transient ST-segment elevation and a significant
coronary artery stenosis. (Level of Evidence: B)
. Provocative testing may be considered in patients with no signifi-
cant angiographic CAD and no documentation of transient ST-
segment elevation when clinically relevant symptoms possibly ex-
plained by coronary artery spasm are present. (Level of Evidence: C)
LASS III
rovocative testing is not recommended in patients with variant angina
nd high-grade obstructive stenosis on coronary angiography. (Level of
vidence: B)
Variant angina (Prinzmetal’s angina, periodic angina) is a
orm of UA that usually occurs spontaneously and is charac-
erized by transient ST-segment elevation that spontaneously
esolves or resolves with NTG use without progression to MI
889). The earliest stages of MI can also be associated with
yclic ST-segment elevations, but MI does not possess the
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ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:e1–157ature of periodic angina. The spasm is most commonly focal
nd can occur simultaneously at more than 1 site (890). Even
oronary segments that are apparently normal on coronary
ngiography often have evidence of mural atherosclerosis on
ntravascular ultrasound (891). This can result in localized
ndothelial dysfunction and coronary spasm.
Patients with Prinzmetal’s angina frequently have coro-
ary artery plaques that can be either nonobstructive or
bstructive (892). Walling et al. (893) reported that coro-
ary arteriography showed 1-vessel disease in 81 (39%) of
17 patients and multivessel disease in 40 (19%). Rovai et al.
894) found a similar high prevalence of obstructive disease
n 162 patients with variant angina.
.7.1. Clinical Picture
lthough chest discomfort in the patient with variant
ngina can be precipitated by exercise, it usually occurs
ithout any preceding increase in myocardial oxygen de-
and; the majority of patients have normal exercise toler-
nce, and stress testing may be negative. Because the anginal
iscomfort usually occurs at rest without a precipitating
ause, it may simulate UA/NSTEMI secondary to coronary
therosclerosis. Episodes of Prinzmetal’s angina often occur
n clusters, with prolonged asymptomatic periods of weeks
o months. Attacks can be precipitated by an emotional
tress, hyperventilation (895), exercise (896), or exposure to
old (897). A circadian variation in the episodes of angina is
ost often present, with most attacks occurring in the early
orning (898). Compared with patients with chronic stable
ngina, patients with variant angina are younger and, except
or smoking, have fewer coronary risk factors (899,900).
ome studies have shown an association of variant angina
ith other vasospastic disorders, such as migraine headache
nd Raynaud’s phenomenon (901). The presence of syncope
uring an episode of chest pain suggests severe ischemia
elated to an acute occlusion, often due to focal spasm.
Most often, the attacks of angina resolve spontaneously
ithout evidence of MI. However, a prolonged vasospasm may
esult in complications such as MI, a high degree of AV block,
ife-threatening ventricular tachycardia, or sudden death
902,903).
.7.2. Pathogenesis
he pathogenesis of focal coronary spasm in this condi-
ion is not well understood. The probable underlying
efect is the presence of dysfunctional endothelium that
xposes the medial smooth muscle to vasoconstrictors
uch as catecholamines, thromboxane A2, serotonin,
istamine, and endothelin (904). Endothelial dysfunction
lso can impair coronary flow-dependent vasodilatation
wing to the decreased production and release of nitric
xide (905) and enhanced phosphorylation of myosin
ight chains, an important step in smooth muscle con-
raction (906). There can be an imbalance between
ndothelium-produced vasodilator factors (i.e., prostacy-
lin, nitric oxide) and vasoconstrictor factors (i.e., endo- ghelin, angiotensin II) that favors the latter (907). There
lso is evidence of involvement of the autonomic nervous
ystem, with reduced parasympathetic tone and enhanced
eactivity of the alpha-adrenergic vascular receptors
905,908,909). Regardless of the mechanism, the risk for
ocal spasm is transient but recurrent.
.7.3. Diagnosis
he key to the diagnosis of variant angina is the documenta-
ion of ST-segment elevation in a patient during transient
hest discomfort (which usually occurs at rest, typically in the
arly morning hours, and nonreproducibly during exercise) and
hat resolves when the chest discomfort abates. Typically,
TG is exquisitely effective in relieving the spasm. ST-
egment elevation implies transmural focal ischemia associated
ith complete or near-complete coronary occlusion of an
picardial coronary artery in the absence of collateral circula-
ion. In variant angina, the dynamic obstruction can be
uperimposed on severe or nonsevere coronary stenosis or
upervene in an angiographically normal coronary artery seg-
ent. Hence, coronary angiography is usually part of the
orkup of these patients and can help orient treatment.
It is noteworthy that spasm often develops spontaneously
uring angiography, which aids the diagnosis in patients with
o previously documented ST-segment elevation; catheter-
nduced spasm is not, however, an indicator of vasospastic
isease. Diagnostic tests for Prinzmetal’s angina are based on
he recording of transient ST-segment elevation during an
pisode of chest pain. Continuous 12-lead ECG monitoring
an be performed for this purpose in-hospital or as an outpa-
ient; recording during numerous episodes of pain improves
iagnostic sensitivity. A treadmill exercise test is also useful;
ne third of patients will show ST-segment elevation, another
hird ST-segment depression, and one third no ST-segment
hange. Interestingly, the results may not be reproducible
ithin the same patients and are more often positive when the
est is performed in the early morning hours. A 2-dimensional
chocardiogram or the injection of a nuclear marker at the time
f chest pain may help document the presence of transmural
schemia. A number of other provocative tests can be used to
recipitate coronary artery spasm when the diagnosis is sus-
ected but not objectively documented. Nitrates and calcium
hannel blockers should be withdrawn well before provocative
esting. These tests are more often used during coronary
ngiography; the spasm can then be visualized before the
ppearance of chest pain and promptly relieved by the intra-
oronary injection of NTG. The test can also be performed in
coronary care unit setting while the patient is monitored for
T-segment elevation, but this is recommended only if the
oronary anatomy is known. Such nonpharmacological tests
nclude the cold pressor test and hyperventilation performed
or 6 min in the morning, alone or after exercise (910).
harmacological tests in general provide a better diagnostic
ield. Ergonovine, methylergonovine, and ergometrin have
een most widely studied and used in the past, but methyler-
onovine and ergometrin are no longer generally available, and
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August 14, 2007:e1–157 ACC/AHA UA/NSTEMI Guideline Revisionhe use of ergonovine is limited. Acetylcholine and methacho-
ine are now predominantly used for this diagnostic purpose.
lthough the spasm is usually promptly relieved with NTG
dministered intracoronarily or intravenously, it may at times
e refractory to therapy with NTG and other vasodilators and
ay be recurrent in the same segment or in other coronary
rtery segments, resulting in prolonged ischemia, MI, or
ccasionally, death (911). For these reasons, provocative tests
re now rarely used and are limited to a few indications, such
s patients with suggestive symptoms that could be helped by
n appropriate diagnosis not otherwise reached, patients in
hom treatment with nitrates and calcium channel blockers
as failed, and patients with a life-threatening disease in whom
he physician wants to verify the efficacy of the treatment.
hus, patients with a positive hyperventilation test are more
ikely to have a higher frequency of attacks, multivessel spasm,
r high degree of AV block or ventricular tachycardia than are
atients with a negative hyperventilation test (910), and high-
isk patients whose tests become negative with treatment are
ore likely to have a favorable long-term course. The investi-
ation of coronary spasm in patients with coronary artery
esions of borderline significance can be complemented by
ther diagnostic procedures such as intravascular ultrasound,
unctional flow reverse, and other functional testing to assess
ore accurately the significance of the obstruction.
.7.4. Treatment
oronary spasm is usually very responsive to NTG, long-
cting nitrates, and calcium channel blockers (912–914), which
re considered first-line therapies. (Beta-blockers have theo-
etical adverse potential, and their clinical effect is controver-
ial.) Smoking should be discontinued. Usually, a calcium
hannel blocker in a moderate to high dose (e.g., verapamil 240
o 480 mg per d, diltiazem 180 to 360 mg per d, or nifedipine
0 to 120 mg per d) is started; patients with very active disease
an require a combination of nitrates and 2 calcium channel
lockers of different classes (i.e., a dihydropyridine with vera-
amil or diltiazem). Alpha-receptor blockers have been re-
orted to be of benefit, especially in patients who are not
esponding completely to calcium channel blockers and nitrates
906). In patients who develop coronary spasm (with or
ithout provocation) during coronary angiography, 0.3 mg of
TG should be infused directly into the coronary artery that is
nvolved.
.7.5. Prognosis
he prognosis of variant angina is usually excellent in
atients with variant angina who receive medical therapy,
specially in patients with normal or near-normal coronary
rteries. Yasue et al. (915) reported an 89% to 97% overall
-year survival rate. In a 7-year follow-up in approximately
00 patients, the incidence of sudden death was 3.6% and
he incidence of MI was 6.5% (915). Patients with coronary
rtery vasospasm superimposed on a fixed obstructive CAD
ave a worse prognosis. In a study of 162 patients with
ariant angina by Rovai et al. (894), patients with normal toronary arteries and single-vessel disease had a 5-year
urvival rate of 95% compared with a rate of 80% for those
ith multivessel disease. Almost identical survival rates were
eported in an earlier study by Walling et al. (893). Occa-
ional patients may require instrumentation with a pace-
aker to prevent transient AV block associated with isch-
mia or with a defibrillator to prevent sudden death
ssociated with ischemia-induced ventricular fibrillation.
reatment can at times be very frustrating in the occasional
atient refractory to standard medication. Cardiac denerva-
ion has been used in these patients with marginal benefit.
.8. Cardiovascular “Syndrome X”
RECOMMENDATIONS
LASS I
. Medical therapy with nitrates, beta blockers, and calcium channel
blockers, alone or in combination, is recommended in patients with
cardiovascular syndrome X. (Level of Evidence: B)
. Risk factor reduction is recommended in patients with cardiovascu-
lar syndrome X. (Level of Evidence: B)
LASS IIb
. Intracoronary ultrasound to assess the extent of atherosclerosis and
rule out missed obstructive lesions may be considered in patients
with syndrome X. (Level of Evidence: B)
. If no ECGs during chest pain are available and coronary spasm
cannot be ruled out, coronary angiography and provocative testing
with acetylcholine, adenosine, or methacholine and 24-h ambula-
tory ECG may be considered. (Level of Evidence: C)
. If coronary angiography is performed and does not reveal a cause of
chest discomfort, and if syndrome X is suspected, invasive physio-
logical assessment (i.e., coronary flow reserve measurement) may
be considered. (Level of Evidence: C)
. Imipramine or aminophylline may be considered in patients with
syndrome X for continued pain despite implementation of Class I
measures. (Level of Evidence: C)
. Transcutaneous electrical nerve stimulation and spinal cord stimula-
tion for continued pain despite the implementation of Class Imeasures
may be considered for patients with syndrome X. (Level of Evidence: B)
LASS III
edical therapy with nitrates, beta blockers, and calcium channel
lockers for patients with noncardiac chest pain is not recommended.
Level of Evidence: C)
.8.1. Definition and Clinical Picture
ardiovascular “syndrome X” refers to patients with angina
r angina-like discomfort with exercise, ST-segment de-
ression on exercise testing, and normal or nonobstructed
oronary arteries on arteriography (916). This entity should
e differentiated from the metabolic syndrome X (metabolic
yndrome), which describes patients with insulin resistance,
yperinsulinemia, dyslipidemia, hypertension, and abdom-
nal obesity. It also should be differentiated from noncardiac
hest pain. Syndrome X is more common in women than in
en (679,916–918). Chest pain can vary from that ofypical angina pectoris to chest pain with atypical features to
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ther atypical features can be prolonged chest pain at rest
nd chest pain that is unresponsive to NTG (919). Most
ften, the chest pain occurs with activity and simulates
ngina pectoris due to stable CAD. However, because chest
ain can accelerate in frequency or intensity or may occur at
est, the patient can present with the clinical picture of UA.
herefore, this syndrome is discussed in this guideline.
The cause of the discomfort and ST-segment depression
n patients with syndrome X is not well understood. The
ost frequently proposed causes are impaired endothelium-
ependent arterial vasodilatation with decreased nitric oxide
roduction, impaired microvascular dilation (non–
ndothelium-dependent), increased sensitivity to sympa-
hetic stimulation, or coronary vasoconstriction in response
o exercise (731,920,921). Increased levels of plasma endo-
helin correlate with impaired coronary microvascular dila-
ion (922). There is increasing evidence that these patients
requently also have an increased responsiveness to pain and
n abnormality in pain perception.
The diagnosis of syndrome X is suggested by the triad of
nginal-type chest discomfort, objective evidence of ischemia,
nd absence of obstructive CAD. The diagnosis can be
onfirmed by provocative coronary angiographic testing with
cetylcholine for coronary endothelium-dependent function
nd adenosine for non–endothelium-dependent microvascular
unction. Other causes of angina-like chest discomfort not
ssociated with cardiac disease, such as esophageal dysmotility,
bromyalgia, and costochondritis, must also be eliminated. In
ddition, in patients with a clinical presentation consistent with
ariant angina, coronary spasm must be ruled out by the
bsence of ST-segment elevation with the anginal discomfort
r by provocative testing. Myocardial perfusion scanning may
e abnormal owing to a patchy abnormal response to exercise
f the microvasculature that can lead to reduced coronary flow
o different regions of the myocardium (731). Magnetic reso-
ance imaging studies also may suggest myocardial ischemia
923,924).
The intermediate-term prognosis of patients with syn-
rome X has been reported to be excellent in older studies
917,919,925). The CASS registry reported a 96% 7-year
urvival rate in patients with anginal-type chest pain, normal
oronary arteriograms, and an LVEF greater than 0.50
926). However, testing for ischemia was not performed in
ASS. More recent data from WISE indicate that the
rognosis in syndrome X, validated by ischemia testing, is
ot entirely benign with respect to risk of cardiac death and
onfatal MI (918,919). The WISE data demonstrate that
he prognosis is related to the extent of angiographic disease
cross the range of 20% stenosis to obstructive lesions (918).
ong-term follow-up shows that ventricular function usu-
lly remains normal (919), although there have been reports
f progressive LV dysfunction, and many patients continue
o have chest pain that requires medication (927).
Additional data from WISE (733,767–774) suggest adverse
utcomes in some women with myocardial ischemia on non- Fnvasive testing and nonobstructive CAD. A number of vari-
bles may be contributory. Intramural lesions, evidence of an
therosclerotic burden, are evident on intravascular ultrasound.
decrease in coronary flow reserve appears to independently
redict major coronary events. In addition, there is important
oronary endothelial dysfunction that may be related to hor-
onal influences, inflammatory markers, or oxidative stress
nd possibly to a clustering of risk factors as is seen in the
etabolic syndrome. Other microvascular dysfunction may be
resent. Although half of the WISE women with myocardial
schemia documented on noninvasive testing had no flow-
imiting coronary obstructive disease at angiography, not only
ere there persisting symptoms, but there was a subsequent
ignificant occurrence of coronary events. Evaluation of the
-year risk-adjusted freedom from death or MI showed that
omen with no or minimal obstructive disease had a total rate
f occurrence of these end points of 9.4% by 4 years. Pending
dditional data, aggressive coronary risk factor reduction ap-
ears to be appropriate.
.8.2. Treatment
ersistence of symptoms is common, and many patients do
ot return to work (919). The demonstration of normal
oronary arteries on angiography can be reassuring. In 1
tudy, after a normal coronary arteriogram, there was a
educed need for hospitalization and a reduction in the
umber of hospital days for cardiac reasons (566). However,
ven minimal atherosclerotic disease on angiography war-
ants risk factor modification.
Both beta blockers and calcium channel blockers have been
ound to be effective in reducing the number of episodes of
hest discomfort (928,929). Beneficial effects with nitrates are
een in approximately one half of patients (930). The use of
lpha-adrenergic blockers would appear to be a rational ther-
py, but the results of small trials are inconsistent (931).
mipramine 50 mg daily has been successful in some chronic
ain syndromes, including syndrome X, reducing the frequency
f chest pain by 50% (932). Transcutaneous electrical nerve
timulation and spinal cord stimulation can offer good pain
ontrol (933,934). Estrogen in postmenopausal women with
ngina and normal coronary arteriograms has been shown to
everse the acetylcholine-induced coronary arterial vasocon-
triction, presumably by improving endothelium-dependent
oronary vasomotion (935), and to reduce the frequency of
hest pain episodes by 50% (936). However, because of
ncreased cardiovascular and other risks documented in
andomized controlled trials of primary and secondary
oronary prevention, hormone therapy is not recommended
or chronic conditions (29). Statin therapy and exercise
raining have improved exercise capacity, endothelial func-
ion, and symptoms (937,938).
It is recommended that patients be reassured of the excellent
ntermediate-term prognosis and treated with long-acting
itrates. If the patient continues to have episodes of chest pain,
calcium channel blocker or beta blocker can be started (929).
inally, 50 mg of imipramine daily has been successful in
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August 14, 2007:e1–157 ACC/AHA UA/NSTEMI Guideline Revisioneducing the frequency of chest pain episodes (932). Cognitive
ehavioral therapy can be beneficial (939). If symptoms persist,
ther causes of chest pain, especially esophageal dysmotility,
hould be ruled out.
.9. Takotsubo Cardiomyopathy
disorder, or group of disorders, with several names
stress-induced cardiomyopathy, transient LV apical bal-
ooning, Takotsubo cardiomyopathy, and broken heart syn-
rome) is an uncommon but increasingly reported cause of
CS. Takotsubo cardiomyopathy is noteworthy for the
bsence of obstructive coronary artery disease, typical pre-
ipitation by intense psychological or emotional stress, and
redominant occurrence in postmenopausal women. The
haracteristic finding of apical LV ballooning is seen on left
entriculography or echocardiography, with transient ST
levation or deep T-wave inversions on the surface ECG.
espite the presence of positive cardiac biomarkers and
requent hemodynamic compromise or even cardiogenic
hock, almost all patients recover completely, typically with
ormal wall motion within 1 to 4 weeks (730,940,941).
. Conclusions and Future Directions
he last quarter century has witnessed enormous strides in the
nderstanding of ACS pathophysiology and its management.
hese have included the critical role of coronary thrombosis
942), the novel concept and suggestion of a therapeutic benefit
f reperfusion therapy (943–946), and finally, the demonstra-
ion of mortality reductions with fibrinolysis in large, multi-
enter trials (531a). However, these trials also uncovered the
aradox that fibrinolysis did not benefit or even harmed
STEMI patients (531a). This central management dichot-
my, together with other differences between STEMI and
A/NSTEMI (13), has been reflected since 2000 in separate
ractice guidelines. Despite these differences, more remains in
ommon than distinct, including the discovery that athero-
hrombosis is an active, inflammatory process (947,948). Fur-
her inquiry has led to the concept of the vulnerable plaque and
he vulnerable patient (949,950).
Whereas the incidence and risk of STEMI have de-
reased over the past 25 years, the relative frequency of
A/NSTEMI has increased, and its risk has remained
elatively high (now comparable to that of STEMI) (951).
ence, improving UA/NSTEMI outcomes remains a chal-
enge for the future.
A contemporary multinational observational study has em-
hasized the benefits of applying evidence-based guidelines in
linical practice (951a). Between 1999 and 2006, 27,558
atients with UA/NSTEMI in 14 countries were enrolled and
ollowed for 6 months after discharge. Increases over the 7
ears of enrollment were observed in the use of interventional
herapy and of major pharmacological therapies, including beta
lockers, statins, ACE inhibitors (or ARBs), low molecular
eight heparin, GP IIb/IIa inhibitors, and thienopyridines.
hese changes were accompanied by marked declines (by one falf) in in-hospital rates of heart failure or cardiogenic shock
nd recurrent MI and in 6-month rates of death (from 4.9% to
.3%) and stroke (1.4% to 0.7%). Improved outcomes occurred
espite an increase in patient risk profile. The future should
mphasize further improvements in evidence-based guideline
pplications.
Improving prehospital and ED assessment should aim at
ore efficient entry into the health care system (e.g., limiting
elays for NTG-refractory angina before calling 9-1-1), diag-
osis and risk stratification (e.g., using marker changes while
hey are still in the normal range; in the future, with the aid of
ontraditional biomarkers), and initiation of therapy. The
uture will see the increasing use of new imaging tests to assess
he chest pain patient. By simultaneously assessing cardiac
unction, perfusion, and viability, CMR can yield a high
ensitivity and specificity for diagnosis of CAD/ACS (296).
ultislice cardiac computed tomography, which combines
oronary calcium scoring with noninvasive coronary angiogra-
hy (current resolution 0.5mm), has undergone favorable
nitial evaluation for assessment of the low- to intermediate-
isk chest pain patient (297). The current status and appropri-
te application of CMR and cardiac CT are addressed in recent
CC/AHA documents (25,294).
The concept of a network of “heart attack centers” has
een proposed as a way to improve MI care in the future
952–954). These heart attack centers would be organized
nd certified to provide the highest levels of care and would
e geographically readily accessible to virtually all patients.
For high-risk patients, the concept of establishing and
aintaining normal levels of myocardial perfusion mechani-
ally continues to gain support, with evidence favoring inter-
ention at even shorter (e.g., less than 6 to 24 h) rather than
onger (i.e., greater than 48 to 96 h) intervals (540). The future
hould bring additional important information on this issue.
In contrast, for low-risk patients, evidence is growing that
n initially noninvasive approach may be preferred (e.g.,
CI shows benefit in high-risk women, as in men, but
arries adverse risk potential in low-risk women) (532,565).
his dependence of therapeutic benefit on disease risk has
lso been shown for antiplatelet and anticoagulant therapies.
ence, there is an increasing need to optimally stratify risk;
ome progress has been made (e.g., with the use of biomar-
ers integrated into an overall clinical risk score; see Section
.2), but further development of risk assessment algorithms
ill be welcome in the future.
Platelets play a critical role UA/NSTEMI, and antiplate-
et therapy continues to undergo testing. Higher (e.g., 600
g or more of clopidogrel) and earlier loading doses of oral
hienopyridine have been tested since the previous guide-
ines were published (see Section 3.2), with evidence of
arlier antiplatelet activity. However, an incremental benefit
f triple-antiplatelet therapy (ASA, GP IIb/ IIIa inhibitor,
nd clopidogrel) over double therapy with clopidogrel plus
SA (without GP IIb/IIIa inhibition) was recently shownor PCI in the setting of UA/NSTEMI (244).
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ACC/AHA UA/NSTEMI Guideline Revision August 14, 2007:e1–157Late thrombosis of DES (400,402,403,955), associated with
elayed endothelialization (399,399a), recently has emerged as
therapeutic issue (401). Thus, longer periods of dual-
ntiplatelet therapy (i.e., at least 1 year) increasingly are
dvocated (see Section 3.2). Missing is an individualized
pproach to antiplatelet management: the future should bring
fficient, validated platelet function testing to allow titration of
he type, intensity, and duration of antiplatelet therapy. More
hoices in antiplatelet therapy can be expected, including
ntravenously administered and rapidly acting ADP receptor
ntagonists and more potent and/or more readily reversible oral
gents. Biocompatible stents can also be expected looking
orward, including biodegradable stents.
Triple-anticoagulant therapy (e.g., ASA, a thienopyri-
ine, and warfarin) increasingly has a potential indication
e.g., PCI plus atrial fibrillation, cardiac or vascular throm-
osis, or mechanical heart valve). Its current Class IIb
ecommendation (to be used “with caution” [1,2]; Fig. 11) is
n need of a firmer evidence base (1,2).
Anticoagulant choices have proliferated since the last guide-
ines were published. Although LMWH (e.g., enoxaparin)
ained recognition as an alternative or preferred anticoagulant
n the previous guidelines, subsequent study in the setting of an
arly PCI strategy has suggested that either UFH or LWMH
s acceptable (423). Meanwhile, agents from 2 new classes have
een tested favorably (see Section 3.2) (424,425). Fondapa-
inux, a synthetic factor Xa inhibitor, was noninferior to
noxaparin at 9 d, with a lower bleeding risk. However,
atheter-related thrombosis with fondaparinux raises concerns
bout its use with PCI, a concern amplified by its failure with
CI in STEMI (433). In contrast, fondaparinux is an appeal-
ng choice with a noninvasive approach to UA/NSTEMI,
specially in those at higher risk of bleeding.
The ACUITY study, which tested bivalirudin for UA/
STEMI, has led to a guidelines change to allow bivaliru-
in as an anticoagulant option (425). Bivalirudin was found
o be noninferior to UFH/LMWH when given with a GP
Ib/IIIa inhibitor. When given without a GP inhibitor,
leeding rates were lower but ischemic risk was higher
nless clopidogrel therapy had been given before the pro-
edure. Bivalirudin use was not tested with a conservative
trategy. These guidelines present several options for anti-
oagulant/antiplatelet regimens, but whether there are clear
references must await additional analysis and an enriched
vidence base and could vary depending on the health care
etting, the preferred treatment strategy (e.g., invasive vs.
onservative), and individual patient factors.
This guideline revision recognizes ongoing developments
n prevention (see Section 5.1.1). More aggressive LDL-C
owering (i.e., to the optimal LDL-C goal of less than 70
g per dL) further reduces cardiovascular events, although
n incremental mortality benefit remains to be shown (956).
n additional tool for smoking cessation has appearedvarenicline), and others are in testing (see Section 5.2). Kigh compliance with recommended secondary prevention
easures has been shown to improve outcomes, but optimal
ompliance is still lacking, including at hospitals peer-rated
s top tier (957). The evidence base for therapeutic lifestyle
hange continues to grow; the challenge for the future is
ore successful implementation (see Section 5.2).
Primary prevention remains a major challenge. Risk is
urrently assessed by traditional factors (e.g., Framingham
isk score) and the intensity of treatment by risk score-
etermined goals. The majority of coronary events occur in
large segment of the population whose risk is intermediate
neither very low nor very high). Routine individual screen-
ng for asymptomatic disease is widely accepted for common
ancers (e.g., colon and breast cancer) but not for athero-
clerosis. Application of an “atherosclerosis test” (e.g., cor-
nary artery calcium scoring or carotid intima-media thick-
ess assessment) to middle-aged adults at intermediate risk
as been proposed (25,294,949,950). The future will deter-
ine how broadly extended primary screening will be
ccepted to identify the “ACS-vulnerable” patient.
Progress in UA/NSTEMI remains uneven, with rapid
volution in some areas but slow progress in others. Our hope
s that guidelines increasingly become based on levels of
vidence A (or B). Writing these guidelines has highlighted
he many holes in the fabric of the current evidence base.
cademia, regulatory agencies, practicing physicians, profes-
ional organizations, and patient advocacy groups, as well as
ndustry, must cooperate to achieve the universal goal of a fully
vidence-based management strategy for UA/NSTEMI in the
uture. Strategies must include not only innovations in diag-
osis and treatment but also fresh approaches to motivating
ifestyle changes, leading to improved diet, weight control,
hysical activity, and tobacco avoidance, as well as to better
ompliance with evidence-based medical therapies (380).
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